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Abstract  
Background and aim: Information support is an integral part of cancer care, but its 
provision can be problematic in busy health settings. The aim of this project was to 
develop and evaluate a health app to facilitate the provision of information support in 
newly diagnosed patients with colorectal cancer (CRC). Instead of delivering information 
using text, three animated embodied virtual agents (VAs) were deployed. The VAs were 
formulated after patients’ treating clinicians (male oncologist, female nurse and female 
pharmacist) to explore the role of familiarity, which has not been addressed in previous 
research.  
Study methods: A multi-stage development process was followed for the app, which 
was provided to the study participants before the beginning of their treatment. A 
convergent parallel mixed methods design involving pre- and post-exposure 
questionnaires (adapted versions of the Toronto Information Needs Questionnaire and 
the System Usability Scale), app usage data and semi-structured interviews was 
deployed to evaluate the intervention.  
Results and discussion: The app was acceptable by the end users and had a good degree 
of usability (mean System Usability Scale score=73.89). The information content was 
appropriate and met patients’ demands to a moderate extent; this was because 
patients utilised other information sources (e.g., printed material) to address their 
needs. Incorporating supportive functions such as a medicinal calendar in addition to 
the information content emerged as an important aspect.  
   iii 
The inclusion of VAs was deemed to be appropriate. The VAs fostered a sense of 
presence, added trustworthiness to the information content and were perceived as 
more interactive than reading text. Having a VA representing a familiar clinician was 
favoured by most users. The vast majority of patients perceived the VAs as cartoon 
figures and suggested that they should be improved to look realistic in order to give the 
impression of having an exchange with a real person. Natural voices were preferred 
over synthetic speech. 
Conclusion: VA-based mHealth interventions are an acceptable way of supporting 
patients with CRC. Appropriate consideration should be given to the requirements of 
the intended user audience to design acceptable interventions that reflect their needs.  
Keywords: Virtual Agents, Embodied Conversational Agents, Information Support, 
Bowel Cancer, Mobile Healthcare  
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Chapter 1: Background, Conceptual Framework 
and Aims 
This chapter will present the background and the conceptual framework of this study. 
The first section will delve into the domain of information support in patients with 
cancer, alongside the issues experienced in this field. The second part will briefly 
explore the field of mobile healthcare and the third part will investigate the application 
of simulation in patient education. The final section will explain how these aspects were 
brought together to formulate the core idea of this research project, followed by its 
aims and objectives.  
1.1. Responding to and coping with a diagnosis of cancer  
“Few words can evoke such an immediate, life-threatening reaction as the word cancer.” 
(Mills and Sullivan, 1999, p.631) 
Albeit the remarkable progress in the field of oncology, cancer still remains the most 
feared condition (Murphy et al., 2018). In a recent publication, Vrinten et al. (2017) 
revealed that cancer is regarded as a “vicious, unpredictable and indestructible enemy” 
(p.1070) that poses a major health concern. The authors suggested that the main fears 
around cancer are associated with the propinquity of the disease, the lack of strategies 
for preventing its onset, the implications (physical, mental and social) of the condition 
and ultimately, the mortality of cancer. 
Considering the public views on cancer, it is reasonable to predict the impact of being 
diagnosed with the illness. Patients receiving a positive diagnosis of a malignant 
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condition can experience considerable distress and anxiety at this stage (Cardoso et al., 
2016). Such feelings can stem from a sense of losing normality (Stegenga and Ward-
Smith, 2009), uncertainty about the future (Sharpley, Bitsika and Christie, 2018) or even 
embarrassment (Iredale et al., 2006).  
Patients with cancer do not only have to face the stress caused by the diagnosis of their 
condition, but they also have to deal with the potential effects of their imminent 
treatment (Adler and Page, 2008). In order to come to terms with this situation, 
patients can deploy several coping strategies. Among a number of copying styles, the 
model proposed by Lazarus and Folkman, (1984) is particularly popular in cancer 
research (Otaghsara et al., 2018). In their work, the authors suggested two types of 
coping, namely problem-focused and emotion-focused coping.  
The emotion-focused approach describes an attempt to control stressful emotions 
through contextual cognitive reconstructions or by disregarding the stressor itself. 
Examples of such efforts include keeping a positive attitude (Asiedu et al., 2014), 
engaging in wishful thinking (Sajadian et al., 2017) and seeking spiritual support (Gall, 
Miguez de Renart and Boonstra, 2000). Denial, in the form of ignoring the condition 
(Kim et al., 2002) or refusing that cancer is there (Vos et al., 2011) is also a highly 
prevalent type of emotional coping.  
Individuals deploying the problem-focused approach endeavour to take control over a 
stressful situation by modifying the stressor itself. This includes seeking social and 
emotional support (Kvillemo and Bränström, 2014), establishing an action plan 
(Miedema, Hamilton and Easley, 2007), setting goals (Clayton et al., 2005), holding 
discussions about the condition and day-to-day life (Elsheshtawy et al., 2014) and 
   3 
seeking alternative treatments (Mosher et al., 2015). Last, but certainly not least, is 
seeking information about their condition and its treatment. Information-seeking is 
indeed an important aspect for patients dealing with cancer (Radina et al., 2011). 
1.2. Information support in patients with cancer 
This section will provide an overview of the information behaviour of patients with 
cancer. The first part will outline the most common reasons that drive patients to seek 
information. Then, the sources through which information is retrieved will be 
presented, followed by the types of information that patients wish to receive, as well as 
factors associated with patients’ information behaviour. Finally, the issues encountered 
in this domain will be presented, alongside the efforts made to address them.  
1.2.1. The importance and benefits of information support in cancer  
Providing adequate, accurate and trustworthy information is considered to be a vital 
component of patient-centred care (Gattellari, Butow and Tattersall, 2001). The 
disclosure of information is among the highest priorities in the National Health Service’s 
(NHS) cancer strategy, which urges healthcare professionals to ensure that the 
information demands of patients with cancer are met efficiently and effectively (DoH, 
2000, 2007).  
Effective information support can provide theoretical, as well as practical benefits. With 
regards to the theoretical benefits, the provision of information increases patients’ 
understanding of their condition and treatment, which in turn enables them and even 
encourages them to get involved in their own care (Dy and Purnell, 2012). This can help 
healthcare more away from a paternalistic model and transition it in a system where 
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informed patients will be able to take part in treatment-related decisions (Gaston and 
Mitchell, 2005). 
Effective information support can also exert a positive influence upon the quality of 
patients’ care (i.e., practical benefits). A systematic review suggested that patients who 
had their information demands fulfilled achieved better Health-Related Quality of Life 
(HR-QoL) and greater satisfaction with care than those who received less effective 
support (Husson, Mols and van de poll-franse, 2011). Patients who received effective 
information support also demonstrated increased compliance with treatment and were 
able to effectively manage adverse events (Blödt et al., 2018).  
1.2.2. Reasons for seeking information 
There are several reasons that drive patients to seek health-related information. 
Loiselle, Lambert and Cooke (2006) suggested that the receipt of a cancer diagnosis can 
prompt patients to look for information in order to familiarize themselves with what 
that diagnosis entails. Patients can seek information in order to reduce uncertainty and 
achieve a sense of control over their illness (Nanton et al., 2009), as well as the effects 
of their upcoming treatment (Ziebland et al., 2004). Becoming knowledgeable is also 
important for participating in the decision-making process (Dy and Purnell, 2012). 
The acquisition of knowledge also necessary for communicating with health providers, 
as it enables patients to discuss disease and treatment-related aspects with greater 
confidence (Lambert, Loiselle and Macdonald, 2009b). For some individuals, the receipt 
of ‘positive information’ is a mechanism for maintaining hope (Loiselle, Lambert and 
Cooke, 2006). After the end of treatment, patients can seek information in order to 
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resume a sense of normality either through guided advice (Tsuchiya and Horn, 2009) or 
by exploring the experiences of fellow patients (Mccaughan, Parahoo and Prue, 2011).  
1.2.3. Sources of information  
An early review revealed that patients with cancer can consult with healthcare 
professionals, access printed material (e.g. brochures, publications) and utilise 
interpersonal sources (e.g. friends, family and fellow patients) to obtain information 
(Rutten et al., 2005). Subsequent studies indicated the importance of the internet as a 
resource, the use of which increased considerably since the early 2000’s (Chua, Tan and 
Gandhi, 2018). Mass media (e.g., radio, television, newspapers) have also been 
mentioned; information obtained through them is referred to as incidental information, 
since patients receive it without actively searching for it (Muusses et al., 2012). 
Healthcare professionals appear to be the most preferred reference (Andreassen et al., 
2006; Nagler et al., 2010; Mekuria, Erku and Belachew, 2016). Research that explored 
this attitude suggested that patients express high preference towards health 
professionals due to trust in their knowledge and expertise (Wright, Holcombe and 
Salmon, 2004), as well as the belief that they act in the patient’s best interest 
(Andreassen et al., 2006). 
1.2.4. Types of information 
Several authors attempted to synthesise findings from this evidence base in order to 
provide an overview of the information that patients wish to receive, as well as to 
determine which information is most important to them. This includes systematic 
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(Rutten et al., 2005; Lim et al., 2017), scoping (Van Mossel et al., 2012) and critical 
reviews (Echlin and Rees, 2002).  
An observation made by several authors was that patients tend to focus upon different 
types of information across the treatment trajectory. Prognostic and cancer-specific 
information appear to be important at the diagnosis/early treatment phase, but higher 
value is placed upon rehabilitation- related information in the post-treatment stage 
(Rutten et al., 2005; Lim et al., 2017). An exception to this is treatment-related 
information (e.g., medicines, side effects, duration of treatment etc.), which appears to 
be the most important type of information and is sought across all stages in the cancer 
care continuum.  
1.2.5. Information avoidance  
In the UK, a large multi-centre study suggested that almost 90% of patients with cancer 
wished to receive all available health-related information, regardless of whether they 
constituted ‘good’ or ‘bad’ news (Jenkins, Fallowfield and Saul, 2001). Yet, some 
patients can refrain from actively seeking information, while others might choose to 
avoid it altogether (Nagler et al., 2010).  
Demographic factors such as age, gender, education and income can play a role in 
information avoidance (McCloud et al., 2013). There are also several reasons that make 
patients avoid cancer- related information. First, some patients can feel that they don’t 
possess adequate intellect in order to process and understand health-related 
information, while others can regard information-seeking as a transgression to their 
role as patients (Leydon et al., 2000). The fear of receiving conflicting information or 
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coming across information that could compromise hope is another negating factor 
(Loiselle, Lambert and Cooke, 2006). Finally, some avoid seeking further information 
after the end of treatment, as doing so helps them towards returning to their normal 
lives before cancer (Lambert, Loiselle and Macdonald, 2009b).  
1.2.6. Challenges in information support for patients with cancer 
Although information support is accepted as an important aspect of cancer care, its 
delivery can be suboptimal. In fact, several reviews identified information as one of the 
most prominent unmet needs among patients with cancer (Harrison et al., 2009; 
Kotronoulas et al., 2017). As a result, patients often have to search for information on 
their own, which can be both burdensome and place them at risk of receiving 
information of questionable quality (Mills and Davidson, 2002).  
A series of UK studies suggested that the limited availability of time in health 
environments can hinder the provision of effective information support. Stafford et al. 
(2001) reported that 84% of clinicians provided patients with their diagnosis and 
discussed treatment options in the course of 15 minutes. Manning and Dickens (2007) 
suggested that due to timely pressures on behalf of the clinicians, the delivery of 
information was performed without the chance of integration. Newell et al. (2004) 
demonstrated that patients also perceived time constraints as an obstacle that 
prevented them from receiving the information they wanted. 
Poor communication is another prominent barrier. Eastman (2019) pointed out that 
health professionals might not necessarily possess the communication skills required in 
order to effectively engage with patients. Furthermore, providers can be reluctant to 
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discuss information, as some consider that full disclosure can diminish patients’ hopes 
and raise anxiety (Gordon and Daugherty, 2003). Patient-related factors can also hinder 
the communication process. For instance, a low level of health literacy has been 
reported to hinder patients’ understanding (Halbach et al., 2016). Moreover, patients 
might not clearly communicate their information demands and consequently, providers 
are unable to respond to address these (Neumann et al., 2011).  
The relevance of information is also a major factor in providing effective support. 
Determining patients’ demands is key towards providing appropriate counselling, but is 
often neglected in practice (Sainio and Eriksson, 2003). Although most patients appear 
to pursue as much information as possible, aspects such as the level of detail, the 
timing and type of information vary considerably across individuals (Leydon et al., 
2000). Rood et al. (2017) proposed that the assessment of information needs should be 
performed on an individual basis and that a ‘one size fits all’ approach is not an effective 
way of providing information support.  
1.2.7. Interventions for information support in cancer care 
The issue of poor information support has been noted and a number of interventions 
for facilitating the provision of health information has been investigated. The findings of 
such studies have been summarised in several systematic reviews, which identified four 
types of interventions; audiotapes (Gaston and Mitchell, 2005; van der Meulen N et al., 
2008), videotapes (Gysels and Higginson, 2007; van der Meulen N et al., 2008; 
Thygesen, Nicolaisen and Mogensen, 2015), computerised/interactive programmes 
(McPherson, Higginson and Hearn, 2001; Salonen, Ryhänen and Leino-Kilpi, 2014) and 
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written material (Gaston and Mitchell, 2005; McPherson, Higginson and Hearn, 2001; 
van der Meulen N et al., 2008).  
A common consideration across all education techniques was the element of 
personalisation. Tailoring the content of these interventions was key for their success, 
as most authors suggested that interventions whose content was adjusted to the 
unique needs of each participant were more successful than those that provided 
general information. An important finding by Gaston and Mitchel (2005) was that 
audiotapes with general information in fact caused confusion to patients rather than 
aiding their understanding.  
Another observation was that non-interactive education techniques were accompanied 
by several drawbacks. For instance, Gaston and Mitchell (2005) explained that 
oncologists might be reluctant to record their meetings with patients, as this could give 
rise to confidentiality issues and impede the consultation process. The same authors 
also argued that producing personalised written material would increase the workload 
of clinicians, who are under considerable time pressures in busy environments. 
Videotapes and recordings can also be problematic, as they can structure information in 
a pre-determined and linear fashion that may not be adapted to individual patients’ 
needs (Gysels and Higginson, 2007). 
Interestingly, computerised programmes and interactive technologies appeared to be 
unaffected by many of these issues. McPherson et al. (2001) pointed out that 
computer-based interventions allow users to control the amount of information, which 
can increase the degree of personalisation. Gysels and Higginson (2007) explained that 
interactive programmes can facilitate users’ learning, as the content of these 
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interventions “can be matched according to a patient’s preferences, needs and coping 
style.” (p.19). In fact, the same authors concluded that interactive technologies 
produced, in some cases, superior results when compared to conventional methods of 
educating patients such as booklets and audiotapes. A subsequent review also 
remarked upon the favourable results of this technology in patients’ knowledge, as well 
as the potential cost-effectiveness (Salonen, Ryhänen and Leino-Kilpi, 2014).  
1.2.8. Summary 
Information support is an integral part of cancer care. Yet meeting these needs still 
remains a challenge. Several interventions have been deployed to support patients, but 
most are accompanied by several drawbacks that would make their implementation 
challenging.  In recent years, the introduction of novel technologies has opened new 
opportunities for reaching patients and offering support. One of these is mobile 
healthcare, which involves the use of mobile devices to facilitate the delivery of health 
services. The next section of this chapter will briefly explore the development of 
mHealth and its application in cancer care.  
 
1.3. Mobile healthcare 
This section will provide an overview of mHealth with a specific focus upon health apps. 
First, the development and application of mHealth will be briefly presented, followed by 
the potential benefits and limitations of this technology. 
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1.3.1. Definition of mobile healthcare 
In an early publication, Laxminarayan and Istepanian (2000) characterised mobile 
healthcare (mHealth) as ‘unwired e-med’. Up to date, a standardised term has not been 
established. This study has adopted the definition offered by the World Health 
Organisation’s (WHO) Global Observatory, according to which mHealth is “the medical 
and public health practice supported by mobile devices, such as mobile phones, patient 
monitoring devices, personal digital assistants (PDAs), and other wireless devices” 
(WHO, 2011, p.6). Examples of mHealth interventions are presented in figure 1.1 
(adopted from Hiplink, 2019).  
Figure 1. 1: Examples of mHealth interventions  
 
1.3.2. Development of mobile healthcare 
Ali, Chew and Yap (2016) performed a review of the types of mHealth interventions 
used between 2007 to 2015 in three distinct periods (before 2007, 2007-2012 and 2013 
onwards). According to the authors, the types of interventions used in each period 
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depended upon the predominant technology at the time. PDAs were the most 
prominent interventions before 2007, while health apps started to gain leverage until 
2012 and ultimately, dominated the mHealth research scene since. This is 
understandable, considering that the introduction of smartphones, tablets and 
wearables (e.g. smart watches), as well as the increased affordability of such devices 
facilitated the uptake of this technology in both developed and developing countries (Al 
Bawab, Al Qahtani and McElnay, 2018). 
In less than one decade since the introduction of commercially available health apps, 
more than 310,000 interventions are now available through the App and Play Stores 
(Larson, 2018). Indeed, the market for mHealth has witnessed an exponential growth in 
recent years. The current size of the global mHealth market is around $46bn (almost 
double in comparison with 2017), with projections estimating as much as $245bn by 
2026 (Statista, 2019). The increased interest around mHealth has sparked a substantial 
amount of research, as well as reviews to summarise the resulting body of evidence and 
suggest further steps.  
1.3.3. Applications of mobile healthcare 
Kao and Liebovitz (2017) offered several examples of commercially available health 
apps and proposed six broad categories, namely “wellness management, disease 
management, self-diagnosis, medication reminders, electronic patient portals and 
physical medicine/rehabilitation” (p.108). These interventions provide users the 
opportunity to retrieve health information, keep track of symptoms and/or 
measurements (e.g. weight, insulin levels) and network with other users, as well as 
healthcare professionals. Kamel Boulos et al. (2014) also presented several examples of 
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health apps aimed for healthcare professionals. These apps are designed to help 
professionals access electronic health records, enhance communication, facilitate 
decision-making, manage appointments, monitor patients and assist learning.  
Health apps have been applied in several therapeutic areas. Examples include diabetes 
(Kitsiou et al., 2017), heart disease (Giebel and Gissel, 2019), kidney disease (Stevenson 
et al., 2019), COPD (McCabe, McCann and Brady, 2017), HIV (Aranda-Jan, Mohutsiwa-
Dibe and Svetla Loukanova, 2014) and mental health (Sucala et al., 2017). Apps have 
also been used to encourage healthy behaviours such as weight management and 
healthy eating (Müller et al., 2016) smoking cessation (Ghorai et al., 2014), promote 
treatment adherence (Svendsen, Andersen and Andersen, 2018), facilitate the delivery 
of healthcare services (Free et al., 2013) and improve sexual health outcomes among 
patients with long-term conditions (Karim et al., 2020)  
Unsurprisingly, a considerable amount of research exploring the application of apps in 
the field of cancer has also been conducted. Several reviews investigated interventions 
targeting specific types of cancer, as well as generalised supportive tools in oncology. 
Cancer-specific research includes interventions for patients with skin (Choi, Cho and 
Woo, 2018), breast (Cruz et al., 2019), and prostate (Rincon et al., 2017) cancer, as well 
as paediatric cancers (Ramsey et al., 2020). Other authors summarised findings from 
peer-reviewed literature around the topic (Osborn et al., 2020), performed an 
investigation of apps that aimed to provide information support (Richards et al., 2018), 
or explored interventions for improving outcomes in survivors of the disease 
(Hernandez Silva, Lawler and Langbecker, 2019). There is also an ongoing systematic 
review exploring apps for screening and awareness of breast cancer (Ruco et al., 2020).  
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1.3.4. Potential benefits 
In an early opinion paper, Tachakra et al. (2003) provided an overview of the advances 
in telemedicine and identified a number of benefits for mHealth. A decade after, 
Steinhubl, Muse and Topol (2013) remarked upon mHealth’s potential to drastically 
transform the healthcare environment. The authors suggested that the unsustainability 
of healthcare’s spending model in healthcare necessitates drastic solutions and 
proposed that mHealth can help reduce costs by limiting the number of unnecessary 
health visits in acute conditions, as well as by offering the capacity for effective 
monitoring and limit complications in chronic diseases. Later publications have also 
remarked upon such benefits (Kitsiou et al., 2017; Giebel and Gissel, 2019). Madanian 
et al. (2019) also reflected upon the opportunity of managing demanding healthcare 
services by integrating a large amount of data through mHealth.  
One of mHealth’s most prominent potential is the improvement of access to healthcare. 
In their report, the WHO pointed out that shortages in the health sector can limit 
peoples’ access to care (2011); this was true not only for developing countries, but also 
for underserved areas in rich nations. According to the report, mHealth could 
potentially help patients connect with health providers in both urban and rural areas, 
thus improving the quality of care and eliminating unnecessary referrals. In a 
subsequent review of mHealth initiatives in African nations, it was suggested that the 
low cost and accessibility of such technologies were key factors explaining the success 
of these interventions (Aranda-Jan, Mohutsiwa-Dibe and Svetla Loukanova, 2014). Later 
studies suggested that mHealth initiatives yielded promising results in developing 
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(Stephani, Opoku and Quentin, 2016), as well as developed countries (Anderson-Lewis 
et al., 2018).  
MHealth can also offer considerable benefits on an individual level. Steinhubl, Muse and 
Topol (2013) proposed that mHealth can grant the opportunity of effectively 
monitoring conditions and preventing complications, while Kamel Boulos et al. (2014) 
argued that it can help users receive personalised care. Later publications suggested 
that mHealth can improve patients’ access to information (Lubberding et al., 2015), 
foster a sense of autonomy (Young-Afat et al., 2016), enhance their communication 
with health professionals (Husted et al., 2018) and promote self-management 
(Desveaux et al., 2018).  
In addition to the potential benefits for patients, mHealth can also assist healthcare 
professionals. Steinhubl, Muse and Topol (2013) proposed that mHealth can help 
reduce clinicians’ involvement in algorithmic procedures, thereby relieving them from a 
substantial amount of workload. The same authors explained that this would also 
enable them to attend more closely to their patients, which could potentially enhance 
their relationships; this was also apparent in a study involving HIV providers, who added 
that such interventions could improve the coordination of care (Swendeman et al., 
2016). In a recent paper, Mesko and Győrffy (2019) added that digital interventions 
could help improve diagnostic accuracy and enhance the efficiency of treatments.  
1.3.5. Pitfalls and limitations 
A series of Cochrane reviews has pointed out that there is not enough evidence for 
informing policy makers, healthcare professionals and members of the public on the 
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effectiveness or reliability of mHealth interventions. This was because of the absence of 
literature around certain interventions (Badawy et al., 2017), the limited number of 
studies, conflicting results and a lack of a strong evidence base due to the inability to 
synthesise findings (Belisario José S et al., 2013). While some promising evidence is 
available for patients with COPD (McCabe, McCann and Brady, 2017), kidney disease 
(Stevenson et al., 2019) and smoking cessation (Marcolino et al., 2018), the authors 
advised that such results should be interpreted with caution, as aspects such as the 
long-term effects or cost-effectiveness of such interventions has not been determined. 
The same would also apply to mHealth interventions in the field of oncology.  
The safety and appropriateness of such interventions is another important 
consideration. According to Paglialonga, Lugo and Santoro, (2018) only apps that 
constitute medical devices are subject to robust regulatory frameworks that demand 
rigorous evaluation, testing and monitoring. As most commercially available health apps 
do not fall under this category and are thereby not obligated to abide by the same 
quality standards, important concerns about their trustworthiness have been raised. A 
recent scoping review revealed several concerns with regards to the quality of content, 
including incorrect and incomplete information, incorrect output (e.g. calculations and 
diagnostics) and innapropriate response to users’ needs (Akbar, Coiera and Magrabi, 
2020). Security and privacy are also important considerations. O’Loughlin et al. (2019) 
pointed out that the vast majority of commercially available apps identified by their 
study did not have adequate security and privacy policies in place; this finding is in line 
with previous research. In a recently conducted survey, security and privacy were 
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identified as major barriers from a user perspective, indicating that developers still 
haven’t paid close attention to this matter (Zhou et al., 2019).  
1.3.6. Summary  
MHealth holds considerable promise for supporting the needs of patients and the 
public. At the same time, it should be noted that the field of mHealth is not without 
concerns regarding safety and effectiveness. Such ambiguity can hinder its effective 
implementation, since stakeholders and policymakers are unlikely to engage and take 
such approaches forward (Chib, Van Velthoven and Car, 2015). It is hence important to 
build robust interventions and conduct high-quality research in order to build a strong 
evidence base, thus strengthening the potential for its effective uptake.  
Another key consideration is the place of mHealth interventions in patient care. A 
recent review suggested that patients indeed favour the use of health apps, but they 
regard them as tools that can strengthen their relationships with providers rather than 
means of replacing them (Vo, Auroy and Sarradon-Eck, 2019). Indeed, the capabilities of 
health professionals “comprise personal attributes, including attitudes, practical skills, 
and soft skills, which mHealth apps cannot currently replace” (Wattanapisit et al., 2020, 
p.11); despite the promise of supportive interventions, the involvement of health 
professionals in patient care is crucial. Yet this brings us back to the issue of health 
professionals’ limited availability. Is it possible to enhance their presence in patients’ 
care while keeping their actual involvement to a minimum? Although this question 
suggests a paradox, simulation could potentially provide an answer.  
   18 
1.4. Simulation in patient care 
Simulation is defined as “a situation in which a particular set of conditions is created 
artificially in order to study or experience something that could exist in reality” (Oxfrod 
Dictionalry, 2021). Silva et al. (2010) presented several examples of systems in which 
simulation has been applied and remarked upon its potential to be used in practically 
any area that “fits the concepts of simulation modelling” (p.429). In healthcare, this 
term is often used in the context of professional education and student learning, with 
examples such as simulated patients (Dafli et al., 2019; Lee and Berge, 2011) and virtual 
learning environments (Humphreys, Rosenorn-Lanng and Bracegirdle, 2014).  
Although the term simulation has rarely been used explicitly in the context of patient 
education and support, interventions that simulate interaction to support patients’ 
learning and enhance their care are indeed evident. This part will briefly explore the 
application of simulation in patient education and support.  
1.4.1. Virtual learning environments 
The first example of virtual learning environments (VLEs) in patient support can be 
traced in the mid-90s, where Rothbaum et al. (1995) explored the efficacy of a novel 
treatment for acrophobia (fear of heights). In this randomised study, college students of 
the treatment group demonstrated significant improvements. A subsequent study by 
Wiederhold et al. (2002) compared a virtual reality (VR) approach to a standard 
treatment for fear of flying and identified significant differences suggestive of 
superiority in the virtual reality group, while Ku et al. (2007) showcased the benefits of a 
VR training course for patients with schizophrenia. Although these studies involved a 
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small number of participants, they demonstrated the potential of VR as a promising 
educative platform for patients.  
An important leap in making VR platforms readily available to patients and the public 
was the release of Second Life, an online augmented reality (AR) environment where 
users can create their avatars (i.e., a virtual representation of themselves) and interact 
with the avatars of other users. Using this platform, health and governmental agencies 
have created 3D-VLEs such as the HealthInfo Island, where patients and the public can 
receive high quality, evidence-based information (Boulos, Hetherington and Wheeler, 
2007; Kamel Boulos et al., 2008). A recent study demonstrated the benefits of using 
Second Life to support patients with type 2 diabetes, while the potential of using this 
approach for other chronic conditions was also noted (Lewinski et al., 2018). 
1.4.2. Chatbots and conversational agents 
Chatbots be broadly described as “computer programs that simulate conversations with 
users” (Tudor Car et al., 2020) and are also known as “conversational agents, interactive 
agents, virtual agents, virtual humans, or virtual assistants” (Palanica et al., 2019). This 
technology made its first appearance in 1966 with ELIZA, a computer program that 
played the role of a psychotherapist and was capable of textual communication with 
users without the need of an operator (Weizenbaum, 1983). Shortly after, Kenneth 
Colby created PARRY, a chatbot designed to behave as a patient with schizophrenia to 
assist learning in young psychiatrists (Colby et al., 1972). Over time, several artificial 
intelligence (AI)-based programs emerged and in recent years, the introduction of 
systems such as Alexa (Amazon), Siri (Apple) and Google Assistant (Google) have made 
this technology widely available to the public (Zemčík, 2019). 
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Conversational agents can respond to users’ textual or verbal input via text or speech; 
figure 1.2 (adopted by Piau et al., 2019, p.20) presents an example of an agent that 
provided a written reply, which was also available in audio format.  
Figure 1. 2: Example of a chatbot communication interface  
 
While some interfaces provide users with a number of fixed choices and respond in a 
pre-determined fashion (e.g., L’Allemand et al. 2018), others offer tailored responses 
according to the users’ unique input; the latter is referred to as natural language 
processing (NLP) (Swartout et al., 2006). In their review, Laranjo et al. (2018) argued 
that there has been increased interest towards conversational agents equipped with 
NLP, as this allows for more sophisticated exchanges compared to interfaces with 
restricted user input and agent output. According to Milne-Ives et al., (2020) 
unconstructed NLP can simulate human interaction with considerable fidelity and give 
the impression of a real conversation. 
Tudor Car et al. (2020) pointed out that while initially referred to simply as ‘talking 
computers’ in the field of healthcare, these interventions have grown considerably in 
sophistication. To date, chatbots and conversational agents have been used to support 
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patients in several therapeutic areas, including asthma (Rhee et al., 2014), type 2 
diabetes (Griol, Carbó and Molina, 2013), mental health (Fitzpatrick, Darcy and Vierhile, 
2017), medication adherence and management (Lobo, Ferreira and Ferreira, 2017) and 
autism spectrum disorders (Ly, Ly and Andersson, 2017). Chatbots have also been used 
with the general public to offer health advice (Liu and Sundar, 2018) and promote 
obesity management (L’Allemand et al., 2018) .  
1.4.3. Embodied conversational agents 
Embodied conversational agents (ECAs) are a type of conversational agents defined 
as “animated computer characters that simulate face-to-face conversation with users” 
(Bickmore et al., 2005, p.712). As the term suggests, ECAs deploy embodiment, or at 
least some kind of visual representation in order to communicate with users using non-
verbal ques such as facial expressions and/or gestures in addition to verbal or textual 
communication (Provoost et al., 2017). An example of an ECA is presented in figure 1.3 
(Lisetti et al., 2013, p.194).  
Figure 1. 3: Example of an ECA 
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In the domain of healthcare, ECAs have been used in a number of health interventions; 
examples include COPD (Easton et al., 2019), diabetes (Gong et al., 2020), mental health 
(Lucas et al., 2017) and clinical psychology (Provoost et al., 2017). Keele University, in 
collaboration with the Stoke-on-Trent Clinical Commission Group (CCG) has created 
Manage your Health, an app that offers information and advice for a range of 
conditions using an ECA that portrays a healthcare professional (Keele University, 2021).  
Bickmore et al. (2018) proposed that the communication channels deployed by ECAs 
can effectively engage users with this technology. Literature in the field of pedagogical 
agents has offered insight as to why this is evident. According to Lane, (2016) the social 
agency theory (Moreno et al., 2001) and in particular, the persona effect (Lester et al., 
1997) argue that the presence of an agent in a virtual environment and the social ques 
derived from it can predispose users towards engaging and interacting with the 
interface, thereby enhancing their learning experience.  
The appearance of ECAs is a central consideration (Gulz and Haake, 2006) and has two 
main variables. The first broadly categorises ECAs based on their appearance and is 
referred to as species, which includes “human, animal, robots, objects, and mystical 
creatures” (Straßmann and Krämer, 2017, p.414). The second variable is realism. 
Straßmann and Krämer (2017) pointed out that the term realism has been 
conceptualised in different ways in the field of ECAs and a universal term has yet to be 
agreed upon. Drawing upon previous work in the field, the authors proposed that 
realism is a multifaceted concept and proposed three dimensions, namely stylisation 
(degree of cartoon-likeness), resolution (same as above) and detailedness (high versus 
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low detail). Figure 1.4 (adopted by Straßmann and Krämer, 2018) provides an illustrated 
example of these dimensions.  
Figure 1. 4: Examples of ECA species and varying degrees of stylisation, resolution and 
detailedness 
 
In their work, Ring, Utami and Bickmore (2014) demonstrated that the appearance of 
ECAs is highly context-specific and the perceived appropriateness of an agent depends 
upon the goals and setting in which this agent is used. For instance, cartoon-like 
characters are usually perceived as friendlier and can hence be used with a younger 
audience (Ring, Utami and Bickmore 2014). Yet, a professional-looking VA might be 
more appropriate for a task or situation where the presence of an ‘expert’ is required, 
such a health intervention (Parmar et al., 2018). Characteristics such as age and gender 
can also play a role; Guadagno et al. (2007) demonstrated that users can express a 
preference for VAs that matched their gender, while Alsharbi and Richards (2017) 
demonstrated that users can be more inclined towards a VA close to their age.  
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Another important concept in ECA’s appearance is the uncanny valley. The uncanny 
valley is a theory introduced by the Japanese professor Masahiro Mori in 1970, who 
argued that “a person’s response to a humanlike robot would abruptly shift from 
empathy to revulsion as it approached, but failed to attain, a lifelike appearance” (Mori, 
MacDorman and Kageki, 2012, p.98). Figure 1.5 (adopted by Geller, 2008, p.12) 
presents a diagrammatic illustration of the concept. As a character approaches a higher 
degree of human likeness, the perceiver’s affinity for it will decrease dramatically in the 
presence of subtle non-human flaws. Motion has an additive effect on this concept, as 
unnatural movements can cause even greater feelings of eeriness and repulsion (i.e., 
steeper slope). While initially developed for use in robotics, this theory has been 
studied extensively in the context of VA development (de Borst and de Gelder, 2015; 
Ciechanowski et al., 2019; Stein and Ohler, 2018), as well a variety of scientific circles 
including psychology (Matsuda et al., 2012) and philosophy (Misselhorn, 2009).  
Figure 1. 5: Illustration of the concept of the Uncanny valley 
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The wide exploration of Mori’s theory and the abundance of empirical findings have led 
to the refinement of this model. In recent years, Kätsyri et al. (2015) distinguished 
between the original theory proposed by Mori (referred to as the naïve hypothesis) and 
two subsequent concepts, namely the categorisation ambiguity and perceptual 
mismatch. With regards to the former, de Borst and de Gelder (2015) pointed out that 
realism itself is not what gives rise to feelings of eeriness and uncanniness but rather, 
the difficulty to categorise an entity to a certain type (e.g., cartoon, animal, robot, 
human etc.). The authors argued that this is evident in characters that stand close to 
the dichotomy of human and non-human, as such characters are difficult to categorise. 
Kätsyri et al. (2015) defined perceptual mismatch as inconsistencies “between the 
human-likeness levels of specific sensory cues”, which proposes that mismatches 
between the naturalness of voice and image can elicit feelings of eeriness and 
displeasure towards a VA (Kang and Watt, 2013; Mitchell et al., 2011; Tinwell, 
Grimshaw and Nabi, 2015).  
1.4.4. Relational agents  
Bickmore and Gruber (2010) described relational agents as a category of conversational 
agents that are capable of establishing a relationship with users. According to the 
authors, this can be achieved through small talk, displays of empathy and references to 
previous interactions. In addition to verbal or textual output, ECAs can accomplish this 
by gestures and/or expressions, as shown in figure 1.6 (adopted by Bickmore and 
Gruber 2010, p.3).  
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Figure 1. 6: Example of a relational agent 
  
The key feature of relational agents is their potential to forge a therapeutic alliance with 
users (Bickmore and Gruber, 2010). Therapeutic alliance has been defined as “a concept 
that describes the trusting, collaborative nature of the transactions that occur between 
a patient and therapist within the context of mental health treatment” (Corso et al., 
2012, p.88) and is regarded as a key component for obtaining favourable treatment 
outcomes in cancer care. An early study demonstrated that this concept can also 
extend to other areas of healthcare and demonstrated that the trusting relationship 
between patients and providers can lead to improved outcomes (Reis et al., 2008) 
Due to their engaging nature and potential to establish relationships with users, 
relational agents-especially those with an element of embodiment-have attracted 
considerable interest as virtual coaches (Bickmore et al., 2005). Examples where 
relational ECAs have been used to coach users include physical activity (Bickmore et al., 
2005), mindfulness and meditation (Gardiner et al., 2017), nutrition (Bickmore, 
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Schulman and Sidner, 2013), smoking cessation (Abdullah, Gaehde and Bickmore, 2018) 
and disease monitoring (Klaassen et al., 2018) 
1.4.5. Current state, benefits and limitations  
Several publications have explored the application of virtual agents (VAs) in healthcare. 
This includes reviews concerned with specific fields such as mental health (Vaidyam et 
al., 2019), as well as healthcare as a whole (Laranjo et al., 2018; Tudor Car et al., 2020). 
While VAs have a long history of application in fields such as marketing and advertising, 
the application of this technology in healthcare appears to be relatively new, as the 
majority of studies have been published in the last decade (Laranjo et al., 2018). The 
field is currently expanding at an exponential rate, with an ever-increasing number of 
studies being conducted each year (Tudor Car et al., 2020).  
While VAs were typically delivered through personal computers (PCs), recent years have 
witnessed a shift of trends towards the use of smartphones as delivery platforms for 
these interfaces in the domain of healthcare (Tudor Car et al., 2020). Lewis Johnson, 
Labore and Chiu (2004) explained that desktop computers can pose a serious limitation, 
as they can limit VAs’ accessibility. This consideration, alongside the increased 
availability and uptake of smartphones (Al Bawab, Al Qahtani and McElnay, 2018) can 
potentially explain why researchers have begun to use handheld devises (i.e., mHealth 
interventions) for delivering this technology to the desired user audience.    
The use of conversational agents can offer a number of potential advantages at both a 
systemic, as well as individual patient level. At a patient level, these interfaces provide 
users with a friendly environment where they can take as much time as they require to 
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address their needs, which is not always possible in practice (Bickmore and Gruber, 
2010). Their constant availability is another major factor, as they can provide continued 
support and respond to users’ demands at all times, thereby increasing impact 
(Brinkman, 2016). 
At a systemic level, VAs can help facilitate the provision of information to patients, 
thereby preventing unnecessary visits (Bibault et al., 2019) and helping reduce 
consultation times (Bickmore and Gruber, 2010). Another potential advantage is the 
capacity for this technology to be accessible to a wide range of users. As Bickmore et al. 
(2010) notes, interfaces such as ECAs do not rely upon the comprehension of text, but 
instead simulate face-to-face conversations, which can be less daunting and more 
accessible to individuals with low IT or health literacy skills, thereby addressing health 
discrepancies.  
Despite the promise of VAs, it is important to acknowledge the limitations of this 
technology. First, the development of these interfaces can be particularly costly in 
terms of time and resources, which can both hinder its effective implementation 
(O’Connor, 2019). Another issue is the limited evidence surrounding the use of VAs in 
the domain of healthcare. Tudor Car et al. (2020) pointed out that the field of VA 
research in the domain of healthcare is still at its infancy and that most studies 
conducted in the field are primarily small-scale pilot investigations, with only a few 
examples of randomised trials. Despite the history of application in patient education 
and support, the evidence base in VR and AR is also weak. Ghanbarzadeh et al. (2014) 
conducted a systematic review of VR in the domain of healthcare, but their work 
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concerned mostly education and training in healthcare professionals, with only limited 
examples of this technology in patient support.  
1.4.6. Simulation in cancer care 
In a recent article reviewing the application of digital technologies in oncology, Garg et 
al. (2018) noticed a paucity in publications of VAs in cancer care. A year later, Bibault et 
al. (2019) conducted a systematic search to identify literature regarding the use of VA-
based interventions in this field, which returned only six studies.  
After a brief exploration of the literature, several studies (conducted after Bibault’s 
review) that used VAs in oncology care were identified. Examples include a support for 
patients with breast cancer (Chaix et al., 2019), symptom monitoring in older patients 
receiving chemotherapy (Piau et al., 2019), promotion of encouragement and wellbeing 
in survivors (Greer et al., 2019), decision aids for screening (Owens et al., 2019; Welch 
et al., 2020) and acquisition of patient reported outcomes (Murad Junior et al., 2020). A 
noteworthy observation is the lack of studies exploring the application of ECAs in the 
context of supportive cancer care (Ponathil et al., 2020).  
1.4.7. Summary  
Albeit the infrequent use of the term in the context of patient care, simulation has been 
applied to support patients in several areas. The field of VA research has witnessed 
considerable expansion in recent years, with most of the literature being published in 
the last decade. Despite its potential and promise, this field of research is still at its 
infancy. This is especially true for the field of oncology; in the most recent literature 
review, Tudor Car et al. (2020) still noted the need for digital health interventions to 
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expand to the field of cancer care. This suggests an important gap that awaits to be 
addressed in future research.  
1.5. The conceptual framework of the project 
Information support is a key component of cancer care. Considering the benefits 
offered by effective information support, it is necessary to ensure that patients are 
provided with high-quality information that are relevant to their needs. However, such 
support is not always provided optimally in practice (see p. 7). Several interventions 
have been applied to combat this issue, with computerised and digital interventions 
holding considerable promise for supporting patients’ information needs (see pp. 8-10).  
In recent years, the introduction of novel technologies has opened new opportunities 
for supporting patients. Health apps have attracted significant commercial as well as 
research interest, with a great number of commercially available interventions being 
available to patients and a considerable amount of research around their effectiveness 
and safety; despite several limitations, mHealth holds considerable promise for 
improving outcomes in oncology care (Osborn et al., 2020). 
Albeit the potential of mHealth interventions to support patients, it is vital to consider 
the role of healthcare professionals in cancer care. The presence of health providers is 
integral, as they can inspire reassurance and help patients maintain hope, which has a 
positive effect upon their quality of life (Amati et al., 2019). Health professionals are the 
most preferred source of information as they are regarded as the most trustworthy 
agents, but time constraints often limit their availability in practice (see p.7).  
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Virtual learning and simulation could offer a solution to this matter. ECAs can constitute 
a viable alternative to face-to-face discussions as they can “produce verbal and 
nonverbal conversational behaviours that signify understanding and mark significance, 
and can convey information in redundant channels of information (e.g., hand gestures, 
such as pointing, facial display of emotion, and eye gaze), to maximize message 
comprehension” (Bickmore, Pfeifer and Paasche-Orlow, 2007). Simulations of a face-to-
face exchange can be accessible even to individuals with little experience in this 
technology, such as older persons. As Bickmore et al. (2005) pointed out, engaging in 
face-to-face exchanges is a skill that is built early and maintained throughout one’s life, 
which is true even for individuals with cognitive impairment. 
The considerations discussed above formulated the conceptual framework of the 
present project, which is illustrated in figure 1.7.  
Figure 1. 7: The project’s conceptual framework 
          
Information 
support mediated 
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The central idea of this project was to deploy an ECA-based app to provide information 
support to patients with cancer. The ECAs of the app resembled healthcare 
professionals, as they are the most preferred and trusted source of information (see 
1.2.3). More specifically, the ECAs were formulated after health professionals known to 
the users of the app. This decision was informed by a concept known as continuity of 
care, which describes the ongoing relationship between a patient and a healthcare 
provider (Van Walraven et al., 2010). This appears to be an important aspect in cancer 
care, especially in the initial stages of the care pathway (King et al., 2007) and can lead 
to better treatment outcomes, as well as satisfaction with care (Plate et al., 2018; 
Tsianakas et al., 2012). Hence, it was hypothesised that using ECAs resembling known 
professionals would potentially appeal to users. To date, there are no studies that 
deployed familiar ECAs to support patients with cancer.   
Chemotherapy was the treatment of focus, as patients receiving it require a substantial 
degree of support (Mitchell, 2007). It was determined that the app would be designed 
around a specific treatment regimen instead of providing generic information about 
chemotherapy, as patients with cancer appear to prefer information tailored to their 
unique needs (see p. 9).  
As several sources have suggested that patients’ information demands typically peak at 
the early stages of the care continuum, the app was given shortly before treatment 
commenced (Halkett et al., 2012; Vogel, Bengel and Helmes, 2008). In order to maintain 
homogeneity in baseline information needs, the app was provided to patients with no 
previous experience with chemotherapy (i.e., newly diagnosed, chemotherapy-naïve 
patients).  
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To maintain consistency, this study focused upon patients with colorectal cancer (CRC).  
The rationale for this decision was twofold. First, CRC is the third most common type of 
cancer in both men and women, with around 42,300 new cases each year in the UK 
(Cancer Research UK 2020). Second, aspects such as chemotherapy, dietary changes 
and stomas can have a profound effect upon patients’ lives, making patients with CRC 
an ideal group for providing continued support throughout treatment.  
1.6. Aims and objectives 
The aim of this project was to develop and test an ECA-based information support app 
for newly diagnosed, chemotherapy naïve patients with CRC. The project had three 
major components, namely the developmental phase, pilot testing and main testing. 
Each phase had its specific objectives.  
1.6.1. Developmental stage  
This phase was concerned with the development of the initial version of the 
intervention and the practical considerations of the project (logistics). The specific 
objectives included the following:  
a) Identification of collaborators and recruitment centres 
b) Identification of the information needs of patients with CRC 
c) Acquisition of resources for developing the draft content of the app 
d) Receipt of patient feedback and advice upon the draft content and functions of 
the app, as well as the research materials 
e) Development of the pilot version of the app 
f) Establishment of the pilot evaluation methodology  
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1.6.2. Pilot testing 
The goal of the pilot study was to test the initial version of the app with real patients 
and validate the initial study design. The specific objectives of this phase were to:  
a) assess the recruitment potential  
b) establish the appropriateness of the data collection tools and study design 
c) address logistical aspects  
d) receive app-related feedback and recommendations for improvement  
e) identify and resolve technical errors   
1.6.3. Main testing  
The final phase of the project was concerned with the formal testing of the updated 
version of the app. The goal was to provide the intervention to a large patient cohort 
and perform a robust evaluation. The objectives of this phase were as following:  
a) establishment of the usability and acceptability of the intervention 
b) users’ satisfaction with information and views on the app’s content 
c) exploration of the app’s use throughout the study period 
d) exploration of patients’ perspectives upon the VAs 
e) exploration of emergent feedback for potential ways of improving the app 
1.7. Chapter summary 
Information support is an integral part of cancer care, but it is not always offered 
optimally in practice. MHealth could potentially address this issue, as it holds 
considerable promise for providing continued and high-quality services to users at any 
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place and any time. To further aid patients’ understanding, a didactic approach 
involving simulation could be used. These elements were brought together to formulate 
the conceptual framework of this research. It was proposed that a VA-based health app 
for newly diagnosed patients with CRC would be developed and tested in order to 
explore its effects and degree of acceptability.  
As discussed in p.8, achieving a good understanding of patients’ needs is the first and 
most important step to effectively address them. Having established the population of 
interest (newly diagnosed patients with CRC), it was crucial to perform a formal 
assessment of their information needs in order to build a robust intervention towards 
meeting them. Hence, it was determined that a systematic review exploring the 
information needs of recently diagnosed patients with CRC would be undertaken. The 
next chapter will present the core principles underpinning systematic searches and 
present the findings of the aforementioned review.  
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Chapter 2: Systematic review and narrative 
synthesis  
As the goal of this project was to develop and test an information support app for 
patients with CRC, it was vital to first understand their information demands so the 
content was designed according to their needs. Thus, it was determined that a 
structured review was necessary to further inform the research project. This chapter 
will outline the process undertaken for this review, present the findings and discuss 
how these informed the development of the app’s content.  
2.1. Reviews and their importance in research 
While all reviews aim to identify relevant literature, analyse the retrieved body of 
evidence and draw conclusions, there are different types of appraisals according to the 
aims and objectives set by the enquirers.  
A key consideration is the way in which relevant literature is identified, which is referred 
to as the search strategy. While some perform informal searches to identify studies of 
interest, others devise rigorous search strategies to collect all available resources. Such 
systematic searches are one of the key components of systematic reviews. This type of 
review utilises robust methods to eliminate bias and increase rigour in retrieving, 
appraising, synthesising and presenting all available evidence to answer a specific 
research question (Aromataris and Riitano, 2014). Coupled with meta-analyses, a 
statistical technique used to combine data across large sets of primary studies, 
systematic reviews are considered to produce the highest quality evidence to guide 
practice (Jahan et al., 2016). 
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Unlike systematic reviews, narrative reviews are not restricted to a single research 
question. Instead, the purpose of a narrative review is to gather, appraise and interpret 
findings from the literature around a subject area in order to produce a critical output 
on the topic (Ferrari, 2015). Yet narrative reviews are often regarded as inferior to 
systematic reviews, as the former do not always abide by the same methodological 
standards as the latter (Pae, 2015).   
In an early editorial note, Collins and Fauser (2005) pointed out that the strengths of 
systematic reviews can easily turn into weaknesses if applied to a topic that needs to be 
examined without using strict methods and/or keeping a narrow focus. A similar view 
was given by Greenhalgh, Thorne and Malterud, (2018) who criticized the perceived 
superiority of systematic reviews and asserted that the dichotomy between them and 
narrative reviews is irrelevant and unproductive.  
Instead of viewing systematic and narrative reviews as enemies, researchers should 
consider the matter at hand in order to decide upon the most appropriate review type. 
In the context of this project, a systematic approach to summarising the literature 
around patients’ information needs was an ideal way of achieving a better 
understanding of their requirements. However, a meta-analysis of such data would 
likely be infeasible, as both the literature around this subject and the assessment 
measures were likely to be considerably diverse. It was hence determined that a 
narrative review, coupled with the core methodological components of a systematic 
review would be the most appropriate way forward.  
To date, a systematic literature review focusing upon the information needs of newly 
diagnosed patients with CRC could not be identified. A recent systematic review by 
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Kotronoulas et al. (2017) identified information as an important aspect of supportive 
care in CRC, but it didn’t go in further detail. A scoping review (Van Mossel et al., 2012) 
identified a large number of papers exploring the information needs of patients with 
CRC, but pooled data from different stages of the cancer care continuum. As the 
information needs can change across different stages of treatment (Kennedy and Lloyd-
Williams, 2009; Pollock et al., 2008), it is likely that this review did not adequately 
reflect the information needs of patients with CRC at the early stages of treatment.  
2.2. Aims and objectives 
The aim of this review was to synthesise the body of research around the information 
needs of newly diagnosed patients with CRC receiving treatment for their condition. 
The specific objectives were to a) identify the various types of information sought by or 
given to these individuals and/or their caregivers, b) determine the desired volume of 
information and c) establish the perceived importance of specific pieces information. 
The present review was registered with the International Prospective Register of 
Systematic Reviews (PROSPERO) to prevent duplication (registration number 
CRD42018117833).  
2.3. Methods 
2.3.1. Search strategy 
A review of the literature published in the last 30 years was conducted in the following 
databases: Allied and Complementary Medicine Database (AMED), Applied Social 
Sciences Index and Abstracts (ASSIA), Cochrane Library, EMBASE, Education Resources 
Information Centre (ERIC), Medline, Web of Science (Social Citation Index and Science 
Citation Index), Cumulative Index to Nursing Allied Health Literature (CINAHL) and 
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PsycInfo. A hand search of five key journals (European Journal of Oncology Nursing, 
Patient Education and Counselling, Journal of Cancer Education, Colorectal Disease, 
Diseases of the Colon and the Rectum) was also performed to retrieve relevant papers 
and screen their reference lists to identify studies that were missed from the initial 
search. 
The search involved variations of the terms information, need, seek, colorectal and 
cancer in order to identify as many relevant studies as possible (van Mossel et al., 
2012). The complete search strategy and results for each database is provided in 
appendix 1.  
2.3.2. Inclusion and exclusion criteria 
Studies were eligible for inclusion if they fulfilled the following criteria:  
• Published in the English language 
• Explored the information needs of patients and/or the relatives/partners/ 
caregivers of patients with a diagnosis of CRC who were actively receiving or 
were about to receive treatment at the point of the study; studies that explored 
the information needs of patients with various types of cancer were eligible for 
inclusion, as long as sub-group analysis was performed 
• Conducted in Western societies (EU, UK, US, Canada, Australia, New Zealand) 
• Original (primary) research studies that followed a qualitative, quantitative or 
mixed method design  
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Previous work seeking to summarise the information needs of patients with cancer 
(Adams, Boulton and Watson, 2009; Rutten et al., 2005; Van Mossel et al., 2012) 
revealed that various study designs were deployed to explore this phenomenon. 
Excluding any study design could therefore lead to the loss of valuable data. The 
present review included both qualitative and quantitative studies, as well as studies that 
followed a mixed method design.  
Papers that pooled different types of cancer without performing a sub-group analysis of 
patients with CRC were excluded. Studies that explored the information needs of CRC 
survivors were also excluded, as the information needs of patients with cancer can 
change across the cancer-care continuum (Halkett et al., 2012; Matsuyama et al., 2013). 
Moreover, studies outside the specified geographic restrictions were excluded as 
cultural differences and dissimilarities in health information communication can affect 
the information-seeking behaviour of patients with cancer (Gaston and Mitchell, 2005; 
del Carmen and Joffe, 2005). Secondary research, letters and opinion papers were also 
excluded. Nevertheless, the reference lists of systematic reviews and scoping searches 
were checked to identify papers that were omitted by the search strategy.   
2.3.3. Study selection  
The process of title and abstract screening were performed by the lead author (AC). 
Studies retrieved in full text were then distributed across the review team. Five pairs of 
reviewers were formed, each comprised by the lead author and one member of the 
review team (SC, AG, NS, CH, OB). The lead author screened every article and each co-
author received one-fifth of the full-text studies, which were screened independently. 
The results were compared within each pair to resolve any disagreements and decide 
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upon which articles would be included in the review. When the reviewers could not 
reach an agreement, the academic supervisor (SC) acted as a third reviewer; this was 
necessary for two studies (Bell et al., 2009; Bronner et al., 2018).  
2.3.4. Data extraction and quality assessment 
The data extracted from eligible studies concerned general characteristics and 
information needs. General characteristics included the following: 
• Purpose and context (aim, setting, geographical location and outcomes) 
• Methods (sampling technique, sample size, study design and data collection 
methods) 
• Participant characteristics (gender, age, stage of condition, treatment approach 
and disease location). 
Information needs included any mention of the following: 
• Information either given to or sought by the patients and/or by their caregivers 
• The desired volume of information (e.g., how much patients and/or caregivers 
wanted to know) 
• The most important types of information (i.e., information priorities) 
• Satisfaction or dissatisfaction with information 
The Mixed Methods Appraisal Tool was used to determine the quality of studies that 
followed a mixed methods design (Pluye, 2013). As this tool examines the quality of 
quantitative and qualitative components separately, it was also used for determining 
the methodological quality of purely quantitative or purely qualitative studies.  
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The lead author performed the data extraction and quality assessment steps for all 
accepted articles. To ensure robustness in this process, each co-author received three 
studies at random, performed these processes independently and compared their 
results with those of the lead author. As there was congruity between the findings of 
the lead author and the co-authors, it was determined that there was no need for the 
co-authors to conduct further extractions and quality assessments. 
2.3.5. Synthesis and presentation of findings 
Due to the heterogeneity of the retrieved data, a meta-analysis was not possible. 
Instead, narrative synthesis was deployed (Popay et al., 2006).  
In order to provide a concise overview of the types of information needs, this review 
drew upon the typology chart in van Mossel et al. (2012). In their work, the authors 
established ten broadly defined categories of information needs, which were then 
broken down in 82 subcategories. A summary table will first present which types of 
information appeared in each study using the ten broadly defined categories of 
information needs, while a more detailed table will provide an extensive account of 
specific pieces of information identified across studies.  
2.4. Results  
The search yielded 11024 titles. After the removal of duplicates, 4458 articles were 
screened against their titles, resulting in 960 articles for abstract screening. Following 
this, 335 documents were retrieved in full-text and were screened against the inclusion 
criteria. Ultimately, 37 articles were included in the synthesis. Figure 2.1 depicts the 
flow of the review process and study selection.   
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2.4.1. General characteristics of included studies  
The descriptive characterisation of the included studies is available in table 2.1. Most 
studies (n=21:37, 56.7%) were around patients’ experiences with diagnosis, treatment 
or care. Six studies (16.2%) explored supportive interventions for patients with CRC, 
three (8.1%) investigated medical decision-making, one (2.7%) focused upon nutrition 
and one (2.7%) upon caregivers’ perspectives. 
11024 
titles retrieved by the search 
4458 
titles for title screening 
960 
titles for abstract screening 
335 




articles identified through reviews 
37 
articles included in the review 
6566 
duplicates 
301 full-text articles rejected 
 
• 68 pooled different types of cancer 
• 60 not about patient information needs 
• 57 about survivorship of >12 months 
post- diagnosis 
• 31 didn’t specify time since diagnosis 
• 30 didn’t include patients with CRC 
• 19 outside geographical restrictions 
• 13 abstracts/posters/presentations 
• 12 pooled different treatment stages 
• 6 reviews 
• 5 about screening and prevention 
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Table 2. 1: Descriptive characterisation of included studies 
 Purpose and Context Methods Participant Characteristics 
 












Bailer (2001) Patients' experiences from pre-
treatment discussions and 
preferences for decision-
making 
Multi-centre (6 cancer 
centres) 
UK (England) 1. Patients' decision-making 
preferences  











Not recorded  58-95 years 
(73.45) 
Not recorded  Surgery, 
chemotherapy and 
radiotherapy 
Not recorded  
Bain and 
Campbell (2000) 
Treatment experiences and 
differences in priorities 
between urban and rural 
patients 
Multi-centre (2 cancer 
centres) 
UK (Scotland) 1. Patients' experiences with 
treatment for CRC  
2. Differences in attitudes and 
priorities between rural and urban 
patients 
22 patients and 10 
relatives, 
purposive 
sampling   
QUAL Focus groups Not recorded  Unclear (70 to 
below 60)  







palliative care  
Not recorded  





UK (Scotland) 1. How patients with CRC perceive 
their care 
2. Comparison of the views and 
experiences of urban and rural 
patients  




QUAL In-depth interviews Not recorded  Not recorded  Not recorded  Surgery, Surgery + 
Radiotherapy, Surgery 
+ Chemotherapy  
Not recorded  




Canada 1. Patient perceptions on adjuvant 







67% female Not recorded  Not recorded  Chemotherapy only 
(adjuvant and 
palliative) 
Not recorded  




Norway 1. Patients' experiences after 
completion of laparoscopic 





QUAL SS interviews 44.5% female 25-85 years 
(no mean) 
Stage 4 Surgery only 55.5% rectal, 
44.5% colon 
Bronner et al. 
(2018) 




Netherlands 1.  Establish patients' anxiety 
2. Monitoring coping style 
3. Changes in anxiety by 









and TMSI) plus 
treatment plans 
34,6% female 62.5 years 
(9.1) 
Not recorded  Chemotherapy or 
surgery 
Not recorded  
Broughton, Bailey 
and Linney (2004) 
Patients' experiences with 
diagnosis and surgery 
Multi-centre study (3 
hospitals) 
UK (England) 1. Patients' experiences following 
a diagnosis of CRC 
2. Patients’ experiences of their 
first follow-up visit after surgery  
3. Caregivers' experiences  
49 patients and 8 
caregivers, 
convenience 
sampling   
QUAL SS interviews and focus 
groups 
47% female 37-92 years 
(69 mean) 
Not recorded  Surgery Not recorded  
Cha et al. (2012) Nutrition in patients with CRC Multi-centre study (3 
health boards) 
New Zealand  1. Patients' information needs and 
satisfaction with dietary 
information  








(modified version of 
the Food Frequency 
Questionnaire) 
31% female >70 (no mean 
or SD) 
Not recorded  Surgery Not recorded  
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Comb (2003) Experiences of a stoma nurse 
caring for a patient undergoing 
surgery for CRC 
Single-centre study 
(cancer centre) 
UK (England) 1. Issues experienced by a patient 
undergoing surgery for CRC  
2. The role of the stoma nurse 





QUAL Fieldnotes Not applicable Not applicable Not applicable  Not applicable  Not applicable  
Cuthbert et al. 
(2020) 
Patients' supportive care needs 
following a diagnosis of CRC 
Multi-centre (cancer 
centres) 
Canada 1. Symptom burden and 
supportive needs of patients 
across different types of cancer 
2. Differences in symptom burden 
and supportive needs across 
different types of cancer 
3. Determine clinical & 
sociodemographic factors related 
to higher symptom severity  
146 patients with 
CRC, convenience  
QUAN 
(descriptive) 
Patient records and 
questionnaires (ESASr 
and CPC) 
51.2% female 64 (19-97) 44.4% local, 44.5% 
metastatic and 10.9% 
N/A 
N/A (due to receive 
treatment) 
Not recorded 
Dintinjana et al. 
(2008) 
The effects of a nutritional 




Croatia Effect of a nutritional support 
programme in nutrition status and 





QUAN (cohort) Clinical characteristics 









Not recorded  
Dronkers et al. 
(2010) 





Netherlands 1. Feasibility of a short-term 
therapeutic programme for 
elderly patients 
2. Intervention’s effect on post-









and validated measures 
of physical activity 





Not recorded  Surgery only Colon 
Harrison et al. 
(2011) 
Patients' unmet supportive 




Australia 1. Unmet supportive needs  
2. How patients’ needs changed 
over a 6-month period post-
surgery  
3. Association between clinical 





QUAN Records (medical and 
service) 
41.8% female 63.8 ACPS stage A: 16.0%, 
B: 32.0%, C: 32.9%,D: 
15.1% 
Surgery only Multiple  
Houldin (2007) Relatives’ experiences Single-centre study 
(cancer centre) 
USA Explore the experiences 
encountered by relatives 





QUAL SS interviews 28.6% female 44.92 (10.08) Stage III or IV Adjuvant 
Chemotherapy (post-
surgery)  
Not recorded  
Houldin and Lewis 
(2006) 




USA 1. Patients' experiences after 
receiving a diagnosis of CRC 
2. Coping strategies, impact on 
daily life and impact on family  




QUAL SS interviews 36% female 27-67 years 
(11.8) 
III and IV Adjuvant 
Chemotherapy (post-
surgery)  
Not recorded  




 UK (Scotland) 1. Self-care strategies 
2. Meaning and importance of 
self-care  
3. Changes in self-care strategies 




QUAL  SS interviews 27% women 65.5 years 
mean (8.5) 





Not recorded  
Knowles (1999) Information needs of patients  Single-centre study 
(university hospital) 
UK (Scotland) 1. Patients' information needs 
2. Factors associated with 
information-seeking 
3. Changes in information needs 
during treatment  








QLQ-C30, STAI, INQ) 
and SS interviews 
Not recorded  62 (10.5) Not recorded  Adjuvant 
Chemotherapy (post-
surgery)  
77% Colon, 23% 
Rectal Cancer 
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Lithner et al. 
(2012) 
Information provision in 
patients with CRC 
Multi-centre study (2 
university hospitals 
and 1 county hospital) 
Sweden 1. Health-Related Quality of Life 
(HRQoL)  
2. How patients perceive 
information after surgery 
3. Information needs 







Medical records and 
Questionnaires (QLQ-
C30, CR38 and INFO25) 







Lithner et al. 
(2015b) 
Information support and 
information needs after 
surgery 
Multi-centre study (3 
hospitals) 
Sweden 1. Information needs after 
discharge 
2. Experiences with information 
support after discharge 





QUAL SS Interviews 37.5% women Not recorded  Not recorded  Surgery Not recorded  
Lithner, 
Jakobsson, et al. 
(2015) 
Information and Health-Related 
Quality of Life (HRQOL) after 
surgery for CRC 
Multi-centre study (2 
university hospitals 
and 1 county hospital) 
Sweden 1. HRQOL and perception of 
information 2 weeks and 1 month 
after discharge  





QUAN Medical records and 
Questionnaires (QLQ-
C30, CR38 and INFO25) 
45% Women, 








Poland et al. 
(2017) 
Development of patient 
education for enhancing 
recovery after CRC surgery 
Multiple (hospital and 
patients' homes) 
UK (England) 1. Understand the role of 
preoperative education 
2. Determine the perceived value 
of enhanced recovery 
3. Modification of existing 
education practices and 
evaluation of these changes.  




QUAL Interviews and focus 
groups 
Not recorded. Not recorded. Not recorded. Surgery Not recorded. 
Reeve et al. 
(2017) 
Establish the most important 
measures of patient-centred 
care in patients with a recent 
diagnosis of CRC 
Multiple sites 
(unclear) 
USA 1. Evaluation of the patient-
centred communication (PCC) 
survey 
2. Selection of items to formulate 





QUAN (survey) Questionnaires (PCC 
and the Health 
Information National 
Trends Survey PCC)  
51% women 66.7 (13.1) Not recorded  Surgery, 
Chemotherapy or 
Radiotherapy 






Patients' experiences following 
reversal of temporary 
ileostomy surgery for CRC 
Multi-centre study (1 
university hospital and 
1 county hospital) 
Sweden Explore patients' experiences 





QUAL Narrative interviews   67 (median, 
range 33-81) 
Not recorded  Surgery Not recorded  
Sanders and 
Skevington (2004) 
Explore factors associated with 





UK (England) Establish factors associated with 
patients' willingness to participate 




QUAL Observations and SS 
interviews 
32.7% women 73.5% above 
65, 26.5% 
below 65 
Duke's stage B 
(16.3%), C 71.4%) and 
D (12.3%) 
Surgery 57.1% Colon, 
52.9% rectum  
Sanders and 
Skevington (2003) 
Explore patients' views 




UK (England) 1. Patients' views in medical 
decision-making 2. Explore the 





QUAL Observations and SS 
interviews 
35.1% women 64.9% above 
65, 35.1% 
below 65 
Duke's stage B (5.4%), 
C 75.7%) and D 
(18.9%) 
Surgery 59.4% colon, 
40.6% rectum 
Sawyer et al. 
(2008) 
Experiences following surgery 
for CRC and perspectives on a 
new patient care model 
Single-centre study 
(cancer centre) 
Canada 1. Explore patients' experiences 
before and after surgery  
2. Explore nurses' perspectives of 
the Milestones project and post-
operative care 




QUAL Telephone interviews, 
patient diaries and 
focus group (nurses) 
16.7% women 66 (range 46-
81) 
Not recorded  Surgery Not recorded  
Scheer et al. 
(2012) 
Decisional needs of patients 
with rectal cancer and gaps in 
recollection of consent 




Canada 1. Describe the decisional needs 
of patients about undergoing 
surgery for rectal cancer  
2. Identify gaps in patients' 
recollections of the discussions 




QUAL  SS interviews (based 
upon the Ottawa 
Decision Support 
Framework) 
24:6 Male to 
female ratio  
65 (42-89 I (33%) 
II (12%) 




















Poland 1. Psychological situation, 2. Social 
situation 
3. Physical situation 









48% women 92% below 70, 
8% above 70 
years 
Not recorded   Not recorded  
Spalding et al. 
(2013) 
Understand patients' 
experiences with pre-operative 
education for CRC and identify 




UK (England) 1. Understand the pre-operative 
experiences of patients and 
caregivers 
2. Ways to improve pre-operative 
education for future patients  
97 patients, 19 




QUAL Observations, SS 
interviews, focus 
groups and review of 




69.7 (39-97) Not recorded  Surgery Not recorded  
Taylor and Norton 
(2000) 
Formulate the content of 
supportive documents for 
future patients 
Unclear UK (England) 1. Explore patients' information 
needs  
2. Update information booklets 




QUAL Interviews and focus 
groups 
66.7% women 42-75 years Not recorded  Surgery alone and 
surgery followed by 
chemotherapy 
Not recorded  
Taylor (2001) Patients' experiences following 
a recent diagnosis of CRC 
Community UK (England) Understand patients' lived 
experiences and establish 





QUAL SS interviews and 
observations 
Not recorded  Not recorded  Not recorded  Not applicable (about 
to receive treatment) 
Not recorded  
Weaver et al. 
(2007) 
Feasibility of a symptom-





UK (England) 1. Explore the feasibility of the 
intervention  





MM (QUAN -> 
QUAL) 
Usage data and 
interviews 




White et al. 
(2012) 
Evaluation of a supportive care 
programme for patients  
Community Australia 1. Changes in supportive care 
needs, depression and anxiety 
between intervention and control  
2. Reduction of symptoms and 
service use between intervention 






QUAN (RCT) Questionnaires (SCNS, 
MOS and HADS) and 
other measures (CRC 
symptoms, service use) 
40% women 64.86 (9.23) Stage 1 (21%), 2 




Not recorded  
Worster and 
Holmes (2008) 
Pre-operative experiences of 
patients with CRC 
Single-centre study 
(district hospital) 
UK (England) Patients' experiences during the 




QUAL Fieldnotes and 
unstructured 
interviews 
50% women 50 to 82 years 
(no mean) 
Not recorded  Surgery Not recorded  
Worster and 
Holmes (2009) 
The experiences of patients 
with CRC shortly after surgery 
Single-centred study 
(district hospital) 
UK (England) Patients' experiences during the 




QUAL In-depth face-to-face 
interviews 
(unstructured) 
50% women 50 to 82 years 
(no mean) 
Not recorded  Surgery Not recorded  
Young et al. 
(2010) 
Acceptability and feasibility of 
an intervention for patients 




Australia 1. Feasibility and acceptability of 
the intervention 
2. Assessment of supportive care 






QUAN (Survey) Questionnaires (SCNS, 
HADS and FACT-C) plus 
custom checklist for 
the study 
50% women 64.5 Duke's stage A (19%), 
B (33%), C (24%), D 
(14%) and unknown 
(9%) 
Surgery Not recorded  
Zafar et al. (2013) Patients' preferences for 
chemotherapy in advanced CRC 
Multi-centre study 
(community) 
USA 1. Patients' role in decision-
making 
2. Quality of communication with 
physicians 
3. Overall quality of care 
4. Treatment preferences 5. 




QUAN Questionnaires (ADE 
and other validated 
instruments) and 
medical records 
 38% women 73% below 75, 
27% above 75 
years  








In these studies, information emerged either as a theme related to patients’ 
experiences along the care pathway or as a factor analysed as part of assessing their 
quality of care. Only a small minority (n=5:37, 13.5%) was dedicated exclusively to the 
information behaviour and needs of patients with CRC (Knowles, 1999; Lithner et al., 
2015b; a; Taylor and Norton, 2000).  
The general characteristics of the included studies are summarised in table 2.2. A 
significant proportion of studies were conducted in the UK (12 in England and 4 in 
Scotland). The majority of the included studies (n=22/37, 59.5%) followed a qualitative 
methodology and almost half of these studies (n=10/22, 45.5%) deployed a 
combination of qualitative methods to obtain their data. Questionnaires in quantitative 
studies were rarely used alone.  
Table 2. 2: General characteristics of included studies (n=37) 
 n %   n % 
Year of publication    Community 2 5.4 
1999-2001 5 13.5  Unclear 2 5.4 
2002-2004 5 13.5  Data collection methods   
2006-2008 7 18.9  Semi-structured interviews 7 18.9 
2009-2011 6 16.2  In-depth interviews 3 8.1 
2012-2015 8 21.6  Focus groups 1 2.7 
2017-2020 6 16.2  Observations/Fieldnotes 1 2.7 
Location    Combination (QUAL) 10 27.0 
UK 16 43.2  Questionnaire 2 5.4 
Europe 9 24.3  Combination (QUAN) 9 24.3 
Canada 4 10.8  Patient records 2 5.4 
US 4 10.8  Mixed (QUAN and QUAL) 2 5.4 
Australia 3 8.1  Treatment approach   
New Zealand 1 2.7  Surgery only 17 45.9 
Study setting    Chemotherapy only 8 21.6 
Single- centre  21 56.8  Combination cohort 10 27.0 




2.4.2. Methodological assessment of included studies  
The complete results of the methodological quality assessment are available in 
appendix 2.  
• Qualitative studies: The majority (n=14/22, 63.6%) of studies with a purely 
qualitative design scored above average. The most common omission, observed in 
13 studies (n=13/22, 59.1%) was not giving appropriate consideration to the 
researchers’ influence upon the findings, while seven studies (n=7/22, 31.8%) also 
didn’t explain how the findings were related to the study’s context.  
• Quantitative studies: Only two (5.4%) of the included studies were RCTs while the 
remaining had either a descriptive (n=5/13, 38.4%) or non-RCT design (n=6/13, 
46.2%). Half of the studies that followed a quantitative design scored above 
average, while most studies with a non-RCT design (n=4/6, 66.6%) scored below 
average. Although most studies that involved questionnaires (n=9/11, 81.8%) used 
validated instruments to collect their data, none of them stated whether or not 
their sample was representative of the population under study. Furthermore, all of 
these studies deployed sampling techniques that would increase selection biases 
such as convenience and consecutive sampling (i.e., non-probability techniques).  
• Mixed methods studies: Studies that followed a mixed methodology scored poorly 
due to shortcomings in either the qualitative or quantitative compartments. While 
the use of mixed methods was justified and was appropriate for addressing the 
research objectives, none of the studies provided a robust theoretical framework 
for using a mixed methods approach.  
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2.4.3. Summary of information needs 
Table 2.3 illustrates the main information categories and table 2.4 provides a detailed 
account of the types of information. The majority of the included studies (n=36/37, 
97.3%) presented information that was both sought by and given to patients. A total of 
567 mentions needs were identified, most of which were sought by patients 
(n=315:567, 55.5%).  
Table 2. 3: Types and sources of information mentioned across studies 
Authors  
Categories of information  
(567 total mentions across 37 studies) 
Information 
input 
Sources of information   































































































































































































































































































Bailer (2001) • • • •      • • • •  • 
Bain and Campbell (2000) •   •    •   • •    
Bain et al. (2002) •  • • •   •  • • •    
Bell (2009) • •  •      • • •    
Boe et al. (2019) • • • •      •  •    
Bronner et al. (2018) • • • •      • • • • • • 
Broughton, Bailey and Linney (2004) • • • • • •  •  • • • • • • 
Cha et al. (2012)  •        • •     
Comb (2003) • • •  •  •   • • • •   
Cuthbert et al. (2020) •  •     • • •  •    
Dintinjana et al. (2008) •          • •    
Dronkers et al. (2010) •          • •    
Harrison et al. (2011) • • •  •     • • •    
Houldin (2007) •  • •  •    • • •   • 
Houldin and Lewis (2006) •  • • • •    • • •   • 
Kidd et al. (2008) •    •  •   • • •  • • 
Knowles (1999) • • • •  • •   • • • •   
Lithner et al. (2012) • • • • •     • • • •   
Lithner, Jakobsson, et al. (2015) • • •  •   •   • • •   
Lithner, Klefsgard, et al. (2015) • • • • • • • •  •  • • •  
Poland et al. (2017) • • •  • • • •  • • • • •  
Reeve et al. (2017) • • • • • •  •  • • •    
Reinwalds, Blixter and Carlsson (2017) • • •  •     • • •  •  
Sanders and Skevington (2003) • • • •  •  •  • • • •   
Sanders and Skevington (2004) •  • •  •    • • • •  • 
Sawyer et al. (2008) • • •       • • • • •  
Scheer et al. (2012) •  •     •  • • • • • • 
Sierko, Werpachowska and Wojtukiewicz (2011) • • • •   •   • • •   • 
Spalding et al. (2013) • • • • • • •   • • • • • • 
Taylor and Norton (2000) • • •  • • •   • • • • •  
Taylor (2001) • • • • • • •   •  •  • • 
Weaver et al. (2007) • •         • •  •  
White et al. (2012) • •  •   •   • • • •   
Worster and Holmes (2008) •  • • • •  •  • • • •   
Worster and Holmes (2009)   • • •   •  • • • •  • 
Young et al. (2010) • •  • • • •    • • •   





Table 2. 4: Detailed types of information mentioned across studies 
N= 37 articles, 567 mentions of information needs  
Mentions per category 
n % 
Treatment-related information 222, 
39.52%1  
(94.6% of articles, n=35/37) 
Side effects of treatment/risks and benefits of treatment 25 11.3 
Tests and procedures involved in treatment  23 10.4 
General treatment-related information 23 10.4 
Surgery 21 9.5 
Treatment plan, treatment description or logistical information 21 9.5 
Medications 15 6.8 
Available treatments/treatment options 14 6.3 
Chemotherapy  13 5.9 
Purpose of treatment 10 4.5 
Treatment success 9 4.1 
How treatment works 8 3.6 
Other patients’ experiences or choices about treatment 7 3.2 
Treatment referrals 6 2.7 
Reducing side effects of treatment 5 2.3 
Clinical trials 5 2.3 
Where to get information about treatment 5 2.3 
Physical limitations during treatment 4 1.8 
Progress during treatment 4 1.8 
Radiation therapy 2 0.9 
Alternative or complimentary treatments 1 0.5 
Physical activity during treatment 1 0.5 
Rehabilitation-related information 133, 
22.26%1  
(64.9% of articles, n=24/37) 
Nutrition 21 15.8 
Bowel management 15 11.3 
General rehabilitation information  13 9.8 
Stoma care/ Stoma management/ Stoma formation 12 9.0 
Self-care issues during recovery 11 8.3 
Physical activity during rehabilitation 10 7.5 
Contact information for healthcare professionals 10 7.5 
Maintaining physical health or physical activity 8 6.0 
Recovery time 7 5.3 
Recognising or preventing complications following treatment 5 3.8 
Long-term post-treatment follow-up care 5 3.8 
Home care issues during recovery 4 3.0 
Immediate post-treatment follow-up care 4 3.0 
Maintaining psychological support during recovery 4 3.0 
Long-term side effects of cancer or treatment 2 1.5 
Where to get medical supplies or medical equipment 1 0.8 
Long-term side effects of cancer or treatment 1 0.8 
Disease-related information 66, 12.06%1 
(72.3% of articles, n=27/37) 
Specific diagnosis information 19 28.8 
General cancer-specific information 12 18.2 
Disease information 11 16.7 
Symptoms of cancer/management of symptoms 7 10.6 
Seeking second opinions  5 7.6 
Type of cancer/nature of disease 5 7.6 
Stage of disease 4 6.1 
Physical side effects of disease 2 3.0 
Aetiology and course of disease  1 1.5 
Prognostic information 62, 11.5%1 
(62% of articles, n=23/37) 
General prognostic information 14 22.6 
Life span or survival rate 10 16.1 
Recurrence of cancer 9 14.5 
Spread of disease or metastasis 8 12.9 
Outcome of no treatment or delayed treatment 7 11.3 
Chance of cure 6 9.7 
Effect on day-to-day activities 5 8.1 
Effect on life plan or long-term goals 2 3.2 
Expectations for future health condition 1 1.6 
Coping information 32, 5.01%1 
(48.6% of articles, n=18/37) 
General coping information 17 53.1 
Emotional reactions, emotional support, coping with cancer 11 34.4 
Support groups 3 9.4 
Community counselling or support 1 3.1 
Interpersonal/ Social information 22, 
4.08%1 
(37.8% of articles, n=14/37) 
Effect on employment or work life 8 36.4 
General interpersonal/social information  8 36.4 
Effect on family, friends or caregivers 4 18.2 
Effect on social life or leisure 2 9.1 
Body image/ fertility/ sexual information 
14, 2.6%1 
(29.7% of articles, n=11/37) 
Sexuality 5 35.7 
Physical appearance/physical attractiveness 5 35.7 
General body image/sexuality information  4 28.6 
Medical system information 14, 2.6%1 
(32.4% of articles, n=12/37) 
Interactions with healthcare providers 9 64.3 
Healthcare systems 3 21.4 
Experience or qualifications of physician and medical staff 1 7.1 
Available research 1 7.1 
Financial/legal information 2, 0.37%1 
(5.4% of articles, n=2/37) 
Cost of treatment, insurance coverage or other financial issues 2 100 
1 Calculated by dividing the sum of individual items for each category by the number of total mentions of information needs (n=567) 
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As the proportion of information given to patients was considerable (n=252:567, 
44.5%), a sub-group analysis was performed (table 2.5). Although there was general 
congruity in terms of priorities, some noticeable differences emerged in certain 
categories.   








narticles Mentions per 
category 
narticles 
Treatment- related information 107 26/37 115 28/37 
Rehabilitation- related information 72 19/37 61 17/37 
Cancer-specific information 37 21/37 29 16/37 
Prognostic information 42 20/37 20 9/37 
Coping information 20 14/37 12 7/37 
Interpersonal/ social information 18 13/37 4 3/37 
Body image/sexuality information 8 8/37 6 4/37 
Medical system information 10 8/37 4 4/37 
Financial and legal information 1 1/37 1 1/37 
Healthcare professionals received most mentions and appeared in the vast majority of 
the included studies (n=35/37, 94.6%). While physicians were most prominent, nurses 
also appeared to be an important source of information. Other types of health 
professionals included physiotherapists and dieticians (table 2.6).  
Table 2. 6: Sources of information (105 mentions across 37 articles) 







Physicians (e.g., doctors, surgeons, GPs) 30 53 
Nurses 19 33 
Other healthcare professionals 8 14 
Printed material 
 (19, 18.1%) 
Leaflets, pamphlets, brochures, booklets 7 37 
General printed material 12 63 
Media 
 (16, 15.2%) 
Internet  8 50 
General (e.g., DVDs, television) 8 50 
Interpersonal 
 (13, 12.4%) 
Friends and family 8 62 
Support groups/other patients 3 23 
General  2 15 
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2.4.4. Satisfaction with information 
17 out of 37 (45.9%) studies remarked upon patients' satisfaction with information. 
These studies either quantified this parameter or explored it from an in-depth 
perspective.   
Six studies presented numerical data on patients' satisfaction with information. In most 
of these papers (Cha et al., 2012; Knowles, 1999; Lithner et al., 2012, 2015a), a 
considerable proportion of participants didn't have their information needs met. In 
Harrison et al. (2011), information provision accounted for almost 1/5 of unmet 
supportive care needs. Although satisfaction with information was not addressed 
explicitly in Reeve et al., (2017) all items in the domain of exchanging information (a 
measure of Patient-Centred Communication) scored a high average, indicating that 
patients received adequate information support during their treatment.  
Eight studies that followed a qualitative design presented findings related to patients’ 
satisfaction with information. In three studies, patients reported low satisfaction and 
concerns about not being adequately informed (Boe et al., 2019; Lithner et al., 2015b; 
Reinwalds, Blixter and Carlsson, 2017). Four studies suggested that patients were 
satisfied with the information they received, with only limited comments on 
improvement (Bailer, 2001; Poland et al., 2017; Spalding, 2013; Taylor and Norton, 
2000). In Sawyer et al., (2008) participants were satisfied with the information given 
before surgery but reflected negatively upon the lack of post-operative information.  
 54 
Two studies did not present data related to satisfaction with information, but several 
findings were indicative of inadequacies in this domain. In Scheer et al. (2012), patients 
were unaware of a variety of surgical outcomes, while in Broughton, Bailey and Liney, 
(2004) the majority of patients didn’t have the opportunity to discuss post-discharge 
matters with their treating clinicians.  
2.4.5. Desired volume/amount of information 
Fourteen studies (n=14/37, 37.8%) presented findings related to the amount of 
information sought by patients. In the majority of these studies (n=10/14, 71.4%), there 
was a clear indication regarding the desired volume of information.  
In three studies that presented numerical data, the majority of participants reported a 
desire for more information (Cha et al., 2012; Lithner et al., 2012, 2015a). In another 
quantitative study, only 1% of patients reported wanting less information and 17% of 
participants wished to know more (Bailer, 2001).  
With regards to qualitative studies, three papers  suggested that patients welcomed all 
available information (Lithner et al., 2015b; Poland et al., 2017; Spalding et al., 2013), 
one study  pointed out that several patients would like more (Broughton, Bailey and 
Linney 2004), while and Bain et al. (2002) suggested that patients can’t always cope 
with too much information. The type and timing of information appeared to play a role; 
in Taylor and Norton, (2000) patients expressed a wish for less pre-operative 
information and more post-operative advice, while Sanders and Skevington (2003) 
reported that some patients can feel that too much information is given at a single time 
point.  
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The remaining studies suggested that the desired amount of information can vary 
among participants. Two papers (Worster and Holmes, 2008; Worster and Holmes, 
2009) pointed out that patients’ needs can range from wanting to know as much as 
possible to just enough information in order to understand their condition and its 
treatment. A similar finding was evident in Knowles et al., (1999) where some patients 
reported that the information provided to them was insufficient, while others felt 
overloaded.  
2.4.6. Most important types of information 
Twelve studies (n=12/37, 32.4%) presented information that was regarded to be most 
important by patients. Forty-three types of information were mentioned, which were 
grouped in broader information categories using the same typology as table 2.3 (p. 50). 
Treatment-related information were most prominent (mentioned 15 times across 9 
papers), followed by rehabilitation (12 mentions across 4 papers), disease (7 mentions 
across 6 papers) and prognostic information (5 mentions across 5 papers). Weight 
management and monitoring/follow-up appeared twice across two papers and 
interpersonal/social information appeared once.  
While the aforementioned studies presented the information that was most important 
to patients explicitly, other papers provided indication as to which pieces were central 
for them. For example, in a survey-based study Lithner et al. (2012), the participants left 
written comments regarding the importance of treatment-related, prognostic and 
coping information. In Kidd et al., (2008) seeking information about treatment-related 
effects emerged as one of the most important coping strategies deployed by patients. 
Although no specific types of information appeared in Bain et al., (2002) the authors 
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emphasised upon the importance of disclosing ‘bad news’ to patients. Finally, 
treatment-related and prognostic information emerged multiple times in two studies 
that investigated the exchanges between patients and health professionals (Sanders 
and Skevington, 2003; Sanders and Skevington, 2004).  
2.4.7. Information needs of patients’ caregivers and/or family members 
Five studies involved caregivers and/or family members of patients with CRC (Bain et al., 
2002; Broughton, Bailey and Liney, 2004; Houldin, 2007; Poland et al., 2017; Spalding et 
al., 2013). Only one study involved caregivers alone (Houldin, 2007). Two studies 
explored the experiences of newly diagnosed patients and their caregivers (Broughton, 
Bailey and Liney, 2004; Houldin, 2007) and one study (Poland et al., 2017) outlined the 
process of developing a supportive intervention, where the authors used the 
perspectives of patients and caregivers in order to formulate its content. Only one study 
concentrated upon the domain of information support (Spalding et al., 2013), while no 
explicit mention of caregivers’ information needs was identified in Bain et al., (2002). 
Treatment-related information was again the main focus, as they appeared in all 
papers. Cancer-specific, as well as prognostic information was also important. The 
desired level of detail varied both across and within studies. In Broughton, Bailey and 
Liney, (2004) caregivers were not always sure about how much they wanted to know, 
whereas two studies (Spalding et al., 2013; Poland et al., 2017) suggested that they 
pursued detailed information. In Houldin, (2007) some caregivers wanted all available 
information, while others wished to concentrate upon positive aspects.  
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Across all studies, caregivers welcomed written information; in Broughton, Bailey and 
Liney, (2004), caregivers expressed dissatisfaction due to the lack of written information 
on post-discharge matters. The same authors suggested that caregivers appreciated the 
support offered by specialist nurses, who were regarded as the principal source of 
information. In Houldin, (2007) one caregiver explained being intimidated by 
information identified through the internet. 
2.5. Discussion  
2.5.1. Appropriateness of the type of review  
The aim of this review was to synthesise the evidence around the information needs of 
patients with CRC at the early stages of treatment. As expected, the literature around 
patients’ information needs was considerably diverse, thus making a meta-analysis of 
the retrieved data unfeasible. While studies that presented numerical data were 
identified, the variety of outcome measures and research methods (i.e., questionnaires) 
would not allow for the merge of this data into a single analysis. Yet, the summary 
typology adopted from van Mossel et al. (2012) was useful for identifying the types of 
information that mentioned in studies that presented findings related to information 
support. 
A decision to conduct a meta-analysis would also result in the exclusion of qualitative 
studies, which accounted for more than half of the research conducted in this field. 
Although the quantification of patients’ information needs provided an overview of 
their priorities, it was qualitative studies that offered invaluable insight in this domain. 
For example, patient satisfaction did not just depend upon delivering the desired types 
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and volume of information, but it was also associated with the setting (Lithner et al., 
2015a; b), framing (Knowles et al., 1999; Spalding et al., 2013), timing (Houldin and 
Lewis, 2006) and clarity of information (Spalding et al., 2013); such factors were key in 
order to better appreciate how to fulfil patients’ needs. Qualitative studies revealed a 
number of other considerations, which will be discussed in detail below.  
2.5.2. Information sources  
The role of health professionals in the provision of information support was significant. 
This was evident from the fact that they were mentioned across the vast majority of 
studies, as well as from explanations given by patients in qualitative papers. Kidd et al. 
(2008) explained that patients relied upon the knowledge and expertise of healthcare 
professionals in order to manage their condition and receive information on how to do 
so. In Reinwalds et al., (2017) patients expressed that they wouldn’t trust information 
they came across unless they were endorsed by their treating clinicians, while Sanders 
and Skevington (2003) explained that the way that the way in which the oncologists 
communicated information played a major role in how patients got involved in the 
process of decision-making.  
The availability of a reference point of information was another important aspect. 
Sanders and Skevington (2004) argued that the amount of information provided during 
the consultations is not always the issue but rather, it is the patients’ inability to process 
them during that time. The availability of a reference point, as well as the repetition 
(Spalding et al., 2013) and endorsement (Poland et al., 2017) of information received by 
health providers appeared to be important for patients at that stage. Indeed, written 
information was the second most popular source across the identified studies. In 
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several papers, patients remarked upon the value of having information in writing, as it 
allowed them to revisit them at their own time (Knowles, 1999; Lithner et al., 2012, 
2015b; Scheer et al., 2012). In Poland et al., (2017) patients welcomed an educational 
DVD, as it helped them interpret the information with greater accuracy. Ensuring access 
to such resources is hence key.  
A surprising finding concerned the role of the internet as a source of information. 
According to Lleras de Frutos et al., (2020) the use of internet has increased 
exponentially in recent years, with as much as 97% of patients with cancer using it on a 
daily basis. However, explicit mentions of patients or caregivers using the internet to 
retrieve information appeared in just six papers and only two (Sawyer et al., 2008; 
Scheer et al., 2013) presented it as an important source. In Kidd et al., (2008) online 
information appeared to be important only during the early stages of treatment. 
Lithner, Klefsgard, et al. (2015) suggested that patients used the internet in order to 
confirm the information they received and learn more about their condition, while 
Reinwalds et al. (2017) asserted that patients turned to online information when they 
were not given sufficient support by healthcare professionals. One caregiver who used 
the internet in Houldin (2007) came across upsetting information and refrained from 
looking further. While it is possible that patients with CRC relied more upon their 
clinicians and printed resources to retrieve information, it is also likely that the use of 
the internet was not represented adequately in these studies. Further and more 
focused research is required in order to achieve a better understanding of the role of 
the internet in patients with CRC.  
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2.5.3. Information priorities and volume of information 
The findings suggested congruity between the top priorities (treatment, rehabilitation, 
disease and prognostic information) that were mentioned explicitly by patients and the 
types of information that appeared mostly across the literature. Yet this finding should 
be interpreted with caution, due to the inability of conducting formal statistical analysis 
of these results. 
Treatment-related information took central stage at this phase of the care continuum 
and rehabilitation- related information were the second most popular domain. The 
latter stroke as an unexpected finding, considering that this review focused upon the 
initial stages of treatment. This could be explained by the large number of studies that 
focused upon patients who received surgical treatment (n=17/37). As most of these 
studies included patients in the early post-operative phase, it is reasonable that such 
information was prevalent, as it was relevant at this stage.  
While nutrition-related information emerged several times, there was only one study 
(Cha et al., 2012) dedicated to patients’ needs around nutrition; furthermore, this 
aspect was not formally assessed or explored in any of the other studies. A similar 
finding was identified in van Mossel’s et al. (2012) scoping review, where the authors 
pointed out that the nutritional needs of patients with CRC did not receive much 
attention by researchers. Apart from Cha’s study, the search revealed only one in-depth 
study (James-Martin et al., 2014) that explored the information needs of survivors and 
patients around nutrition and exercise (which was rejected due to the 
inclusion/exclusion criteria), suggesting that this area still remains relatively under 
researched.  
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As mentioned in Chapter 1, some individuals might want to know as little as possible, 
while others can choose to avoid information altogether (pp. 6-7). Although this review 
did not identify any resources suggesting that patients with CRC completely avoided 
information, results regarding the volume of information and the desired level of detail 
appeared to be in line with findings from the general literature around the information 
behaviour of patients with cancer. This observation indicates the need for assessing the 
demands of individual patients in order to deliver the right volume of information and 
not burden them with unwanted material. 
Indeed, the personalisation of information emerged as an key consideration regarding 
not only the volume, but also the types of information pursued by patients with CRC. 
This was evident in certain studies where the participants explicitly requested 
individualised information about their condition and treatment (Poland et al., 2017; 
Sawyer et al., 2008; Spalding et al., 2013). Lithner et al. (2012) remarked upon the lack 
of personalised post-operative education and pointed out that tailored information 
should be provided through this phase. The significance of providing personalised 
information to patients was also brought up by nurse responders in Worster and 
Holmes (2008). Finally, Taylor and Norton (2000) explained that printed resources 
should not be regarded as a replacement to the process of assessing individual patient 
needs and providing tailored advice according to their requirements. Instead, the 
authors proposed that supporting material should provide a discussion focus or act as 
reminders of what was discussed during the consultations.  
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2.5.4. Pitfalls in information support 
Apart from providing an overview of the information needs of patients with CRC, the 
present review also identified several pitfalls in this domain. An important finding was 
that only a few studies (6/37, 16.2%) were dedicated exclusively to information needs 
and most studies presented them as a secondary finding. This was widely abundant in 
qualitative studies where authors attempted to explore patients’ experiences with a 
diagnosis of CRC and/or their experiences during their treatment. In such studies, 
information emerged as either an important aspect of supportive care or patients 
described the types of information that were discussed with them. In quantitative 
studies, information needs and/or satisfaction with information appeared as sections in 
questionnaires assessing supportive needs, satisfaction with care and health-related 
quality of life.  
A similar observation was apparent in van Mossel et al. (2012), where the authors 
pointed out that studies focusing upon patients’ information demands were scarce. As 
mentioned in the introduction chapter (p. 1), the diagnosis of a malignant disease can 
exert a tremendous impact upon individuals. Studies carried out at this phase of the 
care continuum appeared to provide an overview of what is involved at that stage, 
including lived experiences, psychological responses and general supportive care needs. 
Perhaps this is the reason why information needs were rarely examined alone; rather, 
they were presented or emerged as a key part of a patient’s overall care.  
Due to the limited amount of evidence, it was not possible to draw definitive 
conclusions regarding patients’ satisfaction with information. Yet, the present review 
identified several issues, as the majority of studies where satisfaction with information 
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was either assessed or emerged through the data revealed inadequacies in this domain. 
While poor information support caused uncertainty and worry to some, the limited or 
non-disclosure of information appeared to have a much more detrimental impact upon 
others (Bain and Campbell, 2000; Boe et al., 2018). For example, Reinwalds et al. (2017) 
demonstrated that the limited information on nutrition and medicines resulted in poor 
bowel management, while Scheer et al. (2012) pointed out that the lack of information 
interfered with patients’ capacity of making future decisions about their care.  
The review also identified some factors that had a negative influence upon the 
provision of robust information support. Almost half (48.6%) of the identified studies 
did not mention whether or not patients received written information during this stage. 
Patients appeared to value written accounts, as they provided the potential of revisiting 
aspects that were not retained or discussed during their exchanges with healthcare 
professionals. The lack of such point of reference was perceived negatively by some; in 
Lithner et al., (2015b) patients remarked upon the lack of written material (e.g. 
booklets, leaflets etc), which forced them to look for information themselves. As 
patients felt that they were not always able to process the information they retrieved or 
held doubts about the trustworthiness of such information, they expressed 
dissatisfaction and worry.  
As mentioned earlier, health professionals play a key role in the provision information 
support. However, they can also exert a negative influence upon this process. In some 
papers, patients expressed concerns about having information withheld, which gave 
rise to fear and uncertainty (Bain and Campbell, 2000; Lithner et al., 2015b). In several 
studies, the lack of provision of written information by health providers stood out as a 
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negative, as patients expected them to offer such resources (Lithner et al., 2012; 
Worster and Holmes, 2009). Confusion, misunderstandings and conflicting information 
were also evident, which compromised patients’ trust in their treating staff (Knowles et 
al., 1999; Worster and Holmes, 2009). Some authors also remarked upon the 
differences in perceptions between patients and providers. For instance, Scheer et al. 
(2012) noted clear disparities between patients’ and professionals’ information 
priorities. In Poland et al., (2017) clinicians were concerned that they did not spend 
sufficient time with patients in order to provide them the information they desired, but 
patients felt like they had the chance to discuss everything they wanted, indicating the 
differences in opinions regarding what is adequate.   
2.5.5. Limitations 
As mentioned in the previous section, the vast majority of studies presented 
information needs as a secondary finding or briefly mentioned the types of information 
provided to the study participants. Due to this, the present review should not be 
regarded as a definitive account of the information needs of patients with CRC at the 
early stages of the cancer care continuum. However, it can be argued that the 
information that appeared in these papers represent the most salient types of 
information sought and/or given in practice and therefore provide valuable indication 
as to patients’ priorities.   
Another limitation concerned the identification of relevant literature. In some cases, the 
data of interest was almost ‘hidden’ within articles. For instance, some authors 
presented the information that was given to patients as part of disclosure about an 
intervention they were about to receive (Dronkers et al., 2010; Weaver et al., 2007; 
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Young et al., 2010). These authors presented such information in the methods section 
of their articles, which was an unusual place to identify such data. As a result, it is likely 
that the present review has missed papers that contained such data, despite the 
robustness of the search strategy.  
2.5.6. Recommendations for practice and future research 
The search process identified a large number of papers (>100, including studies rejected 
by titles and abstracts) that focused upon the post-treatment period. This is in line with 
findings from other systematic reviews, where the vast majority of studies were 
concerned with the later stages of the cancer care continuum (Kotronoulas et al., 2017; 
van Mossel et al., 2012). It appears that while there is considerable interest in the post-
treatment phase, the initial diagnosis and early treatment stages have not received 
equal attention in CRC. This indicates the need for further research concentrating upon 
the early stages of treatment in order to better understand the information needs of 
these patients during that time.  
Another finding derived from the search process was that many studies included 
patients at various stages of the care continuum and/or involved patients with different 
types of cancer without performing analyses for the sub-groups in their samples. As 
mentioned in p. 40, the information needs of patients can change across their care 
pathway. Hence, pooling data from patients at different stages of treatment can 
potentially affect the findings and not adequately reflect the overall picture. Combining 
data from patients with different types of cancer can also be problematic, as differences 
between the information needs of patients with different forms of the condition have 
been previously reported (Nagler et al., 2010). Researchers should take these 
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considerations into account in order to achieve consistency in their samples and 
perform sub-group analyses if there is heterogeneity in their participant cohorts. 
Although a meta-analysis of data derived from studies with a quantitative design could 
potentially provide a more concise overview of patients’ needs, it was not possible to 
conduct one due to the variety of measurement tools. Authors should consider using 
validated and consistent data collection methods across their studies in order to enable 
future reviewers to summarise their findings in a robust manner. Another prominent 
consideration was the sample of these studies. Quantitative studies involved a limited 
number of participants (median 100, range 21-702), deployed non-probability sampling 
techniques and only half recruited participants from multiple research sites. This reveals 
the need for larger-scale studies with adequate samples so that findings more 
adequately reflect the needs of the desired patient population.  
Apart from the need for more robust studies to serve the purpose of breadth, this 
review also indicated the need for further in-depth research on patients’ information 
needs. While qualitative studies offered valuable insight, only two studies focused 
exclusively upon the information needs of patients with CRC at the early stages of 
treatment (Lithner et al., 2015b;Taylor and Norton, 2000). Hence, additional qualitative 
studies focusing on this particular aspect are required in order to build a more robust 
evidence base.  
The present review also revealed several considerations for practice. First and foremost 
is the role of health providers in providing effective information support. It appears that 
the communication of information between patients and healthcare professionals can 
be problematic, which is also observed in other studies in the field of cancer care 
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(Parker, Aaron and Baile, 2009; Thorne et al., 2013). This could be improved by 
assessing the needs of individual patients and providing honest information so that 
patients receive adequate support throughout their care. Health providers should also 
take care to ensure that sufficient material is supplied to patients so they can have 
access to a point of reference for their queries.  
2.6. Considerations for the app’s content  
The findings of the present review were significant not only for deciding upon specific 
pieces of information that would be included in the app, but also informed the general 
approach. Perhaps the most prominent finding of this review was that no assumptions 
should be made about what patients wish to know. Indeed, information demands 
appeared to vary across individuals and assuming that everybody wants to know as 
much as possible because the majority of patients has such demands would not be 
valid. This concerns not only the volume, but also the types of information. For 
instance, patients welcomed graphic information, despite the assumption that such 
information would upset them  (Lithner et al., 2015b; Spalding et al., 2013). Henceforth, 
liaising with patients would be necessary in order to validate ideas and receive 
recommendations on what should be included in the app. 
The framing of information emerged as another prominent consideration. Whilst 
appreciating honest advice, being left with hope was also important (Bain et al., 2002). 
Information should be framed in a way that preserves honesty but at the same time, 
does not diminish confidence; indeed, presenting information in an insensitive manner 
can cause uneasiness and upset patients (Bain and Campbell, 2000). The use of plain 
language and avoidance of technical terminology was another key consideration, as the 
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use of technical terms and medical jargon can potentially hinder patients’ 
understanding (Broughton, Bailey and Linney, 2004). Being reassured about the 
availability of support also appeared to be important (Lithner et al., 2015b). Such 
aspects were key in order to formulate content that would not only cover users’ 
information needs, but also consider salient points that would increase comfort.  
Another consideration was the role of health professionals in information support. 
Healthcare professionals appear to be the principal source for health-related 
information, as they were cited in the vast majority of the included studies. Therefore, 
the perspectives of clinicians would also be useful for formulating the content of a 
supportive intervention. It was determined that physicians, as well as nurses with 
experience in cancer care would be consulted in order to offer their perspectives and 
recommendations regarding the content of the app. 
2.7. Chapter summary  
The review explored the information needs of patients with CRC at the early stages of 
treatment. While the initial goal was to provide a summary of the information needs 
identified in eligible studies, the narrative synthesis revealed a number of key points 
that were not considered prior to the conduct of the review. Perhaps the most 
important outcome was the necessity of consulting with the patients rather than 
deploying a ‘one size fits all approach’. While gaining an understanding of these 
patients’ information needs was important, involving patients with CRC in the build-up 
stage would be an integral part of the development of the app. The next chapter of the 
thesis will outline the process of developing the app that was later tested with patients 
in a real setting.  
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Chapter 3: Intervention design and 
development 
 
Chapter 2 outlined the findings of a systematic review around the information needs of 
patients with colorectal cancer (CRC). This chapter presents the overall procedure for 
developing the pilot version of the project’s intervention, a virtual agent (VA)-based 
information support app for patients with CRC. This included two main stages, namely 
the pre-development stage and the draft design stage. Each of these stages included a 
number of components, which will be discussed in detail below.  
3.1. Pre-development stage 
The pre-development stage was concerned with utilising input in order to build the 
initial version of the app, which would be tested in the pilot study. This stage included 
six phases, inspired by the National Health Service (NHS) guide for developing health 
apps (NHS Innovations South East, 2014): 
a. Consultation with stakeholders 
b. Familiarisation with guidelines for developing and evaluating mobile health 
(mHealth) interventions 
c. Identification and review of commercially available apps for patients with CRC 
d. Formulation of the app’s draft content  
e. Utilisation of clinician input on the draft content 
f. Patient and Public Involvement and Engagement (PPIE) 
The abovementioned phases were conducted in chronological order. The following 
sections will expand on each of these phases.  
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3.1.1. Liaison with stakeholders 
Stakeholders were clinicians from the Churchill Hospital, part of the Oxford University 
Hospitals (OUH), who helped identify an appropriate patient population, provided 
access to patients and offered recommendations about the app’s content. Consulting 
with them was also necessary in order to find out if there were any existing apps 
recommended to patients as a part of standard care either at a national or local level, as 
such apps would constitute potation competitors.   
Clinicians suggested that a supportive app would be most beneficial to patients with 
CRC receiving chemotherapy with XELOX (Oxaliplatin and Capecitabine) for the first 
time. This was because XELOX is a highly emetogenic treatment, which requires 
extensive counselling and continued support during chemotherapy. Furthermore, CRC is 
a condition that can cause drastic changes (e.g., dietary, physical, emotional) to 
patients’ lifestyles and hence these individuals require a high degree of information 
support in order to deal with their condition. At the time of the study, there were no 
alternative apps recommended as part of standard care from OUH or the NHS apps 
library.  
3.1.2. Guidelines for developing mHealth interventions  
According to Mosa, Yoo and Sheets, (2012) the development of mHealth interventions 
should be based upon robust frameworks; yet, van Velthoven et al. (2018) pointed out 
that up to date, there are no agreed standards for the development and evaluation of 
mHealth interventions. An exploration of the literature was therefore performed to 
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identify resources around the development of mHealth interventions and bring them 
together to construct a framework for developing this project’s intervention.  
The first identified resource was the NHS Guide for Developing Mobile Healthcare 
Interventions, which provides a thorough development process towards building high-
quality health applications (NHS Innovations South East, 2014). As this guidance focuses 
upon the development of commercial apps, it included directions that did not apply to 
this project. Nevertheless, the sections concerned with the initial development process 
were applicable and were hence utilised.  
Another useful resource was a review published by Darlow and Wen, (2016) which 
explored the development of mHealth interventions for patients with cancer. The 
authors remarked upon the importance of stakeholder engagement, as well as an 
understanding of patients’ needs in order to formulate interventions that address their 
requirements. This resource also provided a theoretical perspective in the development 
process and offered concise directions about the methodological approach for 
developing mHealth interventions by presenting examples from the literature. 
In order to get an appreciation of the characteristics of robust health apps, two 
additional resources were consulted. The first was a checklist from the Royal College of 
Physicians, which was designed to help healthcare professionals identify high-quality 
health apps (Wyatt et al., 2015). The second resource was the Mobile Application Rating 
Scale (MARS), a validated tool designed for researchers and developers for assessing 
the quality of health apps (Stoyanov et al., 2016). Both of these resources provided 
useful insight and were used as checklists for ensuring that the project’s intervention 
was designed under high standards. 
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3.1.3. Review of existing apps for patients with colorectal cancer 
In the NHS Guide for Developing Mobile Healthcare Interventions, identifying what is 
already available to the intended user population is defined as ‘competitive analysis’ 
and constitutes the second step of the pre-development process. Although a 
competitive analysis is mainly applicable to commercial apps, this step was also of value 
for this research project.  
Rationale and aims 
Identifying commercially available apps for patients with CRC was necessary in order to 
find out if any similar apps were available to patients and detect potential competitors. 
An assessment of the features of these apps would also help identify potential pitfalls in 
this domain, which would inform the development process.  
The objectives of this review were to a) provide an overview of the general 
characteristics of commercially available apps with content for CRC, b) perform an 
assessment of their usability and determine the quality of their content and c) compare 
apps with high ratings to apps with low ratings to identify differences. As user ratings 
are considered to be an important indicator of an app’s popularity (Gomes et al., 2016), 
it was determined that this measure would be used to identify the most commercially 
successful apps, which would in turn provide indication of the aspects valued the most 





The major app stores (Apple store and Google Play) were searched at regular intervals 
from January 2017 to June 2018. As developers can use variations of medical terms in 
the description of their apps (Grundy, Wang and Bero, 2016; Paglialonga, Lugo and 
Santoro, 2018), the terms colorectal cancer, bowel cancer, colon cancer and rectal 
cancer were used in order to identify as many relevant apps as possible.  
The apps retrieved by the search were initially screened for eligibility on the basis of 
their description in their respective app stores (Table 3.1). Apps whose description 
fitted any of the inclusion criteria were installed and screened again against the same 
criteria in order to ensure that they were relevant to patients with CRC. Apps whose 
description was either not clear or absent were also installed and screened against the 
same criteria. 
Table 3. 1: Inclusion/exclusion criteria for the apps retrieved by the search 
Inclusion criteria Exclusion criteria 
• Apps intended for use by patients with CRC 
or their caregivers 
• Apps with content specific to CRC 
• Apps with content covering multiple 
conditions (cancer and non-cancer) but also 
included a section for CRC 
• Apps designed for professionals or students 
• Content irrelevant to CRC 
• Content covering multiple conditions without 
a section for CRC 
• Content not available 
• Apps about prevention/awareness of CRC 





The following characteristics were recorded for apps that fulfilled the eligibility criteria 
after full screening: 
• Year of release 
• Origin of the app (Educational organisations, small and medium enterprises (SMEs), 
patient organisations, healthcare agencies, non-government agencies and individual 
developers) 
• Classification of the app (medical, educational, health and fitness, business, news, 
other) 
• User ratings, user reviews and number of downloads 
• Purpose of the app (fundraising, promotion of healthcare professionals and 
practices, disease and treatment information, scientific/research news, dietary 
advice, physical activity, social networking, alternative treatments, treatment diary, 
spiritual support, miscellaneous) 
• Specificity to CRC  
There are two different approaches in appraising apps, namely the description-based 
and content-based appraisal; although the latter is more time consuming, it can allow 
for more reliable assessment, as app descriptions can sometimes be inaccurate or 
misleading (Paglialonga, Lugo and Santoro, 2018). Thus, potentially eligible apps were 
installed and inspected in detail in order to comment upon their quality.   
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The characterisation typology included two criteria, namely the quality of content and 
degree of usability (Giunti et al., 2018; Grundy, Wang and Bero, 2016; Nouri et al., 
2018). Each of these criteria contained certain measures, which in turn included a 
number of parameters (Tables 3.2 and 3.3). Each of these parameters was coded with 0 
if not present and 1 if present in accordance with previous research (Broderick et al., 
2014; Caburnay et al., 2015; Ginossar et al., 2017).  
Table 3. 2: Usability assessment parameters 
Usability measures Corresponding usability parameters 
Organisation of 
content 
Presence of homepage button, presence of menu button, 
presence of back button, presence of search function, 
integration with mail, integration with calendar 
Display of content  Links labelled clearly, use of images, use of bold colours and 
contrast 
Use of plan language Use of everyday words/ avoidance of technical terminology, 
use of personal pronouns, use of action words, use of active 
voice, use of present tense, use of short sentences 
Engagement of users Printer-friendly tools and resources, inclusion of interactive 
content, inclusion of audio or video features 
User support Availability of user support 
 
Table 3.3: Content assessment parameters 
Content quality measures Content quality parameters 
Quality of information Presence of citations, affiliation with credible 
organisation, accordance with guidelines and evidence 
base, clinical involvement 
Currency of information Content updated within the last 12 months 
Authority of developer Credibility and trustworthiness 




Search results  
The search yielded 996 hits in total. 940 apps were derived from the Play store and 56 
from the Apple Store. Duplicates were removed within stores, yielding 316 apps from 
the Play Store and 43 from the App store. 47 potentially eligible apps were identified 
through the Play store and 15 thought the Apple store. Three potentially eligible apps 
were common across stores, which were downloaded from both stores for further 
inspection. In total, 62 apps were candidates for full screening. Apps from the Play Store 
were installed on a Samsung Galaxy A7 and apps from the Apple store were installed on 
an iPhone 6s Plus (both run on the latest software). After applying the exclusion criteria, 
seven of the potentially eligible apps from the Play Store were rejected on the basis of 
their content. Further seven apps from the Play store were also excluded, as they were 
removed from the store before they could be installed for further investigation.  
Ultimately, 33 apps were kept from the Play Store and 15 apps were kept from the 
Apple Store (Figure 3.1). These apps were analysed in their respective store groups and 
were then merged to provide an overview of the apps available to patients with CRC. 
Three duplicates were identified, which were identical in terms of content and layout 




















app titles for description 
screening from Play Store 
269 app titles removed 
• 160 unrelated to CRC 
• 40 designed for health 
professionals 
• 69 in other language 
43 
app titles for description 
screening from App Store 
33 
apps included from Play Store 
28 app titles removed 
• 12 unrelated to CRC 
• 13 designed for health 
professionals 
• 3 in other language 
47 
apps for installation and 
further screening from 
Play Store 
15 
apps for installation and 
further screening from 
App Store 
 
14 app titles removed 
• 7 unrelated to CRC 




apps included from App Store 
45 
apps included in the analysis (3 duplicates across stores) 
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Overall Descriptive Characterisation 
Table 3.4 presents the results of the overall descriptive characterisation. The vast 
majority of apps were available free of charge. Most of the eligible apps were tagged as 
‘Medical’, followed by ‘Health and Fitness’. The majority of apps served a single 
purpose. Nine interventions provided treatment-related information only, while two 
apps focused solely upon research news; most of these apps referred their users to 
websites, journals and organisations to access the latest advancements in research 
around CRC and its treatment. Two apps provided links to medicinal suppliers and one 
app was designed purely for entertainment purposes (classified as ‘other’).  
Data on downloads, customer reviews and ratings were absent for apps derived from 
the Apple Store. In contrast, the Play store provided a detailed account of the number 
of downloads and included ratings, as well as customer reviews for most of its apps. A 
considerable proportion had more than 10,000 downloads and almost half of these 
apps received above 4 stars.  
Most of the identified apps were developed by small and medium enterprises, while a 
considerable proportion was created by individual developers. A limited number of apps 
were developed by non-government agencies or educational organisations in both 
stores and only one app was developed by a healthcare agency in the Apple store. No 
apps originated from patient organisations.  
  
 79 
Table 3. 4: Descriptive characterisation of identified apps 
  iOS, n=15 Android, n=33 Total, n=451 
Year of release 2012 1 2 3 
2013 - 1 1 
2014 3 4 5 
2015 2 2 4 
2016 2 8 10 
2017 3 10 12 
2018 1 6 7 
Not available/ Missing 3 - 3 
Origin of the 
app 
Healthcare agencies 1 1 1 
Non-government agencies  2 1 2 
Educational organisations 1 - 1 
Small and medium enterprises 8 23 30 





Medical 6 18 22 
Education 1 4 4 
Health and Fitness 4 8 12 
Business  1 - 1 
News 2 - 2 
Other 1 3 4 
Price Free 10 31 39 
£0.5-£0.99 1 - 1 
£1.00-£1.99 - 1 1 
£2.00-£2.99 2 - 2 
£3.00-£3.99 1 1 1 
£4 and above 1 - 1 
Rating 1-2.0 - 1 1 
2.1-3 - 1 1 
3.1-4 - 6 6 
4.1-5 - 16 16 
Not available 15 9 21 
Number of 
reviews 
1-10 - 13 13 
11-19 - 3 3 
20-29 - 1 1 
40-49 - 1 1 
50 and above - 6 6 
No reviews 15 9 21 
Downloads 0-10 - 2 2 
11-49 - 2 2 
50-99 - 2 2 
100-499 - 4 4 
500-999 - 8 8 
more than 1000 - 7 7 
more than 10,000 - 7 7 
Not available 15 1 13 
CRC Specific Yes 4 9 11 
No 9 23 32 
Missing/Unclear 2 1 2 




The App store contained more apps serving multiple purposes compared to the Play 
store; overall, fifteen apps served multiple purposes across both stores (Table 3.5). The 
vast majority of these apps provided information about cancer and its treatment, as 
well as information on diet and nutrition. Information about physical activity and special 
exercises were also offered by than a half of these apps. Five apps included a treatment 
and symptom diary function, while three apps provided information about alternative 
treatments.  
Table 3. 5: Purposes of apps for CRC 
 













Fundraising  - - - 2 1 2 
Promotion of health professionals 
and practices 
2 - 2 1 - 1 
Disease/treatment information 1 9 10 6 9 13 
Scientific/research news 2 3 5 2 1 2 
Dietary advice 1 1 1 5 9 12 
Physical activity/special exercises  - - - 6 4 8 
Social networking  - 2 2 3 1 3 
Treatment diary - 3 3 2 3 5 
Alternative treatments - 2 2 2 1 3 
Spiritual support  - - - 2 - 2 
Miscellaneous 1 2 3 1 - 1 
Missing 1 1 2 - - - 
1One duplicate was present, which was identical in both stores; 2Two duplicates were present, which were identical in 
both stores 
Assessment of content and usability 
The content assessment (Table 3.6) indicated mainly weaknesses in the quality of the 
apps’ content. The vast majority of the apps showed no evidence of clinical involvement 
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or affiliation with a credible organisation. The majority of these apps also did not 
present any references for any medicinal claims or information provided, while the 
content of almost half of the apps was outdated by over a year. Almost half of the apps 
(48.7%) were developed by a trustworthy developer (e.g., experienced in developing 
health apps including a health app portfolio, endorsed by a credible organisation) and 
none of them was tested in a study or included in a review.   
Table 3. 6: Quality of content in identified apps 
Content quality  
measures 








Quality of the app’s 
content 
Presence of citations 4 101 132 
Affiliation with credible 
organisation 
6 41 82 
Accordance with guidelines and EB 1 -1 12 
Clinical involvement 4 11 42 
Authority of the developer Credibility and trustworthiness 5 11 42 
Currency of information Updated within the last 12 months 9 151 222 
1 Parameter not applicable for 5 apps and unavailable for 5 apps; 2 Parameter not applicable for 1 app 
and unavailable for 5 apps3Three duplicates present, which were identical across stores 
Overall, the identified apps scored either slightly above or below 50% for most usability 
measures (Table 3.7). The majority included a homepage, menu and back button and 
more than half of the apps used bold colours and contrast, as well as images to aid user 
learning. With respect to the use of plain language, most apps used one or more 
parameters. The most neglected usability parameter was the engagement of users, 
while only a few apps offered integration with calendar. 
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User Support Availability of user support 8 142 222 
Use of plain 
language 
Use of common and everyday 
words/avoidance of technical 
terms 
41 133 185 
Use of personal pronouns 41 113 155 
Use of action words 41 123 165 
Use of active voice 51 123 185 
Use of present tense 51 183 245 
Use of short sentences 51 193 245 
Display of 
content 
Links labelled clearly 7 114 194 
Use of images to facilitate 
learning 
7 144 224 
Use of bold colours and 
contrast 
7 164 254 
Organisation of 
content  
Presence of homepage button 9 204 314 
Presence of menu button 9 194 304 
Inclusion of ‘back’ button 9 194 294 
Search and browse function 4 134 174 
Integration with email 4 134 184 
Integration with calendar 2 24 44 
Engagement of 
users  
Printer-friendly tools and 
resources 
1 64 74 
Inclusion of interactive content 5 44 84 
Inclusion of audio or visual 
features 
6 54 104 
1Parameter not applicable for 1 app; 2Parameter not available for 5 apps;3Parameter not applicable 
for 5 apps and unavailable for 5 apps; 4Parameter unavailable for 5 apps; 5Parameter not applicable 
for 6 apps and unavailable for 5 apps6Three duplicates present, which were identical across stores 
Characteristics of high-rated apps and comparison with low-rated apps  
Sixteen apps received high ratings from users (Table 3.8). All of these apps were derived 
from the Play Store; as the apps offered by the App Store did not have any ratings, they 
were not included in this part of the research. The majority of the highest-rated apps 
were classified as medical, followed by educational. Most of these apps served a single 
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purpose and almost half provided disease and treatment-related information. In 
contrast, the majority of the lowest-rated apps served multiple purposes.  
Table 3. 8: General characteristics of the highest and lowest-rated apps 
 High ratings  
(n=16) 
Low ratings  
(n=8) 
n % n % 
Number of 
reviews 
1-10 6 37.5 7 87.5 
11-19 3 18.75 - - 
20-29 - - 1 12.5 
40-49 1 6.25 - - 
50 and above 6 37.5 - - 
Downloads 100-499 - - 3 37.5 
500-999 7 43.75 1 12.5 
more than 1000 2 12.5 4 50 
more than 10,000 7 43.75 - - 
Classification Medical 10 62.5 4 50 
Education 2 12.5 1 12.5 
Health and Fitness 2 12.5 3 37.5 
Other 2 12.5 - - 
Purpose of 
the app 
Disease and treatment information/ 
educational  7 43.75 1 12.5 
Scientific/research news  1 6.25 1 12.5 
Social networking  2 12.5 - - 
Alternative treatments 1 6.25 - - 
Treatment diary 1 6.25 1 12.5 
Multiple purposes 2 12.5 5 62.5 
Miscellaneous 2 12.5 - - 
Origin of the 
app 
Non-government agencies  - - 1 12.5 
Small and medium enterprises (SMEs) 12 75 5 62.5 
Individual developers 4 25 2 25 
Usability issues were highly prevalent among the highest-ranked apps (Table 3.9). Only 
half of these apps provided user support and only a few deployed user engagement 
strategies. Issues regarding the display of content, as well as the use of plain language 
were similar in both top and low-rated apps. The only domain where the highest-rated 
apps appeared to perform better was the organisation of content.   
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n Mean n Mean 
Use of plain 
language 
Use of everyday words/avoidance of technical 
terms 8
1 0.62 22 0.33 
Use of personal pronouns 51 0.38 32 0.50 
Use of action words 61 0.46 32 0.50 
Use of active voice 61 0.46 32 0.50 
Use of present tense 91 0.69 52 0.83 
Use of short sentences 111 0.85 42 0.67 
Clear display 
of content 
Links labelled clearly 6 0.38 23 0.29 
Use of images to facilitate learning 8 0.50 33 0.43 
Use of bold colours and contrast 10 0.63 23 0.29 
Organisation 
of content  
Ease of access to homepage (homepage 
button) 
13 0.81 33 0.43 
Ease of access to a menu page (menu button) 12 0.75 33 0.43 
Inclusion of ‘back’ button 13 0.81 33 0.43 
Search and browse function 9 0.56 23 0.29 
Integration with email 9 0.56 33 0.43 
Integration with calendar 2 0.13 - - 
Engagement 
of users  
Printer-friendly tools and resources 6 0.38 - - 
Inclusion of interactive content 3 0.19 13 0.14 
Inclusion of audio or visual features 2 0.13 23 0.29 
User 
Support 
Availability of user support 8 0.5 4 0.5 
1 Parameter not applicable for three apps; 2Parameter not applicable for two apps; 3 Parameter not applicable for one 
app 
Only half of the highest-ranked apps included citations, while none of them reported 
clinical involvement in the developmental phase or had content formulated according 
to official guidelines and/or evidence base; moreover, less than half of these apps had 
updated their content within the last 12 months and none of them was developed by a 
credible source (Table 3.10). The apps that received lower ratings also suffered from 
quality issues, as the vast majority did not include any citations, and more than half did 
not update their content in more than a year.  
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Table 3. 10: Content quality parameters of the highest and lowest- rated apps 
Content quality  
measures 






n Mean n Mean 
Quality of the app’s 
content 
Presence of citations 61 0.5 12 0.17 
Affiliation with credible 
organisation 





Updated within the last 12 
months 
7 0.44 3 0.38 
Updated more than 12 months 
ago 
9 0.56 5 0.63 
1 Parameter not applicable for four apps; 2 Parameter not applicable for two apps 
Discussion 
The number of apps for patients with CRC has increased almost ten-fold in less than a 
decade (O’Neill and Brady, 2012). The purpose of this review was to assess 
commercially available apps for patients with CRC to inform the development process 
of the project’s intervention. The search strategy identified 45 apps available through 
the major app stores, which were then screened against a set of objective measures to 
assess the quality of their content and usability.  
Most of the identified apps deployed little usability measures for improving the user 
interface. The identification of these issues in the majority of the top-rated apps was an 
unexpected finding, since the degree of usability is a key aspect affecting users’ 
preference for a particular app (Liew et al., 2019). This could be explained by 
considering that usability can be a subjective matter (Pitkänen, 2016) and therefore, the 
objective measures utilised by this report might have not captured usability as users 
envision it.  
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The vast majority of identified apps did not employ any strategies to engage users. 
Garnett et al. (2015) pointed out that the lack of engagement strategies in mHealth can 
potentially increase attrition rates and compromise the success of these interventions. 
The use of plain language was another issue, as the majority of the apps did not utilise 
measures to achieve it. This issue was also noted in previous research involving apps for 
breast cancer, where the authors pointed out that the use of inappropriate language 
can hinder users’ understanding, which can in turn impede their experience with the 
interface (Ginossar et al., 2017).   
More alarmingly, the findings of this review demonstrated that the content of most 
apps for CRC was of questionable quality. The absence of citations or references in 
more than half of these apps, as well as the outdated content in almost half of these 
interventions also raised concerns about the validity of information. The lack of expert 
input was also apparent. This was also evident in previous research, where authors have 
remarked upon the lack of expert involvement in commercially available apps for cancer 
(Brouard et al., 2016). Such apps have raised concerns about their safety and 
appropriateness and authors continuously call for improvements in this domain 
(Charbonneau et al., 2020).  
A noteworthy finding was the identification of quality issues in the content of the 
highest- rated apps. In contrast with usability issues, this finding was not entirely 
unexpected. Singh et al. (2016) suggested that high ratings are not always indicative of 
quality content, which was also supported by the findings of this review. Henson et al. 
(2019) pointed out that users are not always able to determine the appropriateness or 
safety of health apps, which makes them prone to using interventions of questionable 
 87 
quality that can potentially put them at risk. Although this finding might not be 
surprising, this certainly raises concerns about the impact of such apps, especially 
considering their large uptake.  
At the time of this review there were no CRC- specific apps endorsed by the NHS health 
app library, nor any apps recommended by other official organisations such as 
Maggie’s, Bowel Cancer.org and MacMillan. In the absence of recommendations, 
patients could potentially install apps that have not been assessed for safety and 
appropriateness by credible organisations. This has been previously proposed in Akbar, 
Coiera and Magrabi, (2020) who asserted that official organisations, healthcare 
professionals and support groups should take care to warn patients about the risks of 
such interventions and recommend reliable apps to ensure that patients receive 
appropriate advice based on robust evidence. 
Another noteworthy finding was the absence of ratings and reviews for apps identified 
through the App store. While it could be argued that this was indicative of low 
popularity, the absence of data on the number of downloads would make such an 
assumption unsubstantiated (i.e., the App store does not provide data on the number 
of downloads). Yet, it can be argued that health apps in the App store did not receive as 
much attention as their counterparts did in the Play store. This could be explained by 
considering the size of the operating system (OS) market. A market analysis revealed 
that 85% of smartphone users owned Android devices, while only 15% possessed 
devices that run under iOS in 2018 (IDC, 2020). Hence, the poor uptake of these 
interventions could be attributed to the limited size of the target user audience rather 
than actual popularity.  
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This review has two limitations. The first is the absence of a validated instrument for 
assessing the identified apps. Thus far, the only validated tool for assessing health apps 
is the Mobile App Rating Scale (MARS), but some of its criteria rely upon subjective user 
accounts of the assessors and would introduce bias (Nouri et al., 2018). Wisnieski et al. 
(2019) pointed out that aspects such as usability can be highly subjective and therefore 
should be utilised with caution when attempting to assess a health app. This review 
hence relied upon a custom assessment typology based upon objective criteria 
identified from the literature in order to minimise the risk of bias whilst evaluating the 
retrieved apps. 
The second limitation is that the review did not include generic cancer apps that could 
potentially be utilised by patients with CRC. The app cancer market includes more than 
one-thousand apps (Giunti et al., 2018). Although some apps target specific types of 
cancer, others provide generic services such as symptom tracking, medication 
reminders and glossaries and do not focus upon a particular audience. Hence, unless 
developers used terms related to CRC in the description of these apps, interventions 
that could be used by patients with CRC were inevitably missed by the search.  
Summary of the competitive analysis and implications for the development process 
The findings of this review suggested that the majority of the commercially available 
health apps with CRC-related content suffered from both usability and content- related 
issues. The most prominent concern was the limited degree of clinical involvement and 
lack of evidence-based content, which indicated the need for better quality 
interventions for patients with CRC. This review also demonstrated that apps with 
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higher ratings scored higher in both usability and content quality parameters, 
suggesting that these factors were likely desired by users. 
In addition to addressing the original objectives, this review also revealed some 
problematic areas this field. Healthcare professionals and supportive organisations 
should consider such issues in order to direct patients to high-quality, evidence-based 
interventions to support their care, while developers should consider adhering by 
higher usability standards to optimise the interface of these apps.  
3.1.4. Formulation of the draft content 
The systematic review presented in Chapter 2 acted as a guideline for determining the 
types of information that would be included in the draft content of the app. The 
findings of this review were also triangulated with the results obtained from the 
competitive assessment (3.1.3) to identify gaps and highlight areas for improvement.  
Although most areas of information support were addressed through commercially 
available apps to a greater or lesser extent, none of the identified apps provided 
information regarding the management of treatment-induced toxicity (i.e., side-effects). 
Yet, as the provision of information on that matter emerged as an important aspect of 
information support in the systematic review (p. 51), it was decided that such 
information should be included in the project’s app. With these in mind, five broad 
thematic sections were drafted: 
1. Information about cancer and Treatment: General information about bowel cancer 
(e.g., aetiology, incidence etc.) and the main approaches for its treatment 
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2. Information about diagnostic tests: Information about the tests that might be 
ordered, why they are needed and how they are performed 
3. Information on side effects: List of side effects of XELOX and advice on how to 
prevent or ease them if they happen  
4. Information on medicines: Information and advice about chemotherapy medicines 
and supportive chemotherapy medication  
5. Information about emotional support, help with finances and everyday life: 
Information on the availability of emotional and financial support, dietary advice, 
help with everyday live and useful contacts during treatment 
Each of these sections contained a number of questions and accompanying answers. 
The draft content was formulated by consulting the following resources: Cancer 
Research UK (CRUK), MacMillan, National Institute for Clinical Excellence (NICE), 
Electronic Medicines Compendium (eMC), Bowel Cancer Chemotherapy Protocols 
Provided by Thames Valley and the British National Formulary (BNF).  
In addition to the information sections, two additional functions were proposed. The 
first was a search function that would enable patients identify a question within the app 
(i.e., a ‘search and browse’ function) and the second function was a section that would 
allow patients to keep treatment-related notes in the app. A Word version of the draft 




3.1.5. Clinician input  
The clinicians’ comments on the draft content concerned mainly the wording of the 
answers and information about supportive infrastructures available in Oxford. In 
addition to these comments, the clinicians proposed that the app should also contain a 
function referring patients to the Triage Helpline, a service for reporting chemotherapy-
induced toxicity. At the time, the patient chemotherapy manuals provided by the 
Churchill Hospital contained a simplified version of the UK Nursing Oncology (UKONS) 
symptom chart, which was designed to signpost patients to the Helpline according to 
the severity of their symptoms (UK Nursing Oncology Society, 2016).  
The clinicians suggested an interactive version of this tool, where patients could log 
their symptoms and, receive a custom assessment alert (according to the severity of 
each case) that would either instruct them to contact Triage or advise them to keep an 
eye on their symptoms and contact Triage if they deteriorated. The Triage function will 
be discussed in further detail in section 3.2.2.    
After updating the draft content following the clinicians’ recommendations, it was 
decided that advice should be sought by the targeted user audience. The following 
section will outline the process of obtaining input from patients with CRC as part of the 
project’s Patient and Public Involvement and Engagement (PPIE) scheme.  
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3.1.6. Patient and Public Involvement and Engagement 
Patient and Public Involvement and Engagement (PPIE) is about giving people the 
opportunity to express their opinions, views and recommendations about services they 
are currently receiving or will receive in the future. The implementation of PPIE is 
particularly beneficial in health research, since it can make projects more relevant to 
the needs of patients and the public (Domecq et al., 2014). Involving potential users in 
the development stage is also important for achieving good usability and functionality 
for the intended user population (Darlow and Wen 2016). The following sections will 
outline the design and conduct of the PPIE scheme, present the relevant findings and 
explain how these informed the development process of the project’s intervention.  
Participants 
The participants of the PPIE scheme were patients with CRC receiving XELOX and were 
identified by the clinicians from OUH. Two patients were invited, and both accepted.  
Design, conduct and ethics 
The design and conduct of this PPIE was based upon the latest guidelines provided by 
the National Institute of Health Research (NIHR). The investigator also undertook 
relevant training on planning and conducting PPIE and liaised with experts from Keele 
University for further advice and guidance.  
One month before consulting with the patients, the investigator provided two pieces of 
preparatory material. The first piece was a short document outlining the aims of the 
study and the role of PPIE in its design. This was done to help participants familiarise 
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themselves with the project and achieve a clear understanding of what their role 
involved. The second document contained the draft content of the app, which was 
given to the participants in order to be checked for its relevance and appropriateness.  
According to the NIHR, Ethical approval was not required, as the members of the public 
would act as advisors who would help shape the project rather than study participants. 
This was confirmed with the sponsor (Research Governance of Keele University), as well 
as the Research and Development (R&D) department of OUH.   
Theoretical framework  
As obtaining individuals’ experiences, perceptions and in-depth accounts is best 
achieved via qualitative research (Ritchie et al. 2014), it was decided that a qualitative 
approach was the most appropriate way forward. The method of choice was interviews, 
as holding a focus group was unfeasible due to the limited number of participants and 
logistical restrictions. The interviews were conducted in a semi-structured fashion to 
allow flexibility and maintain focus during the exchange between the investigator and 
the participants (Ritchie et al., 2014).  
The investigator performed one face-to-face interview with the first participant and a 
Skype interview with the second participant. The interviews were recorded with the 
participants’ permission and were transcribed verbatim. At the beginning of each 
interview, the investigator demonstrated ‘Manage your Health’, an existing virtual 
agent (VA)-based app developed by Keele University to help participants understand 
the concept of this project’s app. The investigator also presented a draft version of the 
proposed outline of the app using Google Power Apps.  
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Data analysis 
The transcripts were analysed using the framework method (Ritchie et al. 2014). This is 
a type of thematic analysis whose defining characteristic is the establishment of a 
thematic matrix which enables researchers to move across different levels of 
abstraction (themes, subthemes and cases) without losing sight of the original data, 
thus allowing for rigorous analysis of large datasets (Srivastava and Thomson 2009; Gale 
et al., 2013). Due to its systematic nature, this method was used to analyse the acquired 
data.  
After becoming familiar with the original data, a thematic framework comprised by a 
set of descriptive themes was formulated. Each theme was broken down to a subset of 
related sub-themes, each connected to one or more cases. The process was conducted 
in an iterative manner in order to identify as many themes as possible. The final 
framework was checked by an expert in qualitative research (Dr Alison Gifford) to 
ensure that the analysis was conducted at a high standard.  
Findings 
Four major discussion areas emerged, namely the use of apps in cancer care, views on 
the draft content, recommendations about the functions of the app and perspectives 
on the VAs. Each of these areas will be presented in more detail below.   
The use of apps in cancer care 
Both participants suggested that they would use such an intervention if it was available 
to them. Participant A suggested that the app would enable patients to address aspects 
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that were not covered during the consultations and participant B claimed that it could 
help revisit pieces of information that were not retained after the consultations.   
Both participants remarked upon a number of potential advantages that apps can offer 
compared to conventional sources of information. It was suggested that an app would 
offer a single point of reference and provide better portability over standard 
information material. Participant A also explained that websites often provide 
conflicting answers and/or inaccurate information, which raises concerns about the 
reliability of information. Yet, in the case of this project’s app, the information was 
perceived as and trustworthy, as it was formulated and checked by healthcare 
professionals.  
“...it might be more accessible in a place where maybe I don’t want to pull out all 
sorts of leaflets...” (participant A) 
Apart from their positive views around the app, the participants proposed that the age 
of the intended user population could potentially be a barrier for its uptake. Drawing 
upon the prevalence of CRC among older individuals, participant A thought that the 
targeted patient audience might not be inclined towards utilising such technology. 
Participant B shared a similar view and suggested that as older individuals did not have 
access to apps when they were younger, they are likely to be unfamiliar with this 
technology and therefore, less likely to adopt it.  
“...there is a strong correlation between how old you are and how good you are 
with a lot of the technology...” (participant A) 
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Despite this limitation, participant A suggested that the app would be not be applicable 
exclusively to patients, but it could also be used by patients’ caregivers, partners or 
family members that might accompany them in the consultations or care for them from 
home. This perspective was also shared by Participant B.   
“...if I am fairly elderly, it’s likely that I’m going to be coming and bringing someone 
else along; maybe my daughter or my nephew who’s going to be there and helping 
me anyway and therefore, likely to be able to be using it at that point.  You might 
want to think that maybe this app isn’t being used directly by the patient but by the 
person who is helping them and explaining things to them.” (participant A) 
Views on the draft content 
Overall, both participants were satisfied with the amount and types of information 
included in the content. Participant A thought that the content not only addressed 
information that was personally sought during treatment, but also provided information 
about aspects that weren’t considered at the time. Participant B also reflected 
positively on the content and stated that it covered all relevant areas.  
Suggestions about improving the content were made by both participants. Most of 
these comments concerned minor adjustments (e.g., rewording or rephrasing 
information) to improve comprehension. Participant B made a general remark upon the 
importance of good organisation and emphasised upon its importance. The participant 
thought that the proposed organisation of content was reasonable but pointed out that 
smaller groupings of information would improve navigation.  
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“...If I’ve got a menu system and I’m actively trying to search for something, I 
need to know where it’s going to be before I can find it...” (participant B) 
While participant A made no specific comments regarding the information itself, 
participant B expressed several thoughts about the framing of information, proposing 
that statistical data associated with survival rates should be omitted, as they could 
potentially be daunting for some users. Another recommendation was that the content 
should reassure patients that nurses will be available to help at any time; this theme 
appeared several times throughout the interview.  
Recommendations about the functions of the app 
The participants made several recommendations about the functions of the app. 
Drawing upon the importance of being able to identify a desired query easily, 
participant A recommended that a ‘search and browse’ function should be available so 
that users can quickly identify a query. The same participant also provided several 
technical recommendations to consider whilst developing this function.  
The original idea for the name of the app (Manage your Health) was deemed to be an 
appropriate option, as it did not give away the disease it was designed for. The 
proposed icon of the app (a heart with an ECG line) was also mentioned in this 
discussion and the participant thought that it was appropriate.  
“... the presence of this app on someone’s phone tells other people things about 
them and so you might want to call it something that is not obvious from the 
name that you see on the phone screen...” (participant A) 
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The inclusion of a ‘treatment diary’ function was mentioned by both participants. 
Participant A explained that having a treatment diary in the app could help towards 
keeping all notes in a single place. Participant B had another rationale and explained 
that the inclusion of a treatment diary could potentially enable patients to record their 
symptoms so they can later discuss them with their care team. This participant also 
suggested that the treatment diary could have a function for users to log future 
appointments to be reminded about upcoming events.  
“...being able to record my stuff is the thing that would make [the app] much 
more valuable... I would probably use it even without [the generic content], just 
to keep it all in one place.” (participant B) 
Security considerations emerged shortly after the recommendation of including a 
treatment diary. Participant A thought that usage data, as well as notes entered in the 
app shouldn’t be shared with third parties and that patients should be reassured about 
this. The same participant also suggested providing users with the option of securing 
the app with a password. 
“...the moment I can start entering information into it, you’ve now got my personal 
data in here and you have to be very careful about the security of that.” (participant 
A) 
Perspectives on using virtual agents (VAs) 
The participants identified some positive aspects of using VAs to deliver information. 
Participant A thought that visualising the content could facilitate understanding, while 
Participant B suggested that spoken information are likely to be helpful for older 
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patients, as they are likely manifest some degree of visual impairment. Participant B 
also proposed that having information narrated with an empathic tone could potentially 
appeal to senior users.   
“(…) I could see that for other people, having it spoken to you in a reassuring 
voice could be a good thing.” (participant B) 
Apart from their positive comments, both participants expressed doubts about this 
approach. Both participants were sceptical about the usefulness of spoken information 
over text, unless there was a need for demonstrating a procedure. Participant A 
expressed a preference for reading information instead of having it narrated, as reading 
was considered to be faster. This participant suggested that users could be given the 
option to either read the information or watch a clip of a VA narrating the text.  
“...If I had to sit there and wait for it to be spoken out slowly, I would probably go 
and look it up on the internet or read it somewhere else.” (participant A) 
The graphics emerged as an important aspect. After watching a VA clip from a previous 
version of Manage your Health, both participants explained that the VA resembled 
more of a cartoon character rather than a human being and expressed a preference for 
human-like VAs.  
Both participants remarked upon the importance of the VA’s professional appearance. 
Participant A explained that professional appearance was vital for conveying 
trustworthiness and that VAs should resemble healthcare professionals. A similar 
remark was made from participant B, who emphasised upon the importance of having 
the VAs dressed in typical medical uniforms such as white coats.   
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“...if this [information] was being said by someone who looks like a doctor, that’s 
going to be reassuring to me.  If it looks like it’s being said by my friend from 
home, or someone who looks a bit like them, then that’s perhaps for me less 
valuable.” (participant A) 
Participant A made no further remarks with respect to the type of health professionals 
that the VAs should resemble. Participant B initially thought that this wouldn’t make a 
difference, but later stated that the type of professionals should depend upon the type 
of information sought through the app.  
“...the majority of nurses that I’ve come across during my treatment are female 
and you feel that they’re softer. Whereas the oncologist it’s very serious... 
[information] about what cancer is, the stats and all that kind of stuff, the CT 
scans then maybe someone looking like the oncologist or whatever but then the 
support and the stuff after the treatment could be quite nice coming from 
someone who looks like a nurse...” (participant B) 
Both participants suggested that what counts as a trustworthy VA would likely vary, as 
patients are likely to hold different views with respect to which people inspire trust in 
them. Factors such as gender and ethnicity were also likely to have an influence. Due to 
this, participant A suggested that users should be given the option to create their VA so 
it resembles characteristics of a person who inspires trust in them.  
The VA demonstrated during the interviews did not resemble an individual known to 
the participants. When asked if the VA could look like a healthcare professional known 
to users, participant B thought that it wouldn’t make a difference in terms of 
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reassurance. Yet, the participant appreciated that the concept of formulating the VAs 
after healthcare professionals known to users had merit. 
“(…) it makes it more personal and reassuring and you’ve got the support of 
people who you know on the app (…)” (participant B) 
Participant B held a different view and explained that having information narrated by a 
VA formulated after a known pharmacist would not be reassuring, as the VAs response 
would be standardized (i.e., not personalised). Yet, the participant appreciated that this 
could be perceived differently by other individuals.  
“...it’s still been programmed and [the pharmacist is] just talking, she’s not 
actually talking to me, she’s saying the same thing to everybody else.” 
(participant B) 
Despite this statement, the participant explained that the purpose of the app would be 
to provide information and not reassurance. Yet, the participant acknowledged that 
other patients, particularly older and those who suffer from treatment might find this 
useful.  
Participant A provided a more detailed response to the same question, referencing a 
phenomenon called the uncanny valley. The participant explained that this a situation 
where a user experiences a feeling of eeriness after being presented with an almost-
realistic representation of another person. The participant proposed that if the VA 
representing a known health professional was realistic, it could potentially improve the 
situation. Indeed, both participants suggested that that the VAs should look more 
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human-like than the one presented to them during the interviews, regardless of 
whether they represent a known individual or not.    
“If it appears to me that someone is just pretending to be [my consultant], then I 
don’t trust that as much because I look at that and I say, ‘Okay, you’re trying to 
pretend to be somebody I know’. (participant A) 
Discussion 
Following the formulation of the draft content of the app, it was determined that 
potential end users would be included to the development stage in order to provide 
insight as to how to make the app more accessible to the desired audience. Two 
patients who had previously received XELOX for CRC were interviewed as a part of the 
project’s PPIE scheme. The findings of these interviews are discussed below.  
Potential benefits  
The participants identified several benefits that could be provided through the 
intervention. Portability was mentioned by both; this is one of the most prominent 
benefits of mHealth, since it can provide “information and resources services can reach 
anyone, anytime, and anywhere, by removing geographical, temporal, and other 
barriers” (Gagnon et al., 2016, p.212). Trustworthiness was another important factor, as 
the clinical involvement in the design of the content inspired trusting the information. 
Such perspectives confirmed several core ideas of this project and indicated the 
potential for applying this technology in patient care. 
Potential drawbacks  
 103 
Despite their positive views on the project’s rationale, both participants suggested that 
the age of the target user audience could hinder the uptake of the intervention. This 
perspective was in line with the findings of several studies proposing that mHealth is 
less likely to be of interest to older individuals (Ernsting et al., 2019). Both participants 
suggested that older individuals haven’t grown around information and communication 
technologies and might therefore be less interested in using apps, a notion which was 
also mentioned in Scheibe et al. (2015). Prensky (2001) refers to such users as digital 
immigrants in an attempt to describe their adaptation to the digital world. 
Despite these issues, it must be noted that the poor uptake of mHealth by older 
individuals is not necessarily due to the lack of interest or familiarity with this 
technology. Conde, García-Peñalvo and Matellán-Olivera (2014) suggested that older 
individuals are in favour of using new technologies, but this can be eclipsed by the fact 
that these technologies are not always tailored to their needs, which is also evident in 
Scheibe et al., (2015). Therefore, novel technologies are not the issue per se; instead, 
the focus is considering the needs of end users whilst designing these interventions.  
Content and functions of the app  
The first remark concerned the level of security offered by the app. Security is a key 
consideration for health apps and developers need to ensure that robust measures are 
in place to protect sensitive user data (Nouri et al., 2018). The second recommendation 
concerned the ease of navigation, which is a central usability factor, especially for older 
individuals (Morey et al., 2019). Ensuring that future users can easily navigate through 
the content was regarded as an essential aspect for ensuring satisfaction and 
preventing attrition (Eysenbach, 2005).  
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Another key recommendation was the capacity to keep track of symptoms and 
appointments through a ‘treatment calendar’ function. This finding was not entirely 
unexpected, as interventions supporting patients with cancer can often incorporate 
monitoring functions to help users manage their condition (Richards and Caldwell, 
2018). The incorporation of such function could also help increase engagement, as it 
could encourage frequent use (Baldwin et al., 2017); for the app, this could be true for 
after treatment commences. However, participant A implied that such functions could 
possibly overshadow the app’s role as a repository of information. This was something 
that was taken into account so it could be investigated in the stages of user testing.  
While the first participant provided detailed recommendations regarding technical 
aspects and functions of the app, the second participant offered further insight upon its 
content. A noteworthy comment was that survival data should be removed, as they 
could potentially be intimidating. Yet, a systematic review suggested that patients can 
in fact request information about such matters despite the daunting nature of this topic 
(Hagerty et al., 2005). The authors of this review pointed out that such sensitive 
information should be communicated, but this must be performed in a careful manner, 
which was also implied by participant B; this was an key consideration for amending the 
content.  
VAs; recommendations, risks and benefits  
Although participants were sceptical about the value of the VAs to them, it was 
suggested that using this technology for supporting older patients had its merits. This is 
in line with findings from the literature. In an early study, Bickmore et al., (2005) 
demonstrated that VAs can inspire a sense of presence and be highly acceptable by 
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older adults; subsequent studies also presented promising results (Vardoulakis et al., 
2012; Ring et al., 2013). VAs can also be helpful for senior users who might not be able 
to read lines of text on screens (Chattaraman et al., 2011), which was also suggested by 
the PPIE participants.  
Both participants suggested that the VA should resemble healthcare professionals, as 
they were perceived as the most appropriate agents for delivering health-related 
information. Another recommendation was that different types of health professionals 
could be used to deliver the types of information that best suits their area of expertise; 
this was also evident in a study by Read and Mayberry, (2000).  
One suggestion was to provide users with the option of customising the app’s VAs. This 
suggestion was due to the perception that what accounts as a trustworthy individual 
can vary among patients and hence, some may prefer a character of a specific gender, 
age or ethnicity. This was consistent with findings from the literature (Alsharbi and 
Richards, 2017; Guadagno et al., 2007). In online gaming, users frequently customise 
VAs according to their preferences to formulate a figure with favourable characteristics 
(Turkay and Kinzer, 2014). In the field of learning, Okita et al. (2013) proposed that 
altering aspects of a virtual educator such can help learners feel more comfortable, thus 
facilitating their learning.  
Another central consideration was whether the VAs should be known to users or not. 
While the inclusion of familiar VAs could be of benefit to older individuals and 
vulnerable patients, participant A thought that having known VAs could potentially 
provoke a strange response and referenced the concept of the uncanny valley. This 
concept has been presented in chapter 1 (pp. 24-25) and suggests that users can 
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experience feelings of eeriness and repulsion towards artefacts that look or act almost 
like humans. This concept was considered carefully and will be discussed in further 
detail in 3.2.1 
PPIE summary and implications for the development process 
PPIE played an integral part in the development of the project’s intervention. The 
participants provided a number of key insights for not only improving the app’s 
usability, but also its content in order to make it more relevant to the needs of the 
target population. One limitation was that due to the small number of patients included 
in this phase, the findings might have not addressed all aspects as well as a larger 
sample would. Another drawback was that both participants were considerably younger 
than the intended user audience (<40 years);  since the incidence of CRC is higher 
among older individuals (Cancer Research UK, 2020), participants’ perspectives might 
have not adequately reflected the needs of potential end users. Nevertheless, their 
recommendations from both an IT, as well as a patient perspective, were useful for 
achieving a better initial understanding of the needs of patients with CRC in order to 
design an intervention that would be relevant to them. Participants’ recommendations 
were implemented in the design process, which will be outlined below.  
3.2. Initial design and development stage  
The pre-development stage laid the foundations for building the pilot version of the 
intervention by receiving guidance from the literature, as well as input from clinicians 
and potential end users. Once these phases were conducted, the project entered its 
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development stage, which encompassed two main aspects: the formulation of VAs and 
the pilot version of the app. These will be discussed in detail in the following sections. 
3.2.1. Description of the Virtual Agents 
This part will present the characteristics of the VAs that were used in the pilot version of 
the app and provide justification for each one. These characteristics concerned the type 
of the VAs, the mode of communication with users and the appearance of the VAs. 
Type of VAs 
As discussed in chapter 1 (pp. 19-26), there are three broad types of VAs. This project 
focused upon embodied conversational agents (ECAs) for several reasons. First, the 
element of embodiment can foster a sense of presence and enhance users’ learning 
experience; this is known as the persona effect, which was discussed in chapter 1 (p. 
22). Second, ECAs can deploy non-verbal ques and simulate face-to-face 
communication with users, which can not only improve understanding, but it can also 
be particularly useful for older individuals (Bickmore et al., 2005). Relational agents 
were also considered. Yet, building such interfaces would necessitate a certain degree 
of artificial intelligence (AI) in order for agents to be able to form relationships with 
users (e.g., to remember individuals’ names and refer to previous interactions), which 
was unfeasible in terms of time and resources.  
Another aspect was whether the ECAs should be animated or static. As the former has 
been reported to elicit more intense emotional responses and foster a greater sense of 
presence than the latter (Wu et al., 2014), the app included animated ECAs. 
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Type of user/VA interaction  
There are several ways that interactions between users and VAs can occur. As discussed 
in chapter 1 (p. 20), users can either choose from pre-determined items (e.g., multiple-
choice questions) to receive pre-defined responses or use unconstructed textual/verbal 
input so that the VA responds to them in a tailored manner. The latter is defined as 
natural language processing (NLP), which has received increased attention due to its 
capacity to offer considerable advantages to such interfaces (see p. 20).  
Despite the potential advantages of NLP, its implementation necessitates “a high order 
of artificial intelligence technology” (Shaked, 2017, p.84); as such resources were not 
available, it was not feasible to incorporate NLP in the project’s intervention. Instead, 
the app offered users a number of pre-defined items (i.e., information queries) that 
were answered using pre-recorded messages. These messages were recordings of 
natural voices rather than synthetic speech. This was because natural voices have been 
reported to be more preferrable to artificial from the users’ perspective (Baylor, 2011). 
Appearance of VAs  
Some core considerations regarding the appearance of ECAs have been presented in 
chapter 1 (see pp. 22-25). The concept of VA familiarity was a central consideration, 
which also appeared in the PPIE interviews. Participant B’s comment regarding the 
importance of being cared for by familiar individuals across the care pathway was in line 
with the concept of continuity of care (see p. 32) and supported the project’s idea. It 
was therefore determined that the app would include VAs formulated after clinicians 
that were known to users.  
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Another important consideration that emerged during the PPIE interviews was the role 
of the VA’s static characteristics (e.g., gender, age and ethnicity) and the potential for 
users to customise their VA in the app. After discussing the latter with the development 
team, it was determined that providing this option was not viable, as it would require 
the formulation of new software that would push the project’s timeline considerably. 
Instead, a range of virtual characters was used in order to increase diversity in the VAs.  
Following the recommendations from participant B, a range of healthcare professional-
looking VAs was used according to the types of information delivered. Three clinicians 
from the Churchill Hospital agreed to be represented as VAs in the app: Dr Andrew 
Weaver (consultant oncologist), Professor Nicola Stoner (cancer consultant pharmacist) 
and Ms Eliz Flanagan (senior chemotherapy nurse). Figure 3.2 illustrates these 
individuals in real life and figure 3.3. shows how they appeared in the app. 
The final consideration about the appearance of the VAs was the degree of realism (see 
pp. 22-23). As the goal of this project was to provide VAs that looked like users’ 
clinicians, it was necessary to ensure that users would recognise these individuals. 
Hence, the VAs of the app were realistic, high-resolution representations of the 
aforementioned clinicians; this was also in line with the recommendations from PPIE.  
One of the most prominent concepts in the appearance of VAs is the uncanny valley, 
which also emerged during the PPIE interviews. While this theory has received much 
attention, work on this field has demonstrated that this effect is not always apparent as 
there are several examples where human-like characters and robots were considerably 
successful (Hanson et al., 2005). In a recent publication, Cheetham (2017) pointed out 
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that “an uncanny effect is not generalizable across different individuals, stimuli, 
situations, tasks, and time”. 
Figure 3. 2: The clinicians used to formulate the VAs (from left to right: Dr Andrew 
Weaver, Professor Nicola Stoner, Ms Eliz Flanagan) 
 
Figure 3. 3: The clinicians as virtual agents (VAs) in the app 
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It must be noted that participant who mentioned this concept had a strong IT 
background, and thus approached this technology in an exhaustive and critical manner. 
Hence, people with more limited IT skills and/or less experience in this domain might 
not necessarily share the same thoughts. The concept of the uncanny valley was an 
important aspect that was explored further in the later stages of the project. 
3.2.2. Formulation of the initial version 
Having established the appearance of the VAs and the content of the app, the pilot 
version was developed. This section will outline the steps taken in this process.  
Host platform 
The software development team suggested using an existing platform developed by the 
School of Pharmacy of Keele University. This platform was ‘Manage your Health’, a VA- 
based app for patients with chronic conditions (Keele University, 2021).    
Content and functions of the app 
The information content of the app was amended according to the recommendations 
of the clinicians’ and PPIE participants. Following participant B’s advice, data on survival 
rates were removed but a question regarding general prognostic information was 
included. The content was also updated to reassure and remind patients about the 
availability of help; this was achieved by adding statements such as ‘Your doctors/nurses 
will help you’ or ‘Your care team will ensure that…’ throughout the content.   
Following PPIE participants’ advice, the functions of the app were also updated. First, a 
search function was incorporated so that users could quickly identify a query in the app.  
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A calendar function for noting appointments and tests was also added; this function 
could push notifications so that patients were reminded about any upcoming events. A 
section where patients could keep notes was included as well. Finally, an interactive 
version of the Triage assessment tool was formulated following the clinicians’ advice. 
The pilot version of the app is illustrated in figure 3.4.  
Figure 3. 4: Pilot version of Manage your Health for XELOX 
 
Each information section (sections 1-5) contained a number of items; figure 3.5. 
presents the outline of the first section, which was concerned with general treatment-
related aspects. Patients could tap these items in order to obtain a response to each 
question. Items containing the chat bubble icon were VA clips, while items with the 
page icon contained links to external resources that referred users to official websites 
(e.g., Cancer Research UK, MacMillan) for further information and support.  
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Figure 3. 5: Outline of section 1 (Information about cancer and treatment) 
 
As it was not feasible to integrate the Triage function in the app, an online survey 
version of the tool was created and the link to it was embedded in section 6. The survey 
logic was based upon the Triage decision tree; in essence, the survey assessed users’ 
symptoms and calculated an overall feedback alert that advised them on whether they 
had to contact Triage or not. While this function didn’t constitute a diagnostic tool or 
medical device, ensuring safety for users was imperative. Rigorous steps were taken to 
safeguard that this function would be developed under the highest standards.  
First, the board members of UK Oncology Nursing Society (UKONS) were contacted in 
order to acquire permission to use the latest clinical version of their tool as a reference 
in order to build the survey’s logic (UK Nursing Oncology Society, 2016). Once approval 
was granted, a dialogue was formulated and was checked for its validity with an 
experienced Triage Nurse from the Churchill Hospital. The dialogue was updated and 
fed into Lime Survey, an online survey web application.  
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The first screen of the survey provided brief advice about its purpose. The second 
screen listed the 23 symptoms that appeared in the original Triage Tool, as well as a 
further option for ‘other symptom or side effect not listed above’. On that screen, 
patients were instructed to tick the symptoms they experienced. Depending upon the 
items they ticked, the survey asked them some more detailed information about each 
symptom and calculated a score according to their responses. Depending upon the 
overall score, patients were either advised to contact Triage as soon as possible or 
monitor their symptoms and call Triage if there was any deterioration (Figure 3.6).  
Figure 3. 6: Example of the Triage Survey 
 
The investigator performed rigorous testing to confirm that the draft version provided 
the correct instructions before incorporating the survey link in the app. This involved 
testing all 23 symptoms separately, as well as a combination of those in order to ensure 
that the survey provided the correct responses. To ensure confidentiality, the survey 
responses were not recorded.  
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Formulation of the animations for the clinician VAs  
Having established the host platform and content, the next step was to obtain audio, as 
well as video recordings from the clinicians in order to develop the animations. The 
recordings were performed at a quiet meeting room at the Churchill Hospital. In order 
to improve the quality of the sound recordings, a custom booth was assembled by the 
development team. An iPhone X was placed inside this booth using a tripod, alongside 
with an iPad which functioned as an autocue so that the clinicians could read the 
answers to the various questions.  
In order to speed the animation process, facial capture technology was used instead of 
hand animation. This was achieved through an app called Facial Mocap. This app 
features the TrueDepth Camera which allows for the capture of a series of detailed 
facial movements, thus saving the need for doing these manually. In essence, Facial 
Mocap captured capture the clinicians’ facial movements while they were reading the 
content and transferred this data in an animation software so that the development 
team could later formulate the various VA clips.  
Once the recordings were obtained, the development team used Maya Autodesk®, an 
animation software to build the virtual characters. Once the characters were built, the 
team applied the data from Facial Mocap in order to synchronise the VAs’ facial 
movements with each of the recordings (figure 3.7). Once the full set of animations was 
complete, the development team used Unity®, a cross- platform game engine in order 
to build the pilot version of the ‘Bowel Cancer-XELOX’ information package for Manage 
your Health.  
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Figure 3. 7: Facial Mocap app data transfer process 
 
 
Security considerations  
Due to developmental limitations, it was impossible to establish a two-step 
authentication process i.e., provide a password protection option for the app. Instead, 
users were advised to utilise standard security measures (e.g., password lock) to protect 
any sensitive information they might wish to enter in the app. In a further attempt to 
protect confidentiality, none of the information entered in the app (e.g., notes and 
appointments) were recorded or shared with another party, including OUH and Keele 
University. This was clearly stated in the information leaflets, the consent forms and 
would also be discussed with any potential participants.  
3.2.3. Initial intervention testing  
The goal of this phase was to identify bugs before testing the app with patients. In 
essence, this was an informal testing of the app before proceeding to the pilot study. 
The individuals involved in the initial testing phase were members of the project’s 
supervision team, the clinicians from OUH, members of staff from the investigator’s 
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research institute and the patients who took part in the PPIE interviews. All groups were 
asked to install Manage your Health, explore the content of the app and provide their 
feedback via email.  
The overall feedback was positive. The members of staff from Keele commented 
positively on the layout and the content of the app, with only a few remarks concerning 
spelling errors, broken links or unresponsive content (e.g., animations which didn’t 
work). Such comments were also made by the members of the supervisory team, as 
well as the clinicians from OUH. One academic suggested adding content that would 
help patients understand why blood tests are ordered, as the app only provided 
information about how they are performed. The patients from the PPIE group also 
provided positive feedback and made two key comments. The first concerned the 
search function, as it didn’t appear to yield any relevant results when a search term was 
entered. The second comment was about the ‘back’ button at the end of the 
animations, as the one presented to them was not very clear and led to some 
confusion.  
All comments were summarised and were then discussed with the software 
development team. The points raised were addressed promptly and the app was 
updated according to their feedback. In September 2018, the app was ready to be 
provided to patients from the Churchill Hospital in order to conduct a pilot testing of 
the app.  
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3.3. Chapter summary 
This chapter outlined the process of conceptualising and developing the initial version 
of the project’s intervention. First, a comparative analysis of commercially available 
apps for CRC was performed. The identification and exploration of the highest-rated 
apps not only provided indication regarding the features that are most popular to the 
desired audience, but also pointed out the need for delivering high-quality 
interventions to patients with CRC. The PPIE scheme offered invaluable insight as to the 
most salient points that should be considered from the perspective of potential end 
users and informed the formulation of the initial version of the app, which was then 
refined further before proceeding the project’s pilot study.  
Having formulated the initial version of the app, the next step was to test and evaluate 
it with real patients. According to Darlow and Wen (2016), the evaluation of mHealth 
interventions is best performed by involving both qualitative and quantitative 
approaches, which is commonly referred to as mixed methods research. The next 
chapter will discuss the core philosophical considerations surrounding these 
methodologies and present the theory that underpinned the evaluation process of the 
project’s intervention.  
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Chapter 4: Theoretical and philosophical 
considerations 
The previous chapter outlined the development process of the pilot version of the 
intervention. The aim of this chapter is to justify the approach that was utilised in order 
to evaluate the project’s intervention (i.e., address the aims and objectives listed in 
chapter 1). First, the core philosophical underpinnings of research and the main 
approaches to empirical inquiry will be briefly presented. The chapter will then proceed 
to cite the research approach that was adopted for evaluating the app, as well as the 
author’s (AC) paradigmatic stance in order to demonstrate how this choice is justified in 
the context of inquiry.   
4.1. Philosophical underpinnings of research; ontology, epistemology and paradigmatic 
stances  
The Oxford Dictionary defines research as “the systematic investigation into and study 
of materials and sources in order to establish facts and reach new conclusions” (Oxford 
Dictionaries, 2018). According to Bryman, (2016) this process is affected by the way we 
perceive reality, a matter that has intrigued the human mind for centuries. The 
philosophical study of the nature of reality is known as ontology. In very broad terms, 
there are two main ontological positions, namely realism and idealism. The former 
supports the existence of an external reality, which is independent of our beliefs and 
understandings, while the latter claims that reality is shaped entirely by the human 
mind and is knowable only through it (Ormston et al., 2014). Although both realism and 
idealism have several variants (e.g., subtle realism, naïve realism, collective idealism, 
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radical idealism etc.), this chapter will concentrate upon the two ends of the spectrum 
in order to maintain focus. 
Once an ontological foundation has been laid, the next question is what counts as valid 
knowledge? The branch of philosophy that seeks to answer this question is referred to 
as epistemology. According to Ormston et al., (2014), there are two core 
epistemological positions, namely the inductive and deductive logic. Inductive logic 
involves generating theory through observations, while deductive logic is used to test 
and confirm (or reject) a given hypothesis. The same authors suggested that the main 
epistemological debates are associated with the acquisition of knowledge (induction 
versus deduction), the connection between the researcher and the researched 
(subjective versus objective) and finally, the accuracy of knowledge (relative versus 
absolute).  
Having established their ontological and epistemological positions, researchers then 
formulated sets of propositions that served as guides to inquiry. These came to be 
known as paradigms. A paradigm is defined as “an overarching philosophical or 
ideological stance, a system of beliefs about the nature of the world and ultimately, 
when applied to a research setting, the assumptive base from which we go about 
producing knowledge” (Broom and Willis, 2007, p.17). Since reality and knowledge can 
be conceptualised differently, it is reasonable that several distinct paradigms have 
emerged over time. This work will concentrate upon the paradigms linked to the major 
research traditions. 
The first main paradigm, which is commonly associated with the ‘scientific method’ is 
positivism (Ormston et al., 2014). This philosophical movement claims that reality is 
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fixed and singular, governed entirely by laws and is external to the inquirer (Bruce, Pope 
and Stanistreet, 2008). Positivism advocates that an accurate account of reality can be 
achieved (i.e., truth can be known) and that methods used in the natural sciences are 
suitable for examining the social world. In the  early 20th century, this rigid and almost 
dogmatic view was succeeded by post-positivism (Gray, 2018), which maintained the 
core principles of positivism but proposed that although reality is objective, it can only 
be apprehended in approximation and is translated only as statistical probability 
(Brodsky et al., 2016).  
In stark contrast with the teachings of positivism and post-positivism, there are those 
who argue that neither reality is singular nor knowledge is absolute but instead, they 
are constructed by the human mind (Ormston et al., 2014). These closely related 
schools of thought are known as constructivism and interpretivism, according to which 
reality is not an external and independent entity, but instead, “the knower and known 
interact and shape one another” (Denzin and Lincoln, 2005, p.56). Advocates of these 
paradigms also stress that the social world cannot be studied by the methods used in 
the natural sciences, as social reality is not governed in the same law-like fashion as the 
natural world (Ormston et al., 2014). 
In summary, different ontological and epistemological views have led to the formation 
of distinct paradigmatic stances. Muncey (2009) suggested that these differences have 
underpinned the development of the research process and have led to two main 
research approaches, namely quantitative and qualitative research.  
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4.2. Qualitative and quantitative research 
According to Teddlie and Tashakkori, (2010) quantitative research is the methodology 
traditionally associated with the positivist/postpositivist paradigm. In the field of health 
research, quantitative methodology has cemented its place though the use of methods 
and study designs such as randomised controlled trials, cohort studies and meta-
analyses. Such methods aim to quantify data and make statistical inferences in order to 
apply findings to a wider setting (Broom and Willis, 2007). In the field of social sciences, 
quantitative research has exerted tremendous influence by attempting to quantify 
human behaviour through surveys, self-completed questionnaires and structured 
interviews (Denzin and Lincoln, 2005).  
Qualitative research took an entirely different approach to empirical inquiry and has 
been characterised as a ‘reformist movement’ (Schwandt, 2000). Grounded in the 
constructivist/ interpretivist paradigms, qualitative research introduced an approach 
that opposed the strict doctrines of the quantitative approach and focused upon 
individuals’ lived experiences (Ormston et al., 2014). Rather than pursuing statistical 
inferences and generalisation of findings, advocates of the qualitative approach deploy 
methods such as in-depth interviews, focus groups and participant observation in order 
to obtain information-rich data to achieve a holistic and in-depth understanding of the 
world (Brodsky et al., 2016).  
In the context of this project, a qualitative approach would allow for the acquisition of 
in-depth perspectives, personal views and experiences, which would help to appreciate 
the effects of the app. Yet, quantitative data such as analytics of use, satisfaction with 
information and degree of usability were important in order to determine the overall 
 123 
success of the intervention and perform numerical assessments across the study 
population. Thus, using either a quantitative or qualitative approach in isolation would 
provide only a partial view of the research problem and would not be sufficient to 
address the research objectives of this project.  
Both qualitative and quantitative research have their strengths and weaknesses in 
relation to one another. Yet considering the goals of the present study, it appears that 
the question of superiority of one approach over the other is irrelevant. Instead, the 
interest should be focused upon the appropriateness of the methodological approach 
to address the research objectives. According to Broom and Willis, (2007) the main 
focus are the research questions themselves, since these will determine which 
approach should be utilised in order to best meet the desired objectives (i.e. breadth 
versus depth). Rather than being torn between a methodological Scylla and Charybdis, 
deploying a methodology that combines both quantitative and qualitative elements 
could help reconcile the losses from using a monomethod approach. A mixed methods 
approach was hence determined to be the most beneficial way fromward for this 
project. The following section will provide a brief overview of mixed methods research 
and demonstrate how this was conceptualised in this project.  
4.3. Mixed methods research  
Creswell (2009) noted that research methodology continually evolves and develops. 
One of these developments was the integration of qualitative and quantitative means in 
a single study, an approach that has attracted much attention in recent years and came 
to be known as mixed methods research (Tashakkori and Creswell, 2007).  
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The first systematic use of mixed methods can be traced in the late 1950’s (Creswell 
and Plano Clark, 2011). At that time, the use of quantitative and qualitative methods in 
a single study resembled more of a validation process rather than a distinct 
methodology (Johnson, Onwuegbuzie and Turner, 2007). Yet, after a few decades, some 
began to build robust frameworks to promote the integration of research 
methodologies (Johnson, Onwuegbuzie and Turner, 2007; Reichardt and Cook, 1979). 
Notions regarding the combination of qualitative and quantitative methodologies were 
introduced in close proximity with the ‘paradigm wars’, a period where some scholars 
debated the legitimacy of qualitative research over the well-established quantitative 
approach (Bryman, 2008). According to Scott and Briggs, (2009) the role of mixed 
methods research during that time resembled that of a peacemaker, since it 
encouraged researchers to deploy both quantitative and qualitative means instead of 
choosing sides on the ‘battlefield’. Yet many objected to the notion of joining qualitative 
and quantitative methodologies and methods, claiming that their combination was 
unattainable at a philosophical level (Howe, 2004). These were referred to as purists, 
since they advocated the conduct of either qualitative or quantitative research in 
isolation (Rossman and Wilson, 1985). Despite these criticisms, mixed methods 
research managed to prevail. In later years, this approach witnessed considerable 
expansion not only in the social sciences, but also in healthcare (Halcomb, Andrew and 
Brannen, 2009). 
In the field of mobile health (mHealth), developers are encouraged to use both 
qualitative and quantitative means to perform a holistic assessment of their 
interventions and shape them according to the needs of their intended user population 
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(Darlow and Wen, 2016). A later publication  also proposed that complexity in mHealth 
calls for a mixed methods approach in order to effectively address the research 
objectives of such projects (Alwashmi et al., 2019). This was applicable to the present 
study, as it aimed to answer questions that were associated with breadth (e.g., 
numerical usage data on how the app was used over time), as well as depth (e.g., 
perspectives upon the use of virtual agents).  
In summary, mixed methods started as an informal validation process, which gradually 
developed into a distinct approach to research (Creswell and Creswell 2018). As this 
approach best suited the objectives of the project, it was determined that it would be 
used in order to answer the research questions. At this point, it must be made clear that 
although mixed methods research has evolved and developed markedly, there still 
appears to be a lack of consensus as to what it actually is. Hence, before proceeding 
further, it is necessary to make clear how the author (AC) perceived and in term, 
applied mixed methods.  
Mixed methods was treated as a methodological approach that has both a 
philosophical, as well as a practical basis for implementation (Creswell and Tashakkori, 
2007). The author accepts that qualitative and quantitative methods are associated 
with distinct paradigms, and that although paradigms can be used together in empirical 
inquiry, their uniqueness needs to be respected and acknowledged. Finally, the author 
recognises the practical importance of deploying a mixed methods approach, as it can 
facilitate the communication of findings with members of his research disciplines. 
Considering the above, the following definition was adopted: 
“Mixed methods research is an approach to inquiry involving collecting both qualitative 
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and quantitative data, integrating the two forms of data, and using distinct designs that 
may involve philosophical assumptions and theoretical frameworks” (Creswell and 
Creswell, 2018, p.4). 
After presenting the author’s position as to what mixed methods research is, it is 
necessary to demonstrate how this approach is justified in the context of inquiry. The 
next section will present the core philosophical arguments in mixed methods research. 
4.4. Philosophical debates around mixed methods research  
As mentioned earlier, mixed methods research has received criticism due to the notion 
that qualitative and quantitative research are incommensurable, an argument which is 
known as the incompatibility thesis (Teddlie and Tashakkori, 2003). Although this 
argument was raised during the paradigm wars, the issue of incommensurability still 
haunts this research approach (Lincoln, Lynham and Guba, 2018).  
Hathcoat and Meixner (2017) proposed that the incompatibility thesis encompasses 
three levels of inquiry, namely “the political (i.e., the role of evaluation in society), the 
technical (i.e., the methods utilized to gather information), and the philosophical (i.e., 
the underlying assumptions)” (Hathcoat and Meixner, 2017, p.434). According to the 
authors, the philosophical dispute is mainly what perpetuates this argument. In recent 
years, Lincoln, Lynham and Guba (2018) argued that “at the paradigmatic or 
philosophical level, commensurability between positivist and constructivist worldviews is 
not possible”’ (p.132). Others have suggested that incommensurability goes beyond the 
level of ontology and that even knowledge produced by competing paradigmatic 
approaches will be incompatible with each other (Bryman, 2016; Smith, 1983).  
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To challenge the issue of incommensurability at an ontological level, Morgan (2007) 
argued that if competing paradigms had clearly defined boundaries, this notion could 
potentially be valid. However, the existence of common ground between paradigms 
raises important questions about the merit of incommensurability. In more recent 
years, scholars have acknowledged that “the various paradigms begin to “interbreed”” 
(Lincoln, Lynham and Guba, 2018, p.164) and that qualitative and quantitative research 
are not “monoliths with no interparagmatic variation” (Johnson, 2008, pp.205–206). 
Indeed, it has been proposed that paradigm commensurability is possible, as long as 
paradigms share “axiomatic elements that are similar or that resonate strongly” 
(Lincoln, Lynham and Guba, 2018, p.174). 
At an epistemological level, Sandelowski (2000) and Bergman (2010) argued that 
research methods pay no allegiance to particular research paradigms and hence, 
inquirers can freely combine qualitative and quantitative methods in their research. 
Other methodologists  recognised that research methods are associated with 
paradigmatic assumptions, but argued that the epistemological gap between qualitative 
and quantitative research has been exaggerated, since not only qualitative methods 
draw influence from positivism, but also constructivism has inspired aspects of 
quantitative methods (e.g., Bryman 2004; Robson 2011; Alexander et al., 2008).  
In any event, many academics remarked upon the value of using both qualitative and 
quantitative aspects to address a single research question and encouraged researchers 
towards adopting this approach (Albright, Gechter and Kempe, 2013; Baum, 1995; 
Kettles, Creswell and Zhang, 2011; Steckler et al., 1992; Östlund et al., 2011). This call 
has indeed not fallen on deaf ears.  
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Bringing together elements of quantitative and qualitative research in a single study has 
become increasingly popular, particularly within applied sciences such as healthcare 
(Alise and Teddlie, 2010). Health research, a field once dominated almost entirely by 
the quantitative tradition, is now a discipline where methodological plurality becomes 
increasingly evident (O’Cathain, 2009). As Scott and Briggs (2009) noted, clinical 
knowledge encompasses “what foundational epistemology would regard as 
ontologically incommensurable approaches”(Scott and Briggs, 2009, p.233), since 
observational data are often combined with quantitative measurements  to inform 
decision-making (Mesel, 2013) . This reveals a great paradox for purists, considering 
that an entire professional community labours under otherwise falsified perceptions 
about what constitutes valid knowledge! The same can be argued for mHealth, since 
the use of mixed methods is not just evident, but also encouraged due to the 
complexity of the phenomena that researchers seek to investigate (Alwashmi et al., 
2019; Darlow and Wen, 2016).  
Considering the above, research approaches that utilise both qualitative and 
quantitative elements are now widespread across disciplines and produce valid 
knowledge. Although the dichotomy between qualitative and quantitative research 
appears to be less relevant in our time, the philosophical debate about 
incommensurability still exists (Yardley and Bishop, 2015; Bryman, 2008). Therefore, 
what are the philosophical foundations upon which mixed methods research rests?     
An answer to this question can be provided by the pragmatic approach to research. The 
following section will briefly explore pragmatism and demonstrate how it supports the 
conduct of mixed methods research.  
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4.5. Pragmatism and mixed methods research  
Pragmatism is a philosophical movement founded in the early 20th century to provide 
solutions to issues imposed by metaphysical arguments and the conflict between 
competing paradigms (Sundin and Johannisson, 2005). Johnson and Onwegbuzie 
suggested that pragmatism can be regarded as the “philosophical partner for mixed 
methods research”’ (Johnson and Onwuegbuzie, 2004, p.14), a view shared by 
methodologists and scholars (Morgan, 2007; Creswell and Creswell, 2018; Gray, 2018).  
Feilzer (2010) argued that pragmatism objects to the traditional approach to research, 
which attempts to produce knowledge that best represents reality. Instead, pragmatists 
advocate that the focus should be to generate knowledge that best represents a 
phenomenon and is capable of producing meaningful actions. Gray (2018) claimed that 
pragmatism regards research questions as the driving force of inquiry and rejects the 
top-down approach (figure 4.1) proposed by other paradigms (Morgan, 2007).  
Figure 4. 1: The traditional approach to empirical enquiry 
 
Ontology: Conception of 
the reality in which we exist; 
starting point of inquiry
Epistemology: The kind of 
knowledge we can obtain from this 
reality; stems from ontological 
assumptions
Methodology: Perceptions 
about how knowledge can be 
acquired; dictated by 
epistemological assumptions
Methods: The tools through 
which knowledge is acquired; 
associated with distict 
methodological approaches 
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Despite its popularity and contribution to mixed methods research, pragmatism has 
received considerable criticism. Referred to as an almost anti-philosophical research 
philosophy, pragmatism is often treated as an approach that strips research from its 
philosophical foundations (Robson, 2011). In addition to this, its core concept 
(commensurability of qualitative and quantitative research) is a matter of great dispute, 
since the teachings of the incompatibility thesis appear to still resonate strongly within 
certain research disciplines. Hence, pragmatism has often been discredited as an 
approach that both lacks philosophical insights and supports the unattainable 
proposition of combining qualitative and quantitative inquiry (Biesta, 2010).  
As any other research paradigm, pragmatism is open to philosophical debate (Johnson 
and Onwuegbuzie, 2004). However, the criticisms of pragmatism ought to be examined 
carefully, as it can be argued that they appear to misinterpret and disregard several key 
aspects of this paradigm, which can lead to falsified claims about its illegitimacy.  
To begin with, it appears that discrediting pragmatism resembles more of a 
combination of research agendas, funding hierarchies and discipline politics rather than 
genuine philosophical disagreements (Henwood, 1996; Hesse-Biber and Johnson, 2013; 
Lunde, Heggen and Strand, 2013; Mesel, 2013). Scott and Briggs (2009) suggested that 
‘basic’ science, which is typically grounded in implicit epistemic assumptions, is usually 
favoured among the academic community and is more likely to attract funding. Hence, 
studies adopting a pragmatic approach (i.e., embrace methodological plurality) can 
potentially be placed at a disadvantage or given lower priority over research which is 
driven either by purely positivist/post-positivist or constructivist/interpretivist 
directions.  
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From a philosophical point of view, pragmatism bypasses the challenging issues raised 
by the concepts of truth and reality, accepts (from a philosophical point of view) that 
“there are singular and multiple realities that are open to empirical inquiry and orients 
itself toward solving practical problems in the “real world”” (Feilzer, 2010, p.8).  At an 
epistemological level, pragmatism advocates that “knowledge is not constituted by 
correspondence to a given reality, but is instead reflected by an increased capacity to act 
on and transform experiential circumstances” (Hathcoat and Meixner, 2017, p.436). In 
other words, knowledge is not something we use in order to captivate and explicate a 
pre-defined reality, but it is about gaining insight as to how we should respond in 
relation to an certain environment or given circumstances (Martela, 2015). Considering 
the above, pragmatism indeed positions itself clearly with respect to its philosophical 
assumptions regarding research. Hence, dismissing pragmatism as an ‘anti-
philosophical’ movement due to its objections towards philosophical dogmatism 
indicates a rather poor understanding of pragmatism and its underlying principles. 
4.6. Chapter summary and adoption of a paradigmatic stance 
This chapter presented the main lines of inquiry, with particular focus upon pragmatism 
and mixed methods research. A mixed methods approach allows researchers to harvest 
the strengths of both qualitative and quantitative means in a single study and has 
received considerable attention due to its capacity to address multifaceted research 
problems. Considering the objectives of this project, it was determined that a mixed 
methods approach was the most appropriate way forward. Having established a 
methodological approach, the chapter then proceeded to demonstrate the 
philosophical underpinnings of this choice. 
 132 
Pragmatism rejects the traditional ‘top-down’ approach to research and places 
questions at the epicentre of empirical inquiry, which enables researchers to utilise a 
variety of means to address their objectives (Scott and Briggs, 2009). This offers an 
antidote to the issue of methodological purism and liberates inquirers from operating 
under strict sets of metaphysical doctrines, thus allowing them to produce knowledge 
that can lead to meaningful actions. As Johnson (2008) argued, philosophy should be 
treated as a partner of research and not as its dictator. Hence, pragmatism was adopted 
as the research philosophy that guided the author’s approach to inquiry. The following 
chapter will outline the methodology, as well as the methods that were used in order to 
evaluate the study’s intervention.  
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Chapter 5: Evaluation methodology and 
methods 
The previous chapter outlined the main approaches to inquiry, discussed their 
philosophical underpinnings and presented the author’s (AC) paradigmatic stance and 
approach to empirical enquiry. Exploring these areas was necessary in order to provide 
a robust theoretical framework for the evaluation of the project’s intervention and 
ensure congruity between the research objectives and the approach that was followed 
to address them. This chapter will outline the methodological approach that was 
followed for the evaluation of the project’s intervention, alongside with the study 
design and research methods that were used in the pilot investigation. 
5.1. Methodological considerations 
The choice of methodology was informed by theoretical, as well as practical aspects. 
The following sections will present these in detail.  
5.1.1. Theoretical aspects 
The core theoretical considerations behind the choice of methodology (i.e., 
philosophical underpinnings) have been outlined in chapter 4. Having established the 
methodological approach and its potential advantage over monomethod approaches 
(Ritchie and Ormston, 2014), it is important to demonstrate why and how this choice of 
methodology would benefit this study at a theoretical level. Several authors have 
proposed the key reasons behind researchers’ decision to undertake a mixed methods 
approach; drawing upon the most inclusive identified typology (Bryman, 2006), the 
following reasons were identified: 
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• Triangulation reflects the view that quantitative and qualitative research can be 
combined to triangulate findings so that they can be mutually validated. For 
example, a quantitative assessment of one aspect (e.g., app usability) would be 
validated through an investigation of in-depth user perspectives on this particular 
aspect. 
• Completeness suggests that researchers can achieve a more complete account of 
the area of inquiry by deploying qualitative and quantitative approaches together. In 
the context of this project, coupling numerical findings with qualitative feedback 
would help acquire a more holistic understanding of the benefits and drawbacks of 
the intervention. Quantitative data would help understand how successful (or 
unsuccessful) the app was, while qualitative data would help clarify why this was so.  
• Explanation is the concept of using findings from one research component to help 
explain the findings derived from the other component. This would be helpful for 
interpreting quantitative results using qualitative findings, as numerical data alone 
would not allow for fully understanding users’ feedback (positive or negative).  
• The concept of unexpected results involves the use of qualitative and quantitative 
research in order to understand unexpected results derived by either approach. This 
is in close proximity with the concept of explanation, as findings from one 
component can help interpret unanticipated results derived from the other strand.  
5.1.2. Practical aspects 
In addition to the theoretical considerations, there were several practical aspects that 
informed the decision of choosing mixed methods. With regards to the evaluation of 
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mobile health (mHealth) interventions, guidelines (e.g., Agarwal et al., 2016; Eysenbach 
2011; Wyatt et al., 2015) call for a mixed methods approach, as some evaluation 
measures are best acquired via qualitative methods (e.g., users’ or stakeholders’ 
perspectives and recommendations for improvement), while others are best obtained 
through quantitative approaches (e.g., usage data). Indeed, in the guidance for 
developing and evaluating complex interventions, the Medical Research Council of the 
United Kingdom (MRCUK) suggested that a mixed methods approach can potentially 
benefit such projects (Craig et al., 2008).  
A review exploring the application of mHealth in the field of cancer care demonstrated 
that the majority of studies followed a mixed approach to address their objectives 
(Darlow and Wen 2016). Moreover, the authors recommend that the development and 
evaluation of mHealth interventions should involve both quantitative and qualitative 
measurements, as they can provide a more complete upstanding of the effects of this 
technology. In a later publication, Alwashmi et al. (2019) also emphasised upon the 
importance of utilising a mixed methods approach to evaluate mHealth interventions at 
the early stages of development. Deploying a mixed method approach for the 
evaluation of the app was therefore in line with best practice in mHealth, which could 
potentially help communicate the findings of this work in this research field.  
5.1.3. The research strands 
The evaluation process involved a quantitative and qualitative component. These will be 
referred to as strands throughout the chapter. The quantitative strand was concerned 
with the first three objectives (degree of usability and acceptability, the intervention’s 
capacity to fulfil users’ information needs and use of app throughout treatment), while 
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the qualitative strand focused upon the last three (perspectives upon the content, 
attitudes towards the virtual agents and recommendations for improvement). Findings 
from the qualitative strand also helped enrich quantitative findings. Each strand 
included distinct methods, which are described in detail below. 
5.2. The quantitative strand 
This strand was concerned with parameters that could be readily quantified, such as 
satisfaction with information, degree of usability and the use of the app. In order to 
decide upon the most appropriate research methods for this strand, the methodologies 
followed by previous studies of health apps were considered.  
5.2.1. Self-completed questionnaires 
Surveys are a method concerned with the “collection of quantified data from a 
population for purposes of description or to identify covariation between variables which 
may point towards casual relationships or predictive patters of influence” (Sapsford, 
2007, p.3). The main characteristic of survey research is standardisation; all participants 
are given a consistent set of questions, as the ultimate goal is to get a consistent set of 
answers from the sample. Due to their practicality (e.g., fast turnaround in data 
collection, acquisition of data across large samples) and cost-effectiveness, surveys 
were the method of choice for collecting data related with usability and information 
from the participant cohort (Sapsford, 2007). 
For this project, the collection of survey data served the purpose of description, as the 
sample size was not large enough in order to establish casual relationships or draw 
statistical inferences. Two questionnaires were administered in total, namely a baseline 
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and a post-exposure questionnaire. The former was provided in order to obtain 
demographic data and explore the information needs of the participants before using 
the app, while the latter was administered after they were exposed to the intervention 
in order to explore the satisfaction with information (provided through the app) and 
establish the degree of the app’s usability.  
The development of questionnaires, when performed in an appropriate manner, can be 
a lengthy and resource- consuming process (Sapsford, 2007). Instead of developing a 
series of custom instruments for the aforementioned purposes, a review of the 
literature was undertaken in order to identify existing tools that have already been 
used.  
5.2.2. Information needs and satisfaction with information questionnaires 
The information needs of patients with cancer have been studied from both a 
qualitative, as well as quantitative perspective. Studies that utilised a quantitative 
approach deployed various questionnaires to measure and compare patients’ 
information needs across various participant cohorts (Papadakos et al., 2015). Among 
these, the most thorough instrument was the Toronto Information Needs 
Questionnaire (TINQ), which was originally developed for patients with breast cancer 
(Galloway et al., 1997), but was later adopted for prostate (Templeton and Coates, 
2001), lung (Hsieh, Chou and Guo, 2018) and other types of the disease (Matsuyama et 
al., 2013).  The original version of the TINQ (Galloway et al., 1997) contains 51 items 
(pieces of information) and responders are asked to rate the perceived importance of 
each item on a 5-point Likert scale ranging from 1 (not important) to 5 (extremely 
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important). This tool has five subscales (disease, investigative tests, treatments, physical 
and psychosocial information).  
O’Connor, Coates and O’Neill (2010) adopted the original version of the TINQ for 
patients with rectal cancer a UK treatment centre. This version contained the same 
subscales as the original TINQ and included a total of 53 items. The participants were 
asked to rate the perceived importance of these items and the extent to which these 
items were addressed during their treatment; in essence, patients’ information needs 
and satisfaction with information were measured at a single time point. As the authors 
demonstrated that the adopted version of the TINQ was capable of making consistent 
measurements of CRC patients’ information needs (more information about consistency 
are outlined in p. 143), it was decided that this tool would be used for the present 
study. 
Since rectal and colon cancer share considerable similarities in terms of treatment, 
pathophysiology, diagnostic tests and supportive care, the aforementioned version of 
the TINQ was considered to be an appropriate instrument for exploring the information 
needs, as well the perceived satisfaction with information of patients with CRC in this 
study. This tool was checked with the patients of the project's Patient and Public 
Involvement and Engagement (PPIE) scheme to ensure relevance. No modifications 
were suggested and hence, none of the items of this questionnaire were altered. 
For the present project, the original questionnaire by O’Connor was split in two; in 
essence, participants’ information needs and satisfaction with information were 
assessed at different time points. The items of the baseline questionnaire were prefixed 
with the statement "During my treatment, I believe/feel that it will be important for me 
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to know about..." and patients were asked to state their views in a Likert scale ranging 
from 1 (not important at all) to 5 (extremely important). The baseline questionnaire also 
obtained several demographic data (age, sex, ethnicity, marital status, educational level, 
employment status, health literacy, time since diagnosis, previous treatment for cancer) 
associated with patients' information-seeking (Zeguers et al., 2012; Mayer et al., 2007; 
Matsuyama et al., 2013; Sainio and Lauri, 2003; Gupta et al., 2013). A single question 
regarding IT literacy was also included, as this has been associated with the use of apps 
(Rasche et al., 2018).  
The Satisfaction with Information Questionnaire contained the same 53 items as the 
Information Needs Questionnaire (O’Connor, Coates and O’Neill, 2010) , but this time, 
the items were prefixed with the statement ‘In my view, the app provided enough 
information about...’. Again, participants were asked to state their views in a 5-point 
Likert scale.  
Analysis of Information needs and satisfaction with information questionnaires 
Το decide upon the most appropriate methods for analysing the data generated by the 
aforementioned instruments, it is necessary to first understand the nature of this data. 
Boone and Boone (2012) pointed out that Likert-type items and Likert scales follow 
distinct methods of analysis, as they generate different types of data; according to the 
authors, a Likert scale “is composed of a series of four or more Likert-type items that are 
combined into a single composite score/variable during the data analysis process. 
Combined, the items are used to provide a quantitative measure of a character or 
personality trait”. As such data would fall in the interval measuring scale, mean values 
can be used to determine central tendency and standard deviation can be deployed for 
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measuring variability (table 5.1, adopted from Boone and Boone, 2012). As these 
questionnaires contained Likert Scale data (O’Connor et al., 2010), it was determined 
that these measures would be used for analysing data derived from these 
questionnaires.   
Table 5. 1: Data analysis methods for Likert-type and Likert scale data 
 Likert-type data Likert-scale data 
Central tendency  Median or Mode Mean 
Variability Frequencies Standard Deviation 
Associations Kendall tau B or C Pearson’s r 
Other Statistics Chi-square ANOVA, t-test, regression 
5.2.3. Usability questionnaire 
In their review of health apps used in oncology, Darlow and Wen (2016) encouraged 
developers and researchers towards utilising the System Usability Scale (SUS) in order 
to assess the degree of usability of their interventions. The SUS was originally developed 
by Brooke (1986) in an attempt to produce a straightforward yet reliable instrument for 
assessing the degree of usability in various systems. Since its release, the tool has been 
used widely to measure the usability of hardware, software, mobile devices, websites 
and applications (Bangor, Kortum and Miller, 2008; Lewis and Sauro, 2009; Peres, Pham 
and Phillips, 2013; Orfanou, Tselios and Katsanos, 2015). Lewis (2018) notes that 
despite its humble beginnings and a number of competitors (e.g., the Software Usability 
Measurement Inventory and the Computer Systems Usability Questionnaire), the SUS 
remains the most popular tool for assessing system usability in a variety of fields. 
The SUS contains ten statements (items) assessing subjective user perspectives. Nine 
items measure usability, while one item also assess the degree of learnability. In order 
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to reduce the risk of bias arising as a result of the lack of attention whilst completing the 
scale, the SUS alternates between positive and negative statements; items 1,3,5,7 and 9 
are associated with positive aspects, while items 2,4,6,8 and 10 concern negative 
aspects. All items are set on a 5-point Likert Scale ranging from ‘strongly disagree’ to 
‘strongly agree’. Due to its degree of adaptivity, applicability and reliability, the SUS was 
adopted in order to assess the degree of the project’s intervention. To adopt this 
instrument for the purposes of the study, the term ‘system’ was replaced with ‘app’.   
Analysis of Usability questionnaire 
Although the items of the SUS are constructed in a Likert Scale, the SUS follows a 
custom scoring system. According to Brooke, (1986) the scores of each item should not 
be interpreted separately, as they are meaningless in isolation; instead, the purpose of 
the SUS is to produce a single number that represents a composite measure of an 
intervention’s degree of usability. The author outlined the following procedure:  
“To calculate the SUS score, first sum the score contributions from each item. Each 
item's score contribution will range from 0 to 4. For items 1,3,5,7, and 9 the score 
contribution is the scale position minus 1. For items 2,4,6,8 and 10, the contribution is 5 
minus the scale position. Multiply the sum of the scores by 2.5 to obtain the overall value 
of SU.” (Brooke, 1986) 
Scores obtained from the SUS range from 0 to 100. While the author did not make 
further comments upon the interpretation of the overall scores, the accumulation of 
SUS data over the years enabled researchers to translate SUS scores in a more 
meaningful way. Bangor, Kortum and Miller (2009) later added an adjective rating scale 
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upon the SUS and proposed a comparison between adjective ratings and acceptability 
in relation to the average scores obtained by SUS. This is illustrated in Figure 5.1 
(Bangor, Kortum and Miller, 2009, p.121) and was used as a guide in order to determine 
the degree of usability and acceptability of the project’s intervention. 
Figure 5. 1: Interpretation of SUS scores 
 
5.2.4. Validation of self-completed questionnaires 
Although validated instruments were adopted for the evaluation of the app, several 
modifications were implemented in order to make them fit to the study purposes. For 
instance, while O’Connor et al. (2010) measured information needs and satisfaction 
with information at a single time point, this study aimed to determine information 
needs at baseline and establish the satisfaction with information after the participants 
used the app. Furthermore, the items of the SUS were altered in order to make them 
relevant to the context of the study. Juniper (2009) pointed out even small changes in 
the wording, formatting or timing of administration can exert an effect upon the 
instrument’s accuracy. While this does not prohibit researchers from customising 
validated instruments to match their unique study objectives, it certainly calls for 
validation before altered versions of custom tools are applied in research.  
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According to Tavakol and Dennick, (2011) there are two key elements to a 
questionnaire. The first is validity, which reflects the degree to which a tool can 
measure what it aims to measure. Face validity, the extent to which the questionnaire 
components are comprehensive and relevant to the responders was determined with 
the participants of the Patient and Public Involvement and Engagement (PPIE) group, as 
well as clinicians from the Churchill Hospital. As neither parties recommended any 
changes, the items of the questionnaire were not altered I terms of number and 
wording. The original sequence of items was also maintained. 
The second element was reliability, which determines an instrument’s capacity of 
making consistent measurements. Tavakol and Dennick (2011) proposed that reliability 
can be determined objectively with using Cronbach’s alpha (α), which is used to 
establish internal consistency. According to the authors, “internal consistency describes 
the extent to which all the items in a test measure the same concept or construct” 
(Tavakol and Dennick, 2011, p.53) and should be determined prior to the administration 
of the instrument to ensure consistency. Cronbach’s coefficient alpha ranges from 0 to 
1; higher scores (i.e., values closer to 1) are indicative of higher internal consistency, 
with a range of 0.7 to 0.9 being generally acceptable. The alpha value for all three 
instruments was determined in the pilot study (Chapter 6).   
5.2.5. Delivery of self-completed questionnaires 
A paper version of the questionnaires was provided to the study participants at the 
recruitment site (Churchill Hospital) by a member of the research team. This decision 
was informed by considering the issue or poor response rates in internet- based 
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surveys, which can be attributed to the absence of human interaction during the 
delivery process of the questionnaire (Scott et al., 2011).  
All questionnaires were provided alongside a pre-paid envelope. Patients were asked to 
complete them at their own time and post them to the address of the recruitment site, 
where they were collected by the author (AC). In order to protect participants’ 
identities, the questionnaires were affixed with a unique identification code that 
allowed the author alone to identify the responder. 
5.2.6. App usage data  
User engagement was an significant outcome, as it would reveal the extent to which 
patients utilised the app and provide an overview of how the app was used during the 
study period. Short et al. (2018) proposed two levels of engagement, namely microlevel 
and macrolevel engagement. The former is associated with the “moment-to-moment 
engagement with the intervention, including the extent of use of the intervention (eg, 
number of activities completed) and the user experience (eg, level of user interest and 
attention when completing activities)”, while the latter entails “the depth of involvement 
with the behavior change process (eg, extent of motivation for changing behavior) and is 
linked to the behavioral goals of the intervention.” (Short et al., 2018). As the goal of this 
project was to provide information support without inducing changes in patients’ 
information behaviour, the interest focused upon microlevel engagement. 
In their viewpoint, Short et al., (2018) proposed that engagement can be determined by 
using quantitative, as well as qualitative measures. In a systematic review of mHealth 
and eHealth interventions, Perski et al. (2017) noted that system usage data (i.e., 
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analytics of user activity) are the most common objective measure of user engagement 
across the literature. Short et al. (2018) later categorised usage data among the 
microlevel measures and emphasised upon their importance for assessing user 
engagement. Due to their capacity to provide a detailed and objective account of how 
the app was used throughout the study period, it was determined that usage data 
would be acquired.  
Types of usage data 
Short et al. (2018) proposed four categories of usage data, namely frequency (how 
often a user utilises the intervention), intensity (the proportion of features used in 
relation to the total features available to users), time (the duration of engagement) and 
type of interaction (passive versus active). The authors pointed out that using multiple 
categories in combination can offer greater insight with regards to engagement rather 
than using upon individual data categories.  
In order to achieve a better understanding of how users engaged with the app, it was 
determined that frequency, intensity and type of engagement would be used. The 
duration of engagement would not add to the analysis; the content of the app included 
the virtual agent (VA) clips, which were fixed in terms of duration. Therefore, the 
following aspects were going to be measured:  
• Frequency of engagement: The frequency of engagement refers to the number of 
logins and actions for each user throughout treatment. The number of logins and 
the number of actions, referred to as tap count were obtained for each user.  
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• Intensity of engagement: This measure helped establish the parts of the app that 
were visited by each user. For this project, this revealed which information sections 
and supportive functions of the app were visited (see figure 3.4, p. 112), as well the 
individual items that were accessed during these visits (i.e., VA clips and links to 
external resources). Another important measurement was the items viewed by each 
user in relation to the total items available through the app (referred to as usage 
intensity).  
• Type of engagement: This refers to whether a user engaged with the app in an 
active or passive manner. Active use implies inputting data such as using the triage 
survey, making notes or setting appointments, while passive use entails using the 
app to retrieve information (e.g., watching the avatar clips, tapping on links). As the 
project was not concerned with clinical data (e.g., Triage assessment outcomes, 
symptoms, appointments etc.), it was determined that the content of user entries 
would not be visible to the research team. The analytics would indicate whether 
users visited such sections and inputted data, but they wouldn’t reveal what was 
recorded in the app and/or the Triage survey. In this way, it was be possible to 
determine the proportion of active versus passive use of the app without 
compromising users’ confidentiality.  
Acquisition of usage data 
The version of Manage your Health that was used in the pilot testing had its interface 
connected to Google Analytics (GA). GA is the most commonly used third-party data 
tracking service in eHealth and mHealth interventions (Crutzen, Roosjen and Poelman, 
2013) and can provide information such as the time that individual users interacted 
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with an intervention, the pages visited and the frequency of use. As GA would provide a 
detailed account of the desired usage data, it was determined that it would be used for 
this purpose.  
Analysis of usage data 
In their work, Short et al. (2018) pointed out that a detailed plan of usage data analysis 
should ideally be established before the acquisition of data. Yet, there was no 
consensus with regards to the methods that should be used for analysing usage data in 
mHealth. Some studies used descriptive measures in order to outline how users utilised 
their interventions (Couper et al., 2010; Glasgow et al., 2011; Mohr et al., 2013), while 
others made correlations between the intensity of use and clinical endpoints such as 
weight reduction (Arden-Close et al., 2015) or aspects such as satisfaction with the 
intervention (Baltierra et al., 2016). Considering these studies, the following analysis 
methods would be deployed: 
• Frequency of engagement: This included the number logins per user and the 
number of actions (tap count) undertaken by each user during a login. A total tap 
count would be presented for each user, which would be further broken down to 
tap count before and after the first dose of chemotherapy. Tap counts for each 
information section of the app would also be presented each user, which would be 
also broken down to before and after treatment to explore potential differences in 
the types of information accessed between these phases. The range (lowest and 
highest) mean (or median) and frequency of engagement (number of logins and tap 
count) would be used to summarise the findings for the participant cohort.  
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• Intensity of engagement: Proportion of unique items in relation to the total number 
of items provided (expressed as a percentage) for each user 
• Type of engagement: Proportion of active versus passive use per user 
• Correlations between the tap count and a) mean information needs, b) mean 
satisfaction with information and c) usability score (per user). 
5.3. The qualitative strand  
As mentioned earlier (p. 144), qualitative methods can also be applied for evaluating 
mHealth interventions. Short et al. (2018) identified three approaches namely 
interviews, think-aloud and focus groups. Think aloud entails asking users to reflect 
upon their experiences whilst using the intervention in real-time and capturing their 
perspectives at that time. This approach was not suitable for this project, as the 
participants of the study were going to be given the app to use in their discretion.  
Focus groups have been defined as “a form of group interview that capitalises on 
communication between research participants in order to generate data” (Kitzinger, 
1995, p.299). This method is fundamentally different from group interviews, as it 
depends upon the interaction between the group members (typically 6-8 strong) to 
address the research objectives. Participants present their personal views, but they also 
hear other perspectives, oppose or accept viewpoints and even refine their own, 
ultimately generating rich data, unlike interviews where comments are mediated 
exclusively by the interviewer (Finch and Lewis, 2003). In the context of this project, the 
limited availability of patients was a major logistical obstacle for organising a group 
discussion. As the study participants were going to be approached at specific time 
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points in their treatment (see 5.5.1 for further details), putting together a discussion 
group was impractical.  
In qualitative research, interviewing is the most widely-used data collection method 
(Jamshed, 2014). Interviews enable researchers to elicit narratives in order to construct 
a detailed account of participants’ lived experiences, which allows for achieving a 
thorough understanding of their perspectives (Gray, 2018). As this study was concerned 
with participants’ perceptions around the app, this method would help obtain 
information- rich data towards achieving a better understanding of the reasons that 
encouraged or discouraged them from using the intervention. Interviewing participants 
was also necessary in order to obtain recommendations for improving the intervention. 
Hence, it was determined that interviews would be deployed to meet these objectives.  
According to Ritchie et al., (2014) there are three types of interviews, namely 
structured, semi-structured and unstructured interviews. Structured interviews are 
commonly deployed in quantitative research, as they are highly standardised, while 
semi-structured and unstructured interviews find much wider application in qualitative 
research. With respect to unstructured interviews, Jamshed (2014) pointed out that 
they resemble more of a conversation rather than an interview due to the lack of a pre-
defined set of questions. Semi-structured interviews on the other hand have a 
discussion guide, but they unfold in a conversational manner and enable the 
interviewees to explore matters that are significant to them. This in turn enables the 
interviewer to alter the order of the questions and add or omit questions according to 
previous findings. To maintain focus but at the same time allow for modifications in the 
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interview schedule, it was decided that semi-structured interviews would be deployed 
with study participants. 
Although clinicians were already involved in the development phase of the intervention, 
their experiences with patients who used the intervention were key towards better 
understanding the effects of the app within the patient cohort. Furthermore, clinicians’ 
views for improving the app after witnessing its effects in practice were also important. 
Hence, it was determined that interviews would be conducted with the clinicians of the 
research team. These interviews would also follow a semi-structured fashion. 
5.3.1. Semi-structured patient interviews 
A semi-structured interview guide (SSIG) was crafted to guide the interview process. 
The questions included in the guide were framed in an open-ended manner in order to 
allow for the acquisition of in-depth perspectives from the participants. The choice of 
questions was influenced not only by the research objectives, but also by relevant 
literature, as a degree of familiarity with a particular subject area is necessary in order 
to decide upon the most appropriate topics for discussion (Kelly, 2010). The SSIG 
included the following discussion topics: 
• General perspectives and experiences from using the app: This topic was 
concerned with how the intervention was used before and after the first cycle of 
treatment. The purpose was to explore what the app offered to users, how it 
was used in relation to other sources of information and which sections were 
most relevant to the users.  
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• Usability of the app and perspectives on the virtual agents: As Brooke (2013) 
pointed out, the SUS (5.2.2) is not a diagnostic tool. This means that while it can 
reveal problems related to usability, it does not have the capacity of explaining 
why such issues exist. In this case, it was determined that in-depth accounts 
would help clarify any usability-related issues. The items of the SUS served as a 
guide for formulating open-ended questions that would allow participants to 
reflect upon any issues they experienced whilst using the app. After exploring 
this, the participants would be asked to reflect upon how the inclusion of the VA 
influenced the app. 
• Satisfaction with information: While this aspect would be explored using a 
questionnaire, (5.2.1) this instrument wouldn’t offer indication on issues such as 
the framing or the level of detail of the information provided. Participants would 
hence be asked to reflect upon aspects of the content (organisation, amount, 
appropriateness) and offer recommendations for improving it for future 
patients. 
• General recommendations for improvement: Participants would be asked to 
offer any recommendations to improve the app that was given to them.  
• Overall study experience (pilot study only): This discussion point was concerned 
with the appropriateness of the study design and the research methods. 
Participants were asked to comment on their overall study experience in order 
for the CI to identify issues that had to be addressed before proceeding to the 
main study. 
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In structured interviews, the interview guide must remain unchanged, since the 
purpose of deploying such method is to obtain standardised responses from the 
participants (Stuckey, 2013). In contrast, the flow of a semi-structured interview is not 
determined by the guide but rather, the conversation itself is what drives the process. 
Furthermore, alternations can made for particular participant cases so that the SSIG can 
be further refined during the course of a research project. The aforementioned 
discussion points were going to be piloted and the SSIG would be updated by 
considering salient points raised by the interviewees before proceeding to the main 
study (Kallio et al., 2016). 
5.3.2. Semi-structured clinician interviews 
The semi-structured clinician interviews would be conducted at the end of the main 
study. This was decided in order to allow sufficient time for clinicians to interact with 
patients who used the app. The semi-structured clinician interview guide (available in 
appendix 3) included four discussion topics: 
• Experiences with patients who used the app 
• Observed changes in patients’ knowledge 
• Observed effect on consultation time  
• Personal views and recommendations for improvement  
5.3.3. Interview technique 
Interviews can be conducted in a number of ways. The most commonly utilised 
interview modes (also referred to as techniques) are face-to-face and telephone 
interviews (Adhabi and Anozie, 2017). Each approach is accompanied by certain 
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advantages, as well as drawbacks (Opdenakker, 2006). For instance, while face-to-face 
interviews can be resource-consuming and time-demanding, they are capable of 
producing rich data and detailed accounts of participants’ perceptions and thus remain 
the ‘gold standard’ in qualitative research (McCoyd and Kerson, 2006). On the other 
hand, telephone interviews are regarded as more time and resource-efficient, but have 
also received criticism regarding the depth of data they generate (Opdenakker, 2006).  
Novick (2008) noted that while the effect of modality upon the interview process has 
been documented and examined thoroughly in the context of survey research, the 
differences between telephone and face-to-face interviews have not been explored in 
an equally extensive manner in the domain of qualitative inquiry. The author suggested 
that qualitative researchers might hold certain bias against telephone interviews due to 
potential issues arising as a result of the absence of visual and social ques (e.g., visual 
contact with the interviewee, body language, build of rapport). These issues concern 
losses in contextual, verbal and/or non-verbal data, as well as distortion of verbal data.  
Apart from the theoretical considerations, there were also practical aspects that were 
taken into account in order to decide upon the mode of interviews. Bryman (2012) 
pointed out that telephone interviews might not be an appropriate choice for 
interviews that aim to run for a long time, as they can be more easily terminated by the 
interviewees when compared to face-to-face interviews. Some authors have also noted 
that telephone interviews can be shorter in duration, as participants tend to talk less or 
be less willing to ‘take the stage’ (Irvine, 2011; Irvine, Drew and Sainsbury, 2013).  
Considering the points presented above, it was determined that face-to-face interviews 
were the most appropriate mode for meeting the study objectives.  
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5.3.4. Recording and transcription of interviews 
Keeping an accurate record of interviewees’ accounts was another key consideration. 
According to Kelly, (2010) audio recordings are the best way to document the findings 
of an interview. Note-taking is another way of captivating participants’ responses but 
suffers from several important drawbacks. First and foremost is that the reconstruction 
of an interview through notes is highly susceptible to recall bias on the behalf of the 
researcher, which can compromise the quality of the results. Taking detailed notes 
whilst undertaking an interview can also cause disruptions, hinder the researchers’ 
attention to the conversation and inhibit aspects of interaction such as eye contact. 
Hence, it was determined that audio recordings of the semi-structured interviews 
would be obtained, after promptly obtaining consent from the participants (6.5).  
According to Opdenakker, (2006) the use of recording equipment does not mean that 
researchers shouldn’t make any notes during an interview. Keeping brief notes can help 
track key points such as which questions were addressed and/or any issues 
encountered during the interviews. For each interview, the author would make brief 
notes of significant aspects and review them at the end of each interview in order to 
consider making any necessary modifications to the interview guide.  
Transcription was another key consideration. While performing the transcription 
process would help the researcher to better familiarise himself with the data, such 
activity would be unfeasible considering the project’s timeline. The transcription of 
interviews can be a particularly lengthy process; Gale et al. (2013) proposed that a 60-
minute interview can produce a 15 to 30 page-long transcript. Hence, it was decided 
that recordings would be sent to a dedicated transcription company used by the School 
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of Pharmacy (Keele University). In order to compensate for the investigator’s (AC) 
absence of involvement in the transcription process, the investigator would listen to the 
recordings whilst reading the transcripts. 
5.3.5. Analysis of interviews 
Smith and Firth (2011) proposed three categories of methods used for analysing 
qualitative data. The first was socio-linguistic methods, which are concerned with the 
use of language and the meanings that can be derived from it (e.g., discourse and 
conversation analysis). The second was theory-developing methods, typically involving 
the use of grounded theory and last (but certainly not least), the methods used for 
describing and interpreting views such as content and/or thematic analysis. Vaismoradi, 
Turunen and Bondas (2013) proposed that the choice of the most appropriate analytical 
method should be informed by study objectives, as well as how much is known in a 
particular field of inquiry.  
Thematic analysis is a commonly deployed approach for analysing qualitative data. 
According to Braun and Clarke, (2006) it is a flexible tool that doesn’t owe allegiance to 
any particular epistemological view and can is capable of producing a detailed account 
of the retrieved data. The framework approach, a particular type of thematic analysis 
has gained considerable momentum in the social, as well as health sciences due to its 
systematic nature and capacity to produce high-quality evidence (Gale et al., 2013). 
Framework analysis has a ‘dual’ analytical character, as it begins by drawing upon the 
established set of objectives (deductive) but then proceeds to presenting the original 
accounts and perspectives of the participants (inductive) (Pope, Ziebland and Mays, 
2000). As these attributes were satisfactory from both a philosophical and a 
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methodological viewpoint, it was determined that the framework method would be 
deployed for the analysis of data derived from the semi-structured interviews.  
Gale et al. (2013) proposed a thorough process of applying the framework method. The 
authors established seven distinct stages in the analysis process. The steps are 
described briefly below: 
Step 1-Transcription: The process of transcription has already been outlined in 5.3.4.  
Step 2-Familiarisation with data: During this step, the author (AC) would use the 
recordings, as well as the accompanying transcripts and notes to ‘immerse’ in the data 
in to achieve a holistic view of what was discussed during the interviews. 
Step 3 -Coding: The author would read each transcript carefully and assign a unique 
label (i.e., a code) to relevant passages to describe important points. This step is not 
necessary for purely deductive studies; yet, as the project dealt with a relatively 
unmapped research area (the application of embodied conversational agents in cancer 
care), a certain degree of induction would help identify aspects that were not 
accounted for by the pre-set aims and objectives.  
Step 4-Development of the analytical framework: After conducting the third step for 
several transcripts, the generated codes would be organised in broad categories, which 
would then be clearly defined in order to formulate the analytical framework. Several 
iterations (i.e., going back to the data to ensure congruity) would be performed to 
refine the framework before proceeding to the next step.  
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Step 5-Application of the analytical framework: The analytical framework would be 
applied to all subsequent transcripts. Essentially, the transcripts would be annotated 
using the codes generated in steps 3 and 4 to ensure that all relevant data were 
identified. 
Step 6-Charting of data and formation of the framework matrix: The author would 
create a matrix chart for the themes and corresponding subthemes identified through 
the transcripts. This would reduce the volume of data so they could then be analysed. 
Care was would be taken to ensure that the original meanings, as well as links to the 
original data were retained across the matrix. According to the Gale et al. (2013), the 
structure of this matrix “is visually straightforward and can facilitate recognition of 
patterns in the data ... through drawing attention to contradictory data, deviant cases or 
empty cells” (p.117). 
Step 7-Interpretation: This would be the last and most important part of the analysis. 
Having the entire dataset organised into the matrix would allow for the identification of 
core concepts, as well as the establishment of association between data and 
explanations of phenomena. This would be achieved through constant comparison and 
exploration of the transcripts.   
5.3.6. Reflexivity 
Darawsheh (2014) pointed out that subjectivity is an intrinsic element in the thought 
process of all researchers and can exert an influence upon inquiry. This is central for 
qualitative research, as “qualitative researchers are not regarded as objective observers 
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of social phenomena because of their social, political and cultural positioning in the 
worlds they study” (Walker, Read and Priest, 2013, p.38).  
According to Finlay, (2002) the purpose of reflexivity is for researchers to acknowledge 
the personal values, beliefs and biases that influenced their research process and 
demonstrate how these aspects affected it. Palaganas et al. (2017) remarked upon the 
dual nature of reflexivity, which can be regarded as both a concept and a process and 
offered the following description:  
“Reflexivity pertains to the “analytic attention to the researcher's role in 
qualitative research” ... As a concept, it refers to a certain level of consciousness. 
Reflexivity entails self-awareness (...), which means being actively involved in the 
research process. It is about the recognition that as researchers, we are part of 
the social world that we study (...). Reflexivity as a process is introspection on the 
role of subjectivity in the research process. It is a continuous process of reflection 
by researchers on their values (...) and of recognizing, examining, and 
understanding how their “social background, location and assumptions affect 
their research practice”.” (pp. 427) 
Guillemin and Gillam (2004) explained that reflexivity is an ongoing process that 
expands across every stage of research continuum and ‘saturates’ it. As Smith (2006) 
noted, reflexivity does not just focus upon findings but is instead concerned with the 
entire course of inquiry including conceptualisation, design and conduct. Barrett, 
Kajamaa and Johnston (2020) emphasised upon the importance of keeping a reflexive 
account (i.e., record) throughout the course of research and continuously referring to it 
in order to warrant that the process is performed in the most efficient way.  
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It should be noted that although reflexivity is an essential component of qualitative 
inquiry, Finlay (1998) argued that it can also be of value in quantitative research. Ryan 
and Golden (2006) demonstrated how reflexivity can benefit a quantitative study while 
Walker, Read and Priest (2013) presented its application in a mixed methods 
investigation.   
Albeit the significance of reflexivity, an important consideration is whether it is applied 
in a productive manner. The first question concerns the conceptualisation of reflexivity, 
or simply; do inquirers appreciate what reflexivity is? Barrett, Kajamaa and Johnston 
(2020) pointed out that the terms reflection and reflexivity are sometimes used 
interchangeably, but are indeed different; the authors explained that while the former 
seeks to “question, evaluate and re-think practice, e.g. clinical skills”, the latter aims to 
“facilitate consideration of our understanding of culture, social realities and position” 
(p.10). In other words, reflexivity is about appreciating how our values, beliefs and 
biases shaped the way that we conduct research and influenced the interpretation of 
our findings. Understanding the differences of these concepts is pivotal so that 
reflexivity is applied effectively.  
Having captured the essence of reflexivity, the next question is the extent to which it is 
applied. In an early publication, Finlay (2002) proposed that that reflexivity has its limits. 
Drawing upon their experiences throughout their PhD course, Mauthner and Doucet 
(2003) also remarked upon the limits of reflexivity and explained that while some 
influences (and their effects) can be uttered at the time of the study, other aspects can 
necessitate more time to become evident. Instead of envisioning reflexivity as a single 
process, the authors proposed that “it may be more useful to think in terms of ‘degrees 
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of reflexivity’, with some influences being easier to identify and articulate at the time of 
our work while others may take time, distance and detachment from the research” 
(p.425). This consideration is particularly valuable for newly introduced researchers in 
order to engage reflexively with their work, but also recognise that reflexivity can 
stretch beyond an individual project.  
Despite the abundance of publications that describe what reflexivity entails, the lack of 
consensus as to how it is applied poses a challenge. Atkinson and Coffey (2002) pointed 
out that reflexivity is not a clearly defined term, the meaning of which might sometimes 
be unclear. In the context of this project, publications from nursing research and in 
particular, an article by Allen (2004) helped better appreciate how it can be applied to a 
project in the domain of healthcare. According to the authors, reflexivity involves three 
aspects, namely: 
“a concern with how the field of study is filtered through the very particular 
interpretative lens of the researcher and, as such, reflects their individual history 
and biography as well as their theoretical perspective; an acknowledgement that 
in actively participating in the field, the researcher will have an effect on the 
phenomena being researched (...); and recognition that the field will have an 
effect on the researcher (...)” (p.15) 
Reflexivity would be an essential component of the present study. Findings derived 
from the qualitative compartment of this work could not be treated as factually 
accurate, as they would constitute an amalgamation of participants’ personal accounts 
and the researcher’s interpretation (Walker, Read and Priest 2013). It was therefore 
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vital for the author to demonstrate how his views and values influenced these findings 
in order to achieve transparency add rigour.  
5.4. The relationship of the strands 
After describing the research strands and the methods nested within the each one, it is 
now necessary to explain how the strands were related to each other. According to 
Creswell and Plano Clark, (2011) there are four aspects to consider, namely “(1) the 
level of interaction between the strands, (2) the relative priority of the strands, (3) the 
timing of the strands and (4), the procedures for mixing the strands” (p.64). These 
aspects constitute core decisions for all researchers undertaking a mixed methods 
approach and will be discussed in detail below.   
• Level of interaction between the strands: Greene (2007),  suggested two types of 
interaction, namely independent and interactive. An independent relationship 
implies that the strands are distinct and that the research questions, as well as the 
processes of data collection and analysis are kept separate. In this case, researchers 
mix the two strands at the final stages of a study.  An interactive relationship on the 
other hand indicates that the research strands inform each other, and they are 
mixed before the overall interpretation step. For the present study, the research 
strands shared an independent relationship, as findings from one strand would not 
inform the design or conduct of the other. Instead, the results from each 
component would be merged at the last stage of the investigation (i.e., the 
interpretation step).   
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• Relative priority of the strands: According to Creswell and Plano Clark (2011), this 
aspect is concerned with the emphasis placed upon each strand and proposed three 
types of priorities, namely qualitative, quantitative or even priority. As participants’ 
detailed accounts of personal experiences were more important than numerical 
inferences and statistical significance, the qualitative compartment was given higher 
priority.  
• Timing of the strands: According to Creswell and Plano Clark (2011), the timing of 
the strands is “often discussed in relation to the time the data sets are collected, but 
most importantly, it describes the order in which the researchers use the results from 
the two sets of data within a study” (p. 66). The authors suggested three potential 
timings, namely concurrent (both sets of data are collected and analysed at the 
same time), sequential (one set of data is collected and analysed before the other) 
and multiphase (multiple phases including sequential and/or concurrent timing over 
a study). The qualitative and quantitative strands of this study followed a concurrent 
timing, as they run in parallel. Furthermore, the data from both strands were 
collected and analysed at the same time.  
• Procedures for mixing the strands: The core considerations here are the point of 
inference (the time point when the strands are mixed in the study) and the mixing 
of strategies (how the strands are mixed). As the qualitative and quantitative 
strands shared an independent relationship, the point of inference occurred during 
the final stage of the study.  
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Having established the research strands, their relationship and the methods nested 
within them, it is now necessary to present how these methods were applied. The next 
section will present the study’s design.  
5.5. Study design 
In order to prevent adding burden at a sensitive point of treatment and avoid additional 
hospital visits, the study design was influenced by the treatment schedules of the 
participating patients. Hence, before presenting the study design, it is necessary to 
explore the patient journey in standard care.  
5.5.1. Patient journey in standard care 
The pilot phase of the study involved patients with colorectal cancer (CRC) receiving 
chemotherapy with XELOX (Capecitabine and Oxaliplatin) for the first time. XELOX is a 
combination treatment, which is administered in three- week cycles. On the first day of 
each cycle (fig. 5.2), patients have to attend the treatment centre to be given an 
intravenous (IV) dose of Oxaliplatin, followed by fourteen days of oral Capecitabine 
taken twice daily (BD). The last week of the cycle does not involve any chemotherapy 
medicines.  
Before the initiation of treatment, patients are seen by a consultant oncologist at the 
Churchill Hospital. During this appointment, the consultant explains various aspects of 
chemotherapy to the patients and consented them for chemotherapy. Then, patients 
have to attend the hospital’s Day Treatment Unit (DTU) to receive their first dose of 
treatment. During the last week of the first treatment cycle, patients have to attend the 
hospital for a review appointment.  
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Figure 5.2: Treatment cycle with XELOX 
 
 
The cycle presented above represents the average patient journey in standard care. 
Depending upon the availability of seats in the DTU, patients might have had to initiate 
their treatment earlier or later than 3-4 weeks after their pre-chemotherapy 
consultation. The treatment sequence can be altered according to the patient’s 
response to the chemotherapy. For instance, patients who experience considerable 
toxicity may have additional treatment-free time and/or can be invited to attend a 
review appointment sooner. Nevertheless, as the core components of the cycle (pre-
treatment phase, first dose and follow-up) are consistent for every patient receiving this 
regimen, the treatment schedule was used as a guide for informing the study design.  
5.5.2. Provision of the intervention and administration of the data collection tools 
Considering the timings discussed in 5.5.1, the following study schedule was applied:  
• Recruitment, provision of the intervention and baseline questionnaire: Potential 













(three to four weeks before the first dose of treatment), where they were screened 
for eligibility and then offered a place in the study. If they agreed to take part, 
participants were asked to provide written consent and were then given a unique 
access code for the app, alongside the baseline questionnaire.  
• Pre-chemotherapy interaction phase: During this time, the participants were free to 
utilise the app before their first chemotherapy appointment; usage data were 
collected throughout this period.  
• Provision of the post-exposure questionnaires: Participants were given the post-
exposure questionnaires (satisfaction with information and usability) to complete 
either at the clinic or from home. These questionnaires were provided at the DTU 
on the day of the first chemotherapy appointment by either the author (AC) or a 
member of the research team.  
• Post-chemotherapy interaction phase: Participants were be free to utilise the app 
before their review appointment. During this time, usage data were also collected.  
• Semi-structured participant interviews: On that day, participants were invited to 
attend a semi-structured interview after the end of their first review appointment. 
In order to prevent adding burden to the participants, the interviews were 
conducted at the Churchill Hospital upon the date of their review appointment. 
Patients were contacted a week in advance in order to confirm their attendance and 
arrange for a suitable time.  
Again, this schedule depended upon the treatment schedule for each participant and 
was therefore affected by any alterations made in patients’ treatment schedules.  The 
overall study design is summarised in figure 5.3.  
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Figure 5.3: Participant study journey 
 
Considering each individual participant journey, there was a clear quantitative phase 
(baseline questionnaire, post-exposure questionnaire and analytics of use) succeeded 
by a qualitative phase (semi-structured interviews), indicating that the quantitative and 
qualitative strands were conducted in a sequential manner. Yet, as this project was 
comprised by a series of individual participant journeys which run in parallel, 
quantitative and qualitative data were collected and analysed concurrently. Hence, 
although the quantitative and qualitative phases were conducted in a sequential 
manner for each participant journey, the study as a whole followed a convergent 
parallel design.  
5.6. Study population and eligibility criteria 
As patients with different types of cancer can potentially express unique information 
needs (Nagler et al, 2010), the study focused upon a single form cancer and a specific 
treatment approach to ensure homogeneity across the participant cohort.   
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All patients were recruited from the Churchill Hospital. In order to be able to enter the 
study, potential participants had to fulfil all of the following eligibility criteria:  
• 18 years or older 
• Able to provide consent to the study 
• Understood written and spoken English 
• Had an established diagnosis of CRC, irrespective of stage 
• Eligible to receive XELOX 
• Were chemotherapy-naïve (i.e., didn’t receive chemotherapy in the past) 
• Had (and were able to use) a smartphone or tablet that can accommodate our app 
(the app was compatible with both iOS and Android software). Potential candidates 
who didn’t possess such a device were still able to take part in the study as long as a 
caregiver, a partner or a member of their family had an appropriate device and was 
willing to help. 
5.7. Sample size 
As there was no intention of drawing inferences from the study cohort, no formal 
sample size calculations were performed (Schmidt, Lo and Hollestein, 2018). Instead, 
the sample size depended upon the number of interviews required to reach data 
saturation, which has been defined as “the point at which no new information or 
themes are observed in the data” (Guest, Bunce and Johnson, 2006, p.59) 
While the number of interviews needed to achieve data saturation cannot be 
determined a priori, it is possible to estimate an approximate figure by drawing upon 
existing research (Vasileiou et al., 2018). Previous qualitative studies in the field of 
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mHealth have demonstrated that saturation can be reached with as few as 9 (Fleming, 
Hill and Burns, 2017) to as many as 30 interviews (Goetz et al., 2017). It was therefore 
estimated that approximately 20 in-depth interviews would likely be needed for the 
present project. Assuming that half of the participants who used the app would agree 
to be interviewed, the sample size was estimated to be 40 patients; if saturation was 
established with fewer interviews, the researcher would seize to recruit further 
participants. 
The above considerations concerned the sample size for the main investigation phase of 
the project. The sample size of the pilot investigation was 10% of the estimated sample 
size of the main study (i.e., 4 patients).          
5.8. Sampling strategy  
Teddlie and Yu (2007) grouped sampling techniques in four broad categories; 
probability, non-probability (also referred to as purposive), convenience and mixed 
methods sampling. Probability sampling is primarily deployed in quantitative research, 
since the ultimate goal is representativeness (Bryman, 2016). In contrast, non-
probability sampling is used mostly in qualitative research, as units are selected due to 
the presence of specific characteristics that allow for detailed exploration of the aspects 
which a researcher wishes to investigate (Ritchie et al., 2014). Convenience sampling is 
a technique where the sample is drawn entirely according to the availability of 
resources (Kemper, Stringfield and Teddlie, 2003), while mixed methods sampling is 
generally reserved for mixed methods studies, where researchers can combine more 
than one sampling approach to acquire the desired sample (Teddlie and Yu, 2007). 
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The pilot study deployed convenience sampling, as the goal was to involve a small 
number of patients and therefore all individuals who fitted the inclusion criteria were 
eligible for inclusion irrespective of other characteristics. The sampling strategy for the 
main study was nested mixed methods sampling; for the quantitative strand, patients 
were acquired through convenience sampling while purposive sampling with maximum 
variation was used to obtain participants for the qualitative compartment.  
5.9. Informed consent 
All participants were asked to provide written informed consent (appendix 4). As this 
project did not involve an experimental treatment, a medical device or a surgical 
intervention, potential participants could provide consent on the day they were 
approached. All potential participants were provided with an invitation letter (appendix 
5) and a participant information leaflet (appendix 6) and had the opportunity to ask any 
questions they might had. If potential participants needed time to consider their 
options, they were given the consent form, alongside with a pre-paid envelope and the 
information material and were contacted 2 days after the invitation to state their 
decision. Those who agreed to participate were given a unique access code to install the 
app on their device(s) of choice and asked to return a signed copy of the consent form, 
a completed copy of the information needs and demographics questionnaire.  
Interview participants were asked to provide separate written consent for the 
interviews; this applied to both patients (appendix 7) and clinicians (appendix 8). The 
interviewer (AC) would explain the points outlined in the consent document and answer 
any queries before obtaining consent.  
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5.10. Research ethics and ethical approvals 
Appropriate measures were in place to ensure that this project run in line with the 
Good Clinical Practice (GCP) guidelines and was conducted under high ethical standards. 
The project lead (AC) received appropriate training in GCP, as well as qualitative 
interviewing prior to approaching and interviewing participants. Expert advice was also 
sought by Dr Alison Gifford on interview practices.  
As the project involved patients, ethical approval was required prior to the 
commencement of research activities that would involve study participants. The project 
lead (AC) liaised with Keele Research Governance and submitted the required forms 
through the Integrated Research Application System (IRAS). The study received ethical 
approval by the Health Research Authority (HRA) of England and Whales on the 4th of 
May 2018. The letter of HRA approval is available in appendix 9.  
In the original proposal, the author stated that participants would be able to put a two-
step authentication process in place (i.e., app password lock). Following further 
discussions with the development team, it was determined that this would not be 
feasible. Instead, participants would be advised to utilise their device’s security 
measures (i.e., password lock) in order to protect any personal data that they might 
entered into the app, such as appointment dates and/or any notes. As this constituted a 
major amendment in the original proposal, a notice of substantial amendment was 
submitted to IRAS, which received approval on the 19th of June 2018 (appendix 10).  
5.11. Chapter summary  
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The present chapter outlined the methodological considerations for the evaluation of 
the project’s intervention. Instead of making a forced decision between qualitative and 
quantitative research, it was determined that a mixed methods approach would be 
followed. Each participant journey would include a quantitative phase, which would 
then be followed by a qualitative phase. The data collection methods of the quantitative 
phase were questionnaires (baseline and post-exposure) and usage data, while semi-
structured interviews would be used to collect in-depth data in the qualitative phase. 
The order and timing of the administration of these methods were determined by 
considering the chemotherapy treatment cycle (XELOX). The next chapter will 




Chapter 6: Pilot Study  
Chapter 5 presented the core methodological considerations for evaluating the 
project’s intervention and outlined the methods for acquiring the desired study data. 
The present chapter will outline the conduct of the project’s pilot study. The chapter 
will begin with an outline of the aims and objectives of this preliminary investigation 
and will then present the results obtained from this phase. The findings will then be 
discussed, followed by their implications for the main investigation.   
6.1. Rationale and aims 
Researchers who plan to undertake large projects or conduct studies with elaborate 
designs need to ensure safety and robustness prior to initiating their inquiry. According 
to Arnold et al., (2009) pilot studies are an excellent way of determining such aspects 
before proceeding to large-scale investigations. Thabane et al. (2010) referred to pilot 
studies as vanguard trials or feasibility studies and provided a comprehensive list of the 
reasons for conducting such investigations, as well as the benefits they can offer.  
While some researchers use the terms pilot and feasibility interchangeably, Eldridge et al. 
(2016) pointed out that these are in fact distinct. According to the authors, a feasibility 
study is a type of research whose purpose is to determine whether or not is possible to 
conduct a particular project, while a pilot study is a smaller version of a large investigation 
whose purpose is to indicate if the various components of a large investigation can work 
together.  
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Since the question of feasibility was addressed during the Patient and Public 
Involvement and Engagement (PPIE) interviews, it was determined that a pilot study 
was going to be the next step in this project. Conducting a pilot study was necessary not 
only for establishing the robustness of the proposed methodology for evaluating the 
app, but also for providing insight as to the appropriateness of the app itself.  
6.2.  Objectives 
Several authors have remarked upon the erroneous focus that is often placed upon 
hypothesis testing and assert that the objectives of pilot studies are different from those 
of main investigations (Arain et al., 2010; Whitehead, Sully and Campbell, 2014). This is 
also mentioned in the Medical Research Council’s (MRC) guidance for developing and 
evaluating complex interventions, where the importance of understanding the context in 
which such interventions are applied is emphasised (Craig et al., 2008).  
Considering the above, the purpose of the pilot study was not to solely perform an 
evaluation of the project’s intervention; while receiving initial feedback from app users 
was an important outcome, the main focus of this investigation was to establish the 
robustness of the proposed methodology and study design. Hence, the specific objectives 
involved the following:  
a) Assessment of recruitment potential  
b) Establishment of the appropriateness of the data collection methods and study 
design 
c) Determination of logistical aspects  
d) App-related feedback and recommendations for improvement  
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e) Identification of technical errors   
6.3. Methodology 
The methodological considerations have been presented in chapter 5. The following 
sections will briefly outline the participants, the study design, the methods and the 
analysis plan.  
6.3.1. Participants  
The participants of the pilot study were chemotherapy-naïve patients with colorectal 
cancer (CRC) who were going to receive their first cycle of treatment with Oxaliplatin 
and Capecitabine (XELOX). The eligibility criteria are described in detail in chapter 5 (p. 
167). All participants were recruited from the Churchill Hospital (OUH) from September 
2018 to December 2018. The sample size for the pilot study was 4 patients (i.e., 10% of 
the target for the main study).  
6.3.2. Study design and research methods 
The study design and research methods are discussed in detail throughout chapter 5. 
The pilot study followed a convergent parallel mixed methods design, where 
quantitative and qualitative data were collected concurrently. The pilot study was 
essentially comprised by a series of individual participant journeys, which run in parallel. 
Each participant was given the app approximately 3-4 weeks before the first cycle of 
treatment, alongside a baseline questionnaire (information needs and demographics). 
On the day of their first chemotherapy appointment, participants were given a set of 
post-exposure questionnaires (satisfaction with information and degree of usability) 
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and were finally invited to attend a semi-structured face-to-face interview at the 
Churchill hospital on the day of their review consultation. Analytics of use (i.e., usage 
data) were acquired for each participant from the point of download until the day of 
the interview. The overall study journey for each participant is depicted in figure 5.3 (p. 
166).  
6.3.3. Data analysis 
Descriptive statistics (min, max, means and SD) were used for analysing data derived 
from the questionnaires exploring information needs and satisfaction with information 
(pp. 139-140). The scores obtained from the usability questionnaire were analysed 
according to Brooke's (1996) typology, which is outlined in chapter 5 (pp. 141-142). 
Descriptive statistics (frequencies and percentages) were be used to analyse the usage 
data (pp. 147-148). Data obtained from the participant interviews were analysed using 
the framework method. This process is described in detail in chapter 5 (pp. 156-157).  
6.4. Results 
Four patients were approached, all of which agreed to take part in the study. The mean 
age was 70.5 years and the male: female ratio was 3:1. All participants were retired and 
married. While health literacy was high, IT literacy was modest. Table 6.1 contains a 
summary of the participants’ characteristics.  
All four participants returned the baseline questionnaire and the System Usability Scale 
(SUS) and only one didn’t return the satisfaction with information survey. Out of the 
four participants, three agreed to be interviewed at the end of their treatment cycle. 
The interview times ranged from 45 to 80 minutes (mean 62 minutes). The interviewees 
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were all male above the age of 60. The participants were coded as PS1, PS2 and PS3 for 
the purpose of presenting relevant quotations.  
Table 6. 1: Demographic data (n=4) 
 n %  n % 







































Marital status  Employment status  
Married 4 100 Retired 4 100 
Educational level  Past treatment  
Secondary education 
Higher education 













6.4.1. Recruitment potential 
Although patients were willing to participate, the number of individuals treated with 
XELOX was much lower than expected. According to the hospital’s records, 82 patients 
received XELOX from April 2017 to March 2018. The team expected that six to seven 
new patients would be seen at the CRC department on each month, but only four 
patients were identified in the span of four months (September- December 2018).  
Apart from the issue described above, some patients were missed due to unforeseen 
circumstances. At the time of the pilot study, the author contacted the oncologists one 
day before the colorectal clinics to check if any eligible patients would be available the 
following day. Yet, some patients were missed due to last-minute changes in the 
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chemotherapy schedule (i.e., from another treatment to XELOX) on the day of the 
clinics. With the exception of including only patients receiving XELOX, the remaining 
eligibility criteria were considered to be appropriate.  
6.4.2. Appropriateness of research methods and study design 
The appropriateness of methods and study design were determined by keeping 
fieldnotes and obtaining participants’ insights. Participants were asked to express their 
views upon the study design and the data collection methods during the semi-
structured interviews. This included three areas, namely the process of approach and 
invitation, the timing of the provision of the data collection tools (i.e., study design) and 
the perceived appropriateness of the data collection tools administered to them. The 
findings are presented below.  
Approach and invitation to the study 
Patients reported being comfortable with being approached after their pre-
chemotherapy appointments, but one participant explained that this time might not be 
appropriate for patients in distress. The participant proposed that such patients could 
be contacted via phone at some other point, but also suggested that eligible patients 
would be more likely to agree to take part in the study if recruited face-to-face.  
“you don’t get quite the same commitment that you would get if you see 
somebody and then you get them to sign on the bottom line there and then and 





None of the participants thought that the study design interfered with their treatment 
schedules. The last patient explained that being on chemotherapy had a limiting effect 
upon normal activities and as a result, there was more free time that could be 
dedicated towards research. At the same time, the participants appreciated that other 
patients could potentially be overwhelmed by the study requirements and lose interest, 
especially if they didn’t understand what benefits it could offer.  
“...at the moment I’ve got the time and so I’m happy to help you.  I know that 
you’re just trying to improve things at the end of the day.” PS1 
Data collection methods 
The questionnaires were received well, and no comments were made with regards to 
the clarity of the items or the length of the surveys. One view was that certain items of 
the information needs and satisfaction with information questionnaires gave the 
impression of overlapping, but no specific items were mentioned. All questionnaires 
were completed from home and posted to the hospital using the pre-paid envelopes 
provided. One patient did not complete the satisfaction with information because the 
app wasn’t used enough in order to be able to assess how well it addressed the items 
listed on the survey. With respect to the interviews, all participants felt that the 
interview schedule was appropriate.  
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While the reliability coefficient (Cronbach’s alpha) was acceptable for the baseline 
questionnaire (0.77) and the SUS (0.85), the satisfaction with information questionnaire 
had a low score (0.36), which was indicative of reliability issues for this instrument.  
Major issues were evident for the analytics of use, as only one set of usage data (i.e., a 
single user profile) was identified through Google analytics. This was because the host 
platform (Manage your Health) had a large number of users and the search function did 
not allow for identifying profiles related to the Bowel Cancer version. An attempt to 
identify the user profiles was performed by using the dates in which patients were 
enrolled, but as most of them (3/4) installed the app on different dates at their homes, 
it was not possible to locate them within the entire dataset of Google Analytics. As the 
remaining three user profiles could not be identified, it was not possible to perform a 
formal analysis of such data in SPSS. An informal analysis of the single user profile 
indicated that the patient used the app four times before receiving treatment. During 
these incidents, the user explored different sections of the app. Treatment-related 
information (Sections 2, 3 and 4) received most visits.  
6.4.3. Logistical considerations 
The logistical considerations included the potential changes in the treatment cycles, the 
administration and receipt of the post-exposure questionnaires, and the conduct of 
interviews.  
Changes in treatment cycles  
Fieldnotes revealed that changes in participants’ treatment schedules and hospital visits 
were common. This included the date of the first dose of chemotherapy, as well as the 
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date of the initial chemotherapy review appointment. This was because of treatment-
related aspects (e.g., poor response to the chemotherapy), as well as logistical issues 
(e.g., limited availability of seats in the hospital’s day treatment unit).   
Administration and receipt of questionnaires  
The proposed mode of administration (i.e., provision by a member of the research 
team) and receipt was feasible.    
Conduct of interviews  
Several issues were encountered with regards to the timing and location of the 
interviews. These issues were associated with both the availability of patients, as well as 
venues for conducting the interviews. The first patient could not allocate time on the 
day of the review appointment and was interviewed during his second treatment 
appointment at the hospital’s day treatment unit (DTU) instead. The second patient was 
also interviewed at the DTU at the second chemotherapy appointment, as the chief 
investigator was not able to attend the hospital on the day of the patient’s review 
appointment.  
6.4.4. App-related feedback 
While some feedback regarding the app was obtained through the questionnaires (e.g., 
SUS and satisfaction with information), the interviews allowed for obtaining in-depth 
insight as to patients’ views on the app. The sections below will present findings related 
to the app derived from the questionnaires and the semi-structured interviews.  
General perspectives about the app 
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The participants who used the app believed that it was a valuable tool to have during 
their treatment.  All users agreed that the app offered a good starting point where they 
could receive some initial information and could then utilise other resources if they 
wanted to examine things at greater depth. Another view was that the app was a good 
reference point for revising information. One participant remarked upon the portability 
of the app, which was also perceived to be more directed than other sources of 
information.  
“...if you were starting from scratch knowing nothing, it would be quite handy, in 
a sense, to kind of - you know, go into it and it gives you some information and if 
you need more, then you think, 'Oh, I need a bit more,' and then you go and look 
somewhere else...” PS3 
The role of family emerged as an important theme. All participants demonstrated the 
app to their family members and recalled positive reactions. One participant explained 
that his wife encouraged him to use the app.  
“... [my wife] encouraged me to use it more because it’s more relevant to me. 
(…).  I’m the one who is going to be taking on the consequences of it and so I 
tried to use it a lot prior to starting the treatment and during it.” PS1 
Another participant recalled sharing the app with friends, who appeared to be 
fascinated about it. 
“Yeah, friends.  Just showed them, you know, especially the avatar.  A lot of them 
were quite fascinated by that [laughter].”  PS3 
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Degree of usability  
The overall user experience would be considered to be just above average, as the mean 
SUS score was slightly over 68. An SUS score above 68 indicates an average user 
satisfaction and marginal acceptability (high end), as shown in figure 5.1 (see p. 142) 
The organisation of the content (i.e., the thematic grouping of information) was 
deemed to be reasonable. All participants agreed that navigating through the content 
was easy and did not impede the process of identifying the desired information. The 
degree of usability was satisfactory, as none of the users recalled having difficulties 
while using the app. Furthermore, none of the participants provided recommendations 
for improving this aspect. 
“I think, in general, it's quite obvious how it works. I didn't find any difficulty in 
terms of knowing what I needed to do to get to where I needed to be in the app.” 
PS3 
Although participants suggested that the app could be of benefit to fellow patients, 
they also pointed that some elderly patients might struggle with using it due to a lack of 
familiarity with this technology. However, they suggested that younger caregivers and 
family members could help patients use the app. 
Information needs and satisfaction with information/content 
The information needs of the patient cohort were high, with the means from each item 
ranging from 2.50 to 5.00. Ratings regarding the importance of each item are presented 
in table 6.2. The most important piece of information was knowing which side effects to 
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report to the doctors, followed by information regarding metastasis, recurrence, 
diagnostic tests and contacts for healthcare professionals. The least important piece of 
information was the availability of financial support, followed by information about 
emotional support due to concerns over physical attractiveness. In addition to 
questionnaire results, data on information support was also obtained from the 
interviews.   
One participant focused upon information regarding existing issues and wasn’t 
interested in having information about things that haven’t occurred yet. Another 
patient explained that although theoretical information such as the aetiology of cancer 
was important, practical aspects such as dealing with side effects were more relevant. 
Focusing upon positive information avoiding unpleasant aspects was also evident. One 
individual reflected upon a leaflet given as part of standard care that listed all possible 
side effects and explained that it was particularly distressing.  
“But it’s a frightening list because you think – I couldn’t even read it, there was 
so many things, you might as well go and drop dead than have all those things 
happening to you.” PS2 
Patients also mentioned the sources they used to retrieve information. Two participants 
utilised multiple sources including the app, while the third participant relied largely 
upon the recommendations given by the oncologist, as well as existing knowledge.  
The data obtained from the satisfaction with information questionnaire suggested that 
the participants were generally content with the information provided through the app 
(table 6.2). The means ranged from 2.33 to 4.67 and most items received an above   
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Table 6. 2: Information needs and satisfaction with information 
 How important is for you to 
have each of the following 
types of information? 
Which of the following  
best describes how well the need 
was addressed through the app?  
 n Min Max Mean SD n Min Max Mean SD 
How I will feel during or after the tests 4 4 5 4.75 0.50 3 3 5 4.00 1.00 
If the bowel cancer will come back 4 4 5 4.75 0.50 3 4 4 4.00 0.00 
How to prepare for my treatment 4 4 5 4.50 0.58 3 3 4 3.33 0.58 
How I will feel after my treatment 4 4 5 4.50 0.58 3 4 5 4.67 0.58 
Who to call if I have questions while I am still getting 
treatment 
4 4 5 4.75 0.50 3 3 4 3.67 0.58 
How bowel cancer acts in the body 4 4 5 4.50 0.58 3 3 4 3.33 0.58 
If there are groups where I can talk with other people with 
cancer 
4 2 5 3.50 1.29 3 2 5 3.67 1.53 
If there are ways to prevent or ease side effects of treatment 4 4 5 4.50 0.58 3 3 4 3.67 0.58 
How the illness may affect my life over the next few months 4 4 5 4.50 0.58 3 2 4 3.33 1.15 
If there will be changes in usual things I can do with or for my 
family 
4 3 5 4.50 1.00 3 2 5 3.67 1.53 
If there is cancer anywhere else in my body 4 4 5 4.75 0.50 3 3 5 4.00 1.00 
Who to call if I have questions after all the treatments are 
over 
4 4 5 4.50 0.58 3 3 4 3.67 0.58 
If it is known what causes bowel cancer 4 2 5 3.50 1.29 3 3 5 3.67 1.15 
How the tests are done 4 3 5 4.00 0.82 3 4 5 4.33 0.58 
Why do they need to test my blood 4 3 5 4.00 0.82 3 3 5 4.00 1.00 
Who to talk to about treatment other to 
surgery/chemo/radiotherapy 
4 3 5 3.75 0.96 3 3 4 3.33 0.58 
How the illness may affect my life in the future 4 4 5 4.25 0.50 3 3 4 3.67 0.58 
What the results of my blood tests mean 4 4 5 4.50 0.58 3 2 5 3.67 1.53 
Where my family can go if they need help dealing with my 
illness 
4 4 5 4.50 0.58 3 2 4 3.33 1.15 
How to care for my wound or incision 4 3 5 4.25 0.96 3 2 5 3.67 1.53 
What to do if I become concerned about dying 4 3 5 4.25 0.96 3 2 4 3.00 1.00 
If I can continue with my usual hobbies and sports 4 3 5 3.75 0.96 3 2 4 3.00 1.00 
If I can wear my normal clothing 4 2 5 3.50 1.29 3 3 5 3.67 1.15 
Where I can get help to deal with my feelings about my illness 4 3 5 4.00 0.82 3 2 5 3.33 1.53 
How to talk to my family and friends about my illness 4 3 5 4.00 0.82 3 2 5 3.67 1.53 
If I have side effects, how to deal with them 4 4 5 4.50 0.58 3 2 4 3.33 1.15 
The possible side effects of my treatment 4 4 5 4.25 0.50 3 4 5 4.33 0.58 
What side effects I should report to the doctor or nurse 4 5 5 5.00 0.00 3 3 5 4.00 1.00 
If I am prone to infection because of my treatment 4 4 5 4.50 0.58 3 2 4 3.33 1.15 
How long my wound or incision will take to heal 4 4 5 4.25 0.50 3 2 4 3.33 1.15 
How long will I be receiving treatment 4 4 5 4.50 0.58 3 1 4 3.00 1.73 
How I will feel after the tests 4 4 5 4.25 0.50 3 3 4 3.67 0.58 
Where to get help if I have problems feeling as attractive as 
before 
4 2 3 2.50 0.58 3 1 3 2.33 1.15 
How the treatment works against the cancer 4 3 5 4.00 0.82 3 3 5 3.67 1.15 
If there are any special exercises I can do 4 3 5 4.00 0.82 3 2 5 3.33 1.53 
The medical name for my type of cancer 4 2 4 3.25 0.96 3 2 4 2.67 1.15 
If there are any physical things I should not do 4 4 5 4.25 0.50 3 2 4 3.33 1.15 
If I am going to need help taking care of myself 4 3 5 4.25 0.96 3 2 5 3.33 1.53 
How my treatment is done 4 4 5 4.50 0.58 3 3 5 4.00 1.00 
If the treatment will alter the way I look 4 3 5 3.75 0.96 3 2 5 3.33 1.53 
How to tell if the cancer has come back 4 4 5 4.50 0.58 3 4 4 4.00 0.00 
Which foods I can or cannot eat 4 3 5 4.25 0.96 3 2 5 3.67 1.53 
If I can take a bath or shower 4 3 5 4.25 0.96 3 2 5 3.33 1.53 
What types of treatment are available 4 4 5 4.50 0.58 3 4 5 4.33 0.58 
Why the doctor suggested this treatment plan for me 4 4 5 4.50 0.58 3 3 4 3.67 0.58 
The reason the doctor suggests certain tests 4 3 5 4.00 0.82 3 4 5 4.67 0.58 
How to prepare for the tests 4 4 5 4.25 0.50 3 4 5 4.33 0.58 
What to do if I feel uncomfortable in social situations 4 2 5 3.50 1.29 3 2 4 3.00 1.00 
If my illness is hereditary 4 3 5 4.00 0.82 3 3 4 3.33 0.58 
If my illness/surgery/treatment will affect my 
relationships/sex life 
4 3 4 3.25 0.50 3 2 4 3.00 1.00 
If I will be able to continue with my job after my 
surgery/treatment 
4 1 4 3.00 1.41 3 1 4 2.33 1.53 
If there is any financial support available to me during my 
illness 
4 1 4 2.25 1.26 3 2 4 2.67 1.15 
If I can continue with my usual physical and social activities 4 3 5 4.00 0.82 3 1 4 3.00 1.73 
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average score. The means ranged from 2.33 to 4.67 and most items received score. The 
users were most satisfied with information regarding how they would feel after their 
treatment and the reasons why diagnostic tests were ordered.   
The participants also reflected positively upon the information content during the 
interviews. The content was perceived to be straightforward and easy to understand, 
but at the same time inclusive and thorough; the use of language and the length of the 
answers were both deemed to be appropriate. Overall, the users felt that the 
information content was relevant to their needs and included information that they 
would look up themselves. One user explained that the sections related to side effects 
provided reassurance and help prepare for the upcoming treatment.  
“... it was quite reassuring in some ways to see that those things [side effects] 
are common to lots of people. So, I thought that – I think that’s quite a good 
thing about it, it does give you a bit of reassurance sometimes that you know, 
you’re not unique.”  PS2 
Another view was that the app helped address information needs that were not 
discussed with the consultants.  
“... I don’t think this kind of erm repeats the consultant, I think it’s a good thing 
over and above the consultant to give you general information... [The app] is 
complimentary, definitely complimentary because you can’t go through what is 
cancer with a consultant, you’ve gotta go through something else. This is a good 
way of doing it.” PS1 
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Overall use of the app  
Although usage data could not be acquired, the participants reflected upon the overall 
use of the app during the semi-structured interviews.  
During the weeks before their first chemotherapy appointment, all participants briefly 
went through different sections of the app. The participants did this in order to 
familiarise themselves with the content before their treatment started. Although most 
of the information was not relevant at that stage, flicking through the content was 
useful in order to see what the app could offer for future reference.  
“I skimmed over all the subject headings and then went into what I needed to 
know.  It’s hard to say but at a guess I probably looked at most things in detail 
for 50% to 60%.  With the other 30% to 40% I thought, ‘I know it’s there; I don’t 
really need to know it at this time, but I know where to go if I do.” PS1 
After the first dose of treatment, users explained that they used the app on an ‘as 
needed’ basis. This was because once a reasonable understanding of treatment was 
achieved, patients didn’t feel the need to use the app unless they wanted to refresh 
their memory. Following the administration of the first dose of chemotherapy, 
theoretical information (e.g., aetiology and physiology of cancer) became less relevant 
and the attention shifted upon practical aspects such as the management of side 
effects.  
“So, at the start I looked at what it offered and then when I got into the 
treatment cycle I just cherry picked the bits I wanted.” PS3 
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Comments on the virtual agents (VAs) 
Seeing the virtual clinicians for the first time provoked a humorous response in all 
participants. None of the participants thought that using VAs for delivering information 
was inappropriate; one user explained that it was simply another way of delivering 
information, which was acceptable in his view.  
“I think it’s quite humorous really.  But the information is what’s relevant at the 
end of the day and that’s just a bit of fun.” PS1  
Another participant suggested that this type of technology is likely to appeal to patients, 
as individuals are likely to favour this over plain text.  
“People sort of – kind of I think people expect that these days, they don’t want to 
just to be reading text. Especially with a subject like cancer...” PS2  
One participant believed that the clinician avatars did not add anything to the overall 
experience but didn’t express views suggesting that their inclusion hindered the process 
of delivering information.  
Formulating avatars after healthcare professionals was deemed to be an appropriate 
choice. This was because health professionals were perceived as the most appropriate 
agents for delivering treatment- related information. None of the users thought that 
the avatars should be omitted or that the characters had to be changed in order to 
resemble other individuals. Yet, including clips (videos) of patients undergoing 
diagnostic tests appeared to be important, as one patient explained that this made him 
more comfortable with these procedures. 
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“I thought they were useful at the beginning and quite reassuring and I thought 
that was good. They actually show people going in, having the treatment and 
coming out and they’re not you know, it takes the fear factor away a bit I think 
to show those kinds of things”. PS3 
 Recommendations for improvement 
The participants made two recommendations for improving the content. The first was 
to include more links to external resources so that users can retrieve more detailed 
information; at the same time, it was proposed that the level of detail should be 
considered carefully, as signposting users to resources with complex information could 
potentially overwhelm them. Another suggestion was that the app should offer more 
detailed information about the processes during the first chemotherapy visit.  
Only one recommendation was made for optimising usability. One user accidentally 
installed an information package unrelated to his condition but was unable to delete it 
as the app didn’t offer such option. It was therefore suggested that the app should be 
updated so that information packages that were downloaded by mistake could be 
deleted.  
6.4.5. Identification of technical errors 
No technical errors were identified throughout the pilot study.  
6.5. Discussion and implications for main study 
The pilot investigation offered valuable insight regarding the feasibility of carrying out a 
larger-scale investigation and the integrity of the proposed evaluation methodology. 
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The results obtained during this phase suggested that the intervention was received 
well by the participants and that there was scope for testing the app with a larger 
patient cohort. Nevertheless, several modifications were necessary before proceeding 
to the main study. These modifications concerned the intervention itself, as well as 
certain elements of the study methods 
6.5.1. Methodological considerations  
Recruitment 
Several authors have remarked upon the importance of recruitment and emphasised 
that researches should consider this carefully, as failure to do so can have a detrimental 
effect upon the success of any project (van Teijlingen and Hundley, 2002; Bertram et al., 
2019). Although the present investigation did not suffer from commonly encountered 
issues such as high attrition or refusal rates, the pilot study indicated that the original 
choice of chemotherapy (XELOX only) would raise significant recruitment issues due to 
the limited number of available patients. Adjustments were hence necessary in order to 
obtain the desired sample and abide by the agreed timeframe.  
The process of enrolling patients was deemed to be appropriate. None of the 
participants felt that approaching patients after their pre-chemotherapy consultations 
was inappropriate, but at the same time acknowledged that other patients might need 
to be approached at a later point, as the pre-chemotherapy appointments can be 
overwhelming for some. However, it was suggested that enrolling patients on site (i.e., 
face-to-face) can potentially make individuals prone towards committing more and 
would thus be beneficial to the project. While there is some evidence to suggest that 
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face-to-face invitation is more effective than telephone recruitment (Foss et al., 2016), 
attempting to recruit patients in distress would raise important ethical considerations 
(Wilson, Draper and Ives, 2008).   
Appropriateness of study design and research methods 
Testing the study schedule and the data collection tools was another important aspect 
of the pilot study. Overall, the participants felt that the data collection tools were 
appropriate; the questionnaires were received promptly and none of the participants 
expressed complaints regarding the clarity of the items or the length of the surveys. Yet, 
the reliability issues in the satisfaction questionnaire called for adjustments before 
proceeding to the main investigation. 
One unexpected finding was that none of the patients completed the post-exposure 
questionnaires at the hospital, as they were anticipated to fill them whilst being at the 
DTU. The interview schedules were also deemed to be appropriate and addressed the 
study objectives at a good extent. Yet, it was determined that the guide should include 
more questions around VAs, as certain themes suggested that further exploration of 
this topic was necessary.  
The most prominent methodological consideration concerned the failure in the process 
of acquiring the desired usage data. Although Google Analytics provided a good and 
concise account of user activity, there were two major issues. The first and most 
prominent problem was not being able to identify individual users and acquire the set 
of data they generated. The other major issue was the export of the usage data. Data 
from Google Analytics were exported as JavaScript Object Notation files, which could 
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not be handled by the author. Hence, it was determined that an alternative way of 
obtaining participants’ usage data was necessary.  
Logistical considerations 
The pilot study offered valuable insight with regards to the logistical considerations for 
organising and executing a larger-scale investigation. The following changes were 
implemented: 
• Recruitment process: The recruitment process could be managed entirely by the 
researcher (AC) and there was no need for additional personnel for this task. It 
was also realised that attempting to identify potential participants the day 
before the CRC clinics was problematic, as it could result in missing potentially 
eligible patients due to last-minute changes. Hence, it was determined that AC 
would attend all Thursday clinics in person for performing recruitment. 
• Provision of the app: The researcher would encourage patients who agreed to 
participate to install the app on the day they were approached in the clinic. This 
was decided in order to keep a more concise record of enrolment and avoid 
issues encountered with identifying users in the analytics dataset.  
• Planning of treatment cycles: The treatment schedules varied considerably for 
all participants. As being aware of the date and times that patients were going 
to attend the hospital was essential for administering the necessary data 
collection tools, it was determined that patients’ schedules would be monitored 
more closely (e.g., on a weekly basis) so that any changes would be picked up on 
time to ensure thorough planning.  
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• Conduct of interviews: The changes in treatment cycles and the limited 
availability of patients indicated the need for considering alternative types of 
interviews. This was decided in order to avoid missing and cancelling interviews, 
as well for ensuring convenience for the participants, since it is a principal 
consideration for conducting robust interviews (McGrath, Palmgren and 
Liljedahl, 2019).  
6.5.2. Intervention  
There were two aspects to be considered in relation to the app. The first was concerned 
with its usability and content, while the second was associated with the VAs. 
Usability and content  
The mean usability score indicated that the app was acceptable, but improvements 
could be implemented in order to improve the overall user experience. The content 
appeared to address users’ information needs adequately. Some recommendations 
were made for improving the content, but these constituted minor adjustments rather 
than major amendments to the initial version. The participants proposed that the app 
should be updated according to patient feedback, but also acknowledged that it would 
be impossible to cater everyone’s information demands. This was due to the perception 
that patients’ needs vary considerably, which is in line with findings from the literature 
(Sakamoto et al., 2017). Yet, the app appeared to be adequate at providing general 
information support.  
Findings regarding usage patterns suggested that the app was not used frequently. As 
one user suggested, this could be attributed to the fact that once patients achieve a 
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good understanding of several aspects of their condition and its treatment, they are not 
likely to feel the need to use the app further unless they wish to be reminded of a 
particular point. Another reason that would explain this is that the app, with the 
exception of the Triage survey, didn’t include a function that encouraged day-to-day 
use. Hence, it was determined that the updated version of the app should include a 
function that would make future users more inclined towards using the app more 
frequently, such as a sophisticated symptom diary. However, care was be taken in order 
to avoid requesting frequent input (to the app) from the participants, as doing so can 
potentially disengage users (Whitehead and Seaton, 2016). 
Appropriateness of the VAs 
The VAs appeared to be an acceptable way of delivering information to the patients of 
the pilot study. Although users’ views regarding the role of the virtual characters varied 
considerably, none of the patients provided comments that raised concerns over the 
appropriateness of using VAs to deliver information through the app. All participants 
believed that the choice of formulating avatars after healthcare professionals was 
reasonable, which supported the initial hypothesis and indicated that there was no 
need to change the characters. It was hence determined that using these VAs in a 
larger-scale study was appropriate.  
As the focus of the pilot study was to determine the feasibility of using VAs, this chapter 
did not offer a detailed discussion of the findings around this topic. Instead, data 
regarding VAs obtained during this phase will be combined with data derived from the 
main study, as the same animations and clinician characters were used in the main 
investigation phase.  
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6.6. Chapter summary 
This chapter has presented and discussed the findings of the pilot study. This 
preliminary investigation indicated that there was scope for carrying out a larger-scale 
investigation, as the intervention appeared to be an acceptable way of providing 
information support to patients with CRC receiving chemotherapy for the first time. 
Some minor issues were encountered, but it was feasible to effectively address them 
before proceeding to the main investigation. The major issues were associated with 
recruitment, as the choice of a single chemotherapy regiment proved to be very limiting 
despite the initial estimations. Nevertheless, the patients approached during this phase 
were keen on engaging with the project and suggested that this approach was likely to 
interest fellow patients as well.  
The pilot study indicated which changes that were necessary before proceeding to the 
main investigation. The following chapter will present the changes made as a result of 
the pilot study in detail.  
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Chapter 7: Revised methodology and methods 
for the main study  
The previous chapter presented the conduct and results of the pilot investigation. This 
investigation revealed several methodological aspects that had to be addressed before 
proceeding to the main study. The present chapter will outline the alterations made to 
the initial approach for evaluating the project’s intervention.  
7.1. Study methodology 
The methodological considerations regarding the evaluation of the app outlined in 
chapter 5 remained the same. The main study followed a convergent parallel mixed 
methods design with greater emphasis in the qualitative compartment. Yet, the pilot 
study exposed issues with recruitment, as well as several limitations in the study 
methods. Both of these aspects had to be addressed before proceeding to a larger-scale 
investigation. The following sections are going to outline the changes made to the study 
methods and recruitment for the main phase.  
7.2. Participants, recruitment and eligibility 
Focusing exclusively upon patients receiving XELOX gave rise to considerable 
recruitment issues. As it would have been logistically challenging to collaborate with an 
additional research site (e.g., identifying potential collaborators, setting up new 
research teams, having to travel to another location to recruit participants), it was 
necessary to expand the study population. As patients with different types of cancer are 
likely to express different information needs (Nagler et al., 2010), it was decided to keep 
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the research population as patients with colorectal cancer (CRC) receiving 
chemotherapy for the first time and expand the scope of the study to include additional 
chemotherapy regiments. The first regimen was FOLFOX, a combination treatment with 
folinic acid, 5-fluorouracil and Oxaliplatin. The second chemotherapy regimen was 
CAPE, a monotherapy regiment with Capecitabine which is given either alone (also 
known as induction) or in combination with radiotherapy (also known as adjuvant).  
Another noteworthy aspect was that three new oncologists agreed to join the research 
team to help with recruitment. Although this would help enrol patients at a faster pace, 
it also meant that participants referred by these clinicians would not have members of 
their care team represented as VAs in the app. This was because the VAs were 
formulated after particular individuals (see chapter 3, pp. 109-110) and there was no 
time to create custom animations based on the characteristics of the new members of 
the research team. Although the original goal was to observe how patients would 
respond to a known VA only, captivating the responses of users who had information 
delivered by unfamiliar VAs would allow to compare perspectives between patients 
who had a known avatar and those who didn’t. As this was considered to be an 
interesting domain, it was decided that differences between patients who were familiar 
with the VAs and users who were not would be explored in the interviews.  
Apart from including patients receiving FOLFOX or CAPE, the original eligibility criteria 
outlined in chapter 5 (p. 167) were also applicable for the main study. All participants 
were recruited from the Churchill Hospital using the same enrolment process outlined 
in 5.5.2 (pp. 164-165).  
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7.3. Sample size and sampling strategy 
Considerations regarding the sample size and sampling strategy have been outlined in 
detail in chapter 5 (pp. 167-168 and pp. 168-169 respectively). The sample size of the 
main investigation depended upon the number of interviews required to achieve data 
saturation (see p. 167 for further details) and was estimated to be 40 patients. The 
sampling strategy for the main study was nested mixed methods sampling; convenience 
sampling was deployed for the quantitative strand and purposive sampling with 
maximum variation was used for the qualitative component. 
7.4. Intervention 
The focus of the new versions of Manage your Health remained upon patients with CRC 
receiving chemotherapy. As feedback from the pilot study and the first Patient and 
Public Involvement and Engagement (PPIE) interviews was transferable to other 
chemotherapy regiments, the author (AC) proceeded directly to the development stage 
of the new information packages.  
All three information packages (XELOX, CAPE and FOLFOX) contained the same thematic 
sections (table 7.1). The information content of most sections (1, 3,6, 7 and 8) was 
identical across all three packages, as it contained general information that was not 
related to a particular treatment schedule. Yet, the content of sections concerned with 
chemotherapy medicines (section 5), side effects (section 4) and unique treatment-
related queries (section 2) had to be tailored for each treatment. The author inspected 
the chemotherapy regiments for CAPE and FOLFOX, formulated the new content and 
checked it with the clinicians before developing the new packages. The updated 
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information sections for the packages used in the main study are outlined in appendices 
11 (XELOX), 12 (CAPE) and 13 (FOLFOX).   
Table 7. 1: Thematic sections in XELOX, FOLFOX and CAPE 
Thematic section Section content details 
Section 1: Search for a 
question Enabled users to identify a query within the app 
Section 2: Information 
about cancer and treatment 
General information on bowel cancer (e.g., aetiology 
of the disease) and how chemotherapy medicines 
work   
Section 3: Information 
about diagnostic tests 
Information about why diagnostic tests are ordered 
and external links to demonstrate how they are 
performed 
Section 4: Help with side 
effects 
Outline of the potential side effects of treatment and 
advice how to deal with them and prevent their onset 
Section 5: Help with 
medicines 
Information and advice about chemotherapy 
medicines and supportive medication  
Section 6: Emotional 
support and help with 
finances  
Information about supportive infrastructures available 
in Oxford  
Section 7: Triage survey Link to the interactive version of the Triage assessment 
tool for reporting treatment-induced toxicity) 
Section 8: Symptom diary Record symptoms/side effects during treatment 
The original version of Manage your Health had a major update planned in 2019. In 
March, the development team released a new version of Manage your Health which 
featured easier navigation (e.g., inclusion of a menu button), enhanced graphics (e.g., 
use of bold colours and contrast) and improved functions. This updated version was 
used in the main investigation phase.  
While users could keep track of their symptoms through an informal notes function in 
the previous version of Manage your Health, the updated version provided a more 
sophisticated treatment diary function. For each day of their treatment, patients could 
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rate each symptom according to its severity and could then get an overview of the 
course of this symptom for over time. Figure 7.1. illustrates the diary function in detail.  
Figure 7. 1: Symptom diary in Manage your Health (v.2) 
 
Once the new information packages were prepared, the author performed preliminary 
testing to ensure functionality and identify potential technical problems. Some minor 
issues were encountered (e.g., unresponsive buttons, mute animations, typing 
mistakes), all of which were addressed promptly. The updated version of the app was 
released in May 2019.  
7.5. Questionnaires  
The System Usability Scale (SUS) scored well for reliability (Cronbach’s alpha was 0.85) 
and therefore no alterations were required (p. 178). The questionnaire is available at 
appendix 14. 
The most important consideration was the reliability issues for the satisfaction with 
information questionnaire. This was attributed to a printing mistake, as the instrument 
contained the wrong prefix. This caused confusion to the responders, as they thought 
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that they were given the same questionnaire twice. Hence, before proceeding to the 
main study, it was necessary to change the wording of the prefix to ‘Which of the 
following best describes how well the need was addressed through the app?’. The 
wording of the prefix for the baseline questionnaire was also updated for better clarity. 
The updated versions of the baseline and satisfaction with information questionnaires 
are available in appendix 15 and appendix 16 respectively.  
The process of analysing the questionnaires (descriptive statistics for the information 
needs and satisfaction with information questionnaire and calculation of the usability 
score for the SUS scale) outlined in chapter 5 (pp. 139-142) remained the same.  
7.6. Semi-structured interviews  
Although face-to-face interviews are capable of producing information-rich data, 
logistical limitations can impede their planning and conduct (Opdenakker, 2006). This 
became apparent during the pilot study. Changes in the hospital review appointment 
dates or travel restrictions resulted in having to re-arrange several interviews, which 
was inconvenient for both the author and the participants. Additionally, moving 
interviews at a later time in patients’ treatment could potentially result in recall bias. It 
was therefore decided that the interview mode should allow for more flexibility.   
Advances in telecommunications have opened new opportunities for undertaking 
qualitative research. An early study focused upon videoconferencing and proposed that 
it can be a viable alternative to face-to-face interviews (Sedgwick and Spiers, 2009). 
Hanna (2012) later noted that developments in social media such as Skype made high-
quality videoconferencing readily available to the public, which facilitated its uptake by 
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qualitative researchers. The same author argued that in addition to the benefit of 
synchronous communication, videoconferencing interviews also allow for the exchange 
of non-verbal ques between researchers and study participants. As discussed in chapter 
5 (pp. 153), the absence of non-verbal ques in telephone interviews can potentially give 
rise to certain limitations; yet the use of Skype as a communication medium can help 
compensate for this issue.  
Deakin and Wakefield (2014) proposed that in Skype interviews, rapport can be built as 
effectively as in face-to-face interviews. Furthermore, the authors suggested that a 
platform such as Skype not only allows the participants to choose a suitable time for the 
interviews, but it also enables them to determine the extent of engagement (i.e., audio 
only or video). A recent study that compared face-to-face interviews with video calling 
demonstrated that the former was only marginally superior to the latter and suggested 
that the use of videoconferencing can be justified as an alternative in qualitative studies 
that suffer from logistical constraints (Krouwel, Jolly and Greenfield, 2019). This was 
particularly applicable to the present project. As mentioned above, several interviews 
had to be re-arranged due to unforeseen circumstances. This not only incurred 
considerable cost to the researcher (e.g., additional journeys to Oxford from Keele), but 
also added further time upon the timeline. Considering the above, it was determined 
that the participants of the main study would be offered the option to conduct the 
interview either face-to-face or through a video or audio call. This was also applicable to 
the clinician interviews.  
The updated version of the patient semi-structured interview guide for the main study 
is available in appendix 17. The interviews of the main study (both patient and clinician) 
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would be analysed using the framework method, which has been outlined in detail in 
chapter 5 (see pp. 155-157).  
7.7. Usage data  
As the previous method for collecting usage data proved to be problematic (see pp. 
190-191 for more details), it was decided that usage data would be acquired in a 
different manner. The changes in the participant population also called for certain 
changes in the analysis of the resulting data. These alterations are discussed below.  
7.7.1. Acquisition and types of usage data  
Google Analytics (GA) was used in order to record usage data for the pilot study. 
Although GA has evolved over time, at the time of the project it was aimed more at 
website traffic (i.e., activity) than app reporting. The main limitation was that GA did not 
offer the flexibility of a real-time database for developers to structure the data in a way 
that best suited their objectives. For this project, this involved the identification of a 
user profile within the entire dataset, which was not feasible in the pilot study. Hence, it 
was decided that a different interface would be used for acquiring usage data.  
Google Firebase, a platform specifically designed for apps offered a number of 
beneficial features for app monitoring, including cloud storage and methods to report 
usage. The Firebase features could be used by including the Firebase SDK (software 
developer's kit) in Unity (a cross-platform game engine). This was beneficial because all 
features could be grouped together as part of the same platform and could be easily 
accessible by the app, unlike GA. Furthermore, the Firebase utilised a data format called 
JavaScript Object Notation (JSON), which could be parsed fairly easily into other formats 
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such as Excel. Due to its flexibility and specificity for apps, Firebase was used to acquire 
the usage data for the main study.  
The usage parameters remained the same for the main study and included the 
frequency of engagement (number of taps and logins to the app), intensity of use 
(proportion of items accessed in relation to the total number of items of the app) and 
type of engagement (active versus passive use). These have been described in detail in 
chapter 5 (see pp. 145-146).  
7.7.2. Analysis of usage data  
The considerations for analysing usage data have been outlined in chapter 5 (pp. 147-
148). The participant sample of the main study was comprised by three sub-groups of 
users (FOLFOX, XELOX or CAPE). The members of each group were be given a unique 
version of the app, as not only the number of items in each information package varied, 
but also several items were unique for each package (e.g., chemotherapy medicines). 
Hence, sub-group analysis of usage data associated with the use of thematic 
information sections (sections 1-8, outlined in table 7.1) had to be performed. Three 
distinct datasets were developed, each corresponding to one of the treatments (XELOX, 
FOLFOX and CAPE).  
Data regarding the frequency of engagement, the intensity of use and type of 
engagement were merged into a single dataset for the purpose of overall analysis. This 
was because such data did not depend upon the content of each information package 
(XELOX, FOLFOX and CAPE) per se and could therefore be combined to illustrate the 
overall picture of the participant cohort. Prior to conducting the analysis, the data was 
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prepared rigorously in order to ensure the reliability of the results. The steps of 
preparation and analysis were performed in SPSS, Version 22.  
At first, the usage data for each user was merged in a single data file (in their respective 
treatments). Each case/row represented an action undertook at the application (i.e., a 
tap made by the user). To efficiently represent the layout for each treatment, including 
the different sections, subsections, and items (i.e., the individual animations, external 
links and treatment diary entries), a distinct coding was introduced for each treatment, 
which matched all items to a unique number. These numbers would be indicative of each 
section, subsection or item, as well as their original order in the app. Within each dataset 
developed, three additional variables were introduced. The first represented the actual 
use of the app, as received from the development team; for this variable, it was necessary 
to match the raw input to the app’s layout. A distinct coding for the categories of this 
variable was introduced, based upon the item order within the section or subsection. The 
second variable corresponded to the section where each case (row) belonged. The third 
variable represented the stage of treatment (before and/or after the first dose of 
chemotherapy). The remaining information was retained in its original form.  
While the initial proposal was to use descriptive statistics only, the unexpectedly large 
amount of usage data allowed the conduct of more sophisticated statistical analysis. 
Particularly, for the chi-squared (χ2) test, the general rule of thumb is to have at least five 
cases per cell in the frequency crosstabulation table (Field, 2018); in the acquired dataset, 
this condition was met for most comparisons (XELOX and CAPE, not FOLFOX). Hence, both 
descriptive statistics and statistical inference were used. Within the descriptive statistical 
analysis and since the variables involved were categorical, frequency tables (frequency, 
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percentage), and bar charts (simple, clustered, stacked) were used (Kremelberg, 2011). 
Within the statistical inference analysis, the standard χ2 test was the original choice to 
assess the dependency between section use and the stage of treatment (before/after the 
first dose of chemotherapy). In cases where the condition for a robust χ2 test was not met 
(i.e., Cochran’s criterion-at most 20% of the cells to have expected count less than 5), 
alternative standard tests were considered, particularly, the Fisher’s exact test (Hae-
Young, 2017). The level of statistical significance (a) was set to 0.05 in all cases. 
7.8. Administration of the data collection tools  
The inclusion of new chemotherapy regiments (FOLFOX and CAPE) did not cause any 
alterations in the original study design. Yet, the inclusion of new chemotherapy 
regimens affected the timing of the administration of the data collection tools, as each 
individual study journey had to be designed according to the treatment that was 
allocated to each patient. Hence, the treatment cycles with FOLFOX and CAPE had to be 
considered. 
FOLFOX is a multiagent chemotherapy regimen administered in two-week cycles. On 
the first day of each cycle, patients attend the hospital to receive a chemotherapy 
pump device which delivers 5-fluorouracil (5-FU), oxaliplatin and folinic acid 
intravenously (IV) over two days (figure 7.2). The remaining twelve days of the cycle do 
not contain any chemotherapy medication. Patients then must attend a review 
appointment before the start of the next treatment cycle. This applies to both adjuvant 
and induction treatment.  
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Figure 7. 2: Treatment cycle of FOLFOX 
 
   
 
CAPE is given differently depending on the type of chemotherapy (figure 7.3). The 
induction treatment cycle (left) follows the same pattern as XELOX (three- week cycle 
where treatment is given for the first two weeks). The adjuvant cycle (right) is different, 
as the treatment is administered in weekly intervals, where CAPE is given for the first 
five days of each cycle (figure 7.2).  
Figure 7. 3: Treatment cycles of induction (left) and adjuvant (right) CAPE 
 
 
All study participants received the app, as well as the baseline questionnaire three to 
four weeks before their first dose of chemotherapy, irrespective of the treatment 
schedule. Participants then received the post-exposure questionnaires (satisfaction with 






Oxaliplatin and 5-FU (IV) +

















treatment unit; patients who received CAPE were given this questionnaire alongside 
their medicines by a member of the research team. All questionnaires were provided 
with pre-paid envelopes so that patients could complete them at their own time and 
send post them to the hospital. Finally, participants were invited to an interview on the 
day of their first review appointment. Analytics of use were obtained from the point of 
instalment up to the day of the first review appointment.  
7.9. Ethical approval 
The changes made before proceeding to the main investigation concerned both the 
study’s population and the app. As these alterations constituted major amendments, a 
substantial amendment form was submitted to the Brighton and Sussex Research Ethics 
Committee (REC) prior to their implementation. The approval for these amendments 
was granted on the 5th of April 2019 (appendix 18). 
7.10. Chapter summary  
The present chapter outlined the changes implemented to the study’s intervention, 
participants and methods before proceeding to the main study. In addition to patients 
receiving XELOX, the main study also included patients receiving chemotherapy with 
CAPE or FOLFOX in order to address the recruitment issues encountered in the pilot 
study. Users of the main study received an updated version of the app, which featured 
better usability features and bug fixes of the previous version. The study methods were 
also updated before proceeding to the main investigation to improve the acquisition of 
the desired data. The next chapter will present the findings of the main study. 
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Chapter 8: Main study results 
The previous chapter outlined the amendments implemented to the app’s evaluation 
methodology before proceeding to the main investigation. This chapter will present the 
results obtained from the main investigation phase of the project.   
8.1. Participants  
Out of 40 patients approached, 33 (82.5%) agreed to take part in the study. The main 
reason for not participating was the lack of an appropriate device (smartphone or 
tablet) that could accommodate the app, followed by the lack of time and/or interest to 
the study. Out of the 33 patients who provided consent, four wished to leave the study 
and did not install the app; reasons included a lack of interest, no perceived benefit 
from taking part in the study and not feeling that they could contribute to the project. 
The technical issues with the app that occurred during the study also led to the 
exclusion of six patients, as they had no access to the app during this time. Ultimately, 
23 patients took part in the study. Out of these patients, 10 (43.5%) received treatment 
with XELOX, 5 (21.7%) received CAPE and 8 (34.8%) received FOLFOX.  
The female to male ratio was 14:9. As not all participants returned the baseline 
questionnaire (information needs and demographics), complete demographic data 
were obtained for 13 out of 23 participants (56.5%). The demographic data is presented 
in table 8.1.  
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Table 8. 1: Demographic data (n=13) 
Age n % IT literacy n % 
30-49 1 7.69 Extremely 4 30.77 
50-64 6 46.15 Very 4 30.77 
65-74 2 15.38 Somewhat 4 30.77 
75+ 4 30.77 Not at all 1 7.69 
Employment status n % Health literacy n % 
Full time 4 30.77 Never 11 84.62 
Part time 1 7.69 Some 1 7.69 
Retired 6 46.15 Always 1 7.69 
Unemployed 1 7.69 Level of education n % 
Information refused 1 7.69 Secondary education 4 30.77 
Marital status n % Higher education 9 69.23 
Partnered 1 7.69 Ethnicity n % 
Married 9 69.23 White British 10 76.92 
Divorced 1 7.69 White other 2 15.38 
Widowed 2 15.38 Information refused 1 7.69 
Diagnosis of cancer n % Previous treatment? n % 
Less than 3 months  13 100.00 No previous treatment  13 100.00 
 
 
8.2. Questionnaire data  
 
All study participants (n=23) received three questionnaires in total (one at baseline and 
two after treatment). Out of the 69 expected surveys (i.e., 23 baseline, 23 satisfaction 
with information and 23 System Usability Scale questionnaires), 29 (42%) were obtained 
in total. Only four patients (n=4/23, 17.39%) returned all three questionnaires. The 
baseline questionnaire had the highest return rate (13 out of 23, 56.5%), followed by 
the System Usability Scale (SUS) (9 out of 23, 39.1%) and satisfaction with information 
questionnaire (7 out of 23, 30.4%).  
8.2.1. App usability results 
Table 8.2 presents the results for the degree of the app’s usability (9 responders). The 
majority of responders (n=7/9, 77.8%) scored above 70% in the SUS, suggesting a good 
degree of usability. The mean usability score was 73.89 (range 40-100, SD 16.96).   
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Table 8. 2: SUS scores for the main study (n=9) 
 User ID 


















I think that I would like to use this app 
frequently  5 4 4 4 4 4 2 3 4 
I found the app unnecessary complex 1 1 4 4 2 3 4 2 2 
I thought that the app was easy to use 5 5 3 4 4 4 2 4 4 
I needed the support of another 
person in order to use the app 
1 1 1 1 2 3 1 2 2 
I found that the functions of the app 
were well integrated 5 5 3 2 4 4 1 4 4 
I thought that there was too much 
inconsistency in this app 1 3 2 1 2 2 4 1 2 
I would think that most people would 
learn to use this app very quickly  
5 4 4 4 4 4 2 4 4 
I found the app very awkward to use 1 1 4 1 2 1 4 1 2 
I felt very confident using the app 5 5 3 5 4 4 3 4 4 
I needed to learn a lot of things before 
I could get going with this app 1 1 2 3 2 1 1 2 2 
SUS score 100 90 60 72.5 75 75 40 77.5 75 
8.2.2. Information needs and satisfaction with information results 
The results obtained for participants’ information needs (13 responders) and 
satisfaction with information (7 responders) are presented in table 8.3. The data 
indicated that information needs were high, as the mean for the majority (n=50/53, 
94.34%) of items was above 3. The items that received the highest scores concerned 
treatment-related (recurrence, metastasis, management and reporting of adverse 
effects and length of treatment) and dietary information.  
Results regarding the satisfaction with information provided through the app suggested 
that participants were generally happy with the content, as the mean was 3 and above 
for all items. The items that received the highest mean satisfaction (4 and above) were 
treatment-related information (treatment options, management and reporting of 
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adverse events), information on diagnostic tests and information about support 
(support groups and contact details of healthcare professionals).  
Table 8. 3: Information needs and satisfaction with information 
 How important is for you to 
have each of the following 
types of information? 
Which of the following  
best describes how well the need 
was addressed through the app?  
 n Min Max Mean SD n Min Max Mean SD 
How I will feel during or after the tests 13 3 5 4.08 0.86 7 2 5 3.43 0.98 
If the bowel cancer will come back 13 4 5 4.92 0.28 7 3 5 3.71 0.76 
How to prepare for my treatment 13 2 5 4.15 0.99 7 3 5 3.57 0.79 
How I will feel after my treatment 13 2 5 4.15 0.90 7 2 5 3.86 0.90 
Who to call if I have questions while I am still getting treatment 13 3 5 4.46 0.66 7 3 5 4.29 0.76 
How bowel cancer acts in the body 13 2 5 4.15 0.90 7 3 5 4.00 0.82 
If there are groups where I can talk with other people with cancer 13 1 5 2.77 1.36 7 2 5 4.00 1.15 
If there are ways to prevent or ease side effects of treatment 13 2 5 4.54 0.97 7 2 5 3.71 1.11 
How the illness may affect my life over the next few months 13 2 5 4.38 0.87 7 2 5 3.43 1.13 
If there will be changes in usual things I can do with or for my 
family 13 
2 5 3.69 1.11 7 
2 5 3.71 1.25 
If there is cancer anywhere else in my body 13 4 5 4.85 0.38 7 3 5 3.71 0.76 
Who to call if I have questions after all the treatments are over 13 3 5 4.54 0.66 7 2 5 3.86 1.07 
If it is known what causes bowel cancer 13 1 5 3.85 1.28 7 2 5 3.43 1.13 
How the tests are done 13 2 5 3.85 0.90 7 3 5 4.00 0.82 
Why do they need to test my blood 13 1 5 3.31 1.03 7 3 5 4.14 0.69 
Who to talk to about treatment other to 
surgery/chemo/radiotherapy 13 2 5 3.38 0.87 7 2 5 4.00 1.15 
How the illness may affect my life in the future 13 3 5 4.46 0.66 7 3 5 3.86 0.90 
What the results of my blood tests mean 13 3 5 4.00 0.58 7 2 5 3.71 0.95 
Where my family can go if they need help dealing with my illness 13 1 5 3.62 1.33 7 1 5 3.29 1.38 
How to care for my wound or incision 13 1 5 3.77 1.64 7 2 5 3.43 1.13 
What to do if I become concerned about dying 13 1 5 3.92 1.26 7 2 5 3.14 1.07 
If I can continue with my usual hobbies and sports 13 1 5 3.46 1.33 7 2 5 3.43 0.98 
If I can wear my normal clothing 13 1 5 2.85 1.21 7 3 5 3.57 0.79 
Where I can get help to deal with my feelings about my illness 13 1 5 3.46 1.20 7 2 5 3.57 0.98 
How to talk to my family and friends about my illness 13 1 5 3.46 1.33 7 2 5 3.43 1.27 
If I have side effects, how to deal with them 13 3 5 4.46 0.66 7 2 5 3.57 1.27 
The possible side effects of my treatment 13 3 5 4.62 0.65 7 3 5 4.00 0.82 
What side effects I should report to the doctor or nurse 13 4 5 4.85 0.38 7 3 5 4.29 0.76 
If I am prone to infection because of my treatment 13 3 5 4.46 0.78 7 2 5 4.14 1.07 
How long my wound or incision will take to heal 13 1 5 3.92 1.32 7 2 5 3.57 0.98 
How long will I be receiving treatment 13 4 5 4.77 0.44 7 1 5 3.43 1.40 
How I will feel after the tests 13 2 5 4.31 0.95 7 2 5 3.57 0.98 
Where to get help if I have problems feeling as attractive as 
before 13 
1 5 2.69 1.60 7 
1 5 3.57 1.40 
How the treatment works against the cancer 13 2 5 3.92 1.04 7 3 5 3.86 0.90 
If there are any special exercises I can do 13 1 5 3.77 1.17 7 2 5 3.57 1.13 
The medical name for my type of cancer 13 1 5 3.15 1.07 7 2 5 3.86 1.07 
If there are any physical things I should not do 13 3 5 4.15 0.80 7 2 5 3.43 0.98 
If I am going to need help taking care of myself 13 1 5 3.54 1.05 7 2 5 3.29 1.25 
How my treatment is done 13 2 5 4.08 0.95 7 3 5 3.86 0.90 
If the treatment will alter the way I look 13 1 5 3.46 1.66 7 2 5 3.29 0.95 
How to tell if the cancer has come back 13 2 5 4.69 0.85 7 3 5 3.71 0.95 
Which foods I can or cannot eat 13 2 5 4.08 0.95 7 2 5 3.71 1.11 
If I can take a bath or shower 13 1 5 3.38 1.33 7 2 5 3.29 1.11 
What types of treatment are available 13 3 5 4.46 0.78 7 1 5 3.43 1.27 
Why the doctor suggested this treatment plan for me 13 3 5 4.31 0.75 7 2 5 3.71 1.11 
The reason the doctor suggests certain tests 13 2 5 3.92 0.95 7 2 5 3.71 0.95 
How to prepare for the tests 13 3 5 4.08 0.86 7 3 5 3.71 0.76 
What to do if I feel uncomfortable in social situations 13 1 5 3.00 1.63 7 2 5 3.00 1.00 
If my illness is hereditary 13 1 5 4.23 1.30 7 2 5 3.14 1.07 
If my illness/surgery/treatment will affect my relationships/sex 
life 13 
1 5 3.23 1.48 7 
2 5 3.14 1.21 
If I will be able to continue with my job after my 
surgery/treatment 13 
1 5 3.08 1.80 7 
2 5 3.29 1.11 
If there is any financial support available to me during my illness 13 1 5 2.85 1.41 7 2 5 3.71 1.11 
If I can continue with my usual physical and social activities 13 1 5 3.77 1.09 7 3 5 3.57 0.79 
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8.3. App usage data 
Unlike questionnaires where the acquisition of the desired data depended upon the 
response rate, Firebase provided data use accounts for the entire user cohort (23 user 
profiles). The following sections will present the analysis of the obtained usage data for 
each treatment (XELOX, FOLFOX and CAPE), as well as the overall user audience. 
8.3.1. Overall user audience and correlations 
Table 8.4 summarises the results obtained for the overall use of the app for each 
participant. As there was considerable variation in the obtained usage data, the mean 
value would not be an appropriate measure of central tendency (Manikandan, 2011). 
Hence, median values were used instead. While the median number of logins per user 
was 8, several users (e.g., Users 1 and 16) utilised the app much more frequently 
throughout the study. The median number of logins was similar for FOLFOX and CAPE (5 
and 7 respectively), while a much higher median was recorded for XELOX (12). The 
median number of total tap counts (i.e., number of actions undertook in the app during 
logins) per user was 99 (range 24-881), with a considerable proportion of users 
(n=10/23, 43.48%) having scored lower than this. The majority of users (n=12/23, 
52.17%) accessed at least 4 out of the 8 sections of the app, while several users 
(n=5/23, 21,73%) accessed all available sections.  
Pooling data regarding the unique items accessed by users across the different 
information packages (CAPE, XELOX and FOLFOX) would not be valid, as each of these 
packages had its distinct content. However, as the usage intensity (the number of 
unique items accessed by the user in relation to the total items offered by the app) was 
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expressed as a percentage, it was possible to merge these results in a single dataset. 
The same applied for the percentage of active versus passive use of the app. 
Table 8. 4: Overall app use data 
User ID Treatment 
Frequency of 








(out of 8) 





n n n n % % % 
User1 XELOX 28 583 8 64 39.261 95 5 
User2 XELOX 12 77 5 19 11.661 84 16 
User3 XELOX 12 95 8 20 12.271 87 13 
User4 XELOX 7 120 4 19 11.661 81 19 
User5 XELOX 2 92 5 21 12.881 98 2 
User6 XELOX 12 49 3 10 6.131 96 4 
User7 XELOX 10 63 3 4 2.451 8 92 
User8 XELOX 9 99 6 21 12.881 96 4 
User9 XELOX 13 344 7 33 20.251 74 26 
User10 XELOX 22 881 8 78 47.851 94 6 
User11 FOLFOX 2 156 6 39 24.532 64 36 
User12 FOLFOX 5 105 5 18 11.322 79 21 
User13 FOLFOX 5 72 5 15 9.432 57 43 
User14 FOLFOX 3 24 3 6 3.772 92 8 
User15 FOLFOX 27 388 8 39 24.532 81 19 
User15 CAPE 47 259 5 11 7.053 10 90 
User17 CAPE 3 65 5 17 10.93 89 11 
User18 CAPE 3 26 2 6 3.853 100 0 
User19 CAPE 8 103 4 14 8.973 69 31 
User20 CAPE 8 44 3 8 5.133 95 5 
User21 CAPE 19 541 8 60 38.463 90 10 
User22 CAPE 6 304 6 63 40.383 89 11 
User23 CAPE 2 55 1 9 5.773 100 0 
1 out of the 163 unique items available in the XELOX information package; 2 out of the 159 unique items available in 
the FOLFOX information package; 3 out of the 156 unique items available in the CAPE information package 
The median intensity of use was 12 (range 2.45-47.85). Most users (n=19/23, 82.6%) 
accessed less than a quarter of the items available through the app. The median 
intensity of use was similar across XELOX and FOLFOX (11 and 13 respectively), while a 
lower median was evident in CAPE (8). The vast majority of the participants (n=21/23, 
91.3%) engaged with the app predominately in a passive manner. The figures in pages 
213 and 214 provide an illustration of these results. 
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Figure 8. 1: Usage intensity per user 
 
Figure 8. 2: Logins per user 
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Figure 8. 3: Number of taps per user 
 
Figure 8. 4: Active versus passive use 
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As discussed in section 7 (pp. 202-203), making direct comparisons (e.g., tap counts) 
regarding the use of information sections across different information packages would 
be invalid, as each information package contained a different number of items. 
Furthermore, the information packages were not represented equally (e.g., XELOX had 
10 users, while FOLFOX had 5).  While comparisons between patients who received the 
same information packages will be presented in sections 8.4.1-8.4.3, an overall 
comparison of percentages was possible.  
Figure 8.5 provides an illustration of the section use (as a percentage) across all 
information packages. The most popular section across all information packages was 
the management of side effects (section 4), while general treatment-related (section 2) 
and medicinal information (section 5) were also among the most popular domains. The 
treatment diary (section 8) was considerably popular for FOLFOX and CAPE.  




Comparisons between the overall use before and after treatment were also performed. 
These results are illustrated in figures 8.6., 8.7 and 8.8. The first provides a visual 
account of the differences between the number of logins per user before and after 
treatment, the second presents data on the total number of taps and the third 
illustrates individual user profiles. Table 8.5 contains a detailed summary of these 
findings, which will be necessary for the sub-group analysis. A considerable proportion 
of participants (n=7/23, 30.4%) used the app solely before the first dose of treatment, 
while only one patient (n=1/23, 4.3%) used the app exclusively after treatment. The 
majority of users (n=15/23, 65.3%) used the app both before and after treatment.  
Table 8. 5: Logins and tap counts before and after treatment 
User ID 





Logins after first 
dose 
 Total  
taps 
Taps before first 
dose 
Taps after first 
dose 
n n % n %  n n % n % 
User 1 28 13 46.43 15 53.57  583 231 39.6 352 60.4 
User 2 12 8 66.67 4 33.33  77 53 68.8 24 31.2 
User 3 12 12 100 0 0  95 95 100 0 0 
User 4 7 4 57.14 3 42.86  120 55 45.8 65 54.2 
User 5 2 2 100 0 0  92 92 100 0 0 
User 6 12 2 16.67 10 83.33  49 5 10.2 44 89.8 
User 7 10 2 20 8 80  63 7 11.1 56 88.9 
User 8 9 9 100 0 0  99 99 100 0 0 
User 9 13 7 53.85 6 46.15  344 155 45.1 189 54.9 
User 10  22 2 9.09 20 90.91  881 278 31.6 603 68.4 
User 11 2 2 100 0 0  156 156 100 0 0 
User 12 5 5 100 0 0  105 105 100 0 0 
User 13 5 2 40 3 60  72 21 29,2 51 70,8 
User14 3 2 66.67 1 33.33  24 6 25,0 18 75,0 
User 15 27 5 18.52 22 81.48  388 120 30,9 268 69,1 
User 16 47 46 97.87 1 2.13  259 2 0.8 257 99.2 
User 17 3 3 100 0 0  65 65 100 0 0 
User 18 3 3 100 0 0  26 26 25.2 0 74.8 
User 19 8 2 25 6 75  103 26 77.3 77 22.7 
User 20 8 6 75 2 25  44 34 0.7 10 99.3 
User 21 19 2 10.53 17 89.47  541 4 92.8 537 7.2 
User 22 6 2 33.33 4 66.67  304 282 0 22 100 
User 23 2 0 0 2 100  55 0 0.8 55 99.2 
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Figure 8. 6: Number of taps before and after treatment 
 
Figure 8. 7: Number of logins before and after treatment 
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The number of logins did not always follow the same trend as the number of taps. For 
example, although users 5 and 8 performed a similar number of taps (around 90), user 
8 performed many more visits. Some marked differences were also observed for users 
16 and 22, whose tap count and number of logins followed a completely different 
trend. For user 16, it appears that the user performed less logins after treatment but 
accessed more items during these visits; the opposite would be true for user22. 
Differences were also detected for users 4, 9 and 14.  
Scatterplots were developed to investigate the correlations between three different sets 
of variables; a) mean satisfaction with information score versus number of taps (figure 
8.9), b) mean information needs score versus number of taps (figure 8.10) and c) usability 
score (from SUS) versus number of taps (figure 8.11). A trend/regression line was added 
in each graph. In both (b) and (c), the number of taps is the dependent variable, while the 
mean information needs score and SUS scores are the independent variables, 
respectively. In both cases, a positive linear correlation is revealed, i.e., the number of 
taps is positively linearly dependent from the respective independent variables.The 
Pearson correlation coefficient for (b) is 0.372 (p-value=0.211) and 0.488 (p-value=0.183) 
for (c). In (a), the Pearson correlation coefficient is -0.300 (p-value=0.513), indicating 
negative linear dependency; this value is heavily influenced by the outlier value of user 
10. In summary, the plots revealed that all correlations were weak and non-significant. 
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Figure 8. 9:  Correlation between satisfaction with information and app use 
 
Figure 8. 10: Correlation between information needs and app use 
 
Figure 8. 11: Correlation between usability and app use 
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8.3.2. Section use for XELOX 
Results regarding the overall use of the XELOX information package (nusers=10/23) are 
presented in table 8.4 and illustrated in figure 8.7. The total tap count for XELOX was 
2403 and individual tap counts ranged from 49 to 881. As the results were considerably 
skewed, the median for the total tap count was used, which was 97. Two users (1 and 
10) accounted for 51% of total use. 
The results for section use for the XELOX information package are tabulated in table 8.6. 
The sections that received most visits were those associated with treatment-related 
information; section 4 (help with side effects) was the most popular section, followed 
by section 2 (information about cancer and treatment) and section 5 (help with your 
medicines).  
Table 8. 6: Section use breakdown for XELOX 
Total taps: 2403 (10 users)   
App Section  Tap count % 
Section 1 (Search for a question) 52 2.2 
Section 2 (Information about cancer and treatment) 506 21.1 
Section 3 (Diagnostic tests) 125 5.2 
Section 4 (Help with side effects) 734 30.5 
Section 5 (Help with your medicines) 409 17.0 
Section 6 (Emotional support and help with finances) 291 12.1 
Section 7 (Triage Survey) 39 1.6 
Section 8 (Symptom diary) 247 10.3 
 
Table 8.7 provides a breakdown of individual XELOX user profiles in relation to the 
thematic sections of the app. While some participants visited all sections, the majority 
of users (nusers=7/10, 70%) did not access several parts of the content. Most of these 
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participants (4/7) accessed more than half of the available app sections (range 4-7), 
while others focused almost exclusively upon a certain part of the app; for instance, 
more than 90% of the total use for user 7 was allocated to section 8 and 71.4% of the 
total use for user 6 was performed in information section 2 (information about cancer 
and treatment).  






1 2 3 4 5 6 7 8 
User1 
Tap count 26 40 31 263 112 81 10 20 583 
 %  4.5 6.9 5.3 45.1 19.2 13.9 1.7 3.4 100 
User2 
Tap count 4 35 0 0 21 5 0 12 77 
 % 5.2 45.5 0 0 27.3 6.5 0 15.6 100 
User3 
Tap count 2 45 14 10 10 2 3 9 95 
 % 2.1 47.4 14.7 10.5 10.5 2.1 3.2 9.5 100 
User4 
Tap count 0 0 0 65 32 0 5 18 120 
 % 0 0 0 54.2 26.7 0 4.2 15 100 
User5 
Tap count 0 14 20 28 28 0 2 0 92 
 % 0 15.2 21.7 30.4 30.4 0 2.2 0 100 
User6 
Tap count 0 35 0 0 0 12 2 0 49 
 % 0 71.4 0 0 0 24.5 4.1 0 100 
User7 
Tap count 0 0 3 2 0 0 0 58 63 
 % 0 0 4.8 3.2 0 0 0 92.1 100 
User8 
Tap count 12 41 2 13 0 27 0 4 99 
 % 12.1 41.4 2 13.1 0 27.3 0 4 100 
User9 
Tap count 0 79 2 100 42 32 15 74 344 
 % 0 23 0.6 29.1 12.2 9.3 4.4 21.5 100 
User10 
Tap count 8 217 53 253 164 132 2 52 881 
 % 0.9 24.6 6 28.7 18.6 15.0 0.2 5.9 100 
 
Table 8.8 presents the findings obtained for the overall use of the XELOX package 
before and after treatment, expressed as number of taps. The results indicated that the 
frequency of use was similar during the study period, with a small majority allocated 
after the first dose of treatment (ntaps=1333/2043, 55.5%, p<0.01). The pattern of 
section usage in each phase of treatment was also similar in terms of the priority given 
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to the different information areas. Figure 8.12 illustrates the differences for each 
section before and after treatment expressed as a percentage of the total tap count for 
each section.  The most noticeable differences were observed in sections 2 (information 
about cancer and treatment) and 4 (help with side effects), both of which were visited 
mostly before treatment (60.28 and 66.62% respectively).  




Before first dose of chemotherapy After first dose of chemotherapy 
Tap count (n= 1070, all 
XELOX users) 
% Tap count (n=1333, all 
XELOX users) 
% 
Section 1 28 2.6 24 1.8 
Section 2 201 18.8 305 22.9 
Section 3 60 5.6 65 4.9 
Section 4 245 22.9 489 36.7 
Section 5 237 22.1 172 12.9 
Section 6 169 15.8 122 9.2 
Section 7  21 2.0 18 1.4 
Section 8  109 10.2 138 10.4 
 
Figure 8. 12: Section use breakdown before and after treatment for XELOX 
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8.3.3. Section use for FOLFOX 
Details regarding users who received FOLFOX (nusers=5/23) have been presented in table 
8.4 and the user profiles have been illustrated in figure 8.7. The total tap count for 
FOLFOX (745) was smaller than that of XELOX (2043) and CAPE (1397). In FOLFOX, a 
single user (user15) dominated over the data. The median tap count was 105 (range 24-
388). Usage data (see table 8.2) revealed that two users (user 11 and user 12) used the 
app exclusively before treatment and collectively represented more than half of the 
total before treatment tap count for FOLFOX (ntaps=231/408, 63.9%). On the other 
hand, user 15 accounted for the vast majority of the total after treatment tap count for 
the entire FOLFOX package (ntaps=268/337, 79.5%). 
Table 8.9 presents the section breakdown (i.e. number of taps for each section) for 
FOLFOX .Information on medicines (section 5) and side effects (section 4) were the  
most visited sections. The symptom diary section (section 8) accounted for almost a 
quarter of the total tap count allocated to FOLFOX.   
Table 8. 9: Total taps and section breakdown for FOLFOX 
Total taps: 745 (5 users)   
App Section  Tap count % 
Section 1 (Search for a question) 20 2.7 
Section 2 (Information about cancer and treatment) 92 12.3 
Section 3 (Diagnostic tests) 32 4.3 
Section 4 (Help with side effects) 178 23.9 
Section 5 (Help with your medicines) 192 25.8 
Section 6 (Emotional support and help with finances) 46 6.2 
Section 7 (Triage Survey) 10 1.3 
Section 8 (Symptom diary) 175 23.5 
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Table 8.10 presents the results obtained for the section breakdown per user for 
FOLFOX. The majority of FOLFOX users (n=4/5, 80%) accessed more than half of the 
available app sections, while one user (user 15) utilised the entire set of sections. User 
15 was also the only user to access section 6 (emotional support and help with 
finances). A similar use pattern in sections 2,4,5 and 8 was observed for users 11, 12 
and 15.  
Table 8. 10: Section breakdown per user for FOLFOX 
User ID 
 App Section 
Total 
1 2 3 4 5 6 7 8 
User11 
Tap count 0 18 2 36 44 0 2 54 156 
 % 0 11.5 1.3 23.1 28.2 0 1.3 34.6 100 
User12 
Tap count 0 12 0 29 42 0 2 20 105 
 % 0 11.4 0 27.6 40 0 1.9 19.0 100 
User13 
Tap count 0 9 10 22 0 0 2 29 72 
 % 0 12.5 13.9 30.6 0 0 2.8 40.3 100 
User14 
Tap count 4 0 0 18 0 0 0 2 24 
 % 16.7 0 0 75 0 0 0 8.3 100 
User15 
Tap count 16 53 20 73 106 46 4 70 388 
 % 4.1 13.7 5.2 18.8 27.3 11.9 1.0 18.0 100 
A before and after treatment section use analysis was also conducted for this treatment 
regimen (Table 8.11). In the case of FOLFOX, the majority of use was performed before 
the first dose of treatment (54,8% versus 45.2%). In a similar manner with XELOX, the 
pattern of section usage (in terms of which areas were most popular in each treatment 
phase) was similar before and after the initiation of chemotherapy. The exception to 
this was section 3, which was utilised more at the post-treatment phase.  
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Before first dose of chemotherapy After first dose of chemotherapy 
Tap count (n=408, all FOLFOX 
users) 
% 
Tap count (n=337, all FOLFOX 
users) 
% 
Section 1 4 1 16 4.7 
Section 2 58 14.2 34 10.1 
Section 3 6 1.5 26 7.7 
Section 4 105 25.7 73 21.7 
Section 5 108 26.5 84 24.9 
Section 6 26 6.4 20 5.9 
Section 7  6 1.5 4 1.2 
Section 8  95 23.3 80 23.7 
Figure 8.13 presents the differences between each section before and after treatment 
as a percentage of the tap counts allocated in each section. For most thematic sections, 
the majority of use was conducted before the first dose of treatment. Two exceptions 
to this were sections 1 and 3, which were used mostly after the first dose of 
chemotherapy.  




8.3.4. Section use for CAPE 
 
Table 8.4 and figure 8.7 presented the results obtained for the user profiles of the CAPE 
information package (nusers=8/23). The tap count ranged from 26 to 541, with a median 
value of 84. Again, certain users dominated over the dataset; users 21 and 22 
accounted for more than half of the overall use in CAPE (ntaps=845/1397, 60.49%).   
An overview of the overall section use breakdown for CAPE is provided in table 8.12. 
Again, treatment-related information was the most popular domain, as sections 2 and 4 
accounted for almost half of the total visits (ntaps=684/1397, 48.96%).  
Table 8. 12: Section use for CAPE 
Total taps: 1397 (8 users)   
Section  Tap count % 
Section 1 (Search for a question) 24 1.7 
Section 2 (Information about cancer and treatment) 329 23.6 
Section 3 (Diagnostic tests) 28 2.0 
Section 4 (Help with side effects) 355 25.4 
Section 5 (Help with your medicines) 99 7.1 
Section 6 (Emotional support and help with finances) 201 14.4 
Section 7 (Triage Survey) 13 0.9 
Section 8 (Treatment diary) 348 24.9 
 
The section breakdown for each user (table 8.13) revealed that while sections 2 and 4 
were used by the majority of users (7/9 and 5/9 respectively), a single user (user 16) 
was primarily responsible for the total use of section 8 across CAPE (ntaps=232/348, 
66.7%). Similar to the other information packages, the majority of CAPE users (n=6/7, 
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85.71%) did not explore all available content; as with XELOX, some users (e.g., users 16, 
18 and 20) concentrated upon a single section, while others (users 22 and 23) 
distributed use across multiple sections.  




1 2 3 4 5 6 7 8 
User16 
Tap count 4 6 0 15 0 0 2 232 259 
%  1.5 2.3 0 5.8 0 0 0.8 89.6 100 
User17 
Tap count 0 16 0 32 10 0 1 6 65 
% 0 24.6 0 49.2 15.4 0 1.5 9.2 100 
User18 
Tap count 0 20 0 0 6 0 0 0 26 
%  0 76.9 0 0 23.1 0 0 0 100 
User19 
Tap count 0 57 0 0 14 0 2 30 103 
%  0 55.3 0 0 13.6 0 1.9 29.1 100 
User20 
Tap count 10 32 0 0 0 0 2 0 44 
%  22.7 72.7 0 0 0 0 4.5 0 100 
User21 
Tap count 10 172 18 127 47 115 6 46 541 
%  1.8 31.8 3.3 23.5 8.7 21.3 1.1 8.5 100 
User22 
Tap count 0 26 10 126 22 86 0 34 304 
%  0 8.6 3.3 41.4 7.2 28.3 0 11.2 100 
User23 
Tap count 0 0 0 55 0 0 0 0 55 
%  0 0 0 100 0 0 0 0 100 
 
For CAPE, there was a greater difference with regards to app use in relation to the 
treatment phase, as the majority of use was performed after the administration of the 
first dose of treatment (68.2 versus 31.8%, p<0.01). In CAPE, there were several 
differences with respect to the priority given to different sections according to the 
phase of treatment. Section 4 was given considerably lower priority in the post-
treatment phase, while sections 5 and 8 were more popular during this time (table 
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8.14).  Figure 8.14 provides an overview of the differences within section use before 
and after treatment in CAPE. The most noticeable differences were observed in sections 
5 (16.16% before versus 83.84% after) and 8 (13.79% before versus 86.21% after).  




Before first dose of chemotherapy After first dose of chemotherapy 
Tap count (n=439, all CAPE 
users) 
% Tap count (n=958, all CAPE 
users) 
% 
Section 1 6 1.4 18 1.9 
Section 2 108 24.6 221 23.1 
Section 3 12 2.7 16 1.7 
Section 4 158 36.0 197 20.6 
Section 5 16 3.6 83 8.7 
Section 6 86 19.6 115 12.0 
Section 7 5 1.1 8 0.8 
Section 8 48 10.9 31.3 31.3 
  





8.4. Semi-structured participant interviews 
 
Out of 23 participants who used the app in the main study, thirteen (56.5%) agreed to 
be interviewed. Nine were interviewed alone, while the caregivers of patients were also 
involved in four interviews. Six of these interviews were conducted face-to-face at the 
research site and seven were conducted via video calling. All interviews were recorded 
and transcribed verbatim. The interview time ranged from 25 to 80 minutes (mean time 
54 minutes). The patient characteristics are presented at table 8.15. As the animations 
remained the same across the first and second version of Manage your Health, 
perspectives upon the virtual agents (VAs) obtained from the pilot study were included 
in the main investigation.  
Table 8. 15: Interview participant characteristics 
User ID Interview 
ID 






User 1 M1 Male Face-to-face Yes Yes 
User 2 M2 Male Face-to-face Yes Yes 
User 3 M3 Male Face-to-face Yes No 
User 7  M6 Male Video call No Yes 
User 8 M7 Male  Video call Yes No 
User 11 F1 Female Face-to-face No No 
User 12 M4 Male  Face-to-face No No 
User 13 M5 Male Video call Yes No 
User 15 M8 Male Video call No No 
User 18 F2 Female Face-to-face Yes Yes 
User 19 F3 Female Video call Yes No 
User 21 F4 Female Video call No No 
User 22 F5 Female  Video call No No 
PS1* PS1* Male Face-to-face Yes No 
PS2* PS2* Male Face-to-face Yes No 
PS3* PS3* Male Face-to-face Yes No 
 * Participants from the pilot study 
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The semi-structured interview guide is provided in appendix 17. There were five main 
discussion points, namely: 
 a) general perspectives on the app 
 b) app usability 
c) perspectives upon the VAs,  
d) information needs and satisfaction with information  
 e) recommendations for improvement. The following sections will present the results 
for each discussion point.  
8.4.1. General perspectives on the app 
Overall, the app received positive feedback from users. A recurring theme was its 
capacity as a reference point that patients could use in order to revisit information that 
was not retained from consultations or obtain new information that was not provided 
by healthcare professionals. Some participants explained that the app inspired a sense 
of reassurance, as it confirmed the information they received, helped them understand 
that what they went through was normal and that help would be available if needed. 
The app also helped patients prepare for their upcoming treatment, provided advice on 
how to make right use their medicines and prompted them to seek help when required.  
“...So, everything is new and so this is all a big learning curve, the whole medical 
process. So, there’s lots of questions that you can’t think of asking all at the same 
time. So as things come into your mind you can then refer to the app to get some 
answers.” (M6) 
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Several participants reflected upon some potential benefits the app could offer. 
Reflecting upon their experience, users thought that the app could help other patients 
who were on their own during treatment. Others explained that the app could save 
time for the clinicians, as the patients used the app to retrieve information instead of 
referring to them. One participant made multiple remarks upon the potential cost-
savings for the NHS, as the app could help limit the resources that patients would use in 
order to fulfil their information needs.  
“... I think that would have saved the NHS some money because it meant I didn’t 
ring anybody up and bother them [mmm] because I got the answer that I 
wanted, that I needed, and it was trustworthy and reliable and accurate and it 
helped put my mind at ease ...” (M2) 
App versus other sources of information  
Several users identified a number of benefits that the app provided over other 
information sources. Some users explained that the app offered a greater degree of 
accessibility to information, as it was regarded to be more convenient, portable and 
allowed users to better navigate through the information they were after. The app was 
also considered to be more engaging and supportive than printed material and web 
information. The content of the app was deemed to be more targeted and reliable, 
especially compared with the information retrieved from the internet.  
“... for me, the app has been designed by somebody who knows what they are 
talking about and is giving actual useful advice for my problem so that would be 
the place I would go to when I wanted some new information.” (F3) 
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While the app was received well, the majority of participants expressed a preference for 
information sources offered as part of standard care. Some users explained that printed 
material was more comprehensive and more usable than the app. Two users appeared 
to value information sources that were endorsed by the healthcare professionals, 
including leaflets and official websites. A recurring theme was that older patients were 
not used to referring to apps in general, while utilising printed material to retrieve 
information was a much more familiar practice. Printed material appeared to be the 
most common source of information among the sample, followed by health 
professionals and the internet.    
“As much as computers want to take over the world and make us a paperless 
state, I'm afraid there will always be lists of things somewhere [yeah] [mhmm].  
You, you just need something on paper.” (F3)  
Just over half of the respondents had used at least one health app in the past. This 
included built-in health apps (e.g., iHealth), apps for weight management, fitness and 
NHS apps (e.g., Patient Access). When asked to compare Manage Your Heath with 
these, most users thought that the study’s intervention offered a number of benefits 
over past health apps. Manage Your Health was regarded as being completely different 
to these apps, more reassuring and interactive. 
“...But [Manage your Health] is way more detailed [mmm] the one that you’ve 
created, [there] is absolutely no comparison and it’s basically like having, like at 
any time of day, like a nurse available that you could just ask questions to so it 
was really helpful in that respect.” (M2) 
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Some patients thought that Manage your Health was more targeted than previous 
health apps, as it was tailored to their unique treatment regimen. Yet, some 
participants regarded the project’s app to be less specific.  
“... I think it has its limitations, which is fair enough because it a general 
application...I suppose it's a bit more basic in that it's not - well, at least it didn't 
feel that it was... tailored to me specifically... although, working out the calories 
and food is different whole thing but it - I don't know, somehow it felt more - 
they felt a bit more personal somehow.” (F5) 
One patient explained that the app was not perceived as personalised due to the lack of 
unconstrained user input.  
“... I suppose it's not possible to have an app that can instantly respond to what 
you're telling it... it was more one way, wasn't it really? It was just erm, 'I-, if it's 
this, go to this.'... although it was responding to what you're clicking on, it's not 
responding to how you would if you were talking to it...” (F5) 
The role of family and caregivers  
The majority of users shared the app with members of their family and/or their 
caregivers. One user also mentioned sharing it with friends and received positive 
feedback from them. In general, the patients were the ones who used the app mostly. 
In the case of M1, the patient’s caregiver was the principal user of the app and 
encouraged the patient to use. User F1 shared the app with her partner, with whom she 
used it equally. One patient explained that users who might struggle with using apps 
could utilise help from their family environment.  
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“Well, there’s always somebody in the family [yeah] who’ll be able to help you or 
extended family who’ll be able to help you.  They might have to show them a few 
times, but they eventually will, will comprehend, mmm.” (M3) 
Overall use of the app  
A similar pattern of use among the participants was identified through the interviews. 
The app was provided to patients and/or their caregivers a few weeks prior to their first 
treatment cycle with CAPE, XELOX or FOLFOX. During this time, users appeared to 
explore the various sections of the app in order to familiarize themselves with the 
content. Some participants explained that they used the app more frequently at this 
stage, while others explained that it was not relevant to them. The information that was 
sought after the most concerned the upcoming treatment, with particular emphasis 
upon the potential side effects of chemotherapy.  
“... when I first had the app downloaded, I went through it completely so that I 
could see exactly what information was contained in there so that in the future if 
something came into my head, I would know that I could find the information on 
the app.” (M7) 
While patients used the app to search for general information in the pre-treatment 
phase, they appeared to seek more targeted information after receiving the first dose 
of chemotherapy.  
“... So, you look at the general picture but then later on in your treatment, you 
just want specific information.” (F4) 
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In general, the use of the app declined at the post- treatment phase.  
“To start with, I wanted to use it all the time and now, as it’s gone on, I don’t 
really use it ... at the beginning, you want to know all the information and just 
visit whatever you can [mhmm] but now I’m just taking it easy, so I don’t really 
look into anything.” (F1) 
After receiving the first dose of chemotherapy, the majority of participants explained 
that they used the app on a ‘as needed’ basis in order to check any new side effects of 
treatment, find out whether what they experienced was alarming or remind themselves 
about aspects that they forgotten. A few patients used it in order to keep a record of 
their symptoms, while others explained that the app wasn’t helpful to them at this 
phase, as it didn’t contain any relevant information. One user explained that once being 
reassured that what was experienced was normal and there was no immediate risk, the 
app was not needed anymore.  
“... I suppose it became erm, more personal to what I, I was experiencing 
physically, so that's when I used it and erm, I was getting a bit alarmed by some 
of the side effects.” (F5) 
 Phone versus tablet version  
Five users had installed Manage your Health on a tablet device. Out of them, four also 
had it on their phone and one was using it exclusively from his tablet. Two of these 
users preferred the phone version, as it offered better portability.  
 238 
“On my phone because I’ve always got my phone with me.  It means going 
upstairs to get the iPad er, to come down, to do exactly what I can do in my 
phone.” (M3) 
The other two users preferred the tablet version, as it was easier to use the app on a 
large screen.  
“I use the tablet more but that's because I can't see the phone properly [mhmm].  
My, my eyesight is not good enough anymore, so the, the iPad was just much 
easier to read.” (F3) 
One user had the app installed on a personal tablet and had the phone version on the 
caregiver’s phone. The caregiver explained that having the app on a personal device 
was a good thing, as it offered better privacy.  
“...I think it’s a good idea for him to have it so that he can, in private, without, if 
he didn’t want to go through me [oh yeah], he didn’t wanna worry me or 
something, if he’s got it on his tablet, then he can access it without involving me, 
if he’s worried about something and wants to check it direct...” (partner of M1) 
Barriers to use and factors affecting use  
The age of users was the most frequently mentioned barrier to use. One prominent 
view was that as older individuals who did not have access to apps when they were 
younger, they are less likely to use them as part of their everyday routine. 
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“... If you’re used to using apps then I think it would be very easy. It’s only for my 
generation that weren’t brought up on apps; it’s a whole learning curve for all of 
us in all sorts of apps. And yours in no harder than any others.” (M7) 
One argument was that apps might be more relevant to younger users.  
“I think an app for younger people is very apt. ...  Younger people don’t read 
books, but they’ll read er, what’s on an app and I think that’s very relevant for [a] 
younger generation.” (partner of M3) 
Another age-related issue was the degree of information technology (IT) literacy. Again, 
it was suggested that older individuals might not possess adequate IT skills, which 
would make the prospect of using apps challenging. Yet, several users older users 
explained that despite their limited IT skills, the app was not hard to use.  
“I think you need to be a bit confident about using apps. I think as an older 
person, it’s a little bit daunting at first, you think, oh it’s going to be difficult, but 
it isn’t, it’s very easy, it’s very straight forward.” (F2) 
In addition to the barriers outlined above, there were also several factors that affected 
the use of the app. It appeared that users who tolerated treatment well and did not 
suffer from much toxicity didn’t need to use the app much after treatment, as they did 
not experience symptoms or side effects that they felt necessary to refer to the app for.  
“... So erm I’m getting through the chemotherapy itself quite well. So, I haven’t 
felt for that reason a need to use the app...” (M5) 
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In another instance, a patient who tolerated treatment well refrained from using the 
app in order to avoid coming across any unpleasant information.  
“...we were focused more on us to enjoy how he was instead [of] looking for 
something [that] we didn’t experience, [that] we didn’t see in him because he 
was ok every single day from this first day till today I would say he didn’t have 
chemo even, he’s so good, it means err I didn’t want to look for something [that] 
I didn’t need and even I was maybe a bit scared to look for something and find 
something which already I didn’t have...this was the main reason why err I didn’t 
err touch [the app]...no need to go deeper because I thought we were relatively 
ok, good, and we were focused just, you know, to keep him going in this good, 
erm, err spirit...” (M6) 
The other important factor was the level of users’ knowledge. A repeated finding was 
that patients didn’t feel that the app was going to add to their knowledge, as much of 
their information needs were already met. As these users were already familiar with 
various aspects around their condition and its treatment, they did not need to use the 
app often.  
“...I suppose as I already had a reasonable amount of knowledge already 
provided for me, I suppose I didn't need to go over as much of that, maybe, as 
someone else who hadn't taken onboard all the stuff - the information that 
you're given at the start.” (F5) 
Finally, as the level of knowledge increased throughout treatment, users didn’t feel the 
need to refer to the app.  
 241 
“To start with, I wanted to use it all the time and now, as it’s gone on, I don’t 
really use it because... just at the beginning, you want to know all the 
information and just visit whatever you can [mhmm] but now I’m just taking it 
easy, so I don’t really look into anything.” (F1) 
8.4.2. Comments on usability and content 
After presenting their general perspectives upon the app, the participants were asked 
to comment on the usability and the content of the app. Only one user did not consider 
the app to be usable. This was because this user struggled with the symptom calendar 
function, which ultimately led to attrition.  
“I stopped using [the app], and I used the booklets instead (...), just because er... I 
suppose - frustration, [because when] I tried to use the diaries and so on and I 
didn't find it usable, [I] started doubting [the] relevance of the thing and I started 
looking elsewhere...”. (M4) 
The remaining patients believed that Manage your Health was easy to use and did not 
require help in order to utilize the app. This was true even for certain patients with 
limited IT skills.  
“It was very easy and I'm a complete technophobe.  I'm not very good with 
computers and things... So, if I found it easy, you're a winner [laughter].” (F3) 
Some users (both young and senior) explained that regardless of age and IT literacy, the 
app should be straightforward for most individuals.   
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“...if you only [use] the phone for calling someone erm, and you're not, not used 
to technology, then obviously it's going - it's slightly problematic but I think most 
people - people who are my age now are erm, coming around to the convenience 
of being able to use a Smartphone. So, I should think it - they would find it quite 
easy.” (F5) 
The users also reflected positively upon the app’s content. The vast majority expressed 
satisfaction with the content, as well as the way that the information was organized. 
The information within the app was considered to be reliable, straightforward and 
relevant to users’ needs.  
“…if you’ve entered the questions and you’ve designed the app and this is a trial, 
that’s a really impressive job that you’ve done so far because it’s pretty much 
there I think so nothing, nothing that I would change.” (M2) 
While most users appeared to be satisfied with the amount of information, some 
expressed a desire for more in-depth explanations through the app.  
“...I think probably on some of the questions, and I can’t remember which ones, 
maybe the answers could’ve been slightly longer. They were a little bit short. Erm 
yeah, I think some of them could’ve been slightly longer answers to the 
question.” (M7) 
8.4.3. Virtual agents 
Interview data from the pilot study around this topic were incorporated into the main 
study’s dataset. This was because the VAs of the updated version of the app were not 
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altered and therefore, feedback obtained from the users of the pilot study was still 
relevant. The details of the patients from the pilot study can be found in table 6.1 (p. 
176). Ultimately, the part of VA-related analysis for the main study included 16 patients.  
Six main thematic categories emerged from the interview data, namely: 
• general comments, 
• effect of VAs upon information, 
• effect of VAs upon user experience, 
• perceptions on the appearance of the VAs, 
• perceived role of the VAs, and 
• quality of graphics and VA realism 
These categories are presented in detail below.  
General comments  
When patients came across the VAs for the first time, many identified a humorous 
element in them. Most of these users explained that the reason behind this reaction 
was that the VAs were perceived as cartoon versions of the treating clinicians.  
“Erm, why would it be funny?  Erm, well, I suppose because you've seen them in 
real life and then there's limitations to the technology, so they look - although 
they're similar to how they look, they're not really how they look.  So, it's like 
erm, more of a caricature than - er, than the real thing.” (F5) 
One view was that this could potentially help some to better concentrate upon the 
information.  
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“... You know, if it does raise a bit of a giggle, maybe it’ll get their attention a bit 
more... you know [okay]. There’s a, there’s a positive out of it like that.” (M3) 
In general, the use of VAs appealed to users. Several participants made statements 
indicating that they were impressed by the VAs and one user (M1) mentioned receiving 
positive feedback from friends who saw the app. However, some explained that they 
were not keen on this concept, primarily due to the perceived poor quality of graphics, 
while others suggested using video recordings of the clinicians instead of VAs. Yet one 
participant pointed out that unlike videos, VAs gave the impression of interaction, 
which was important for engagement. 
“... at least when you click on the avatar, you’re drawn to it because it’s talking 
like, ‘Hi hello.’  In a video, you click on it and then you think, ‘Oh, I can’t actually 
be bothered to watch this,’ so then you just pause it and stop.” (F1) 
One prominent theme was the benefits of using verbal over written information. Three 
participants explained that having VAs narrating information was more appealing than 
having to read text.  
“The fact [that the oncologist] is there and he’s saying something in a normal 
human voice and erm, I think that’s – I think that’s good. People sort of – kind of 
I think people expect that these days, they don’t want to just to be reading text. 
Especially with a subject like cancer...” (PS1) 
Written information was sometimes perceived as tiring and confusing, while verbal 
information was considered easier to follow. According to some, verbal information 
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allowed for placing emphasis upon the most important points, which is not always 
possible with text.  
“... the important part of a sentence can be emphasised in speech, but you can't 
emphasise it properly in a text, unless you're going to be underlining or making it 
big, big and even then, you can read it wrong.” (F3) 
Some participants also explained that verbal information would be a suitable alternative 
for users with limited language skills, particularly reading, as well as users with learning 
difficulties. Yet, one view was that users should be given the option to choose between 
verbal and written information, while another suggestion was that the decision to 
animate the content should depend upon the complexity of information.  
Effect of VAs upon information  
Participants made several comments regarding the effect of VAs upon the information. 
A finding was that the VA made the process of information-giving less formal, which 
wouldn’t be the case if a video recording was used instead. The humorous element of 
the VA also provided some relief, as conversations around cancer were deemed to be 
‘heavy’.  
“I think [the VA) makes it better. I think it gives a bit of light relief in a heavy 
subject. I think it’s a little bit of amusement there, erm if that’s the right word 
[laughs]. [when asked to explain this further, the participant continued:] Well 
just it makes it more real, but there’s a little bit of – perhaps a little bit of humour 
erm added into it which makes it not quite such – I don’t know – lightens it 
slightly.” (M7, VA familiar) 
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The humorous element of the VAs did not necessarily distract attention from the 
information.  
“...I think you would look at it initially and have a quick laugh, but then you get 
down to the real point of what you’re trying to get the information...” (PS1, VA 
familiar) 
Some users thought that the inclusion of a VA aided their understanding, which was 
counteracted by others who believed that the VAs didn’t have an influence upon the 
comprehension of information. This was either because the patients were comfortable 
with written information or because they were not satisfied with the graphics. 
“Obviously some people don’t understand stuff when they read it.  Well, I, I don’t 
and – but someone saying it and it actually looks like a person, so you think, 
‘Okay, this is actually coming from someone,’ it sinks in a bit more.” (F1, VA 
unfamiliar) 
Comments regarding the influence of a familiar VA upon the information emerged as a 
separate theme. Some participants expressed that having a familiar VA made them 
listen to the information more closely.  
“... you’ve had that connection with that person [the clinician representing the 
VA), so you listen intently to what he’s saying, [mmm] yeah.” (M3, VA familiar) 
Another patient who wasn’t familiar with the healthcare professionals portrayed by the 
VAs believed that having a VA of a familiar clinician would provide better consistency 
and explained that this could help settle users.  
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“I would probably click on [my oncologist] because that would be your doctor 
explaining stuff... at least you know your doctor is giving you that information 
and it’s not different information from different people. [when the patient was 
asked what difference a familiar VA would make, the following response was 
obtained:] Yeah, because [mhmm] it just settles you a bit... Settles you a bit like 
thinking, ‘Okay, that’s my doctor. They’re telling me this.’ It’s not a different 
person every time, like [laughter] telling you different things.” (F1, VA unfamiliar) 
One prominent theme (i.e., repeated by a lot of participants) was that information 
provided by a familiar VA was deemed as more reliable than having a generic VA. This 
was attributed to the trust that patients had upon their doctors’ knowledge and 
expertise.  
“And I think it gives you more of a... sense of gravitas and security that that is 
your doctor and so he's telling you that's the information, so you - that's it.  I'll 
believe him, you know.  I've met him.  I know him.” (F3, VA familiar) 
Effect of VAs upon user experience 
In addition to the influence of the VAs upon information, the participants also offered 
several comments regarding the effect of the VAs upon their general user experience. A 
repeated theme was that the VAs added a personal touch to the app. This was 
suggested primarily from users who were familiar with the clinicians represented by the 
VAs, although participants who didn’t know these clinicians also brought this up.  
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“... after a few seconds, you forget it’s just [an] avatar, you just think you are 
talking to the other person, when you are in difficult times it’s important that you 
feel it’s somebody’s eyes you can talk to ...” (M6, VA unfamiliar) 
Some participants believed that the VA gave the impression of a face-to-face 
conversation. One patient thought that the VAs could inspire empathy, while another 
explained that the VA provided the impression of human contact during adversities.  
“... the important thing is the people that are doing the speaking come across as 
human, ..., you can understand what they’re saying and there’s a bit of you 
know, there’s a bit of empathy there. They’re not sort of laying down the law to 
you; they’re just giving you friendly advice.” (PS1, familiar VA) 
While some participants identified an interactive element in the VAs, others did not get 
such impression. These users explained that as there was no input from their side, they 
did not perceive the VA to be interactive. One of these individuals suggested that the 
interactive element could be introduced if users were able to speak to the VAs in order 
to ask questions and/or keep a record of how they felt.  
“... if there was a little avatar that popped up, I suppose, and said, 'How are you 
feeling today?' or 'Isn't it marvellous you're halfway through your treatment?’...” 
(F5, unfamiliar VA) 
The influence of having familiar VAs emerged as a separate theme. Several users 
mentioned that having a familiar VA made the app more relevant to users. The most 
prominent theme was that having a familiar VA inspired a sense of confidence and 
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reassurance. This perspective was offered by users who were familiar with the VAs, as 
well as users who didn’t know these individuals. 
“... if you’ve seen [the healthcare professional] and if you’ve got the connection 
with [the healthcare professional], so his voice is reassuring, if you saw a doctor 
– heard a doctor and this voice, you’d think, ‘Oh, well I don’t know this man. He 
doesn’t know anything about me.’  That’s how some people will think.” (M3, 
familiar VA) 
One participant explained that having an established personal relationship with the 
oncologist upon whom the VA was based could potentially inspire a sense of security 
upon users.  
“... I suppose the influence [of having a familiar oncologist] wouldn't be that 
great erm, for me because I didn't really have much of a relationship with 
them ... but if it was someone who was more affected by the disease ... and had 
far more appointments and had built up erm, a relationship, then I, I would guess 
that that would be quite - erm, quite an influence, I'd say, yeah. [when the 
patient was asked to explain this further, the following response was given:] Er, 
well, in the way of making you feel more secure; making you feel that you 
weren't quite on your own with it; and erm... that erm, there was a, a general 
'we are looking after you' feeling, you know erm, even if you are at home sort of 
thing on your own.  I would imagine that's how you would feel.”  (F5, VA 
unfamiliar) 
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One view that linked with the comment above was offered by M8, who explained that 
despite not having extended interactions with the treating consultant, having a virtual 
version of this consultant made a difference and explained beginning to form a 
relationship with the VA. Another participant suggested that a familiar avatar can give 
users the impression of connecting with the real health providers, who might not 
always be available in practice.  
“... you don't see your oncologist very much which I understand because they're 
very busy ... and they're obviously working very hard in the background, but I 
guess, you know, psychologically, you would think that your oncologist was 
talking to you maybe.  I don't know.  I, I, I guess... so it might be a nice touch.”  
(F4, familiar VA) 
Appearance of VAs (characteristics) 
The appearance of the VA was the most extensive thematic category. Three main 
themes emerged: a) professional appearance, b) familiarity and c) customization 
potential.  
Users suggested that the VAs should look like health professionals. The most prominent 
reason was that such professionals possess the knowledge and expertise and were 
therefore were the most appropriate and trustworthy agents to deliver medical 
information. One participant also explained that this introduced a sense of realism (e.g., 
simulated a real-life scenario where advice would be sought by an expert). It was also 
suggested that fellow patient VAs would be useful for narrating patient experiences 
with treatment.  
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“Erm well if you’re being told something about a medical issue by a doctor and 
that person appears to be a doctor erm you’re gonna take more notice of it than 
if erm you deal with somebody who isn’t a doctor but erm is just handing out 
information. ...” (M5, familiar VA) 
Another suggestion was that different types of health professionals should be used 
according to the types of information provided. Expertise emerged again as the most 
important consideration.  
“... So, you have to have the pharmacist who does the drugs, and then you have 
to have the nurse who tells the patient about the personal stuff, and you have to 
have the oncologist and maybe you should have the surgeon as well. ... I think 
you should, you should show that everybody's involved.” (F4, unfamiliar VA) 
Several participants explained that having different types of VAs would give the 
impression of having a team of healthcare professionals attending to their unique 
needs.  
“But I suppose that’s true of every medical condition but err, I think for the first 
time, having you know, being in the centre of it really, you can appreciate how 
there is a whole dedicated group of people with different expertise err, and 
different knowledge, all combining to provide the best outcome for the 
individual ...” (M1, familiar VA) 
The familiarity of VAs emerged as another major theme during the interviews. Out of all 
participants who remarked upon this, most of them expressed a preference for a 
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familiar VA. These users explained that having an established relationship with their 
clinicians made them want to see them at the app.  
“... So, it’s almost – it’s not as good as [having a conversation with the real 
clinician] obviously – but it’s like being able to talk to the doctor that’s got 
control of your case or the nurse that you’re used to being with or the 
pharmacist. So erm I think there’s a value in having that relationship.” (M7, 
familiar VA) 
The trust bestowed upon the treating clinicians was another major reason. Also, some 
users believed that having familiar VAs introduced a more personal and realistic 
element to the app.  
“... I believe it’s a big connection between your doctor who you believe is saying 
the truth and wants to… which wants to help you erm, to carry on as long as is 
possible, it means for me, 100%, seeing the same face, advice from the same 
face, the same nurse for example, yes, this is very important for me and I would 
like to carry on this way ...” (M6, unfamiliar VA) 
While some participants explicitly expressed a preference for a familiar or unfamiliar 
VA, others explained that this wasn’t important, as they identified other priorities. Most 
of these users placed emphasis upon the content and thought that the mediator was 
not important.  
“From my point of view, I don’t mind who gives that information as long as it’s 
correct and they’re telling us the right information.  It’s not really that 
relevant. ...” (PS2, familiar VA) 
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One user believed that familiarity was not important but suggested that the VAs should 
look like healthcare professionals.  
“Does it really matter who, who, who it is, as long as they’re wearing a white 
coat and a stethoscope.” (M1, familiar VA) 
The quality of graphics was another reason that made familiarity irrelevant, as some 
users believed that the VAs did not resemble real humans. 
“To be honest, I think it wouldn't, it wouldn't make any difference [mhmm] 
because it's - er, to me, it's not terribly lifelike, if I could put it in those terms.” 
(PS3, unfamiliar VA) 
The logistical limitations of having every health professional turned into a VA for the 
purposes of the app was also brought up.  
“... So, in an ideal world, I suppose every consultant oncologist would [be given] 
one of those scripts and erm but that’s not necessarily very practical. I think 
getting that done would be a big ask. And erm so maybe just somebody who 
identifies as an oncologist, a consultant oncologist, not necessarily the treating 
consultant would be a good halfway house.” (M5, familiar VA) 
Two users explicitly stated that they didn’t want the VAs to be formulated after familiar 
health providers.  
“I’d probably prefer the generic person, I mean every time I go to the doctors, I 
see somebody different anyway [mmm] and I think, I’d open it up and I’d think 
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Jesus!! That’s my doctor, that’s a bit weird!! [fair enough] so probably just 
somebody I didn’t know really.” (M2, familiar VA) 
The customisation potential was another discussion point. Being able to formulate a 
custom VA in Manage your Health was not important for some, while one user thought 
that this would overcomplicate the app.  
“No, no. I think that would just complicate it and erm – and some people will say, 
‘Well what’s all this about?’. I think you would undermine what you’re doing.” 
(M5, familiar VA) 
The matter of gender was mentioned several times; most users thought that this was 
not important, but some participants explained that cultural influences or receiving 
information on sensitive/personal matters could potentially predispose some users 
towards choosing avatars that they would feel more comfortable with.  
“... I think if it's something very personal, I think - and aimed at a woman, I think 
they would prefer to be spoken to by a woman and I expect a man would feel the 
same way ...”. (F3, familiar VA) 
Quality of graphics and VA realism 
The last thematic category concerned the quality of graphics and the realism of the VAs. 
In general, users thought that the VAs were not realistic (i.e., they didn’t accurately 
represent their treating clinicians). Several users expressed that the VAs were seen as 
cartoon/caricature versions of the actual healthcare professionals represented in the 
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app. This was brought up by users who were familiar with the VAs, as well as users who 
did not encounter them before treatment.  
“So, I mean I referred to it as a cartoon because it's, it's not like I'm looking at 
you just now.  It's looking at somebody that's just kind of you know - painted isn't 
the right word for it but you know what I mean; just kind of erm, related to 
certain characteristics.” (PS3, unfamiliar VA) 
As mentioned in the first section, this elicited a humoristic response in most users.  
“Erm... it's funny when you see somebody made into sort of a, a cartoon type 
character, you know - er, an avatar.  It just, you know - 'Oh yeah!'  It's, it's - it just 
made me giggle, didn't it?” (F3, familiar VA) 
For some, the quality of graphics did not have an impact upon their user experience. 
Some users explained that they paid more attention to the fact that the avatars 
successfully conveyed the information.  
“... what matters is the speaking part of it. You do see somebody, okay it’s not 
brilliant, but you see somebody and they’re speaking clearly, and it gives you 
enough I think.” (PS1, familiar VA) 
On the other hand, the graphics appeared to undermine the user experience for some. 
One patient explained that watching a VA that closely resembled a known person 
caused discomfort and eeriness.  
“... it makes you feel a little bit queasy, when you are watching a nearly person, 
[mmm] it’s like watching a zombie movie because you are thinking like that’s 
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kind of like what a person looks like but not really [mmm] yeah, it’s a bit off-
putting.” (M2, familiar VA) 
One user made a stronger comment that indicated a clear sense of repulsion towards 
the VAs.  
“Well, I, I think, at the moment, they're a bit scary.  You know, [they're not], not 
particularly attractive to look at [mhmm].  ...  You know, you don't really want to 
look at them [laughter].” (F4, unfamiliar VA) 
A considerable proportion of users believed that the graphics could be improved in a 
future version of the app. Most of these users suggested to make the VAs more life-like.  
“Erm, I suppose more human like would be good. ... I mean it, it was the limit of 
the technology, wasn't it?  But I suppose these days, you can get - and probably 
quite expensive technology to get hold of but you can get more realistic 
representations, can't you?  So, that would be a good - that would be a plus I 
would think.” (F5, unfamiliar VA) 
When given the option of choosing between a realistic VA or a cartoon version of an 
individual, most users expressed a preference for a realistic VA.  
“... I would love to see the creation of an avatar as human as possible [mmm] yes 
because for me it’s very important, if I want to deal with something, if I want to 
ask something, if I want to hear erm, advice, the best way is to see somebody’s 
face, it’s the most erm… erm beneficial for me, yes ...” (M6, unfamiliar VA) 
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While most users favoured realism, others preferred to have a cartoon version of 
healthcare professionals.  
 “... I think it might be quite fun to hear from a cartoon because erm, children like 
cartoons and, and they're easy - you know, people have good associations with, 
with cartoons. ... this business is all a bit serious; you know.  Cancer is rather 
serious so actually, to make it - to lighten it up a little bit, you know, a cartoon 
might, might not be a bad idea.” (F4, unfamiliar VA) 
It was also suggested that the VAs should either be realistic or look like cartoon versions 
of the actual healthcare professionals.  
“... if it was so good that you couldn’t actually tell whether that was not a person 
speaking to you, the face, that would be fine, but when it’s not quite there as a 
person, the way it looks like a person or it moves in a little bit of an unusual way, 
I would prefer it to be totally the other end of the scale and clearly not a person, 
like a cartoon face or something”’ (M2, familiar VA). 
8.4.4. Information needs and satisfaction with information  
Types and volume of information  
In general, it appeared that patients actively sought information both before and after 
treatment. While some expressed a desire for as much information as possible, others 
preferred to focus upon existing issues and/or avoided information that could 
potentially be upsetting.  
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“... I’ve been trying not to err dwell on the problem and… and only look up 
information if I feel like I really need to know ... I don’t necessarily want to flick 
through all the things that could go wrong and all the symptoms because then 
you start to believe you’ve actually got that thing sometimes...” (M2) 
The most important types of information concerned treatment-related matters. What 
seemed to concern most patients were the side-effects of their treatment and what 
happens during the course of chemotherapy. Cancer-specific information such as the 
aetiology of the disease was another important area. While some users mentioned 
explicit categories, others believed that the importance or relevance of information was 
related to the phase of treatment; in other words, information needs change across the 
care pathway.  
“...I think the section, the sections were all very – they were all very good and 
very relevant er, in terms of the app but sometimes may not be applicable to the 
person at that time...” (M3) 
One prominent theme was the issue of ‘information overload’. Several patients 
received an overwhelming amount of information during their consultations and 
explained that this was difficult to cope with. One participant explained that this is not 
only time-consuming, but it can also induce a considerable amount of stress upon 
patients.  
“...I was having to take in so much information that day that erm it was – it was 
a bit too much in erm – in a short period of time...” (M6) 
Sources of information 
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Most participants utilised a variety of sources in order to retrieve information. The most 
prominent source was printed material (mentioned 9 times), which included leaflets 
from the hospital and/or supportive organizations (e.g., MacMillan). This type of 
information material was received well by all participants. Printed material was deemed 
as straightforward, inclusive, reliable and relevant to patients.  
“...Because I’m an older person I tend to read more than use apps. But I think 
when I get used to working with apps then it could take the place of the reading 
material, but it’s just a generational thing, I think...” (M7) 
Although the internet was the second most popular source, several users explained that 
they were cautious when looking for information online. Some explained that they 
often came across conflicting and/or confusing information, while two participants 
expressed concerns regarding the reliability of information that patients might come 
across on the internet.  
“...I sometimes use the internet but erm, not that much because it’s sort of, it’s 
so vast and you know, the amount of information on there sort of can be a bit 
confusing...” (M6) 
Clinicians were the third most common source of information. Patients appeared to be 
comfortable to refer their queries to healthcare professionals and recalled having 
positive experiences with information exchange. Three participants stated that health 
providers were their most preferred source of information, as they inspired a sense of 
reassurance and comfort.  
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“I think seeing - probably erm, face-to-face with the nurse, I suppose that was 
reassuring.  Erm, you saw her once a week on an appointment basis erm, but - 
although, you could see her any time and when, when the symptoms were a bit 
more severe erm, I did see her more often.  So, I think that was the most 
reassuring really”’ (F5) 
8.4.5. Recommendations for improvement 
General recommendations 
The users made a series of recommendations for improving the app. Some general 
recommendations concerned making the instalment process easier, fixing several 
unresponsive buttons, improving the search function and continuing with a home 
rather a cloud version of the app (i.e., an app that functions without the need for 
internet connection). 
Some participants proposed implementing changes that would encourage more 
frequent use of the app. These patients proposed that the app could push notifications 
in order to encourage the user to engage with the app. These notifications included 
notices about appointments, reminders about taking medications and alerts about side 
effects. One user suggested that these notifications could be pushed via avatars instead 
of text.  
“...it would give you a reason to check in every day as well, if you had an alarm or 
something... an avatar popping up on your screen on your phone saying, 'Have 
you remembered to take your chemo,' or 'Did you remember not to take your 
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chemo today because it's Saturday?'  You know that sort - that's the sort of 
interaction I suppose that it was lacking...” (F5) 
The same patient also suggested to use avatars in order to encourage patients 
throughout their treatment.  
“...It's, it's just saying, 'You've done really well so far. This is, you know, a 
milestone. This is your first week out of the way,' and, you know, all those sorts 
of things.” (F5) 
Finally, one patient suggested that the app could include a function for tailored dietary 
advice, such as caloric consumption according to the user’s physical activity.  
“...you know the app thought well you’ve done 3,000 steps today, therefore you 
probably don’t need as much food, here’s some dietary advice [mmm] or you’ve 
done 15,000 steps today, you could probably eat some more, here’s some dietary 
advice…” (M2) 
Medicines section  
Two users suggested enriching the ‘Help with your Medicines’ section by adding 
functions that would allow patients to create a personalised record for their medicines, 
take notes of the doses and the frequency of administration for their medicines and 
receive advanced alerts about running out of medicines.  
“Does it link to anything sort of within the hospital, I mean is there anything in 
the app that sort of, you know, if you were recording what medication you were 
on, on there, if you were able to do that and you were running out of it…” (M2) 
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Treatment diary  
The participants offered several recommendations about improving the treatment 
calendar. The most commonly encountered issue was the input of data, as the 
participants who made negative remarks didn’t appear to know how to record the side 
effects they experienced. Another recommendation was to allow patients to record not 
only the intensity of the adverse event, but also the number of incidents and the time 
they were encountered. 
“...if one can have - er, can add to it when it happened, the time and what have 
you, that would be, that would be useful, yeah, [mhmm], yeah.” (M4) 
Some participants suggested that the calendar function should allow users to enter test 
results and measurements such as body temperature and blood pressure. Two 
participants suggested that the diary should provide a visual output such as a graph so 
that users could observe the course of a particular side effect over time. One user 
suggested that the treatment diary could be connected to a hospital database in order 
to record real-time data and that it could alert patients to call triage if they experienced 
any significant toxicity.  
“...there should be like a function that's integrated with the diary and what have 
you.  [If I log] my symptoms regularly and [this is] linked to this thing that alerts 
you to like contact triage and what have you...” (M4) 
One user suggested that the diary function should allow users to keep a food calendar; 
this user also suggested that the calendar could indicate if the consumption of any 
particular foods had a negative effect on patients.  
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Information content  
Recommendations for improving the content included better explanations of side 
effects, improving the readability of written information, and embedding patient videos. 
Some users also expressed a desire for more personalised information. One indirect 
finding was that the information on staging was not in accordance with the hospital’s 
staging system, which caused confusion in one patient; this piece of information should 
therefore be altered for future users.  
8.5. Semi-structured clinician interviews 
Five members of the research team took part in the interviews (table 8.16). The first 
member was interviewed at the research site (Churchill Hospital) and the remaining 
interviews were conducted remotely via Microsoft Teams due to logistical and time 
restrictions. All interviews were recorded with the clinicians’ permission and were 
transcribed verbatim. There results of the semi-structured clinician interviews are 
outlined below.  
Table 8. 16: Clinician characteristics 
Clinical specialty  Gender Participant code 
Consultant Oncologist  Female Oncologist1 
Consultant Oncologist  Male Oncologist2 
Consultant Oncologist  Male Oncologist3 
Colorectal Specialist Nurse Female SpNurse 
Consultant Cancer Pharmacist Female CPharmacist 
8.5.1. Experiences with app users 
Most clinicians could not recall specific comments made by app users but asserted that 
most feedback they received throughout the study was positive.   
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“...I couldn’t tell you who it was exactly, but I mean, all the replies that I got were 
positive...in those patients I spoke to [were] very positive about the app. Erm, you 
know found it easy to use erm, straight forward from that perspective.” 
(Oncologist 2) 
The specialist nurse presented recollections indicating feelings of reassurance and a 
sense of trustworthiness on the patients’ behalf.   
“So erm, we’ve had sort of feedback from patients that it’s been really helpful to 
be able to erm, have 24-hour access to erm, the clinician’s advice... They didn’t 
elaborate much just said that it was helpful to have that on their mobile device, 
cause otherwise if in the middle of the night, they were worrying about 
symptoms, so probably look on Google and not always get the right advice so 
they found it reassuring to know that they just had to look at the app and they 
could find the right information.” (SpNurse) 
The consultant pharmacist recalled one incident where the app encouraged a user to 
contact the Triage helpline, which turned out to be necessary.  
“...it sort of reinforced for me that actually the app had kept that patient safe... It 
may well have been that they would have used some of the paperwork we have 
given them and they have come to the same conclusion and it might have been 
the same outcome, but the patient specifically told me, in clinic, that it was due 
to using the app that they have contacted Triage.” (CPharmacist) 
The third consultant and the pharmacist, both of who appeared as VAs in the app 
recalled having patients mentioning that they recognized them in the app but did not 
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receive any further comments on how this affected the process of receiving 
information.  
“...well they laughed because those that had met [the pharmacist] and myself, 
they made some comments about how we looked [laughed] but they did 
recognise us and what you know what the app was trying to do. [when asked to 
explain whether this was a positive or negative aspect, the oncologist replied:] 
Well, they certainly didn’t say it was negative I mean they didn’t specifically say it 
was positive [laughs] they were just amused by the actual avatar I think.” 
(Consultant 3) 
8.5.2. Effect of the app on patients’ knowledge 
Some thought that the app could have exerted a positive effect upon patients’ 
knowledge, since it offered an additive source of information that would reinforce 
advice provided as part of standard care and allow patients to access information at 
their own time. Yet, such effects did not become apparent throughout the study. Two 
clinicians suggested that this was due to the absence of a set of standardised measures 
for captivating any benefit on knowledge, as well as a ‘control’ group to compare 
findings with.  
“...maybe it would have been better to actually formalise our thoughts and 
maybe we could have done a simple questionnaire on going through with a 
patient who was using the app and had some structured questions and going 
through those same questions for somebody that didn’t have the app, just to see 
if you could tease out any differences...” (Oncologist 3) 
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8.5.3. Effect on consultation time 
The consultants did not observe any changes in the duration of the consultations. The 
first oncologist explained that the app wouldn’t have any effect upon the pre-
chemotherapy consultation, as the consent process involves explaining a considerable 
deal of information that needs to be addressed thoroughly, irrespective of patients’ 
previous knowledge. For subsequent consultations (e.g., first chemotherapy review 
appointment), this consultant believed that the app could potentially help speed the 
process of toxicity review if patients logged their symptoms throughout treatment.  
“...the treatment diary is actually quite useful...because it would be a, a quick 
glance at toxicity and seeing it objectively written down rather than trying to 
tease it out of somebody who doesn't specifically know what you're asking for.  
So, from that perspective, it might be helpful, I think, and it might sort of speed it 
up and just more quickly get a more accurate view of what their toxicity has 
been.” (Oncologist 1) 
A similar remark was made by the second oncologist, who explained that the way in 
which patients present toxicity can add considerable time to the consultation and could 
potentially be improved through the app. This oncologist also thought that the app 
could potentially help patients prepare for their review consultations, which could in 
turn facilitate the process.  
“I don’t think there was a huge difference [in the duration of consultations], I 
think probably though, you know you were able to focus on the salient points a 
bit quicker in those patients that had the app. [Because] they sort of had an 
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understanding of what we were going to ask them, and you know, and had a 
more of an idea. I mean you do get some patients who you know come in with 
reams and reams of paper...which often takes twice as long to do a consultation 
with them. Whereas you know if you’ve got that information already on an app, 
you sort of bypass that side of things.” (Oncologist 2) 
8.5.4. Perspectives on the app and recommendations for improvement 
The clinicians presented several potential benefits that the app could provide to users. 
One oncologist explained that becoming knowledgeable is a common strategy that 
patients deploy in order to of take control over their condition and the app could 
potentially be of benefits in this respect.  
“Anything that allows [patients] to take some control over their disease is useful 
and erm, there certainly will be a subset of patients who - they like being able to 
be actively involved and this will allow them to do that. So I think that - I'm all for 
that.  I think that's very useful.” (Oncologist1) 
Another remark concerned was the portability offered through the app. The pharmacist 
explained that patients are given an excessive amount of paperwork in order to receive 
information, while the app could help them organise it all in one place and access it in 
their own time. The colorectal nurse mentioned that the app would be easily accessed 
in occasions where patients would need quick access to such information.  
“... they might be away on holiday or visiting family and they happen to 
experience something that they might think is associated with their treatment 
erm and they have a quick of accessing the information they need.” (SpNurse) 
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The second oncologist asserted that the app could potentially help patients better 
understand toxicity, which could in turn help the communication of such issues with 
their treating clinicians. 
“... sometimes you get patients in clinic and you know they’ll say, ‘oh no, 
everything was fine’ and then you go through the checklist and you'll suddenly 
find out that everything wasn’t fine because they’ve been having all these 
problems. Whereas those ones that were using the app I think probably were a 
bit more aware of the side effects they were having because it flagged it up to 
them.” (Oncologist 2) 
The clinicians also suggested several recommendations for improving the app. These 
included adding functions that would inform patients about upcoming appointments, 
test results and changes in medication. The most common recommendation was that 
the app could transmit real-time data related to toxicity (i.e., side effects that patients 
recorded in the app) so that the oncologists could perform closer monitoring. Yet, one 
oncologist pointed out the importance of objectivity in order to obtain reliable data for 
each individual.  
“...it’s still quite subjective, you know erm, even though they're putting in sort of 
relatively objective data, there's still a degree of subjectivity you know and 
actually having that information so that we can drum down with the patient in 
clinic and say, well actually that’s not that severe and that is, you know normal. 
That would be useful so that, again it probably would help us in clinic just to be 
able to like I say become more erm, focused and precise with what we need to 
talk about.” (Oncologist 2) 
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The first oncologist proposed to include a section that would inform patients about the 
course of their cancer markers (CEA) throughout their treatment.  
“...actually, a CEA trend - there would be quite a lot of patients who would like 
that because quite a lot of them will come in and ask what it is, and they follow 
it, and they want to know what it is, and, and, you know, want to know it's 
coming down.  Erm, so yeah, that might be useful.” (Oncologist 1) 
Another recommendation offered by the same consultant was to create a single app 
that would support patients across the entire cancer care continuum.  
“...you don't want a patient to have a chemo app and then to have a separate 
one for surgery, and for stoma care...you'd want somebody to download a 
colorectal cancer app and within that app, to have everything that they might 
need...you know, surgeons - colorectal surgeons, liver surgeons, stoma...that 
would be a nice goal to get to; that this is going to look after you across your 
entire journey of colorectal cancer and all the appropriate people will be in here 
somewhere..”. (Oncologist 1) 
8.6. Chapter summary 
This chapter presented the findings obtained from the main investigation stage. There 
were two types of findings, namely quantitative and qualitative data. The former 
included questionnaire data (baseline information needs, satisfaction with information 
through the app and degree of app's usability) and analytics of app use (frequency, 
intensity and type of engagement, as well as section use for each treatment regimen), 
while the latter included results from the semi-structured interviews with the study 
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participants and clinicians. The next chapter will perform a discussion of these results in 




Chapter 9: Discussion of main study findings  
The previous chapter presented the findings obtained from the project’s main study. 
This chapter will discuss these findings and demonstrate how they relate to the current 
body of literature. This chapter will also present the integration of the qualitative and 
quantitative data, as outlined in chapter 5 (p. 163).  
Some of the specific objectives of this project focused upon the app itself, while others 
were specifically concerned with the VAs. The first part of this chapter will focus upon 
the use of the app as a whole, while the second will focus upon the virtual agents (VAs).  
9.1. App-related discussion  
The app-related discussion will focus upon the following aspects: 
• Usability and acceptability of the app 
• Overall use of the app  
• Use of the app before and after treatment  
• Satisfaction with information and views on the content 
• Recommendations for improving the app 
The study also revealed a number of issues that impeded with users’ engagement, 
which will be discussed at the end of the section.  
9.1.1. Usability and acceptability 
The system usability scale (SUS), a commonly utilised tool for assessing the degree of 
usability in a variety of systems suggested that the intervention had a good degree of 
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usability, as the mean SUS score was 73.89, with most users (n=7/9) scoring above 70. 
Although it could be argued that the small sample size (n=9) would not adequately 
reflect the degree of the app’s usability, Brooke (2013) suggested that the SUS can 
provide a reliable assessment of a system’s degree of usability even with a small sample 
of responders (e.g., 8-12). Hence, despite the limitations in the sample size, it can be 
claimed that the updated version of Manage your Health was acceptable to the end 
users and had a good degree of usability. The interview data also backed up the SUS 
tool measures with regards to usability. Apart from one user who experienced issues 
with the symptom diary (section 8), the remaining interviewees found that the app was 
usable and did not experience any usage-related issues. These users were also happy 
with the organisation of the content.   
The improvements made to Manage your Health after the pilot study had a positive 
effect upon the app, as higher degrees of usability (68.75 versus 73.89) and 
acceptability (marginally acceptable versus acceptable) were obtained in the main 
investigation phase. The present project is an example where the incorporation of user 
input led to the improvement of an intervention during the early stages of 
development. 
The role of expert involvement in the acceptability and uptake of the intervention 
emerged as a noteworthy aspect. Throughout the interviews, some users explained that 
information on the internet and/or other apps is not necessarily checked for its validity, 
which is in line with findings from the literature (van Velthoven and Powell, 2017). Users 
made positive remarks upon the fact healthcare professionals took part in the 
development process, as this made them feel confident that the content of the app was 
 273 
trustworthy. This was somewhat expected, given that healthcare professionals are the 
most trusted sources of information among patients (see Chapter 1, p. 5).  
Apart from their positive influence upon the perceived trustworthiness of the content, 
the involvement of clinicians in the recruitment process could have made a positive 
contribution to the intervention’s uptake. Previous studies have demonstrated that 
expert endorsement can exert a positive effect in the promotion and adoption of 
products and/or services (La Ferle and Choi, 2005; Wang, 2006). According to Shelton 
and Chiliya, (2014) the success of endorsement relies considerably upon perceived 
credibility of the endorsing source. A repeated theme throughout the interviews was 
that the oncologists were seen as experts that acted in the patients’ best interest, which 
fostered a sense trust; one user explained that the app would not be used if the 
oncologist didn’t refer them to the study. Hence, the oncologists’ referrals could have 
played an important role in the uptake of the project’s app.  
9.1.2. Overall use of the app  
Exploring the overall use of the app did not only help demonstrate how the app was 
utilised throughout the study period, but it also allowed for understanding the most 
salient points within the app content from user’s perspective. The analytics of the use 
revealed the areas that were most popular among users, while qualitative data helped 
understand the aspects that were most important for them.  
The analytics of use revealed that treatment- related information (e.g., management of 
side effects, information about chemotherapy medicines) were the most popular 
information domain across the entire study sample. This was expected, as treatment-
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related information is particularly important to patients with cancer during the initial 
stages of the care continuum; this has been cited in the general cancer literature 
(Rutten et al., 2005) and is also supported by the findings of the project’s systematic 
review (see chapter 2). Since the study participants were still early in their treatment, it 
was reasonable that this information domain was utilised the most in Manage your 
Health. Another noteworthy finding was that the information priorities of patients were 
similar during the entire study period. Again, this could be attributed to that patients 
were at the early stages of the cancer care continuum, so their priorities likely remained 
the same. 
One key realisation was the capacity of the app to be a multivalent tool rather than 
simply a resource for information. Although most patients used the app for information 
purposes, some users appeared to place particular emphasis upon its added functions. 
For instance, one patient (User 12) focused upon the treatment diary; although this 
patient made some negative remarks about this particular function, he continuously 
expressed how important keeping track of his symptoms was. Whilst appreciating that 
Manage your Health was at an early development stage, this user strongly suggested 
that the diary function should be improved and ultimately be incorporated into active 
patient care (e.g., by sending live information about any side effects to his doctors). In 
general, this patient appeared to believe that added functions related to condition 
management and decision-making would be the most important aspect of this app and 
that they should be included in future versions. Similar views were also held by other 
users (e.g., User 21).  
 275 
A similar observation was apparent after analysing the clinician (i.e., stakeholder) 
interviews. Healthcare professionals appeared to focus primarily upon matters that 
concerned patient safety. While this included patient education, with information 
support being an important factor, their priorities focused upon the app’s capacity to 
‘keep the patient safe’, through functions concerning symptom alerts, as well as the 
potential to aid the processes of monitoring and reporting of toxicity. The exception to 
this was the specialist nurse, whose comments largely concerned the app’s capacity to 
provide patient support and empowerment throughout the treatment course. This was 
not an unexpected finding, since nurses tend to pay attention to patients’ personal 
viewpoints rather than concentrating exclusively upon clinical outcomes (Arvidsson et 
al., 2010). 
9.1.3. Use of the app before and after treatment 
As discussed in Chapter 2 (p. 40), the information needs of patients with cancer can 
change across the cancer-care continuum. More specifically, these needs typically peak 
before treatment due to the uncertainty surrounding antineoplastic therapies, as well 
as a desire to prepare for their eminent treatment. Both of these reasons for seeking 
information appeared in the semi-structured participant interviews. Several patients 
reported using the intervention more intensively before treatment, while others felt 
that it was relevant exclusively to this stage. These findings, in conjunction with 
directions from the literature suggested that the majority of the app’s use would have 
taken place before the initiation of treatment. Yet, this was not supported by the 
analytics of use.  
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The app usage data revealed that the majority of patients (n=13/23, 56.52%), 
performed most of their logins after the first dose of treatment. Furthermore, the total 
number of taps performed after treatment (n=2628/4545, 57.82%) revealed that a 
significant proportion of users explored the app further at that stage. Although two user 
profiles (users 10 and 21, see figure 8.6) dominated the tap count data, the remaining 
profiles indicated that a considerable number of users utilised the app more frequently 
after receiving the first dose of chemotherapy.  
This observation can be explained in a number of ways. First and foremost is that 
patients were still at a very early stage of the cancer care continuum (i.e., first cycle of 
treatment), meaning that their information needs were still high, even after the first 
dose of chemotherapy. Interview data revealed that following the first dose of 
treatment, aspects such as the treatment-induced toxicity and the use of medications 
became more relevant and encouraged further and more frequent use of the app. 
Another consideration was the ‘information overload’ that was experienced by certain 
individuals at the pre-treatment stage. It is possible that some individuals did not use 
the app much before treatment due to the sheer volume of material provided to them 
as part of standard care, but progressively started using the app once they felt less 
burdened by the information.  
9.1.4. Satisfaction with information and views on the content 
Questionnaire data suggested that patients were generally content with the 
information provided through the app, as most items in the satisfaction with 
information questionnaire scored above average. Albeit this finding should be treated 
with caution due to the low response rate (see p. 209), data from the semi-structured 
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interviews also supported that users were generally satisfied with the app’s content 
(see p. 240). Users expressed that the app included the right amount, types and depth 
of information and offered only limited comments for improving its content.  
9.1.5. User engagement 
Despite receiving positive feedback from users (see p. 232-233), usage data revealed 
that the app was used seldom throughout the study period. More than a quarter of 
patients (n=6/23, 26.1%) used the app only a few times before treatment and didn’t 
return to it after receiving the first dose of chemotherapy. The interview data revealed 
several reasons that helped explain this phenomenon. These can be broadly categorised 
in app-related and user-related factors. 
User-related factors  
The most prevalent user-related factor was the preference for standard information 
material such as booklets and leaflets provided as part of usual care. This stemmed 
from a number of reasons. The most common reason was the perceived superiority of 
printed material over the app (e.g., easier to read and understand), as well as a 
preference for written information. For some patients, the treating clinicians were 
perceived as very informative and helped them to address their information needs fully. 
One user preferred printed material due to limited IT skills, while another expressed a 
clear dislike of using technological means for the purpose of exploring information; in 
this case, the app was used primarily by the caregiver (the patients’ wife). It should also 
be noted that while not all users expressed a clear preference for standard information 
material, the vast majority explained that they utilised such sources in order to retrieve 
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information. As patients obtained information from such material, it is possible the app 
became less relevant.  
The preference for conventional resources also extended upon toxicity tracking.  
Several patients explained that they preferred to keep a written diary of any symptoms 
or side effects they experienced throughout treatment, as they were more used with 
this practice. The age of users could have played a role here. The study sample of this 
project was comprised by older individuals; Anderson (2017) demonstrated that 
tracking health or fitness via health apps or websites was among the least popular 
activities undertaken by older users (undertaken by 24% of responders).   
Another factor that resulted in reduced engagement was the knowledge that patients 
acquired throughout the care pathway. As mentioned in other studies, the information 
needs of patients with cancer can decrease while moving away from diagnosis, since 
they become more knowledgeable along the way (Hsieh, Chou and Guo, 2018; Mistry et 
al., 2010). This was also apparent in this project. Participants explained that as they 
progressed through the care pathway, they obtained a considerable deal of knowledge 
on their condition and treatment. As patients believed the app could not make further 
contributions to their knowledge past a certain point, they felt that the app was not 
needed, unless they came across something that they didn’t experience before. 
One user also refrained from seeking further cancer-related information past a certain 
point (see pp. 236). This could be explained by information overload, as well as an effort 
to resume normality by refraining from cancer-related information. In their work, 
Lambert, Loiselle and Macdonald (2009) demonstrated that patients with cancer can 
refrain from seeking information regarding their condition, as doing so helps foster a 
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sense of returning to their normal lives (i.e., before being diagnosed with cancer). 
Hence, it is possible that the aforementioned patient stopped using the app to avoid 
coming across further cancer information in order to resume a sense of normality.  
The caregiver of participant M6 refrained from using the app in fear of coming across 
unwanted information (see pp. 239). This is another coping strategy employed by 
patients with cancer and/or caregivers; in an early qualitative study, Leydon et al. 
(2000) explained that avoiding unwanted or upsetting information can help maintain 
hope and cherish positive outcomes during treatment. It is possible that certain users 
stopped using the app in an attempt to keep an optimistic outlook and concentrate 
upon positive aspects.  
Throughout the interviews, a common theme was that the app was used on an ‘as 
needed’ basis following the first dose of treatment. For some, this meant reminding 
themselves about aspects of treatment that might have been forgotten, while others 
focused on more practical aspects, such as dealing with treatment-related toxicity. 
Several users explained that as they tolerated the medicines well, they did not engage 
frequently with the app after receiving the first cycle of chemotherapy because they did 
not require any particular support; this was also confirmed by the analytics of use (e.g., 
users 3, 12, 13, 17 and 22). Therefore, it is possible that patients who tolerated their 
treatment well possibly didn’t engage with the app as much as those who experienced 
adverse events and/or compactions. Unfortunately, it was not possible to investigate 
this with other user profiles, as not all interview participants commented on this. 
Furthermore, the study did not acquire data related to patients’ health status and/or 
 280 
quality of life in order to explore the relationship between these factors and the use of 
the app.  
Apart from the issue of limited engagement, a noteworthy qualitative finding was that 
several interviewees were not aware of certain functions of the app such as the triage 
survey. One potential reason for this could be the lack of user training. Upon installation 
at the clinic, the author (AC) briefly went through the app with the participants (and 
caregivers when present) in order to demonstrate the sections and answer any 
questions they might had. Information regarding the content and functions of the app 
was also available in the participant information leaflet that users received upon 
consent. Yet, this brief training session and the supporting material might not have 
been adequate, as several users did not know that functions such as the Triage survey 
and the capacity of creating appointment alerts were available to them through the 
app. One factor that may have had an impact was the timing of providing the training 
and the supporting material. As these processes took place right after patients’ first 
consultation with the oncologists, it is possible that patients were unable to retain the 
information discussed with AC.  
App-related factors  
The absence of engagement prompts could potentially explain the infrequent use of the 
app. Druce, Dixon and McBeth (2019) pointed out that the inclusion of push factors 
(i.e., strategies that encourage individuals towards using an intervention) are key in in 
increasing engagement in health apps. These strategies include, but are not limited to 
reminders, notifications and prompts such as text messages in order to encourage users 
towards entering data or check if they experienced any issues with the app. The VAs 
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could also help in this respect by delivering these prompts (Ring et al., 2013). If the goal 
of the study was to obtain high retention rates and make use of clinical data (i.e., 
patient reported outcomes), such techniques would potentially offer considerable 
benefits with regards to engagement. However, as the inclusion of push factors could 
potentially introduce bias and not reflect the ‘natural’ use of the app-which was among 
the most important considerations of this study-, it was decided that they would be 
avoided.  
9.1.6. Recommendations for improving the app  
The majority of participants offered detailed perspectives on how to improve the app 
for future users. Most of these comments and recommendations concerned the 
functions of the app, such as the improvement of the treatment diary, its integration 
with Triage and the addition of sections such as a medicinal calendar. One noteworthy 
finding was the limited number of comments about improving the information listed in 
the app. This suggested that the information content likely fulfilled patients’ needs to a 
good degree so that no major modifications were required; this was supported by 
questionnaire data (i.e., satisfaction with information), as well interview findings which 
revealed that patients were generally satisfied with the volume and types of 
information available through the app.  
Another key aspect was the multivalent nature of the intervention. Participants 
suggested that the app could be improved in order to cover several aspects of care 
rather than concentrating solely upon information support. Considering this, it was 
clear that supporting interventions in cancer should attempt to address a range of 
needs rather than focusing upon a particular area for support. This is particularly 
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applicable for interventions that aim on providing information support. This project 
demonstrated that focusing upon this aspect could potentially lead to attrition as 
patents move away from diagnosis, since the need for information support can decline 
as individuals progress in their treatment.  
The participating clinicians also appeared to hold similar views regarding the nature of 
the app. While appreciating that the intervention could help patients by making them 
more knowledgeable around their treatment, they quickly proceeded to make 
suggestions on what could be included in order to aid their efforts in achieving better 
patient safety, such as recording patients’ symptoms in real time. This was not an 
unexpected finding. The acquisition of patient reported outcomes (PROs) has attracted 
considerable attention in the field of oncology, as their use beyond clinical trials has 
become an increasingly attractive prospect (Toumi et al., 2019). In a recent systematic 
review, Lu et al. (2020) identified a number of commercially available apps able to track 
PROs and remarked upon the potential of using mHealth interventions for that purpose. 
Yet, the authors pointed out that validation of these apps would be necessary in order 
to ensure quality in the acquired PROs; this was also mentioned during the clinician 
interviews, where oncologists emphasised upon the importance of accuracy in 
obtaining reliable PROs. 
The personalisation element emerged as another important aspect. While some users 
thought that the app was tailored to their needs, predominately because it referred to 
their chemotherapy treatment, other users believed that the app had a rather generic 
character. These users explained that this was because there was limited input from 
their side (e.g., logging personal details), as well as output from the app. This was an 
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unexpected finding, considering that patients were able to input data in the app and the 
triage survey, as well as the treatment diary functions produced individualised 
assessments according to the data that users entered. Yet, a comment from participant 
F5 helped to shed light in this (see p. 248). This comment concerned the VAs’ capacity 
for recognising users’ verbal or textual input, which is referred to as natural language 
processing (NLP, see p.20).  
Tudor Car et al. (2020) pointed out that NLP is an important element towards the 
personalisation of conversational agents, since their responses are tailored according to 
users’ input. Considering the above and the user’s recommendation, it is possible that 
incorporating NLP to the project’s intervention could have fostered a sense of 
personalisation, as well as the impression of a real conversation. As both of these 
emerged as important aspects throughout the participant interviews, the incorporation 
of NLP could have potentially benefited the intervention. Unfortunately, its 
implementation was unfeasible for practical reasons (see chapter 3, p. 108) 
Apart from the recommendations obtained by participants and healthcare 
professionals, the present project also indicated the importance of providing adequate 
training before users utilise the intervention, as well as additional supportive material 
(such as instructional videos) to help them better understand its functions.  
9.2. Virtual agents  
This part will concentrate upon users’ perspectives on the virtual agents (VAs) used to 
deliver the information through the app and discuss the following aspects: 
• Appearance of the VAs 
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• Realism 
• Uncanny valley 
• Voice and embodiment  
• Familiarity 
• Customisation  
9.2.1. Appearance  
According to Straßmann and Krämer (2017), input from the intended end-user 
population is essential in order to successfully design engaging VAs. To the best of our 
knowledge, this is the first study that performed an in-depth exploration of end-user 
perspectives of using VAs in the context of information support for colorectal cancer 
(CRC). The following section will discuss findings regarding the appearance of the VAs 
and present how they relate to the current body of literature.  
Types of VAs  
As discussed in Chapter 1 (p. 21), VAs can be formulated to resemble humans, animals 
or other species. In the present study, the patients expressed a preference for a human-
like VA but appreciated that younger users might be comfortable with other types 
(species) of VAs. This was in line with the findings of Sträfling et al., (2010) where 
university students expressed a preference and interacted longer with a zoomorphic 
(animal-like) VA in comparison with an anthropomorphic (human-like) agent. A later 
study provided a range of VAs and compared preferences among younger and senior 
users; the authors demonstrated that while younger users can relate to and express a 
preference for animals, robots and/or voice-only interfaces, older users have deemed 
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the inclusion of human or humanoid VAs as more appropriate (Straßmann et al., 2020). 
This could be attributed to the desire to co-operate with VAs in a similar manner to 
humans, as senior individuals stated that they wished to be able to address them in a 
human-like manner, such as looking them in the eyes (Straßmann and Krämer, 2017), 
which was also evident in the present project (see quote by M6, p. 248).  
General features  
General features of the VAs such as age, gender and ethnicity appeared to be received 
well, as none of the users remarked negatively upon them. This was expected, given 
that some participants had VAs formulated after their clinicians in the app (i.e., were 
already familiar with these characters). For users who weren’t treated by the clinicians 
that the VAs were formulated after, this could be attributed to that patients were 
already familiar with the diversity in NHS staff, and were therefore comfortable with the 
VAs in the app.  
Several studies have suggested that users can express a preference for a particular 
gender, for example female over male VAs (Esposito et al., 2019; ter Stal et al., 2020). 
Ethnicity also appeared to play a role in the determination of the most proffered VA for 
education purposes (Rosenberg-Kima et al., 2010). In general, users appear to express a 
preference for VAs that resemble individuals of their own in-group (Baylor, 2011); yet, 
this was not evident in this project, as none of the patients expressed a preference for 
specific VA features such as age and gender. Nevertheless, some participants suggested 
that other users might feel more comfortable with VAs that resemble their 
characteristics (e.g., female VAs for female users who wished to discuss sensitive 
matters).  
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It should be noted that in the present project, the VAs generally matched the 
participants’ demographics, so it was reasonable that patients did not object to them. 
Yet, it is also possible that patients refrained from expressing a particular preference for 
factors such as age, gender or ethnicity in order to avoid being perceived in a negative 
way (i.e., politically incorrect) by the interviewer (AC). This is referred to as social 
acceptability bias, which has been defined as “the general tendency of individuals to 
present themselves in a manner that makes them look positive with regard to culturally 
accepted standards of behaviour.” (Chung and Monroe, 2003, p.292).  
Professional appearance 
The professional identity of the VAs emerged as a major theme throughout the 
interviews. Regardless of whether the clinicians in the app were known to the users or 
not, the majority of responders believed that the VAs should resemble the 
characteristics of healthcare professionals. This was because health professionals were 
regarded to be the most appropriate and reliable agents to deliver health-related 
information, as they possessed the knowledge required for this task. This is in line with 
findings from the literature. As discussed in chapter 1 (p. 23), the appearance of a VA 
depends upon the context, goals and setting in which the VA is used. A recent 
publication demonstrated that senior individuals pay attention to the professional 
occupation of VAs (Esposito et al., 2019). The same authors suggested that clothing 
played a role in users’ preferences, which was also apparent in the present project 
through users’ comments (e.g., see quote by M1, p. 252) 
Zhang, Bickmore and Paasche-Orlow (2017) used three different types of VAs (a patient, 
a healthcare professional and a federal agent) to facilitate the consent process in a 
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research project. The results suggested that patients were more inclined towards 
collaborating with the patient VA and offered comments indicating that this was due to 
a sense of trust arising from perception that these VAs were ‘on their side’. A similar 
finding emerged from the interviews in this project, as some users recommended 
including a VA that would resemble a fellow patient with CRC for sharing treatment- 
related experiences. One view was that exploring the experiences of patients who 
completed treatment would be reassuring, possibly because patients could relate to 
such a VA. This further endorses the context-related argument, since participants can 
express a preference for different VAs according to the purpose for which these VA are 
used.  
Apart from their preferences for human VAs resembling healthcare professionals, users 
also had specific views for how realistic these VAs should be. 
 9.2.2. Virtual agent realism 
As discussed in Chapter 1 (p. 22), realism (in the context of VA research) encompasses 
three dimensions (stylisation, resolution and detailedness). While some examined these 
dimensions in isolation (e.g., van Wissen, Vinkers and van Halteren, 2016), while others 
(e.g., McDonnell, Breidt and Bülthoff, 2012; Straßmann and Krämer, 2018) compared 
between different degrees of the aforementioned aspects in a single study. Although 
participants were not asked to comment on these dimensions explicitly in the present 
project, these aspects emerged after asking participants to express their views on the 
VAs. Patients’ views concentrated upon the stylisation dimension, which refers the 
degree to which a VA resembles a real human being over a cartoon figure. 
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Preference for realistic VAs 
The majority of participants in the present study expressed a preference for realistic 
VAs. The argument of context dependency is again applicable here, as the degree of 
realism makes a VA fit for purpose depending on the context in which it is being used. In 
their work, Ring, Utami and Bickmore (2014) suggested that cartoon figures can be 
perceived as friendlier in a social context, but realistic agents were deemed as more 
suitable for medical tasks; this was supported by a subsequent study that examined 
patients’ preferences for a virtual health coach in chronic diseases (van Wissen, Vinkers 
and van Halteren, 2016).  
As discussed in p. 284, older users have been reported to express a preference for 
human VAs. Hence, it is reasonable that these users wanted the VAs to resemble 
human beings as closely as possible, which can be achieved with increasing the degree 
of realism. Several studies have explored how varying degrees of stylisation (e.g., 
naturalistic, humanoid, cartoon) are perceived by individuals from different age groups 
and it appears that older individuals generally express a preference for realistic VAs. 
Two qualitative studies that explored senior individuals’ views on VAs demonstrated 
that their participants opted for realistic VAs (Straßmann and Krämer, 2017; Tsiourti et 
al., 2014). Recent studies in which participants commented across a variety of VAs 
(ranging from cartoon to realistic) again demonstrated that older individuals were 
inclined towards realistic agents (Straßmann et al., 2020; Ter Stal et al., 2020).  
Another aspect that could have played a role in patients’ preference for more human-
like VAs was the voice of the characters. The messages provided by the VAs were pre-
recorded responses of the real healthcare professionals in their natural voices. In a 
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recent publication, Moore (2017) argued that interacting with artefacts such as robots 
equipped with natural human voices can make users overestimate the aptitudes of 
these entities (e.g. expect them to function like human beings). In the context of the 
present study, the naturalness of the VAs’ voices potentially made users to expect that 
they would come across real humans in the app. This would explain why they expressed 
a desire for realistic VAs i.e., so congruity could be achieved between their voice and 
their appearance. The role of voice is discussed further in 9.2.4. 
Perception of VAs 
Although patients generally reflected positively upon the VAs, the majority of users did 
not perceive these characters as accurate (realistic) representations of healthcare 
professionals and suggested that they should be changed to become realistic. This view 
was offered by patients who were familiar with the clinicians, as well as those who 
weren’t. The most common theme concerning the appearance of the VAs was that the 
agents were seen as caricatures of the actual healthcare professionals, or as patients 
put it, ‘cartoon’ versions of real people. While some patients thought that the inclusion 
of a cartoon figure introduced a humorous element which made the provision of 
information less intimidating, the majority of patients believed that the graphics should 
be improved so that a realistic VA with a professional appearance would deliver the 
information, as such an agent was regarded to be most suitable for this task.  
The only identified study that used a variety of VAs in the field of cancer was Robertson 
et al. (2015), who tested a VA-based decision support intervention for patients with 
prostate cancer. In this study, the authors presented several VAs whose appearance 
ranged from realistic to highly stylised (cartoon) in two focus groups. The first group 
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expressed dislike for the cartoon version, as participants believed cartoons were 
disproportionate to the seriousness of the condition. Yet, the second group deemed the 
cartoon version as acceptable, as it was perceived to be ‘softer’ than the photographic 
agent. The authors pointed out that while it is not possible to cater the needs of every 
user, the risks of including a highly stylised (i.e., cartoon) VA could potentially outweigh 
the potential benefits for a condition such as cancer (e.g., users could potentially think 
that the agent was not ‘serious’ enough to offer advice and help).  
Although the VAs used in Manage your Health were realistic, high-resolution 
representations of the real clinicians (see figure 3.3, p. 110) and not highly stylised 
versions of them, they were still referred to as cartoon versions of healthcare 
professionals by the study participants. Yet, none of the users made comments similar 
to those in Robertson et al. (2015) i.e., that the VAs were inappropriate for the task they 
were set out to due to a perceived lack of seriousness. This may have been because the 
virtual characters in Manage your Health did not bear any cartoon features such as 
exaggerated facial characteristics or voice exclamations. It is also possible that some 
patients’ use of the term ‘cartoon’ did not necessarily reflect the meaning of the term 
used in VA literature, but rather referred to an artificial representation of an individual.  
Despite their recommendations for improving the VAs, the majority of participants 
appeared to be generally satisfied with the virtual clinicians . Strasmann et al. (2020) 
argued that as older individuals are likely to be unfamiliar the use of VAs, they can 
appreciate such technology and be satisfied by it. Yet, as younger individuals are more 
familiar with such technologies, satisfying their demands would be more challenging. 
Both aspects were evident in this study. The majority of participants of this study were 
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older individuals and did not have any previous experience with VAs; most had positive 
recollections of using the VAs, while some expressed that they were ‘impressed’. 
Younger participants held different views. One participant from the main study (user 3) 
and another one from the PPIE (participant A), both of which were younger than the 
average and were both familiar with the use of avatars expressed less satisfaction with 
the VA and both reflected upon the concept of the uncanny valley. 
9.2.3. Uncanny valley  
The concept of the uncanny valley has been discussed in detail in chapter 1 (pp 24-24). 
According to this concept, users begin to experience feelings of eeriness and repulsion 
when human-like interfaces approach, but are not successful at achieving lifelikeness 
(Mori, MacDorman and Kageki, 2012). As this project involved realistic VAs resembling 
familiar individuals, this theory was particularly relevant, and its potential application 
was hence explored.  
Findings from the semi-structured interviews revealed that the uncanny valley effect 
was not evident across the entire participant sample. All users were presented with VAs 
that were realistic, high-resolution representations of healthcare professionals that 
portrayed them with a high degree of accuracy, but were not identical (e.g., 
photographic) to them (see figure 3.3, pp. 110). While feelings of repulsion were 
apparent among a minority of users, this phenomenon was not evident among other 
individuals, particularly the older patients.  
Contrary to the concept of the uncanny valley, older users in this project expressed a 
preference for VAs with greater degrees of human likeness (i.e., realism) than the 
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healthcare professional avatars presented to them. This finding was not entirely 
unexpected, as several studies have demonstrated that senior users can express a 
preference for realistic VAs (p. 287). In a recent publication, Tu et al. (2019) pointed out 
that older users do not necessarily abide by the uncanny valley theory, given that they 
can opt for more realistic agents.   
Such controversies are not new. As discussed in chapter 3, the concept of the uncanny 
valley is not necessarily generalisable (p. 111). Over the years, the accumulation of 
empirical findings indicating divergencies in Mori’s theory have raised questions 
regarding the extent of its application and led to the refinement of this model 
(Zlotowski, Proudfoot and Bartneck, 2013). Two concepts, namely the categorisation 
ambiguity and perceptual mismatch have been proposed (see Chapter 1 p. 25) and 
were both explored in the context of this project.  
Perceptual mismatch 
While mismatches between the voice and appearance of the VAs have been reported to 
discourage people from engaging with these interfaces (Kätsyri et al., 2015), none of 
the patients in the present project stated that they stopped using the app due to this. 
One explanation for this would be that users prioritised information support over the 
VAs’ appearance. This emerged in some interviews, and it is also apparent in a paper by 
McDonnell, Breidt and Bülthoff, (2012). In this study, the authors provided a range of 
VAs raging from highly realistic to stylised and used natural voice to perform the 
required tasks. In their discussion, the authors argued that participants were so focused 
on the task, so that the appearance of the VA was placed in lower priority. Hence, it is 
possible that the participants of this study placed emphasis upon the provision of 
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information, and they did not allocate as much attention to the inconsistencies in the 
appearance of the VAs.  
In a recent study, Stein and Ohler (2018) also found that inconsistences between facial 
proportions and vocal realism resulted in VAs being perceived as less credible and 
attractive Yet, these inconsistencies did not impact the agents’ persuasive success. A 
similar finding was also present in this research, as such inconsistencies didn’t hinder 
the perceived value or trustworthiness of the information. In the aforementioned work, 
the authors explained this observation through the Elaboration Likelihood Model (ELM), 
introduced by Petty and Cacioppo, (1984).  
The ELM proposes that persuasive success relies on two routes on processing 
information, namely the central and the peripheral. The former route has to do with the 
message itself (e.g., rationality and logical merit), while the latter is associated with the 
source of the message (e.g., perceptions of the agent who delivers it). This model also 
suggests that most people will focus upon the central route, as long as they have 
sufficient time to process the information they received (Petty and Cacioppo, 1984). 
Although it is possible that this applied to the present project (i.e., patients had six to 
eight weeks to interact with the VAs and process the information to assess their logical 
merit), it should also be considered that the patients were either familiar with VA in the 
app or were aware that the VAs represented clinicians that worked in the hospital and 
collaborated with their oncologists (i.e., were part of the same team). The element of 
trust in these clinicians might also gave rise to the peripheral route, even if the graphics 
did not satisfy the users.  
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For human-like VAs, convincing (i.e., natural) movement and facial expressions are of 
critical importance (Geller, 2008). McDonnell, Breidt and Bülthoff (2012) argued that 
while users might be prepared to ‘forgive’ motion irregularities in cartoon characters, 
they are likely to not be as tolerant towards human-like VAs. The authors theorised that 
this is because humans are innately used in analysing the expressions of fellow humans, 
so any anomalies in motion would give rise to strong feelings of uncanniness. In the 
present study, although there was a good degree of coordination between the dialogue 
and the VAs’ facial movements, the synchronisation was not identical to that of a real 
person. While younger users thought that facial expressions should be improved, none 
of the senior users remarked upon this during the interviews. One potential explanation 
for this is that senior individuals have been reported to not be as efficient as younger 
individuals at processing and evaluating facial expressions in VAs (Beer, Fisk and Rogers, 
2010; Beer et al., 2015).  
Categorisation ambiguity  
Only a minority of users provided responses that resembled the issue of categorisation 
ambiguity. This could be attributed to that the majority of patients placed the VAs in the 
‘cartoon’ spectrum. This could explain the absence of feelings of uncanniness across 
most users, as they appeared to be certain about which category the VAs fell into. It 
must be noted that users who perceived the VA as strange were younger, while users 
who treated the VAs as cartoon figures were older, suggest potential differences 
between individuals from different age groups.  
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9.2.4. Voice and embodiment  
Although some of the participants made negative remarks upon the appearance of the 
VAs, there was no negative feedback regarding their voice. Several users even placed 
emphasis upon the voice of the VAs and even prioritised it over their appearance. This 
was not unexpected; in multimedia learning, voice can be of critical importance (Mayer, 
Dow and Mayer, 2003). In this study, voice played an integral role in older individuals’ 
experiences with VAs, which was also in line with findings from the literature (Esposito 
et al., 2019b). One aspect that influenced users’ perceptions was that the VAs’ voices 
were natural. Several publications  pointed out that natural voices can be favoured by 
users, which can explain why these were perceived well by the study participants 
(Baylor, 2011; Parmar et al., 2020).  
One participant who was not satisfied with the appearance of the VAs suggested that 
the element of embodiment could be removed, and the voice could be kept instead in 
order to deliver the desired information. A similar proposal was evident in a review that 
critically appraised VAs (Campbell, Grimshaw and Green, 2009). In this work, the 
authors drew upon the effect of the uncanny valley and suggested that people are 
generally capable of recognising the artificial nature of a VA in terms of appearance and 
sound. The authors suggested that in order to bypass this, the element of embodiment 
could be removed, and communication could instead be mediated by means such as 
telephones and forms of textual communication (e.g., emails and text messaging) in 
order to ‘disguise’ features (e.g., voice) that might become recognised as artificial by 
the end users.  
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Although the above proposal has its merits, the findings of the present work suggested 
that this wouldn’t necessarily align with patients’ preferences. Any negative comments 
regarding the VA were associated with its appearance, not its presence in the app. 
Patients generally wanted to have embodied agents to deliver information but 
demanded that graphics should be improved to make them realistic. The participants of 
this study deemed the inclusion of the VAs to be beneficial, as it offered a sense of 
presence and for some, even resembled a conversation with a healthcare professional. 
This was in line with the findings of a systematic review, which demonstrated that the 
inclusion of embodied VAs induced a greater sense of social interaction in comparison 
with non-embodied agents (Yee, Bailenson and Rickertsen, 2007).    
Distorting the voice of the VA (as proposed by Campbell, Grimshaw and Green, 2009) 
could also have potentially have negative consequences to some, as several participants 
favoured the fact that the VAs had human voice. In their work, Chérif and Lemoine 
(2019) demonstrated that the human voice can create a stronger sense of social 
presence and build greater trust in users when compared to a synthetic one. While the 
first observation (social presence) appeared in some interviews, the latter (trust) was 
more evident. Patients favoured having information delivered to them in a natural 
voice, while those who were familiar with the healthcare professionals represented by 
the VAs expressed that having their doctor’s voice to explain things inspired a sense of 
reassurance, as they trusted their knowledge and capacity to help them get better. As 
one patient stated, hearing the clinician’s voice on the app resulted in listening more 
closely to the VA.  
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Considering the above, using natural human voices can offer several advantages to 
older users. When using a natural voice, several aspects need to be considered 
carefully. One of them (perceptual mismatch) has already been outlined in p. 291; if a 
natural voice is to be used, care should be taken so that the appearance of the VA is 
realistic in order to match it. Another consideration is the restrictions imposed using 
natural voices entail, as using recordings (i.e., the only way of achieving natural voices) 
can limit the potential range of applications of embodied conversational agents (ECAs). 
For example, pre-recorded messages do not allow for the personalisation of the ECAs’ 
responses to users, which is an important aspect of formulating successful relational 
agents (Campbell, Grimshaw and Green, 2009). 
9.2.5. Familiarity 
While the initial plan was to test these characters with patients who were treated by at 
least one of the healthcare professionals represented as VAs, the project also included 
users that were not familiar with these professionals, which allowed for an exploration 
of similarities and differences between these groups.  
The most prominent comment from users who had their clinicians as VAs in the app 
was that their presence inspired a sense of reassurance. Patients appreciated having 
familiar clinicians in the app and explained that this was due to the trust bestowed upon 
them, as well as the desire to be treated by the same health professionals across their 
therapeutic journey. The latter resembles a dimension of continuity of care, which 
describes “an ongoing therapeutic relationship between a patient and one or more 
providers” (Haggerty, 2003, p.1220). Continuity of care plays a key role in individuals 
receiving treatment for cancer, as the enduring alliance between patients and 
 298 
healthcare professionals can foster a sense of reassurance and security (Bakker et al., 
2001; King et al., 2008). It is therefore not a surprise that patients wished to have 
avatars of their treating clinicians to support them through the app. Patients who 
weren’t treated by any of the clinicians who appeared as VAs also saw merit in having 
their treating professionals on the app.  
The aforementioned patients also received a sense of reassurance by the VAs’ 
presence. One explanation for this emerged in an interview, where the user was aware 
that the VAs represented colleagues of his treating consultants working at the Churchill 
Hospital, which inspired a sense of reliability. Zhang, Bickmore and Paasche-Orlow 
(2017) demonstrated the importance of organisational affiliation in users’ perceptions 
regarding the trustworthiness of a VA. The findings of the present project support these 
results, since virtual clinicians affiliated with the Churchill Hospital were regarded as 
reliable agents to deliver information support.  
In the interviews, patients explained that they trusted their clinicians, as they deemed 
them to be knowledgeable and were also confident that they acted in their best 
interest. Being aware that their clinicians and/or members of their care team were 
involved in the development of the app fostered a sense of reassurance that the app 
provided reliable support (p. 236). For some patients, it appeared that the sense of 
trust extended to the familiar virtual characters, while others felt that they were looked 
after by their doctors through the app. This was an interesting finding, as patients were 
aware that these characters were virtual entities and not their actual doctors. How 
could they trust them or feel like they were being taken care of via an app? A potential 
explanation is that “the effects of all kinds of social support are primarily a function of 
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the perception of support by the one receiving it, rather than the perceptions, intentions 
or actual behaviour of the person providing it” (Bickmore and Schulman, 2006, pp.1–2). 
It is hence possible that users bestowed trust upon the VAs resembling their treating 
clinicians and felt that they were looked after, even if they were aware that they were 
artificial.  
It appears that the role of VA familiarity has not received much attention within 
research studies, as it has been addressed in only a few publications. The first identified 
study was conducted by Tsiourti et al., (2014) where the authors provided a variety of 
static VAs ranging from highly stylised (i.e., cartoons) to highly realistic and included 
characters that both were known and unknown to the participants. Yet, this study had 
considerable methodological differences compared to the present project (e.g., not 
conducted in the context of healthcare, static agents and no indication as to the voice 
of the VAs).  
Another study later explored the role of familiarity in animated VAs in the context of 
healthcare (van Wissen, Vinkers and van Halteren, 2016). In this experiment, the 
authors tested three virtual characters representing health coaches, two of which they 
were unknown to users and one that users were familiar with. The users rated the 
familiar VA as least desirable; the authors explained that this could be attributed to 
participants’ disappointment, as the VA did not accurately represent the individual that 
was known to them. These findings were in contrast with the present project. While 
users of Manage your Health believed that the VAs could be improved to be more 
realistic, the preference for interacting with a familiar VA in the app was still evident.  
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To interpret this contradiction, it is necessary to consider the differences between the 
present study and the above-mentioned experiment. In van Wissen, Vinkers and van 
Halteren, (2016) the voice of the familiar VA did not match the voice of the individual 
that the VA was formulated after. This incongruity could have given rise to feelings of 
eeriness and uncanniness (see 9.2.3), which would make users less inclined towards 
using them. In the present study, the voices of the VAs were natural and matched the 
voices of the patients’ healthcare professionals. The users reflected positively upon 
having a familiar voice, which inspired them towards preferring the known VAs. 
Another major difference was that van Wissen, Vinkers and van Halteren (2016) used 
highly stylised agents with mismatching voices, whereas the VAs used in the present 
study were realistic, high-resolution representations of the healthcare professionals 
with matching natural voices. As discussed in 9.2.3, discrepancies in the VA’s voice and 
poor graphics can have a negative effect upon users’ satisfaction, as they do not 
provide an accurate representation of an individual. This could potentially be further 
aggravated if the agents portray individuals known to the users, since users are likely to 
be able to spot differences between the VA and the individual represented by the VA 
more easily. It is therefore possible that the participants in van Wissen’s study 
expressed a dislike for the known VA, as it did not resemble the known individual with 
an acceptable degree of fidelity. While there were inconsistencies between the 
naturalness of voice and the appearance of the VAs in the present study, these 
mismatches were not as striking as the ones in van Wissen’s study. This can also explain 
why users of the present project expressed a preference for familiar VAs, even if they 
didn’t represent the actual individuals with photographic accuracy.  
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9.2.6. Customisation potential and ethical considerations 
In virtual environments, the customisation of avatars and VAs is an integral part of the 
user experience (Waltemate et al., 2018). Recent reviews (e.g. Kocaballi et al., 2019; 
Schachner, Keller and von Wangenheim, 2020; Tudor Car et al., 2020) have explored 
the personalisation in ECAs and VAs’ in healthcare, but focused exclusively upon agents’ 
output according to users input (e.g. personalised responses). After a brief exploration 
of the literature around ECAs in healthcare, only one study where users were able to 
formulate their VAs was identified (Hunter et al., 2018). This study involved an 
intervention for supporting children with cancer, where children were able to fully 
customise their VA companions; users could choose between a panda bear and a 
penguin, as well as a range of accessories that they could pick from. Yet, views on the 
customisation of human-like VAs in healthcare hasn’t attracted much research interest 
to date. 
Although this project did not address this concept formally, the potential of VA 
personalisation emerged in some patient interviews; all responders expressed that an 
option of personalising their VAs would be unnecessary. While no assumptions can be 
made regarding how other individuals would respond to such possibility, it is important 
to point out that offering the option of choosing between different health providers can 
give rise to certain ethical dilemmas. Such issues were addressed in Graber and Graber 
(2011) and more recently, in Hallqvist, (2019) wherein arguments for and against the 
customisation of health providers in supportive interventions were presented. A 
prominent issue concerned the VAs’ gender and ethnicity; while some patients might 
establish better therapeutic relations with providers that have the same characteristics 
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as themselves, granting the opportunity of choosing between individuals on such basis 
could potentially jeopardise diversity and give rise to prejudice. Instead of providing the 
option of personalising avatars, our proposal would be to offer a range of VAs in order 
to reflect the diverse character of the healthcare environment; this was also in line with 
findings from the interviews.  
9.3. Reflexivity 
The theoretical considerations around reflexivity have been presented in chapter 5 (pp. 
157-160). Reflexivity can be seen as both a concept and a process and is concerned with 
the role and influences of the researcher in the context of inquiry (Palaganas et al., 
2017). As a researcher newly introduced to qualitative research, this concept was 
entirely new (and somewhat foreign). My initial understanding of reflexivity mainly 
involved its role as a validation process and resembled that of ‘tick-boxing’. Yet, my 
course through the PhD programme made its actual purpose and value widely clear, not 
only for the research process, but also myself. The following sections will demonstrate 
the various influences that my personal and professional journey exerted upon the 
conduct of my research.  
9.3.1. Research ‘through the looking glass’  
Entering the realm of empirical inquiry was an arduous quest. Although my adventures 
were not as daunting as that of the protagonist in Lewis Carroll’s Alice Through the 
Looking Glass, venturing into the land of qualitative research drastically altered my 
perspectives on how knowledge is conceptualised, captured and generated.  
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As a pharmacist with a master’s project in organic catalysis, my training was shaped 
entirely by positivist/post-positivist directions, whereby knowledge is apprehended 
through well-established, air-tight methods and expressed as statistical probability 
(Brodsky et al., 2016). This created a certain perception of reality, as well as the process 
of research, both of which were challenged during my doctoral studies. At the early 
phase of the course, I took an interest upon research philosophy, with particular focus 
on the interpretivist/ constructivist movement and qualitative research. Exploring these 
domains made me envision research not just as a microscope, whereby a phenomenon 
is placed under observation in a controlled environment, but also as a kaleidoscope, 
where the same phenomenon can be looked from a different angle to reveal an entirely 
new picture. Drawing upon the pragmatist paradigm, I came to realise that research is 
not a mere tool used to comprehend a pre-defined reality, but instead, a toolbox that 
can be utilised in order to provide thorough answers in multiple research questions.  
Re-thinking the concept of inquiry also made me reconsider the matter of subjectivity. 
During my undergraduate studies, I had to distance myself from the observed in order 
avoid ‘contaminating’ my findings and introducing subjectivity in my research. At the 
time, I regarded it as a threat with destructive potential for validity in research. As a 
doctoral student, I came to realise that subjectivity is an inherent characteristic of a 
researcher’s thought process and that denying its existence would be the real threat to 
validity. Hence, instead of trying to eliminate subjectivity in a feeble attempt to portray 
an objective reality, I realised that the wisest course of action was to ‘exploit’ it in order 
to demonstrate how it affected my research, as well as the steps taken to ‘contain’ its 
impact.  
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9.3.2. Researcher’s effect on research  
There are three main aspects where I considered my effect upon the research process. 
First and foremost was the effect of my theoretical perceptions upon the choice of 
methodology, followed by my influences upon the conduct of interviews and the 
interpretation of qualitative findings. Below, these will be described in further detail.  
Choice of methodology and research methods  
In chapter 4, I presented an overview of my exploration of research philosophy. This 
directly influenced the choice of methodology, which in turn informed the selection of 
the most appropriate research methods for addressing the study’s objectives. While 
these decisions were successful in addressing the research objectives, it is important to 
acknowledge how issues inherent to these methods could have affected the findings. 
According to Deakin and Wakefield, (2014) the most prominent challenges associated 
with video conferencing is the lack of interviewee’s familiarity with such technology, the 
encounter of technical issues and the potential of premature termination from the 
interviewee’s behalf. The only challenge encountered in this project was experiencing 
technical issues (e.g., signal cuts, frozen image, sound distortion) whilst conducting two 
video interviews. This caused disruptions that inevitably affected the quality of the 
conversation. In one of these interviews, the issues were so profound that the video 
had to be turned off in order to continue the discussion. This had a direct impact upon 
the interview, as the delays resulted in terminating the interview earlier. It is also 
possible that the technical issues also caused frustration to the interviewee, which 
could have exerted an impact upon her engagement.  
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Apart from the aforementioned instance, the interview mode did not have an impact 
upon the length of interviews, as face-to-face conversations and individual 
videoconferences were similar in terms of duration and total amount of words. This 
finding is in line with Krouwel, Jolly and Greenfield, (2019) although differences in the 
number of themes and/or individual statements were not investigated in the present 
project. None of the users appeared to be unfamiliar with the use of videoconferencing 
and/or struggled with this interview mode; this was expected, as users’ IT literacy was 
somewhat evident since they consented in a study that involved the use of a VA-based 
app. 
Another consideration was the length of the information needs and satisfaction with 
information questionnaires (appendix 15 and 16.). These instruments were formulated 
after the Toronto Information Needs Questionnaire (TINQ) and provided a thorough 
account of patients’ needs and satisfaction with information; nevertheless, it is possible 
that their length had a negative impact upon the return rate. Although this was not 
evident in the pilot study (i.e., 4/4 returned the information needs instrument, 3/4 
completed the satisfaction with information questionnaire and no complaints about 
their length), the return rate in the main study was considerably lower (i.e., 7/23). This 
made me reconsider the potential risks of providing such exhaustive instruments.  
Conduct of interviews 
The idea of conducting interviews with patients provoked a deal of stress. Although not 
exploring a contingent social issue, I still had to be careful about approaching vulnerable 
individuals at a sensitive point of treatment. Yet, participants’ willingness to engage 
with the project and offer structured feedback increased my comfort and made the 
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process flow a lot easier than I anticipated. Drawing upon my experience as a qualified 
pharmacist also had a favourable effect. Being experienced with patient 
communication, as well as aspects such as active listening and simultaneous notetaking-
which are both part of the pharmacy learning and practice curriculum-equipped me 
with skills that facilitated the conduct of the interviews.  
My occupation as a pharmacist would make me-as Bonner and Tolhurst (2002) defined- 
an ‘inside’ researcher. Although this offered several advantages, it also posed certain 
threats to my capacity as a researcher. For example, being familiar with aspects of 
information support could result in making assumptions about what was observed and 
refraining from pursuing clarifications. With this in mind, I took care to seek as many 
explanations as possible, despite any pre-existing knowledge. Another aspect was my 
view of the participants. During the first couple of interviews, I struggled to separate my 
professional ‘instinct’ from my role as a researcher and focused on the interviewees’ 
capacity as patients rather than study participants. This could have created an excessive 
degree of rapport, which would in turn affect the findings (Bonner and Tolhurst, 2002). 
Yet, the fact that I was not involved with any clinical aspects of their care helped me to 
untangle myself from this confusion.  
Apart from my leverage upon the interview process, another important consideration 
was the way that I was perceived by the study’s participants. The effect of the 
researcher upon study participants is a well-recognised matter, especially in the domain 
of healthcare. Kelly (2010) pointed out that when interviewing in a healthcare setting, 
perceived power dynamics between providers and patients can exert a profound 
influence upon the interviews. These dynamics can also affect the way in that 
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interviewers are perceived, irrespective of their background, as responders (i.e., 
patients) can regard them as experts. This imbalance of power can make participants 
hesitant towards providing feedback that can be perceived as negative or deviant in 
fear that doing so can jeopardise their relationships with their providers, or even, their 
access to care.  
Although participants knew that I was not a part of neither their clinical nor supportive 
care team, they were aware that I collaborated with their treating clinicians and that 
they were also involved in the development process of the app. It is therefore possible 
that they framed their responses in a positive way in order to avoid causing indirect 
unpleasantness to the clinicians. While participants were generally comfortable with 
providing negative feedback, some could have potentially responded in a positive 
manner in order to not ‘displease’ the research team. 
Another aspect of my professional dimension was the role of attire upon the 
participants’ perceptions. At the time, my dress code matched that of the male 
members of the clinician team (i.e., formal trousers, shirts and ties). During the first 
interview, the participant emphasized upon the importance of professional attire in 
healthcare professionals and asked a technical question about chemotherapy medicines 
towards the end of the interview. This made me realise the way I dressed could 
potentially make patients focus upon my capacity as a healthcare professional rather 
than a researcher who was not actively involved in their care. As discussed above, 
power dynamics in healthcare can affect the way that patients respond to professionals. 
Following the encounter with the first participant, I adjusted my clothing in order to 
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present myself in a more informal manner (e.g., chinos, plain t-shirts and casual blazers) 
in order to reduce this effect.  
Another reason that could have inclined participants to provide positive feedback was 
my role in the development process of the app. Being aware that I was involved in the 
development of the intervention could have fostered the idea that my goal was the 
promotion Manage your Health rather than its evaluation it in the context of research. 
In order to avoid this, I abstained from commenting on my role as a developer and 
reminded participants that the purpose of the interviews was to obtain honest accounts 
of users’ experiences rather than a glorified appraisal of the app.  
Analysis and interpretation of qualitative findings  
The analysis of qualitative findings was by far the most challenging part of my academic 
work. The in-depth interviews produced an immense amount of data, which had to be 
reviewed systematically, organised in a reliable manner and be interpreted in a 
meaningful way. Due to its systematic nature, framework analysis was chosen for this 
purpose. While this approach generated findings of quality, it was is also complex and 
laborious. This posed a significant challenge, especially considering that this was 
something entirely new for me. To ensure robustness, I continuously refined the initially 
developed framework and abided closely by the process of iteration in order to create a 
vigorous framework. This was performed under the watchful eye and assistance of my 
supervisors, whose expertise helped to increase the robustness of the analysis.  
Apart from the practical challenges, my personal leverage upon the analysis of the 
qualitative findings was also a key aspect. At the early stages of the interpretation 
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process, I realised that being intimately connected with my work predisposed me 
towards concentrating upon positive feedback and paying less attention to negative 
comments. With this in mind, I took care to carefully examine negative views and 
deviant cases in order to captivate a reliable collective account of users’ perspectives 
upon the intervention. The potential of biasing users was also taken into consideration 
whilst analysing the transcripts (see p. 305-308 for further details). While it is possible 
that I had an effect upon the users’ responses, the presence of positive and negative 
feedback was indicative of honest accounts, as well as a good degree of rapport 
between the participants and the interviewer.  
9.3.3. Research’s effect on researcher 
Having to leave the UK in urgent notice due to the COVID-19 pandemic and supporting 
the family business (pharmacy) in this volatile time forced me to temporarily put my 
research aside. Although this resulted in requiring additional time to complete my 
thesis, it also granted the opportunity of viewing my academic work away from the 
pressures of the academic environment. As Mauther and Douchet (2003) proposed, the 
realisation of certain influences can sometimes necessitate “time, distance and 
detachment from the research” (p.425). In my case, this time helped to not only 
appreciate my influences upon the research process, but also to understand the 
influence of the research process upon myself. 
The most valuable outcome of my academic Odyssey was familiriasing myself with the 
research process. The PhD course equipped me with knowledge, as well as an array of 
skills that will be of the upmost importance in my future research endeavours. This 
includes the design of projects, the coordination of teams (academic, clinical and 
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developmental), the conduct of systematic reviews and experience in qualitative 
inquiry.  
Another important aspect was a better grasp on mHealth and VAs. Before engaging 
with this project, one of the outmost considerations was the impact of these 
interventions in healthcare. Whilst appreciating the positive effects, I was concerned 
that such technology could potentially replace clinicians (to a greater or lesser extent). 
Yet, I realised that this was not the case for two reasons. Human communication is an 
integral part of supportive cancer care. Although this can be supported by mHealth 
interventions and VAs, it cannot be replaced by them. The same would be true for the 
app’s capacity to keep track of toxicity and make assessments according to patient’s 
input. Although such aspects could facilitate patient care, they could not by any means 
subsidise the role of healthcare professionals, whose non-linear reasoning is integral for 
making the most appropriate decisions for patients’ health.  
As a concluding reflexive remark, I drew upon the work of Mauthner and Doucet, (2003) 
who argued that there are limits to how reflexive one can be. Although strenuous 
efforts were made to engage reflexively with my research, I appreciate that there is still 
much to be learned throughout my course as a researcher in the future.  
9.4. Chapter summary 
The present chapter discussed the major findings of this research project, which 
concerned the intervention itself (app-related discussion) and the VAs (VA-related 
discussion) that were used to deliver the information support. The use of a mixed-
methods approach was particularly helpful at conceptualising quantitative results using 
findings from the in-depth interviews, which also helped explain controversies and 
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unexpected findings. The next chapter will outline the conclusions of this research, 
present the strengths and limitations and point out directions for future work. 
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Chapter 10: Conclusions, limitations and 
directions for future work  
The previous chapter discussed the findings of the main study. The present chapter will 
provide an outline of the key findings, along with their potential implications and will 
then proceed to the strengths and limitations of this project, followed by directions for 
future work. 
10.1. Key findings and implications 
The aim of the project was to develop and evaluate a virtual agent (VA)-based mobile 
health (mHealth) intervention for patients with colorectal cancer (CRC). The following 
objectives were set, which were addressed through a convergent parallel mixed 
methods design.  
• Objective 1: Determination of the app’s degree of usability and acceptability  
• Objective 2: Satisfaction with information and views on the content 
• Objective 3: Exploration of the app’s use throughout the study period 
• Objective 4: In-depth exploration of users’ perceptions of the VAs 
• Objective 5: Potential ways for improving the app 
A number of insights were also offered by the systematic review (Chapter 2), as well as 
the competitive analysis undertook as part of the development process (Chapter 3). The 




• Objective 1:  Degree of usability and acceptability of the app  
The System Usability Scale (SUS) revealed a good degree of usability and acceptability 
(mean SUS score 73.89), which was also supported by the interview findings (e.g., 
minimal negative feedback regarding usability). Users who didn’t regard themselves as 
tech-savvy found the app easy to use and suggested that fellow patients, even those 
who wouldn’t be very familiar with apps would find it easy to use. This project is an 
example where a multistage process informed by the latest directions to best practice 
was followed in order to build and refine an intervention for use in patient care. Future 
investigations can draw upon this process to develop similar interventions in the field of 
mHealth. 
The involvement of health professionals in the recruitment process and indirect 
‘endorsement’ of the app appeared to have exerted a positive effect upon its uptake. 
This finding emphasises the benefits from including healthcare professionals in the 
promotion of health apps and can be of potential value to future developers; this does 
not only include doctors, but also pharmacy, as well as nursing staff.  
• Objective 2: Satisfaction with information and views on the content  
The satisfaction with information questionnaire demonstrated that the app addressed 
patients’ needs at a moderate degree. Throughout the in-depth interviews, patients 
reported being satisfied with the information that was available through the app, but 
also reported utilising a variety of other resources (e.g., printed material, healthcare 
professionals). In general, the app was not the principal source of information. 
According to users’ comments, the app was seen as an additional resource that could 
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help endorse existing information, confirm new information and remind them of 
aspects that were forgotten throughout treatment.  
Users reflected positively on the content of the app. This included the types of 
information, the organisation of the content in thematic categories, the amount of 
information and the level of detail. The inclusion of health professionals in the 
development process also increased patients’ confidence regarding the quality of the 
content. Again, this highlights the potential benefits offered by involving healthcare 
professional in the development of such interventions. 
• Objective 3: Use of the app throughout the study period 
The interview data revealed an overall usage pattern during the study period. The 
participants explored various sections of the app in order to familiarise themselves with 
the content before treatment and used the apps on a ‘as needed’ basis after the first 
dose of chemotherapy. The usage data revealed that the degree of engagement (e.g., 
number of logins, tap count) varied considerably across the participant sample. 
Nevertheless, the majority of users accessed the app more frequently after receiving 
the first dose of chemotherapy. This could be attributed to that patients were still at an 
early phase of their care pathway, so their information needs remained high.  
Throughout the interviews, it appeared that the extent of the app’s use was affected by 
the wellbeing of the patients and how well their treatment was tolerated, with frail 
patients and those heavily affected by treatment being more likely to need it. This could 
not be examined further, as the research did not involve access to patients’ health 
records.  
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• Objective 4: Users’ perspectives on the VAs 
Although the application of conversational agents has gained momentum in recent 
years, the use of embodied conversational agents (ECAs) in cancer care remains an 
under researched area. This project adds insight in the use of embodied VAs for 
supporting patients with cancer and is the first to deploy realistic VAs in oncology care. 
The results demonstrated that the VAs were received well by the participants and were 
deemed to be an appropriate way of providing patient support. It must be noted that 
these findings can have potential implications not only for clinical, but also for 
pharmacy practice, since a new type of interaction between patients and pharmacists 
emerged throughout the interviews. 
The inclusion of the VAs fostered a sense of reassurance, facilitated the process of 
information- giving and had a positive effect upon the perceived trustworthiness of the 
content. This project included patients who had at least one of their treating clinicians 
represented as a VA in the app, as well as patients who were not familiar with the 
virtual characters. The results indicated that being familiar with the healthcare 
professionals represented by the VAs can play an important role. Overall, users 
favoured having their treating clinicians as VAs in the app, as they felt that the 
healthcare professionals’ care extended to them through the app. This was in line with 
the initial hypothesis. The importance of organisational affiliation (i.e., the VAs being 
affiliated with the treating establishment) was also highlighted.  
The most prominent comments concerned the appearance and voices of the agents. 
The VAs included in the app were perceived as cartoon figures and not real humans by 
most users. The general consensus was that the VAs should resemble healthcare 
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professionals, look realistic (i.e., human-like), and have natural voices. Another 
prominent finding was that older users do not necessarily experience the phenomenon 
of the uncanny valley, where users can manifest feelings of eeriness when encountering 
realistic representations of humans in virtual environments (see pp. 24-25). 
The abovementioned points offer insight for developers and researchers who wish to 
deploy VAs in cancer care. It should be pointed out that these findings concern this 
particular group and should not be directly applied to other types of users. For instance, 
a cartoon-type ECA can be more appropriate for children with a malignant condition 
(e.g., Hunter et al., 2018). Developers and researchers should consider this carefully in 
order to design VAs according to the expectations of the intended audience to optimise 
the user experience.  
• Objective 5: Potential ways for improving the app 
The participants offered several recommendations for improving the intervention. 
These mainly concerned the supportive functions of the app, with only a limited 
number of remarks about the information content. Comments included the 
incorporation of a medicinal calendar section and integration of the symptom calendar 
function with Triage. The element of personalisation (i.e., tailored feedback according 
to users’ input and information on their unique treatment) also emerged as a desired 
aspect. Healthcare professionals also provided comments on how the app could be 
improved and focused mainly upon its potential as a toxicity-monitoring tool. Patient-
reported outcomes (PROs) emerged in most interviews.  
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The app’s capacity as a multivalent tool rather than just an information resource was 
another major insight. Interventions aiming exclusively at information support are likely 
to be placed at a disadvantage due to the presence of ‘competing’ information sources 
and the fact that once patients become familiar with information, the intervention 
might cease to be utilised. This is particularly applicable for interventions with 
commercial intentions. This finding calls for developers to consider that supportive 
interventions should address a range of needs (e.g., symptom tracking, toxicity 
checking, coaching etc.) rather than focusing upon a single dimension of support in 
order to be relevant across the entire care pathway. 
• Systematic review (Chapter 2) 
The systematic review not only offered directions for designing the intervention, but it 
also made a contribution to the evidence base around the information needs of 
patients with a recent diagnosis of CRC. This is the first review to investigate this group 
of patients at the early stages of the cancer care continuum. 
Treatment-related aspects were the most prominent type of information across the 
included studies. Patients with CRC can utilise a variety of resources to obtain 
information, with healthcare professionals being the most trusted and preferred source 
across studies. The review also identified a number of pitfalls in the provision of 
information support to patients with CRC; these concerned the lack of written 
information and issues in patient/provider communication.  
The systematic review offered key insights that can be utilised by health professionals in 
order to optimise the provision of information support to patients with a first-time 
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diagnosis of CRC. This includes the information priorities (i.e., which types of 
information appear mostly in the literature), as well as the necessity of assessing 
individual needs in order to offer tailored advice. 
• Competitive analysis (Chapter 3) 
This was the first review of commercially available health apps for patients with CRC, 
which informed the development process of Manage your Health and offered insight to 
the quality of these interventions. The competitive analysis revealed several quality-
related issues associated with the content of publicly available apps for CRC (e.g., 
absence of references and adherence to evidence-based practice). The poor quality of 
content in commercially available mHealth interventions is a common concern 
(Charbonneau et al., 2020), and the present project demonstrated that health apps in 
the field of CRC care are not free of such issues. This has implications in both a practice 
and policy level. Healthcare professionals, including pharmacists can help raise 
awareness regarding the risks of these apps, while health organisations and 
policymakers can draw upon these findings to call for more robust regulatory 
frameworks surrounding the content of these apps to ensure that patients with CRC 
receive high-quality advice for interventions with an evidence-based content. 
10.2. Strengths of the project  
The work undertaken in this project offers insight into the under-researched area of 
using embodied VAs to support patients with cancer. While the use of ECAs is abundant 
in healthcare (El Kamali et al., 2020; ter Stal et al., 2020a), their use in cancer care still 
remains scarce. The present study investigated the role of familiarity in embodied VAs, 
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another area that hasn’t received much research interest. A particular strength is that 
unlike previous studies on the role of familiarity, the present project utilised a 
qualitative approach and performed formal analysis of the findings, thereby providing 
an in-depth understanding of users’ preferences and perspectives. This study was also 
the first to perform qualitative comparisons between patients who had their clinicians 
as VAs through the app and users who didn’t, thus offering insight as to similarities and 
differences between these groups.  
The use of mixed methods was particularly beneficial for addressing the research 
objectives. A combination of usage parameters (e.g., number of logins, intensity of use, 
number of taps etc.) provided an overview of how the app was used over the study 
period, while questionnaires helped to quantify patients’ information needs, the degree 
of the app’s usability and patients’ satisfaction with information. Qualitative data from 
the in-depth interviews helped to conceptualise the quantitative findings, explain 
controversies and most importantly, obtain exploratory views that not only increased 
the understanding around the effects of the intervention, but also suggested key 
aspects for improvement and further investigation.  
Testing the intervention in a real setting was perhaps the most prominent strength of 
this project. While some studies (Dixon and Michaud, 2018; Reade et al., 2017) 
excluded users that did not engage with the intervention in a pre-defined manner, this 
project allowed patients to use the app as they saw fit. During the consent process, all 
study participants were explicitly told that there was no right or wrong way of using the 
app but instead, they could use it in their own discretion. Hence, instead of attempting 
to control the environment in which patients used the app or test it within a specific 
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setting (i.e., laboratory testing), this study offered insight as to how such interventions 
can be utilised in a real-world situation, away from the influence of the researcher. 
10.3. Limitations of the project 
Despite the strengths of the project, there were also several limitations. While efforts 
were made in order to address the issue of recruitment (i.e., the creation of two 
additional information packages), identifying eligible patients remained a challenge. 
Although widening the patient net by creating a generic app (e.g., an app for general 
symptom management) was considered, this was dismissed as it would eliminate the 
treatment-specific character of the app, which appealed to patients.  
Another limitation is that the study concentrated upon the first cycle of chemotherapy. 
A study that expanded over a larger period of time, such as the whole treatment could 
potentially allow for better understanding how the app would be used over patients’ 
therapeutic journey, thereby adding further insight as to changes in patients’ 
information needs, as well as their relationships with the VAs.  
Apart from the limitations arising from the study design, there were certain drawbacks 
that were innate to study techniques. These were discussed in 9.6 (Reflexivity).  
The COVID-19 outbreak of 2020 also imposed considerable limitations. The first was the 
restricted access to the research site. Although this did not affect recruitment, it forced 
the researcher to conduct more asynchronous interviews (in terms of location). The 
pandemic also added great pressure on the NHS staff, which severely limited the 
clinicians’ availability; as a result, some clinicians were not able to take part in the 
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interviews. Nevertheless, the final sample of clinicians included professionals from 
nursing, medicine and pharmacy so that each discipline had some representation. 
10.4. Directions for future work 
Alongside with its contributions, this project also highlighted several areas in which 
further research can be conducted. First, the systematic review indicated the need for 
more studies focusing upon the dimension of information support, as most papers 
investigated this within the general supportive framework and did not perform a 
detailed assessment of patients’ information needs. Qualitative studies would be of 
particular value in this regard, as they can allow for addressing multiple aspects of 
information support (e.g., desired types of information, volume of information etc.) and 
obtain in-depth perspectives. 
Findings from the main study suggested several promising areas for future work. The 
first would be to explore the use of hyper-realistic humanoid avatars with patients in 
cancer care. The majority of patients in this study regarded the VAs as cartoon figures, 
as they were not photo-realistic representations of the healthcare professionals they 
portrayed; the patients recommended that making the VAs more human-like would 
likely improve their user experience. A future study could use cutting-edge graphics in 
order to produce highly realistic VAs and perform testing in order to establish the 
acceptability this approach.  
Another area for future exploration would be the effects of familiar and unfamiliar VAs 
upon users. The interview data revealed that differences are evident and that patients 
generally opted for having their clinicians on the app, but the project did not examine 
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the effects of familiarity on aspects such as intention to use or user satisfaction. A 
future study could test this with a larger patient sample and attempt to such explore 
relationships to offer further insight in that matter.  
Some patients did not perceive the VAs as interactive due to restrictions in user input 
(e.g., patients could only choose between pre-set questions). The use of embodied VAs 
with natural language processing is gaining momentum in healthcare (Laranjo et al., 
2018; Milne-Ives et al., 2020), but their application in oncology remains scarce. El 
Kamali et al. (2020) argued that since language is the cornerstone of building human 
relationships, the use of unrestrictive user input and language understanding in VAs can 
potentially increase their capacity as companions for older individuals. This would be a 
promising area for future exploration in cancer care. It is important to note that such 
studies will have to expand over long periods in order to observe how this virtual 
relationship unfolds with time.  
10.5. Concluding remarks  
The present project used a mixed method approach to evaluate a novel health app that 
used highly realistic, embodied VAs in the field of oncology care. Unlike previous 
research, the VAs used in this study represented clinicians that were known to the 
users. The findings of this study demonstrated that this was an acceptable approach for 
supporting the information needs of patients with CRC during their first cycle of 
chemotherapy. This project made a series of original contributions to the fields of 
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Appendix 1: Systematic review search strategy 
 
Cochrane Library 
Search terms Hits 
1 MeSH descriptor: [Consumer Health Information] explode all trees 472 
2 educat* near/4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire* or support*):ti,ab,kw 5725 
3 learn* near/4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*):ti,ab,kw 1485 
4 advise near/4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*):ti,ab,kw 44 
5 advice near/4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*):ti,ab,kw 764 
6 literacy near/4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire*):ti,ab,kw 145 
7 counseling near/4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire*):ti,ab,kw 1136 
8 counselling near/4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire*):ti,ab,kw 1136 
9 info* near/4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*):ti,ab,kw 6436 
10 knowledge* near/4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire* or support*):ti,ab,kw 8955 
11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 22908 
12 MeSH descriptor: [Colorectal Neoplasms] explode all trees 7912 
13 colorectal near/4 (neoplas* or cancer* or tumour* or tumor* or 
carcinoma*):ti,ab,kw 14571 
14 colon* near/4 (neoplas* or cancer* or tumour* or tumor* or 
carcinoma*):ti,ab,kw 6108 
15 Bowel* near/4 (neoplas* or cancer* or tumour* or tumor* or 
carcinoma*):ti,ab,kw 654 
16 rectal near/4 (neoplas* or cancer* or tumour* or tumor* or 
carcinoma*):ti,ab,kw 3933 
17 rectum near/4 (neoplas* or cancer* or tumour* or tumor* or 
carcinoma*):ti,ab,kw 1990 
18 anal near/4 (neoplas* or cancer* or tumour* or tumor* or 
carcinoma*):ti,ab,kw 443 
19 sigmoid* near/4 (neoplas* or cancer* or tumour* or tumor* or 
carcinoma*):ti,ab,kw 274 
20 #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 21201 
21 11 and 20 406 
Notes: None. 
 
Web of science 
 364 
Search terms Hits 
1 ts=(learn* near/4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire* or support*)) 45391 
2 ts=(educat* near/4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire* or support*)) 63530 
3 ts=(advice near/4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire* or support*)) 5899 
4 ts=(advise near/4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire* or support*)) 1116 
5 ts=(literacy near/4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire*)) 2474 
6 ts=(counseling near/4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire*)) 5752 
7 ts=(counselling near/4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire*)) 5752 
8 ts=(info* near/4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire* or support*)) 138011 
9 ts=(knowledge* near/4 (require* or attitude* or priorit* or need* or seek* 
or demand* or desire* or support*)) 85640 
10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 325389 
11 ts=(colorectal near/4 (cancer* or malignan* or tumor* or tumour* or 
growth or neoplasm* or carcinoma*)) 194165 
12 ts=(colon* near/4 (cancer* or malignan* or tumor* or tumour* or growth or 
neoplasm* or carcinoma*)) 132685 
13 ts=(rectal near/4 (cancer* or malignan* or tumor* or tumour* or growth or 
neoplasm* or carcinoma*)) 36447 
14 ts=(rectum near/4 (cancer* or malignan* or tumor* or tumour* or growth 
or neoplasm* or carcinoma*)) 5257 
15 ts=(bowel* near/4 (cancer* or malignan* or tumor* or tumour* or growth 
or neoplasm* or carcinoma*)) 10177 
16 ts=(anal near/4 (cancer* or malignan* or tumor* or tumour* or growth or 
neoplasm* or carcinoma*)) 5912 
17 ts=(sigmoid* near/4 (cancer* or malignan* or tumor* or tumour* or growth 
or neoplasm* or carcinoma*)) 2416 
18 #11 or #12 or #13 or #14 or #15 or #16 or #17 314397 
19 #10 AND #18 1897 
Notes: All searches were performed under “advanced search”. All years were included. The 
search was limited to the Science Citation Index Expanded (SCI-EXPANDED)—1970-present 
and Social 38Sciences Citation Index (SSCI)—1970-present. 
 
ASSIA 
Search terms Hits 
1 (colorectal* or colon* or rect* or bowel* or anal) near/4 (cancer* or 
malignan* or tumor or tumour or growth or neoplasm* or carcinoma*) 5439 
2 SU.EXACT.EXPLODE("Colorectal cancer") 1480 
3 
((colorectal* or colon* or rect* or bowel* or anal) near/4 (cancer* or 





(educat* or learn* or advice or advise or literacy or counseling or counselling 
or inform* or knowledge) near/4 (require* or attitude* or priorit* or need* 
or seek* or demand* or desire* or support*) 
121947 
5 SU.EXACT.EXPLODE("Health information") 3341 
6 
((educat* or learn* or advice or advise or literacy or counseling or counselling 
or inform* or knowledge) near/4 (require* or attitude* or priorit* or need* 




(((colorectal* or colon* or rect* or bowel* or anal) near/4 (cancer* or 
malignan* or tumor or tumour or growth or neoplasm* or carcinoma*)) OR 
SU.EXACT.EXPLODE("Colorectal cancer")) AND (((educat* or learn* or advice 
or advise or literacy or counseling or counselling or inform* or knowledge) 
near/4 (require* or attitude* or priorit* or need* or seek* or demand* or 
desire* or support*)) OR SU.EXACT.EXPLODE("Health information")) 
1863 
Note: This search terms are used in this way because a previous attempt revealed technical 
issues. No explode terms were identified. Duplicates are automatically removed in ASSIA. 
When used SU.EXACT.EXPLODE(“Colorectal Cancer”) and combined it with search 1, I 
obtained the same number of results (indicating that search 1 identified all studies under the 
explode term).  
 
EMBASE (HDAS) 
Search terms Hits 
1 educat* ADJ4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire* or support*).ti,ab,au 70816 
2 learn* ADJ4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*).ti,ab,au  27516 
3 advice ADJ4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*).ti,ab,au  8720 
4 advise ADJ4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*).ti,ab,au  541 
5 literacy ADJ4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire*).ti,ab,au  1547 
6 counseling ADJ4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire*).ti,ab,au  4722 
7 counselling ADJ4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire*).ti,ab,au  2459 
8 info* ADJ4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*).ti,ab,au  102855 
9 knowledge* ADJ4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire* or support*).ti,ab,au  72039 
10 exp “CONSUMER HEALTH INFORMATION”/ 3782 
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 237741 
12 colorectal ADJ4 (cancer* or malignan* or tumor* or tumour* or growth or 
neoplasm* or carcinoma*).ti,ab,au  181892 
13 colon* ADJ4 (cancer* or malignan* or tumor* or tumour* or growth or 
neoplasm* or carcinoma*).ti,ab,au  134059 
14 rectal ADJ4 (cancer* or malignan* or tumor* or tumour* or growth or 
neoplasm* or carcinoma*).ti,ab,au  45723 
 366 
15 rectum ADJ4 (cancer* or malignan* or tumor* or tumour* or growth or 
neoplasm* or carcinoma*).ti,ab,au  8071 
16 Bowel* ADJ4 (cancer* or malignan* or tumor* or tumour* or growth or 
neoplasm* or carcinoma*).ti,ab,au  13805 
17 anal ADJ4 (cancer* or malignan* or tumor* or tumour* or growth or 
neoplasm* or carcinoma*).ti,ab,au  8303 
18 sigmoid* ADJ4 (cancer* or malignan* or tumor* or tumour* or growth or 
neoplasm* or carcinoma*).ti,ab,au  4094 
19 Exp “COLORECTAL TUMOR”/ 28624 
20 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 340085 
21 11 and 20 2345 




Search terms Hits 
1 
(educat* adj4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*)).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, 
unique identifier, synonyms] 
51004 
2 
(learn* adj4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*)).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, 
unique identifier, synonyms] 
21325 
3 
(advi#e adj4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*)).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, 
unique identifier, synonyms] 
6165 
4 
(literacy adj4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire*)).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary 




(counsel?ing adj4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire*)).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary 




(info* adj4 (require* or attitude* or priorit* or need* or seek* or demand* or 
desire* or support*)).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary 




(knowledge* adj4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire* or support*)).mp. [mp=title, abstract, original title, name 
of substance word, subject heading word, keyword heading word, protocol 
150154 
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supplementary concept word, rare disease supplementary concept word, 
unique identifier, synonyms] 
8 exp consumer health information/ 9000 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 297431 
10 
(colorectal adj4 (cancer* or malignan* or tumo?r or growth or neoplasm* or 
carcinoma*)).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary 




(colon* adj4 (cancer* or malignan* or tumo?r or growth or neoplasm* or 
carcinoma*)).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary 




(rectal adj4 (cancer* or malignan* or tumo?r or growth or neoplasm* or 
carcinoma*)).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary 




(rectum adj4 (cancer* or malignan* or tumo?r or growth or neoplasm* or 
carcinoma*)).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary 




(bowel adj4 (cancer* or malignan* or tumo?r or growth or neoplasm* or 
carcinoma*)).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary 




(anal adj4 (cancer* or malignan* or tumo?r or growth or neoplasm* or 
carcinoma*)).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary 




(sigmoid* adj4 (cancer* or malignan* or tumo?r or growth or neoplasm* or 
carcinoma*)).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier, 
synonyms] 
6373 
17 exp colorectal neoplasms/ 198364 
18 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 283994 
19 9 and 18 2624 
Notes: The option “Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed 
Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present” was selected. 
 
EBSCO AMED 
Search terms Hits 
1 educat* N4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*)  2000 
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2 learn* N4 (require* or attitude* or priorit* or need* or seek* or demand* or 
desire* or support*)  742 
3 advi?e N4 (require* or attitude* or priorit* or need* or seek* or demand* or 
desire* or support*)  169 
4 literacy N4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire*)  28 
5 counsel#ing N4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire*)  136 
6 info* N4 (require* or attitude* or priorit* or need* or seek* or demand* or 
desire* or support*) 1718 
7 knowledge* N4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire* or support*)  1476 
8 DE “patient satisfaction” 2327 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8  7956 
10 colorectal N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  507 
11 colon* N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  533 
12 rectal N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  89 
13 rectum N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  17 
14 Bowel* N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  79 
15 anal N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  10 
16 sigmoid* N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  6 
17 DE “colorectal neoplasms” 356 
18 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 1048 
19 9 and 18 19 
Notes: The terms “consumer health information” did not provide any relevant terms apart 
from “Patient satisfaction”, which was included in the search. 
 
EBSCO CINAHL 
Search terms Hits 
1 educat* N4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*)  46744 
2 learn* N4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*)  16412 
3 advi?e N4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*)  4464 
4 literacy N4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire*)  1309 
5 counsel#ing N4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire*)  3328 
6 info* N4 (require* or attitude* or priorit* or need* or seek* or demand* or 
desire* or support*) 58246 
7 knowledge* N4 (require* or attitude* or priorit* or need* or seek* or 33190 
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demand* or desire* or support*)  
8 (MH "Consumer Health Information+")  16944 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8  161469 
10 colorectal N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or carcinoma*)  34293 
11 colon* N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or carcinoma*)  16578 
12 rectal N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  7342 
13 rectum N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  662 
14 bowel N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  2224 
15 anal N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  1466 
16 sigmoid* N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  600 
17 (MH "Colorectal Neoplasms+")  41287 
18 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 53719 




Search terms Hits 
1 educat* N4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire*)  89226 
2 learn* N4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire*)  32633 
3 advi?e N4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire*)  695 
4 literacy N4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire*)  4328 
5 counsel#ing N4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire*)  2659 
6 info* N4 (require* or attitude* or priorit* or need* or seek* or demand* or 
desire*) 28859 
7 knowledge* N4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire*)  15832 
8 (DE "health promotion")  8038 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8  164816 
10 colorectal N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  77 
11 colon* N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  63 
12 rectal N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  5 
13 rectum N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  3 
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14 Bowel* N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  3 
15 anal N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  4 
16 sigmoid* N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  5 
17 (“10 or 11 or 12 or 13 or 14 or 15 or 16”) 140 
18 9 and 17 38 
Notes: No thesaurus terms for colorectal cancer (had generic for cancer or colorectal 
diseases, which were not relevant to our search). The term “neoplasms” did not include 
colorectal) colon or rectal) neoplasms. The terms “consumer health information” did not 
provide any relevant terms apart from “Health Promotion”, which was included in the search.  
 
EBSCO PsycInfo 
Search terms Hits 
1 educat* N4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*)  53975 
2 learn* N4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*)  42025 
3 advi?e N4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire* or support*)  2933 
4 literacy N4 (require* or attitude* or priorit* or need* or seek* or demand* 
or desire*)  2278 
5 counsel#ing N4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire*)  6561 
6 info* N4 (require* or attitude* or priorit* or need* or seek* or demand* or 
desire* or support*) 50371 
7 knowledge* N4 (require* or attitude* or priorit* or need* or seek* or 
demand* or desire* or support*)  56014 
8 DE “Health Promotion” 32848 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8  222220 
10 colorectal N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  3002 
11 colon* N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  1204 
12 rectal N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  249 
13 rectum N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  49 
14 bowel N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  195 
15 anal N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  125 
16 sigmoid* N4 (cancer* or malignan* or tumo#r or growth or neoplasm* or 
carcinoma*)  43 
17 10 or 11 or 12 or 13 or 14 or 15 or 16 4251 
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 18 9 and 17 800 
Notes: No thesaurus terms for colorectal cancer (had generic for cancer or colorectal 
diseases, which were not relevant to our search). The terms “consumer health information” 
did not provide any relevant terms apart from “Health Promotion”, which was included in the 
search.   
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Appendix 2: Quality assessment of included studies 
 


















RCTs Quantitative non-RCT Descriptive studies 





Bailey (2001) Y Y Y N                75% or *** 
Bain and Campbell (2000) Y Y Y Y                100% or **** 
Bain et al. (2002) Y Y Y N                75% or *** 
Bell et al. (2009) Y Y Y Y                100% or **** 
Boe et al. (2018) Y Y Y Y                100% or **** 
Broughton, Bailey and Linney (2004) Y Y N N                50% or ** 
Comb et al. (2003) Y Y N N                50% or ** 
Houldin (2007) Y Y N N                50% or ** 
Houldin and Lewis (2006) Y Y Y N                75% or *** 
Kidd et al. (2008) Y Y Y Y                100% or **** 
Lithner et al. (2015a) Y Y CT N                75% or *** 
Poland et al. (2017) Y Y Y Y                100% or **** 
Reinwalds et al. (2017) Y Y N N                50% or ** 
Sanders and Skevington (2003) Y Y N N                50% or ** 
Sanders and Skevington (2004) Y Y N N                50% or ** 
Sawyer et al. (2008) Y Y N N                50% or ** 
Spalding et al. (2013) Y Y Y N                75% or *** 
Scheer et al. (2012) Y Y Y N                75% or *** 
Taylor and Norton (2000) Y Y Y Y                75% or *** 
Taylor et al. (2001) Y Y Y Y                100% or **** 
Worster and Holmes (2008) Y Y Y Y                100% or **** 
Worster and Holmes (2009) Y Y Y Y                75% or *** 
Dronkers et al. (2010)     Y Y Y Y            100% or **** 
White et al. (2012)     Y N Y Y            75% or *** 
Bronner et al. (2018)         CT Y Y Y        75% or *** 
Dobrila-Dintinjana, Krznarić and Guina (2008)         CT Y CT CT        25% or * 
Harisson et al. (2010)         CT Y Y Y        75% or *** 
Lithner et al. (2012)         N Y Y Y        50% or ** 
Lithner et al. (2015b)         N Y Y Y        100% or **** 
Young et al. (2010)         N Y Y Y        75% or *** 
Cha et al. (2012)             N CT N Y    25% or * 
Cuthbert et al. (2019)             N CT N Y    25% or * 
Reeve et al. (2017)             N CT Y N    25% or * 
Sierko, Werpachowska and Wojtukiewicz (2011)             N CT N Y    25% or * 
Zafar et al. (2013)             N CT Y CT    25% or * 
Knowles et al. (1999) Y Y Y Y         Y N Y Y Y Y N 50% or ** 
Weaver et al. (2007) Y Y N N         N N Y Y Y Y N 25% or * 
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MMAT Assessment Criteria (Pluye et al., 2011, p.2) 
 
“1.1. Are the sources of qualitative data (archives, documents, informants, observations) relevant to address the research question (objective)? 
1.2. Is the process for analysing qualitative data relevant to address the research question (objective)? 
1.3. Is appropriate consideration given to how findings relate to the context, e.g., the setting, in which the data were collected? 
1.4. Is appropriate consideration given to how findings relate to researchers’ influence, e.g., through their interactions with participants? 
2.1. Is there a clear description of the randomization (or an appropriate sequence generation)? 
2.2. Is there a clear description of the allocation concealment (or blinding when applicable)? 
2.3. Are there complete outcome data (80% or above)? 
2.4. Is there low withdrawal/drop-out (below 20%)? 
3.1. Are participants (organizations) recruited in a way that minimizes selection bias? 
3.2. Are measurements appropriate (clear origin, or validity known, or standard instrument; and absence of contamination between groups when 
appropriate) regarding the exposure/intervention and outcomes? 
3.3. In the groups being compared (exposed vs. non-exposed; with intervention vs. without; cases vs. controls), are the participants comparable, or 
do researchers take into account (control for) the difference between these groups? 
3.4. Are there complete outcome data (80% or above), and, when applicable, an acceptable response rate (60% or above), or an acceptable 
follow-up rate for cohort studies (depending on the duration of follow-up)? 
4.1. Is the sampling strategy relevant to address the quantitative research question (quantitative aspect of the mixed methods question)? 
4.2. Is the sample representative of the population understudy? 
4.3. Are measurements appropriate (clear origin, or validity known, or standard instrument)? 
4.4. Is there an acceptable response rate (60% or above)? 
5.1. Is the mixed methods research design relevant to address the qualitative and quantitative research questions (or objectives), or the qualitative 
and quantitative aspects of the mixed methods question (or objective)? 
5.2. Is the integration of qualitative and quantitative data (or results*) relevant to address the research question (objective)? 
5.3. Is appropriate consideration given to the limitations associated with this integration, e.g., the divergence of qualitative and quantitative data 
(or results*) in a triangulation design?” 
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Appendix 11: Layout of the XELOX information package 
 
 
Section 2: Information about cancer and treatment  
Animation 
button:  
What is cancer? 
Cancer is a condition where cells in our body get damaged 
multiply without control. To watch a video explaining what 







Although we know what cancer is, we are not sure as to what 
triggers it. Research suggests that cancer is due to genetic 
factors such as family history, as well as environmental factors 
such as air pollution, chemicals, smoking, an unhealthy diet and 
excessive alcohol consumption.  
Animation 
button:  
Has the cancer 
left its original 
site and spread in 
my body? 
If you are told that you have stage four, advanced or metastatic 
colorectal cancer, this means that the cancer has spread to other 
parts of your body. If you are unsure about the stage of your 





What are the 
treatment options 
for cancer? 
The general treatment options for bowel cancer are surgery, 
chemotherapy, radiotherapy or a combination of these. In some 
cases, doctors suggest clinical trials, where experimental 
treatments are given.  
Animation 
button:  
I will be given 
chemotherapy 
with XELOX. How 
does this 
treatment fight 
bowel cancer?  
In order for tumours to grow and spread, cancer cells need to 
divide and multiply. XELOX fights tumours by preventing this 
from happening. Since cancer cells are not able to multiply and 
some of them die, the tumours will stop growing and will 






Your treatment contains two medicines called Oxaliplatin and 
Capecitabine. Capecitabine comes as a tablet and you will be 
taking it at home. Oxaliplatin will be given to you at the hospital 
as a drip over two hours.  
Animation 
button:  
Is there any 
preparation 
Yes. Before or on the day that you will be given Oxaliplatin at the 
hospital, a qualified person will take a blood sample to check if it 
is okay for you to take the medicine. Also, before you get 
oxaliplatin at the hospital, a nurse will give you some anti-
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before I get 
XELOX? 
sickness medication.  
Animation 
button:  
How will I feel 
during and after 
my treatment at 
the hospital?  
There is no single answer to this question, since patients tolerate 
the treatment differently and we can’t now until you have it. 
Generally speaking, patients can get sickness or feel generally 
worn out after they get Oxaliplatin. Don’t worry, a nurse will be 
with you to help.  
Animation 
button:  
If XELOX cures my 
cancer, what are 
the chances of it 
coming back? 
There is no definite answer to this question, as the risk of the 
cancer coming back is different for each patient. However, bear 
in mind that your doctor will arrange for regular check-ups after 
your treatment is finished to check for signs indicating returning 
cancer. If you are concerned about this, please discuss this with 
your oncologist.  
Animation 
button:  
How can I tell if 
the cancer has 
come back? 
If cancer has returned and progressed, you might get symptoms 
similar to those that you got before your first diagnosis. 
However, bear in mind that your doctor will arrange for regular 
check- ups after your treatment is finished, so it is very unlikely 
that the cancer will return without your doctors knowing it. If 
you are concerned about this, please discuss this with your 
oncologist. 
 
Section 3: Diagnostic tests for cancer  
Animation 
button: What is a 
CT scan and why I 
might have one?  
CT stands for Computerised Tomography, which is performed 
using a CT scanner. A CT scanner will take detailed images of the 
inside of the body, which is done to diagnose cancer and monitor 
your condition. A CT scan also helps doctors decide upon further 
tests or future treatment. To see how a CT scan is done, tap on 




button: What is a 
PET scan and why 
I might have one? 
PET stands for Positron-Emission Tomography, which is 
performed using a PET scanner. A PET scan is used to diagnose 
cancer and determine its stage. It also helps doctors decide 
which treatment is best for you and see how well your current 
treatment works. To see how a PET scan is done, tap on the link 




button: What is 
an MRI scan and 
MRI stands for Magnetic Resonance Imaging. This is performed 
by an MRI scanner, which uses a powerful magnet to create an 
image of the inside the body. An MRI scan helps doctor locate 
tumours, determine their size and find out if the cancer has 
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why I might have 
one? 
spread. To see how an MRI scan is done, tap on the link below 
when I finish talking. 
YouTube link: https://www.youtube.com/watch?v=NUbifL_MAro  
Animation 
button: What is 
an ultrasound 
scan and why I 
might have one? 
An ultrasound scan uses sound waves to build an image of the 
inside of the body and it is used to locate a tumour or determine 
if the cancer has spread. To see how an ultrasound scan is done, 
tap on the link below when I finish talking. 
YouTube link: https://www.youtube.com/watch?v=vTLvg6XR9Tc  
Animation 
button: What are 
X-Rays and why 
are they 
performed?  
X-Rays use high energy rays to build an image of the inside of the 
body.  Patients with bowel cancer will have this to find out if the 
cancer has spread to another part of the body. To see how X-
Rays are performed, tap on the link below when I finish talking. 
YouTube link: https://www.youtube.com/watch?v=l3YqLAbs5lg  
Animation 
button: What is a 
PET-CT scan and 
why I might have 
one? 
A PET-CT scan combines a PET and a CT scan. It is used to 
monitor your condition and determine how well your treatment 
is working. The procedure of carrying out a PET-CT scan is the 
same with this of a PET scan. To see how a PET scan is done, tap 




button: Why do 
doctors order 
blood tests?  
Doctors order blood tests to check your general health and 
markers that indicate cancer. To watch a video explaining this in 
detail, tap on the link below when I finish talking. 
YouTube link: https://www.youtube.com/watch?v=bqSt7wLxCDQ  
 
Section 4: Side effects of XELOX 
Subsection 1: Common, less common and uncommon side effects of XELOX 
Animation button:  
What is the risk of 
getting the very 
common side 
effects of XELOX? 
(Animation) 
Imagine a group of 10 people going on a field trip. Out of them, 
at least one will leave because of feeling unwell. We cannot 
know which one this will be, but older individuals or those with a 
medical condition are more likely to leave. The same is true for 
chemotherapy. There is no way to tell who will get side effects, 
but the risk is generally higher in older patients or people with 
pre-existing medical conditions. However, your doctors will 
make sure to minimise the risk of you getting such side effects.  
Very common 
side effects (more 
than 1 in 10 
people) 
(text) 
• Blood disorders: Decreased red blood cells, decreased 
number of neutrophils, decreased number of cells 
responsible for blood clots, decreased number of white 
blood cells, decreased number of lymph cells (if they occur, 
these will be picked in blood tests) 
• Metabolic and nutrition disorders: Loss of appetite, high or 
low blood sugar, decreased potassium and sodium levels in 
the blood 
• Nervous system disorders: Peripheral sensory neuropathy, 
sensory disturbance, taste disturbances, Headaches  
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• Respiratory, thoracic and mediastinal disorders: Difficulty in 
breathing, cough 
• Gastrointestinal disorders: Feeling sick, being sick, tummy 
pain, mouth soreness, constipation, diarrhoea 
• Liver problems: Liver function test abnormalities (picked up 
in blood tests) 
• Skin disorders: Palmar-plantar erythro-dysesthesia syndrome 
(hand-foot syndrome), skin disorders, hair loss  
• Musculoskeletal disorders: Back pain 
• General disorders and administration site conditions: Feeling 
tired, fever, pain, injection site reaction, nosebleeds 
Animation button:  
What is the risk of 
getting the 
common side 
effects of XELOX? 
Imagine that 100 people are at a town fair on a warm summer 
day. Out of them, a maximum of ten people will feel it’s too hot, 
while the rest will be comfortable in that temperature and enjoy 
their time. In a similar manner, common side effects can affect a 
maximum of 10 out of 100 patients. However, bear in mind that 
the possibility of not getting them is higher than the like hood of 
experiencing them.  
Common side 
effects of XELOX 
(up to 10 in 100 
people) 
(text) 
• Infections and infestations: Herpes viral infection, nose and 
throat infection, lower or upper respiratory tract 
infection, neutropenic sepsis 
• Blood disorders: Blood creatinine increase, severely low 
number of neutrophil blood cells (if they occur, these will be 
picked in blood tests) 
• Metabolism and nutrition disorders: Dehydration, weight 
loss 
• Nervous system and psychiatric disorders: Sleepiness, pins 
and needles, dizziness, problems with coordination, 
meningism, sleeplessness, low mood 
• Eye disorders: Increased tearing, eye infections, visual 
disturbances 
• Vascular disorders:  Blood clots in veins, bleeding, painful 
redness, deep vein thrombosis, pulmonary embolism, 
increased blood pressure 
• Respiratory disorders: Runny nose, hiccups  
• Gastrointestinal disorders: Gastrointestinal bleeding, 
stomach pain, indigestion, flatulence, dry mouth, gastro 
esophageal reflux, rectal bleeding 
• Liver problems: Jaundice (yellowing of the skin due to a 
blockage in the liver) 
• Skin disorders: Rash, redness, dry skin, skin hyper-
pigmentation, nail disorder, excessive sweating 
• Musculoskeletal disorders: Pain in extremity, back pain, joint 
pain, bone pain 
• Kidney and urinary disorders: Blood in urine, difficulty in 
urination 
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• General disorders and administration site conditions: Leg 
swelling, general feeling of discomfort, chest pain 
Animation button:  
What is the risk of 
getting the 
uncommon side 
effects of XELOX? 
Imagine that 1000 people are attending a concert at the Royal 
Albert Hall. Out of them, only ten will leave because they feel 
unwell, while the 990 will remain at the venue to watch the 
performance. In a similar manner, uncommon side effects can 
affect up to 10 in 1,000 patients. There is no guarantee that you 
won’t get any of these side effects, but we know that the risk of 
experiencing them is very low.   
Uncommon side 
effects of XELOX 
(up to 10 in 1000 
people) 
(text) 
• Infections and infestations: Sepsis, urinary tract infection, 
skin infections, tonsillitis, throat infection, oral candidiasis, 
influenza, gastroenteritis, fungal infections, tooth abscess 
• Blood disorders: Decreased number of all blood cells (if it 
occurs, it will be picked up in blood tests) 
• Immune system disorders: Hypersensitivity 
• Metabolic and nutrition disorders: Diabetes, malnutrition, 
increased triglycerides, metabolic acidosis 
• Nervous system and psychiatric disorders: Difficulty in 
speech and writing, memory impairment, problems with 
coordination, syncope (passing out), balance and sensory 
disorder, confusion, panic attack, decreased libido, 
nervousness 
• Eye and ear disorders: Visual acuity reduced, double vision 
• Ear and labyrinth disorders: Vertigo, ear pain  
• Heart and vascular problems: Myocardial infarction 
(decreased blood flow in the heart muscle), atrial fibrillation, 
irregular heartbeat, deep vein thrombosis, low blood 
pressure, hot flush, peripheral coldness 
• Respiratory disorders: Pulmonary embolism, spitting blood, 
asthma 
• Gastrointestinal disorders: Intestinal obstruction, bloating, 
inflammation in the bowel, stomach or oesophagus, difficulty 
in eating), abdominal discomfort, gastroesophageal reflux, 
blood in stools, lack of movement in the bowels 
• Liver problems: Liver failure, cholestatic hepatitis  
• Skin disorders: Blistering, skin ulcer, hives, sensitivity to light, 
swelling face, intense redness 
• Musculoskeletal disorders: Joint swelling, facial pain, 
stiffness, weakness 
• Kidney and urinary disorders: Kidney swelling, urinary 
incontinence, night urination 
• Reproductive system and breast disorders: Vaginal 
haemorrhage 
• General disorders and administration site conditions: 
Swelling, Chills, -influenza-like illness, lipoma (fatty lump on 
the skin) 
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Animation button:  
What is the risk of 
getting the rare 
side effects of 
XELOX? 
Imagine that 10,000 people are going to Wembley stadium to 
watch a football match. Out of them, ten will leave because they 
feel unwell, while the rest will stay to watch the game. In a 
similar manner, rare side effects can affect up to 10 in 10,000 
patients. Although we cannot guarantee that you won’t get any 
of these side effects, we know that the risk of experiencing them 
is extremely low, so you are very unlikely to get them. 
Rare side effects 
of XELOX (less 
than 1 in 100 
people) 
(text) 
• Blood disorders: Immunoallergic thrombocytopenia, 
haemolytic anaemia  
• Nervous system disorders: Toxic leukoencephalopathy (brain 
damage), slurred speech 
• Eye disorders: Lacrimal duct stenosis, corneal disorders, 
keratitis, visual field disturbances, damage of optic nerve, 
transient vision loss 
• Ear and labyrinth disorders: Transient loss of hearing  
• Cardiac disorders: Ventricular fibrillation, QT prolongation, 
slow heartbeat, constriction of blood vessels   , 
• Respiratory disorders: Interstitial lung disease, pulmonary 
fibrosis 
• Gastrointestinal disorders: Colitis including clostridium 
difficile diarrhoea, pancreatitis 
• Skin disorders: Cutaneous lupus erythematosus, severe skin 
reactions such as Stevens-Johnson Syndrome and toxic 
epidermal necrolysis 
Subsection 2: Help with side effects 
Part 1: Help with very common side effects 
Animation button:  
Loss of appetite 
You might find it helpful to eat small portions of food and have 
snacks instead of large meals. Also, don’t fill up your stomach 
with fluids before you eat. Remember, if you don’t feel like 
eating one day, you can make up for the calories the next day. If 
you lose your appetite and become worried about losing weight, 
let your GP or nurse know. They can recommend some high 
calorie drinks that can help you not lose weight. 
Animation button:  
Diarrhoea 
If you have diarrhoea after your treatment, let your doctor or 
nurse know. They can recommend or prescribe medicines to 
help you. While being on treatment, make sure to drink plenty of 
fluids. Diarrhoea makes you lose a lot of water from your body, 
so you need to replace it to stay hydrated. Ideally, aim for 8 
glasses of water a day. If you find this hard, you can try things 
such as drinking flavoured water or eating water- rich fruits and 
vegetables, such as cucumbers, courgettes, and watermelons. 
Animation button:  
Nausea (feeling 
sick) and vomiting 
(being sick) 
To ease or prevent feeling sick, try to eat small portions of food 
throughout the day. Also, avoid eating heavy, spicy or fatty 
foods, as they might make you feel sick. Fizzy drinks can also 
help. Ginger, either as tea, ginger ale or crystalized stem ginger is 
a natural alternative that some patients find useful. Finally, if you 
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don’t feel like eating, you can try sipping high calorie drinks, such 
as smoothies and milkshakes.  
Animation button:  
Mouth sores and 
ulcers 
Clean your mouth and wash your teeth every morning and 
evening, as well as between meals. If you are prescribed a 
mouthwash, use it as advised. If you notice that it stings, let your 
GP or nurse know. They might change it or advise you to dilute it 
with water.   
Avoiding certain foods and drinks will also help reduce the 
irritation in your mouth. Avoid spicy, sour or salty foods, alcohol 
and acidic drinks like orange juice. 
Animation button:  
Numbness or 
tickling in fingers 
and toes 
If the weather gets cold, wrap up warm and keep your fingers 
and toes warm by wearing gloves, warm shoes and warm socks. 
Avoid cold drinks and cold food if you know that it makes things 
worse. Also, be careful when you use hot water, as you might 
not feel how hot it is and burn yourself. Finally, I recommend 
that you moisturise your hands and feet with a cream. 
Animation button:  
Soreness, redness 
and peeling on 
palms and soles 
Keep your hands and feet cool and avoid hot water. If your 
hands or feet get swollen, avoid tight fitting gloves or socks. If 
your hands or feet become scaly, you can use a moisturising 
cream. Go for a non-perfumed cream, as they are less likely to 
irritate your skin. 
Animation button:  
Feeling tired 
(Fatigue) 
There are some things you can do to feel more energised. For 
example, maintain a healthy sleep pattern and make sure to take 
rest during the day. A healthy diet and mild exercise will also 
help you.   
You might find it useful to keep a diary of how you are feeling 
each day. This can help you make notes of what might make you 
feel better or worse. You can use the “My Notes” section of the 
app to do this. 
Animation button:  
Breathlessness 
and looking pale 
(due to decreased 
number of white 
blood cells and/or 
red blood cells)  
Chemotherapy can reduce the number of red blood cells, which 
can make you feel breathless and look pale. If you feel 
breathless, you must contact the Triage Helpline straight away. 
They will order some tests to check the levels of red blood cells 
in your blood. If the levels are very low, you might get a blood 
transfusion, which will help you be less breathless and look less 
pale. 
Animation button:  
Taste 
disturbances 
(changes in taste) 
This is a temporary side effect which resolves soon after 
treatment. If it happens, it is important to not put yourself off 
food, but instead experiment to find out what you like. You can 
try things such as adding spices and sauces to your food to make 
it tastier. For more information and tips about this, follow the 
link below this message. 
Animation button:  
Constipation 
To prevent or ease constipation, sure to drink plenty of fluids. 
Ideally, aim for 8 glasses of water a day. If you find this hard, you 
can try things such as drinking flavoured water or eat water- rich 
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fruits and vegetables, such as cucumbers, courgettes, and 
watermelons. Also, eat as much fruits and vegetables as you can, 
as they can help your bowel movements. Some mild exercise 
such as walking will help as well. 
Animation button:  
Tummy pain 
Tummy pain is a common side effect, but it is something that 
needs to be assessed at once if it happens. If you get any pain in 
your tummy, you need to call the Triage assessment team as 
soon as possible. 
Animation button:  
Hair thinning or 
hair loss 
You might notice that your hair becomes thinner or falls out 
while you are on chemotherapy. However, in most cases this is a 
temporary effect and your hair is likely to grow back once 
treatment is finished. If you are concerned about this, please talk 
to your nurse keyworker. Cancer Research UK and MacMillan 
can also support you with this and provide a range of advice. 
Their contact information can be found at the ‘useful contacts’ 
section of the app. 
Animation button: 
Skin problems 
Your skin might become more sensitive during treatment, so it’s 
important to avoid things such as unprotected exposure to 
sunlight, strong cleansing products and chlorinated water. If your 
skin becomes dry, use a non-perfumed cream to moisturise. 
Also, you need to watch out for skin rashes. If your skin becomes 
red, itchy and irritated or if you have an existing rash that has 
become worse, you will need to call Triage straight away. 
Animation button: 
Reaction at the 
site of the 
injection 
(Oxaliplatin only) 
Sometimes patients get redness, itchiness, pain and swelling 
around their central lines while having their medicines. At the 
hospital, a nurse will keep an eye on you and take appropriate 
action if this happens. If you get this at home while using the 
infusion pump, you need to call Triage immediately. 
Animation button:  




Pain caused by no apparent reason such as injury is something 
that needs to be assessed at once. If you notice any new pain or 
existing pain becomes worse and persists or interferes with your 
normal activities, you need to call Triage as soon as possible. If 
you get any chest pain, you need to call 999 immediately.  
Animation button:  
Headaches 
To prevent headaches, it is important to stay hydrated and rest 
during the day. Relaxation techniques can also help, as reducing 
stress can prevent headaches. If you get headaches, you might 
find it useful to use the ‘my notes’ section of the app to note 
what makes headaches better or worse. If headaches persist or 
become worse, please let your GP know, as they can 
recommend medicines that can help. 
Part 2: Help with common side effects 
Animation button:  
Weight loss 
Please keep a regular track of how much you weight and let your 
doctors know if you start to lose too much, as they can find out 
why this happens and help you maintain your normal weight. 
Cancer Research UK and MacMillan also provide a range of 
advice about how to maintain your weight through eating 
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healthily. Please visit the links below this message for more 
information. 
Link button:  MACMILLAN LINK FOR DIETARY ADVICE 
Link button:  CANCER RESEARCH UK LINK FOR DIETARY ADVICE 
Animation button:  
Sleeplessness 
(Insomnia)  
] If you have trouble sleeping, let your pharmacist or GP know. 
They can make changes to your existing medicines to reduce this 
side effect or recommend medicines that can help you sleep. 
There are also plenty of things that can help with sleeping 
difficulties. Please visit the link below this message for more 
information. 
Link button: MACMILLAN LINK FOR ADVICE ON SLEEPLESSNESS 
Animation button:  
Depression – low 
mood 
Patients can sometimes feel very sad, which is completely 
normal. If this persists or becomes worse, then it could be a sign 
of depression. Please remember that help will always be 
available if you feel like this. This includes the members of your 
care team, as well as experts who can help you with your 
feelings. Patient support groups are also available. Please visit 
the ‘emotional support’ section of the app for more information. 
Animation button:  
Dizziness 
Keeping hydrated is key for preventing dizziness, so make sure to 
drink plenty of fluids throughout the day. If you get dizziness for 
the first time or if you feel dizzier than you usually do, you need 
to call Triage straight away. 
Link button: CANCER NET LINK FOR TASTE DISTURBANCES 
Animation button:  
Eye problems 
(runny eyes, eye 
irritation, eye 
infections) 
Chemotherapy can cause eye problems such as dryness, 
irritation or excessive tearing. If you notice any of these, please 
let you doctor, pharmacist or nurse know, as they can 
recommend products that can help. However, if you notice any 
changes in your vision such as reduced eyesight, blurred or 
double vision, or if you get any pain in your eyes, you need to 
call Triage straight away. 
Animation button:  
Bloating 
Chemotherapy can slow down the movement of food across the 
digestive tract, which can make you feel overly full after a meal. 
To prevent this or ease it if it happens, make sure to drink plenty 
of fluids and avoid food that you cannot digest easily. Some mild 
exercise such as walking can also help. For more information and 
tips, please visit the links below this message. Please note that if 
bloating becomes painful, you need to call Triage straight away.  
Link button: LINK FOR ADVICE AND TIPS ON BLOATING 
Link button: LINK FOR FOODS AND RECIPES TO REDUCE BLOATING 
Animation button:  
Dry mouth 
Mouth dryness is temporary and resolves soon after treatment. 
To ease it if it happens, it is important to drink plenty of fluids 
throughout the day. Also, try eating moist foods, vegetables and 
add gravy or sauces to your meals to moisten them. Maintaining 
good oral hygiene also helps; use a soft toothbrush and rinse 
your mouth with water throughout the day. If your mouth 
becomes too dry, please let your doctor or nurse know, as they 
can recommend products that can help.  
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runny nose, sore 
throat) 
Chemotherapy medicines can weaken the immune system, and 
this can increase the risk of you getting ill. This is a common side 
effect of XELOX. If your temperature is higher than normal or if 
you feel you are getting ill, you MUST contact the Triage Helpline 
IMMEDIATELY. If you have an infection, your doctor or nurse will 
prescribe you antibiotics. You will have them as either tablets, 
which can be taken at home, or as an injection, which is given at 
the hospital. 
Animation button:  
Heartburn 
Spicy, fatty or oily foods are not digested easily and can cause or 
worsen heartburn. Alcohol, caffeine and acidic juices can also 
make this worse, so it’s best to avoid them as well. There are 
also several non- prescription medicines that can help. Please 
speak to your doctor or local pharmacist to make sure that it’s 
safe to take them.  




This can be caused by the treatment, but it can also be a sign of 
infection. If you notice excessive sweating, keep a regular track 
of your temperature and call Triage at once if it is higher or 
lower than normal. If sweating is caused by the medicines and 
not an infection, your doctor can recommend medicines that can 
help. 





In most cases, the uncommon side effects of Capecitabine are 
important and need to be assessed by the Triage team as soon 
as possible. After this message is finished, please read through 
the list below and call Triage at once if you have any of the side 
effects that appear on that list.  
List of uncommon 
side effects that 
need to be 
reported to Triage 
at once: (text) 
 
 
• Joint swelling, bone pain, stiffness, muscular weakness 
• Incontinence, blood in wee, having to wake up at night to 
wee 
• Vaginal haemorrhage (unexpected blood flow from the 
vagina) 
• Tummy pain, blood in stools 
• Severe skin problems (blisters, ulcers, sensitivity to light, 
swelling in the face) 
• Jaundice (skin turning yellow because of liver problems) 
• Heart problems (changes in the way your heart beats, high or 
low blood pressure) 
• Severe breathing problems (being unable to breathe 
properly or finding it hard to breathe) 
• Spitting blood (also known as haemoptysis) 
• Memory/cognitive disorders (problems with movement, 
coordination and speech, memory problems, confusion) 
• Visual problems (clarity of vision reduced, double vision) 
• Vertigo (feeling that everything around you is spinning),  
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• Infections (urinary tract infection, skin infections, tonsillitis, 
pharyngitis, fungal infections, influenza, gastroenteritis, 
tooth abscess) 
• Lipoma (small, fatty lumps on the skin) 
Part 4: Help with rare side effects 
Animation button: 
Loss of hearing or 
Loss of vision  
These are rare side effects and develop gradually rather than all 
of the sudden. If you notice any problems with your vision or 
hearing, please report them to your doctor or Triage as soon as 
possible. They can help stop your hearing or vision from 
deteriorating and reverse any damage made by chemotherapy.  
Ringing in your 
ears (tinnitus) 
This is a very uncommon common side effect, which affects 1 
out of 100 people. Ringing in your ears is also known as tinnitus. 
This often gets better after treatment. If you experience ringing 
in your ears, let your doctor or nurse know.  
 
Section 5: Help with side effects 
Subsection 1: Chemotherapy medicines 
Animation button:  
Oxaliplatin (drip) 
Oxaliplatin will be given to you as a drip over two hours at the 
hospital at the first day of each chemotherapy cycle.  
Animation button:  
Capecitabine 
(tablets) 
Capecitabine comes as a tablet, which you will get for the first 
two weeks of each chemotherapy cycle.  
Animation button:  
How should I take 
the Capecitabine 
tablets? 
Capecitabine should be taken twice daily. Swallow the tablet 
whole, after food or a meal. It is important to eat something 
before you take it, as the medicine works best with food.  
Animation button:  
What happens if I 
miss a dose of 
Capecitabine? 
If you forgot to take a Capecitabine tablet, do not take two 
together. Please call your doctor or pharmacist for instructions 
on what to do. 
Animation button:  
What happens if I 
vomit after I take 
Capecitabine? 
If you vomit IMMEDIATELY and you can still see the tablet, you 
should take another tablet an hour after. If you vomit later, 
even 5 minutes after you took the tablet, DO NOT take another 
dose. Please contact your doctor for information on what to do.  
Animation button:  
If I get side effects, 
from XELOX, how 
long will they last 
for?  
XELOX can have short term side effects that can last for weeks, 
and long-term side effects that can last for several months. 
Please note that all side effects get better after the treatment is 
finished. Your care team will also help you deal with them.  
Subsection 2: Chemotherapy supportive medication 
Anti-diarrhoea medication 





If you get diarrhoea during your treatment, let your doctor or 
nurse know. They can prescribe Codeine or recommend a 
medicine called Loperamide, which is available to buy over the 
counter.  
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Animation button:  
Loperamide  
Loperamide comes as a capsule. Only take it if it is 
recommended by your doctor, nurse or the Triage Helpline. The 
usual dose is two capsules at first, and then one capsule after 
each loose stool, if required. Take no more than 8 capsules a 
day.  
Animation button:  
Codeine  
Codeine comes as either tablets or syrup. Let your doctor or 
nurse which one you prefer. Please note that this medicine 
might make you sleepy. Avoid driving, operating machinery and 
drinking alcohol when you have it.   
Mouth care and mouthwashes 
Animation button:  
General 
information about 
mouth care  
If your mouth becomes sore, there is a number of things that 
the doctor or nurse might recommend. Remember to brush 
your teeth and clean your mouth regularly to prevent your 
mouth from becoming sore.  
Animation button:  
Salt water 
mouthwash 
This is used to prevent your mouth from becoming sore. You 
can make this at home by adding one teaspoon of salt in a glass 
of lukewarm water. Use this to clean your mouth after food. 
Remember to rinse out with water afterwards.  
Animation button:  
Aspirin 
mouthwash  
This is used to relieve soreness in your mouth. Only use this if it 
has been recommended by your doctor or nurse. You can make 
this at home by adding two tablets of soluble aspirin in a glass 
of water. Wait for them to dissolve and then use this as a 
gargle. It is very important to take care not to swallow this.   
Animation button:  
Difflam 
mouthwash 
This is used to relieve soreness in your mouth. Difflam 
mouthwash is available to buy over the counter, but only use it 
if it has been recommended by your doctor or nurse. Use one 
tablespoonful three times a day to rinse your mouth. If it stings, 
you can mix one tablespoonful of Difflam with one 
tablespoonful of water and use it as regular.  
Animation button:  
Difflam oral spray  
This is used to relieve soreness in your mouth. This is available 
to buy over the counter, but only use it if it has been 
recommended by your doctor or nurse. Please ask your doctor 
or pharmacist for an appropriate dose. 
Medicines for constipation 





Chemotherapy can cause constipation to some patients. If this 
happens, let your doctor or nurse know, as they can 
recommend or prescribe a laxative. Note that you must not self-
medicate with laxatives and you should use them only if they 
have been prescribed or recommended by your doctor or 
nurse.   
Animation button:  
Macrogol  
This is available to buy over the counter. Only use it if it is 
recommended by your doctor or nurse. Macrogol comes as 
sachets, which are dissolved in water. Please ask your doctor or 
pharmacist for an appropriate dose.  
Animation button:  
Senna 
This is available to buy over the counter. Only use it if it is 
recommended by your doctor or nurse. Senna comes as tablets, 
granules or a syrup. Senna is taken at night, ideally before 
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bedtime. Please ask your doctor or pharmacist for an 
appropriate dose. 
Non-prescription painkillers 
Animation button:  
General 
information about 
over the counter 
painkillers  
There are several over the counter painkillers you can take 
during your chemotherapy. Always ask your doctor or nurse 
before you start taking such medicines, as some of them are not 
suitable for all patients.  
Animation button:  
Paracetamol (over 
the counter) 
Paracetamol is a common painkiller and it is available over the 
counter. Make sure that you don’t exceed the recommended 
daily dose, which is 8 tablets a day. Also take care not to mix 
paracetamol- containing products together.  
 
Section 6: Emotional support, help with finances and everyday life 
Subsection 1: Emotional support 
Animation button:  
Are there any 
groups where I can 
talk with other 
people with cancer? 
Yes, there are. Talk to your keyworker, such as your Specialist 
Nurse to get more information on how to contact such groups. 
Alternatively, you can contact MacMillan or Maggie’s for local 
support groups. You can also link up with fellow patients 
through Beating Bowel Cancer.org. Contact information for 
these organizations can be found on the “Useful contacts” 
section.  
Animation button:  
Where can my 
family go if they 
need help dealing 
with my illness? 
This is something that MacMillan or Maggie’s can help you 
with, as they have great experience in this respect. Their 
contact information can be found on the “useful contacts” 
section. 
Animation button:  
How to talk to my 
family and friends 
about my illness? 
Same as above 
Animation button:  
Where can I get 
help to deal with my 
feelings about my 
illness? 
This is something that your keyworker, such as your Specialist 
Nurse will help you with. This is also something that MacMillan 
or Maggie’s can help you with. Their contact information can 
be found on the “useful contacts” section. 
Animation button:  
What to do if I 
become concerned 
about dying? 
If you become concerned about dying, please talk to any 
healthcare professional that looks after you. This includes your 
GP, as well as any member of your cancer care team. This is 
something that Maggie’s or MacMillan can also help you with. 
Contact information for both can be found on the “useful 
contacts” section. 
Animation button:  
Where can I get 
help if I don’t feel as 
attractive as 
before? 
This is something that MacMillan or Maggie’s can help you 
with, as they have great experience in this respect. Their 
contact information can be found on the “useful contacts” 
section. 
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Animation button:  
What to do if I feel 
uncomfortable in 
social situations? 
Same as above 
Subsection 2: Financial support / help with finances 
Animation button:  
Will there be any 
financial support 
available to me 
during my illness? 
Yes. MacMillan can provide advice and help you with your 
finances. Pending what is available in local Trusts, something 
like a citizens’ advice bureau will be available. This will assist 
you in applying for benefits and has plenty of information for 
patients who are already receiving benefits or tax credits. 
Contact details are provided in the “Useful contacts” section.  
Subsection 3: Help with diet and everyday life 
Animation button:  
Who to call if I have 
questions while I am 
still getting 
treatment? 
You can refer your questions to your consultant or nurse 
keyworker after treatment. Your consultant or nurse have 
provided you with a 24-hour emergency number if you have 
an urgent question or if you need to report a side effect or 
complication of treatment.  
Animation button:  
Who do I have to 
call if I have any 
questions after the 
treatment is 
finished? 
You will still be able to refer your questions to your consultant 
or nurse keyworker after treatment. Maggie’s and MacMillan 
can also help you. Keep a list of these questions so you can re-
visit them when you want. You can use the “My Notes” section 
of the app to create your custom questions and have them all 
saved in one place.  
Animation button:  
Who to talk to 
about alternative 
treatments? 
This is something that your consultant, nurse or pharmacist 
can help you with. Refer to them for further information about 
this.  
Animation button:  
How may the illness 
affect my life over 
the next few 
months? 
This is different for each patient and will depend on the stage 
of your condition, as well as how well you will tolerate your 
treatment. You can discuss this with any member of your 
medical care team.  
Animation button:  
How may the illness 
affect my life in the 
future? 
This is different for each patient and will depend on the stage 
of your condition, as well as your general health state. You can 
discuss this with your consultant or your nurse Keyworker.  
Animation button:  
Will there be 
changes in usual 
things I can do with 
or for my family? 
Same as above. 
Animation button:  
Will I be able to 
continue with my 
usual hobbies and 
sports? 
Patients are generally able to continue with their usual 
activities and hobbies. In some cases, you might need to make 
several modifications, which can be either temporary or 
permanent. This will depend on how well you tolerated 
chemotherapy and how well it worked. The members of your 
care team will discuss this with you.  
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Animation button:  
Will I be able to 




Same as above 
Animation button:  
Will the illness or 
treatment affect my 
relationships/sex 
life? 
Chemotherapy can have some effect on your sex life. 
However, we cannot know until after you have had several 
doses of the medicines. Your doctor or nurse will provide a 
range of advice at different stages of treatment.  
Animation button:  
Are there any 
physical things I 
should not 
do/avoid? 
Generally, there are no physical things that you should avoid. 
However, if you had recent surgery for your condition, you 
must avoid stooping or lifting weights for several weeks after 
surgery. Your surgeon will provide more advice about this.  
Animation button:  
Are there any 
special exercises I 
can do? 
Patients are highly encouraged to maintain normal activity and 
perform mild exercise. With respect to special exercises, this 
would depend on your symptoms and on whether or not you 
had previous surgery for bowel cancer. Your surgeon or 
surgical nurse will provide you with information about this.  
Animation button:  
Am I going to need 
help taking care of 
myself? 
This will depend upon your symptoms and how you tolerate 
treatment, both of which will determine the level of care 
required, as well as its duration. If you are concerned about 
this, ask your doctor or nurse keyworker for further 
information.  
Animation button:  
Will I be able to take 
a bath or shower? 
Generally, yes. If you are concerned about needing help during 
showering or advice around how to shower if you have a 
stoma, ask your doctor or nurse keyworker for further 
information.  
Animation button:  
Are there any foods 
I should avoid 
during treatment?  
Yes. This is because chemotherapy can cause side effects that 
can make your mouth, stomach and tummy more sensitive. 
Generally, you should avoid fatty, spicy or heavy foods, as 
these can irritate your stomach or tummy. Sour foods and 
drinks, as well as alcohol should also be avoided if your mouth 
becomes sore.  
Animation button:  
After treatment is 
finished, will I be 
able to return to my 
normal eating 
habbits? 
Patients should avoid some foods and drinks because 
chemotherapy can cause side effects which can affect the 
mouth, stomach and tummy. However, these side effects are 
usually temporary and disappear after treatment. Hence, you 
will be able to gradually return to your normal eating habits. 
Animation button:  
Can I wear normal 
clothing? 
Yes, you should be able to wear normal clothing before and 
after treatment. If you have a stoma, you might find it helpful 
to prefer clothing that is easily unbuttoned and does expose 
the area around the stoma bag.  
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Animation button:  
Will treatment alter 
the way I look? 
Side effects such as looking pale, weight or hair loss can 
change the way you look, but these do not occur in every 
patient. Moreover, such side effects usually resolve after 
treatment, so even if you get them, you are likely to go back to 
the way you looked before treatment.  
Animation button:  
How long will it take 
for my incision or 
wound to heal? 
If you had surgery, the skin wound takes 7-10 days to heal. You 
will be given plenty of information about this on discharge by 
your surgeon and your surgery nurse.  
Animation button:  
Am I prone to 
infection because of 
my treatment? 
Yes. XELOX makes you more susceptible to infections, meaning 
that you are at higher risk of getting ill. Your doctor and nurse 
will tell you what you need to do to do to protect yourself 
from infections.   
Animation button:  
How should I care 
for my wound or 
incision? 
You will be given advice, information and material about how 
to care for your wound or incision by a specialist nurse in 
wound care. You will also be referred to district nurses if 
required.  
Animation button:  
Will I be able to 
continue my job 
after my treatment? 
Generally, the answer is yes. Your doctor will discuss this with 
you in order to decide if it is safe and when it is safe for you to 




Appendix 12: Layout of the CAPE information package 
 
Note: Sections 1, 3, 6, 7 and 8 were the same as XELOX.  
 
Section 2: Information about cancer and treatment  
Animation button:  
What is cancer? 
Same as XELOX 
Animation button:  
What causes 
cancer? 
Same as XELOX 
Animation button:  
Has the cancer left 
its original site and 
spread in my 
body? 
Same as XELOX  
Animation button:  
What are the 
treatment options 
for cancer? 
Same as XELOX 
Animation button:  
I will be given 
chemotherapy 
with Capecitabine. 
How will it fight 
cancer? 
Cancer tumours are made by cancer cells. In order for tumours 
to grow and spread, cancer cells need to divide and multiply. 
Capecitabine fights tumours by preventing this from happening. 
Since cancer cells are not able to multiply and some of them will 
die, the tumours will stop growing and will gradually shrink, 
which is important for treatment. 





Your chemotherapy contains a single medicine, which is called 
Capecitabine. Capecitabine is given in cycles of treatment, each 
lasting for three weeks. Capecitabine comes as tablets, which 
you will take twice daily for the first two weeks of each 
chemotherapy cycle. 
Animation button:  
Is there any 
preparation before 
I get Capecitabine? 
Your doctors will order some blood tests in order to make sure 
that it is safe to take Capecitabine. Once the results are back, 
your doctor will tell you when your treatment will start. 
Animation button:  
Do I need to be at 
the hospital for my 
treatment? 
Dome chemotherapy regiments contain medicines that need to 
be given at the hospital. However, your treatment does not 
contain such medicines, so you don’t need to worry about this. 
Capecitabine comes as tablets, which you will take from home. 
Animation button:  
If Capecitabine 
treats my cancer, 
what are the 
Same as XELOX 
 423 
chances of it 
coming back? 
Animation button:  
How can I tell if 
the cancer has 
come back? 
Same as XELOX 
 
Section 4 (Help with side effects) 
Subsection 4.1.: Side effects of CAPE 
Part 1 Button  
 
Very common side 
effects (more than 
1 in 10 patients) 
 
Animation button: How likely am I to get a very common side 
effect? - Same as XELOX 
 
(Text) List of very common side effects: 
 
• Loss of appetite 
• Diarrhoea 
• Nausea (feeling sick) and vomiting (being sick) 
• Mouth problems (sore mouth) 
• Pain in your stomach 
• Numbness or tickling in fingers and toes 
• Soreness, redness and peeling on palms and soles 
• Feeling tired (Fatigue) 
• Feeling ill (Asthenia) 
Part 2 Button 
 
Common side 
effects (up to 10 in 
100 patients) 
 
Animation button: How likely am I to get a common side effect? 
-Same as XELOX 
 
(Text) List of common side effects: 
 
• Cold sores (herpes viral infection)  
• Breathlessness and looking pale (due to decreased number 
of white blood cells and/or red blood cells)  
• Weight loss 
• Sleeplessness (Insomnia)  
• Depression – low mood 
• Headaches 
• Dizziness  
• Taste disturbances (changes in taste) 
• Eye problems (runny eyes, eye irritation, eye infections) 
• Thrombophlebitis (formation of blood clots) 
• Constipation 
• Tummy pain 
• Bloating 
• Changes in liver function 
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• Skin problems (rash, dry skin, skin inflammation) 
• Hair thinning or hair loss 
• Pain (chest pain, pack pain, generalised pain the body) 
• Infections (generalised or respiratory) and getting/feeling ill 
(fever, cough, runny nose, sore throat) 
Part 3 Button 
 
Uncommon side 
effects (up to 10 in 
1,000 patients) 
 
Animation button: How likely am I to get an uncommon side 
effect? Same as XELOX 
 
(Text) List of uncommon side effects: 
 
• Joint swelling, bone pain, stiffness, muscular weakness 
• Kidney problems (incontinence, blood in wee, having to 
wake up at night to wee) 
• Vaginal haemorrhage (unexpected blood flow from the 
vagina) 
• Gastrointestinal problems (tummy pain, discomfort, blood in 
stools) 
• Severe skin problems (blisters, ulcers, sensitivity to light, 
swelling in the face) 
• Jaundice (skin turning yellow because of liver problems) 
• Heart problems (changes in the way your heart beats, high 
or low blood pressure) 
• Severe breathing problems (being unable to breathe 
properly or finding it hard to breathe) 
• Spitting blood (also known as haemoptysis) 
• Memory/cognitive disorders (problems with movement, 
coordination and speech, memory problems, confusion) 
• Visual problems (clarity of vision reduced, double vision) 
• Vertigo (feeling that everything around you is spinning),  
• Infections (sepsis, urinary tract infection, skin infections, 
tonsillitis, pharyngitis, fungal infections, influenza, 
gastroenteritis, tooth abscess) 
• Lipoma (small, fatty lumps on the skin) 
• Blood problems (changes in the composition of blood, which 
doctors will pick up from blood tests) 
• Metabolic disorders (diabetes, low potassium levels, high 
triglyceride levels, which doctors will pick up from blood 
tests) 
• Mood disorders (anxiety, low sexual drive) 
• Ear pain 
Part 4 button 
 
Rare side effects 
(up to 10 in 10,000 
patients) 
 
Animation button: How likely am I to get a rare side effect? - 
Same as XELOX 
 
(Text) List of rare side effects: 
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• Severe eye problems (lacrimal duct stenosis, corneal 
disorders, keratitis and punctate keratitis) 
• Severe heart problems (ventricular fibrillation, QT 
prolongation, torsade de pointes, Bradycardia, Vasospasm) 
• Severe liver problems (hepatic failure, cholestatic hepatitis) 
• Severe skin problems  
Subsection 4.2.: Help and advice on dealing with side effects 
Part 1 Button 
 























Same as XELOX 
 Animation 
button:  
Pain in your 
stomach  


























Same as XELOX 
Part 2 Button  
 























Same as XELOX 
 Link button: 
Link for 
MacMillan 
Same as XELOX 


































Same as XELOX 
 Link button: 
Link for 
Cancer Net 



















Same as XELOX 




Same as XELOX 












(rash, dry skin, 
skin 
inflammation) 




or hair loss 
Same as XELOX 
Animation 
button:  


















Same as XELOX 





 Animation button: General advice for uncommon side effects- 
Same as XELOX 
 
List of uncommon side effects that need to be reported to 
Triage at once:  
 
• Joint swelling, bone pain, stiffness, muscular weakness 
• Kidney problems (incontinence, blood in wee, having to 
wake up at night to wee) 
• Vaginal haemorrhage (unexpected blood flow from the 
vagina) 
• Gastrointestinal problems (tummy pain, discomfort, blood in 
stools) 
• Severe skin problems (blisters, ulcers, sensitivity to light, 
swelling in the face) 
• Jaundice (skin turning yellow because of liver problems) 
• Heart problems (changes in the way your heart beats, high 
or low blood pressure) 
• Severe breathing problems (being unable to breathe 
properly or finding it hard to breathe) 
• Spitting blood (also known as haemoptysis) 
• Memory/cognitive disorders (problems with movement, 
coordination and speech, memory problems, confusion) 
• Visual problems (clarity of vision reduced, double vision) 
• Vertigo (feeling that everything around you is spinning),  
 
Section 5: (Help with your medicines) 
Subsection 1: Chemotherapy medicines 
Animation button:  
Capecitabine 
(tablets) 
Same as XELOX 
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Animation button:  
How should I take 
the Capecitabine 
tablets? 
Same as XELOX 
Animation button:  
What happens if I 
miss a dose of 
Capecitabine? 
Same as XELOX 
Animation button:  
What happens if I 
vomit after I take 
Capecitabine? 
Same as XELOX 
Animation button:  
If I get side effects, 
from XELOX, how 
long will they last 
for?  
Same as XELOX 






Appendix 13: Layout of the FOLFOX information package 
 
Note: Sections 1, 3, 6, 7 and 8 were the same as XELOX.  
 
Section 2: Information about cancer and treatment  
Animation button:  
What is cancer? 
Same as XELOX 
Animation button:  
What causes 
cancer? 
Same as XELOX 
Animation button:  
Has the cancer left 
its original site and 
spread in my body? 
Same as XELOX 
Animation button:  
What are the 
treatment options 
for cancer? 
Same as XELOX 
Animation button:  
I will be given 
chemotherapy with 
FOLFOX. How does 
this treatment fight 
bowel cancer?  
In order for tumours to grow and spread, cancer cells need to 
divide and multiply. Your chemotherapy contains three 
medicines, which work in combination to fight cancer. 
Oxaliplatin prevents cancer cells from multiplying, while 5-
fluorouracil works by killing them. Folinic acid is not a 
chemotherapy medicine, but it is given to boost the effects 5-
fluorouracil, so it can kill more cancer cells. All these effects 
make tumours stop growing and gradually shrink, which is 
important for treatment. 




Your chemotherapy is known as FOLFOX and contains three 
medicines. These are Oxaliplatin, folinic acid and 5 fluorouracil, 
also known as 5-FU. These medicines are given as cycles of 
treatment, each lasting for 14 days. To find out more about 
these, please use the ‘help with your medicines’ section of the 
app. 
Animation button:  
Is there any 
preparation before I 
get FOLFOX? 
Same as XELOX 
Animation button:  
How will I feel 
during and after my 
treatment at the 
hospital?  
Same as XELOX 
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Animation button:  
If FOLFOX cures my 
cancer, what are the 
chances of it coming 
back? 
Same as XELOX 
Animation button:  
How can I tell if the 
cancer has come 
back? 
Same as XELOX 
  
Section 4 (Help with side effects) 
Animation button: Meet the Oncologist (Andrew) Same as XELOX 
Subsection Button: Side effects of FOLFOX 
Part 1 Button  
Very common side 
effects (more than 
1 in 10 patients) 
Animation button: How likely am I to get a very common side 
effect? - Same as XELOX 
List of very common side effects (grouped according to the 
system they can affect)  
 
• Blood disorders: Bruising, decreased production of blood 
cells, decreased red blood cells, decreased white blood 
cells, decreased neutrophils, decreased lymph cells, 
decreased number of cells responsible for blood clots 
• Gastrointestinal side effects: Tummy pain, loss of appetite, 
constipation, diarrhoea, difficulty in swallowing, feeling or 
being sick, heartburn, mouth soreness, redness and pain 
around the anus 
• Immune system disorders: Allergy/allergic reaction to the 
medicines, reaction at the site you got your injection or drip 
(redness, pain, swelling, itchiness), fever, weakening of the 
immune system, increased risk of infections 
• Skin problems: Hair thinning or hair loss, Palmar-plantar 
erythrodysaesthesia syndrome (hand-foot syndrome), 
sensitivity to light 
• General disorders and administration site conditions: 
Asthenia (feeling Ill), back pain, bleeding (nose bleeds), 
delayed wound healing, fatigue (feeling tired), pain 
(generalised) 
• Heart problems: Ischemic ECG abnormalities (changes in 
the way your heart works) 
• Respiratory system problems: Cough, difficulty in breathing 
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• Metabolic disorders: Increased blood sugar, increase in liver 
enzymes, weight gain, decreased levels of potassium and 
sodium 
• Nervous system problems: Headaches, peripheral sensory 
neuropathy (nerve damage), sensory disturbances (changes 
affecting your vision, taste, hearing etc.) 
Part 2 Button 
Common side 
effects (up to 10 in 
100 patients) 
Animation button: How likely am I to get a common side effect? 
- Same as XELOX 
List of common side effects 
 
• Blood disorders: Febrile neutropenia and neutropenic 
sepsis (manifests with symptoms similar to those of the flu 
like fever, chills and/or sweating, sore throat, cough, 
diarrhoea) 
• Gastrointestinal side effects: Dyspepsia (difficulty in 
digesting food), gastro-oesophageal reflux (heartburn), 
gastrointestinal haemorrhage (bleeding across the 
gastrointestinal tract, which makes stools darker than 
normal), hiccups, rectal bleeding 
• Skin problems: Flushing (redness), skin exfoliation (peeling 
of the skin at hands and feet), nail disorder (nails becoming 
soft and/or brittle, discoloration in nails), skin rash (skin 
becoming dry, red, scaly and/or itchy) 
• General disorders and administration site conditions: Joint 
and/or bone pain, dehydration, hyperhidrosis (excessive 
sweating), meningism (manifests with neck stiffness, 
sensitivity to light and headaches) 
• Heart problems: Deep vein thrombosis (which manifests 
with pain, swelling, redness and itchiness in one of your 
legs, usually the calf), hypertension (high blood pressure) 
• Eye problems: Conjunctivitis (eye infections), visual 
disturbances (blurred vision, double vision, reduced 
eyesight, decreased tolerance to light)  
• Respiratory system problems: Pulmonary embolism (similar 
symptoms to deep vein thrombosis plus fever, sweating, 
dizziness and/or rapid heartbeat), rhinitis (blocked or runny 
nose), upper respiratory tract infections (manifest with 
blocked nose, cough, difficulty in breathing, sore throat 
and/or fever) 
• Nervous system disorders: Depression (low mood), 
dizziness, insomnia (sleeplessness), motor neuritis (difficulty 
in coordinating your movements, including the movement 
of the eyelid) 
• Urinary disorders: Dysuria (discomfort while weeing), 
haematuria (presence of blood in urine), changes in how 
often you wee 
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Part 3 Button 
Uncommon side 
effects (up to 10 in 
1,000 patients) 
Animation button: How likely am I to get an uncommon side 
effect? - Same as XELOX 
 
List of uncommon side effects 
 
• Gastrointestinal side effects: Ileus (decrease in the 
movement of the bowels), intestinal obstruction (blockage 
in your intestines which manifests with constipation and 
tummy pain), dehydration (lack of water in the body), 
gastrointestinal ulceration (ulcers across the 
gastrointestinal tract) and bleeding  
• Immune system disorders: Sepsis (severe form of infections) 
• Skin problems: Hyperpigmentation of the skin (darkening of 
the skin), depigmentation near the veins (lightening of the 
skin around the veins) 
• Heart problems: Arrhythmia (irregular heartbeat), 
myocardial infarction (known as heart attack, which 
manifests with chest pain, shortness of breath and 
dizziness), myocardial ischemia (decreased blood flow in 
the heart, which gives symptoms similar to those of 
myocardial infarction), myocarditis (damage of the heart’s 
muscles, which gives symptoms similar to those of 
myocardial infarction), hypotension (low blood pressure) 
• Ear problems: Ototoxicity (problems to your ears, which can 
cause ringing in your ears or affect your hearing) 
• Metabolic disorders: Damage to your kidneys (which will 
manifest through changes in your wee), damage to your 
liver (if they become severe, they can manifest as yellowing 
of the skin and the white of the eyes) 
• Nervous system disorders: Nervousness, nystagmus (feeling 
sleepy), symptoms of Parkinson's disease (such as tremor in 
hands, loss of memory etc.), euphoria (intense feeling of 
happiness or excitement) 
• Fertility problems: Problems with spermatogenesis 
(producing sperm cells) in men and ovulation disorder in 
women 
Part 4 button 
Rare side effects 
(up to 10 in 10,000 
patients) 
Animation button: How likely am I to get a rare side effect? - 
Same as XELOX 
 
List of rare side effects 
 
• Blood disorders: Haemolytic anaemia, immunoallergic 
thrombocytopenia 
• Gastrointestinal side effects: Colitis (inflammation of the 
blows), including clostridium difficile  
• Immune system disorders: Generalized allergic reactions, 
anaphylaxis, and anaphylactic shock. 
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• Heart problems: Cerebral ischaemia (decreased blood flow 
to the brain) , intestinal ischaemia (decreased blood flow to 
the bowels), peripheral ischemia (decreased blood flow 
across the body), Raynaud's syndrome (decreased blood 
flow in the body, which usually makes fingers and toes go 
white), thromboembolism (manifests with chest pain, 
shortness of breath and dizziness), thrombophlebitis/vein 
tracking (manifests as veins hardening and going darker in 
colour, limb pain, swelling in arms and/or legs)  
• Ear problems: Deafness 
• Eye problems: Optic neuritis (damage of the eye nerves), 
gradual loss of vision  
• Respiratory system problems: Interstitial lung disease, 
pulmonary fibrosis (gives symptoms such as persistent and 
intense cough, difficulty in breathing etc.) 
• Metabolic disorders: Pancreatitis (damage of the pancreas), 
increase of T4 (total thyroxin), increase of T3 (total 
triiodothyronine). 
• Nervous system disorders: Dysarthria (difficulty in speech, 
slurred speech), reversible Posterior Leukoencephalopathy 
syndrome 
Subsection 4.2.: Help and advice on dealing with side effects 
Part 1 Button 
Help with very 
common side 
effects 
Animation button:  
Tummy pain Same as XELOX 
Animation button:  
Loss of appetite Same as XELOX 
Animation button:  
Constipation Same as XELOX 
Animation button:  
Diarrhoea Same as XELOX 




Same as XELOX 
Animation button:  
Feeling or being 
sick 
Same as XELOX 
Animation button:  
Heartburn Same as XELOX 
Animation button:  
Mouth soreness Same as XELOX 
Animation button:  
Reaction at the site 
you have your 
Same as XELOX 
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injection, drip or 
infusion 
Animation button:  
Increased risk of 
infections 
Same as XELOX 
Animation button:  
Hair thinning or hair 
loss 
Same as XELOX 





Same as XELOX 
Animation button:  
Asthenia (feeling Ill) Same as XELOX 
Animation button:  
Fatigue (feeling 
tired) 
Same as XELOX 
Animation button:  
Pain (local or 
generalised) 






Same as XELOX 
Animation button:  
Headaches 
Same as XELOX 
Animation button:  
Taste disturbances 
(changes in taste) 
Same as XELOX 
Link button: Link for 
Cancer Net 
Same as XELOX 
Part 2 Button  










Same as XELOX 
Animation button:  
Eye problems 
Same as Capecitabine 




Animation button:  
Dizziness 
Same as XELOX 
Animation button:  
Insomnia 
(sleeplessness) 
Same as XELOX 
 
NEW Link button: 
Link for MacMillan 
Same as XELOX 




Animation button:  
Ringing in your ears  
Same as XELOX 
Animation button:  
Feeling tired and/or 
sleepy 




fertility (both men 
and women) 
Same as XELOX 
Part 3 Button  
Help with rare side 
effects 
Animation button:  
Pain (chest pain or 
generalised pain)  
Same as XELOX 
New Animation 
button: 
Loss of hearing or 
Loss of vision  
Same as XELOX 
 
Section 5: Help with side effects 
Subsection 5.1: Chemotherapy medicines 
Animation button: 




FOLFOX-4 and FOLFOX-6 are two different ways of getting your 
treatment, but they both contain the same medicines. In Folfox-
6, you get a long infusion of 5-FU over 2 days, while in Folfox 4, 
you get two slower infusions of 5-FU, each lasting for 22 hours. 
In both schedules, the treatment cycle lasts for 14 days and you 
only get chemotherapy medicines for the first two days. 
Animation button: 
Where will I get 
my treatment?  
 
Oxaliplatin and folinic acid will be given to you at the hospital. If 
you have a catheter or a port, you will be able to take 5-FU from 
home through a chemotherapy pump. However, if you have 
neither of those, you will need to stay at the hospital for the 
first two days of each chemotherapy cycle. Your doctor will 
discuss this with you. 
Animation button:  
If I get side effects, 
from FOLFOX, how 
long will they last 
for?  
Same as XELOX 
Subsection 2: Chemotherapy supportive medication- Same as XELOX 
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Subsection 3: Your chemotherapy pump 
Animation button: 
What is a 
chemotherapy 
pump? 
A chemotherapy pump is a device that delivers a steady amount 
of chemotherapy medicines to your blood over several hours. 
The pump is a small device and will be given to you with a bag 
or belt holster, so you can carry it with you. 
Where do I get a 
chemotherapy 
pump and how do 
I use it? 
Your chemotherapy pump will be prepared for you at the 
hospital on the first day of each cycle. A pharmacist will check 
the medicines that go in and a nurse will set it up and attach it 
to your catheter or port through a tube. The nurse will also give 
you instructions and printed material on how to use your pump 
from home. 
Will I be able to 





You should be able to carry out your normal activities while 
having your treatment through the pump. However, please 
avoid activities that may cause pulling of the tube, such as 
exercise and playing with children or pets. Also, when taking a 
bath or shower, avoid getting the catheter dressing wet and do 
not let the pump go underwater. 
How to take care 
of my pump at 
home? 
Please always keep the pump in the pouch supplied by the 
hospital. Please do not expose the pump to extreme 
temperatures and protect it from light, as both can affect the 
way the device works and damage the medicine. 
How can I check if 
my chemotherapy 
pump is working 
properly? 
The chemotherapy pump contains a balloon filled with the 
medicine. Over time, this balloon will shrink gradually to deliver 
the medicines to your body. The nursing staff will show you how 
to check that this is done correctly. Please remember to check 
the pump every 8 hours to make sure that the balloon is 
shrinking at the correct pace and call Triage at once if you 
notice something wrong. 
What should I do if 
I notice a spillage 
or leakage of the 
medicines from 
the pump? 
Before you go home, your nurse will provide you with special 
equipment and a set of written instructions on what to do in 
the event of a spillage or leakage of medicines from the pump. 
Please follow these instructions to clear any spillage and report 































































Appendix 18: Approval of the second substantial amendment 
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